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Preface 
Abstract 
This thesis explores the value of risk-adjusted colorectal cancer screening using the faecal 
immunochemical test (FIT). Following the FIT pilot study in the English Bowel Cancer 
Screening Programme (BCSP), there was opportunity to investigate a risk-adjusted approach 
to screening. This thesis was informed by several evolving areas of research including risk 
prediction modelling, test accuracy, as well as the use of electronic health records (EHRs) 
and the statistical methods best applied to utilise these data. The emphasis of the research 
was on routine data and used the Bowel Cancer Screening System (BCSS) as well as 
anonymised GP records for model development (THIN – The Health Improvement Network). 
Three statistical modelling techniques were investigated to build a risk prediction model for 
use in screening referral based decisions. A conventional approach using logistic regression 
was investigated first, which showed an improvement in both model performance and test 
accuracy for the risk-adjusted model over the FIT alone. This model was then extended 
further by investigating a machine learning algorithm in the form of an artificial neural 
network. An advantage of this approach is the flexibility to model complex nonlinear 
associations. The performance of this model (discrimination), as well as the sensitivity when 
applied as a test, was significantly better than the logistic regression model. Next an 
anonymised GP record was investigated for additional predictors to add to a risk-adjusted 
model using survival analysis, which exploits the longitudinal nature of the data. Two models 
were produced; one which combined the faecal occult blood test (FOBT) with lab test results, 
symptoms and other predictors and another which was developed for those with negative 
FOBT results only, to determine whether additional predictors could be used for referral 
decisions. In order to utilise EHRs for research, the methods need to be reproducible and 
transparent. An Acceptable Electronic BCSP (AEB) date was developed for quality assurance 
of the primary care data as well as to help determine a screening cohort for analysis. As a 
collective, these studies show evidence for improved performance of risk-adjusted screening 
over using the FIT alone. Future research should focus on further BCSS predictors and 
external validation of a risk-adjusted model in the BCSP. Machine learning approaches may 
be better placed for more complex electronic data. Future risk prediction model studies 
should encompass the whole pathway from model development to external validation and 
model impact before being implemented in practice with the ultimate aim of improving 
patient outcomes. 
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Optimising the FIT: Risk adjusted Colorectal Cancer Screening 
using Routine Data 
 
The introduction is based in part on the following editorial publication: Cooper, J. A., et al. 
(2016). "FIT for the future: a case for risk-based colorectal cancer screening using the faecal 
immunochemical test." Colorectal Dis 18(7): 650-653. 
1.0 General Introduction 
The lifetime risk of developing some form of cancer has increased to over 50% (1 in 2) for 
people born after 1960.1 Worldwide, colorectal cancer (CRC) is the 3rd most common cancer 
in men and the 2nd most common in women with over half the cases occurring in more 
developed regions including North America, Australia, and Europe.2 There were around 
694,000 deaths from colorectal cancer globally in 2012.2 In the UK, there were 41,804 new 
cases in 2015 and 15,903 deaths in 2014.2 The lifetime risk in the UK for developing CRC in 
2012 was 1 in 14 for men and 1 in 19 for women.3 In 1975, the lifetime risk of CRC was 4% 
this has now increased to 6% in females and 7% in males in 2010.4  
 
Public health screening is a process to identify individuals who may be at increased risk of a 
condition or disease.5 Further investigation, treatment and information can be offered to 
these individuals to reduce their risk of developing the disease or to minimise complications 
that may arise.5 A further definition by Raffle and Gray is summarised in the Box below and 
emphasises the focus of screening on the programme and not solely the screening test to 
identify these individuals.6 A report published in 1968 for the World Health Organisation 
(WHO) by Wilson and Jungner defined ten principles of screening.7 These principles have had 
a lasting influence on policy making for screening programmes with many countries using 
these principles or variations of them when deciding whether to implement a screening 
programme.8 These principles have evolved into the 20 criteria which the UK National 
Screening Committee (NSC) use to appraise the viability, effectiveness and appropriateness 
of a screening programme.9 These include aspects which relate to the condition, the test, 
the intervention, the screening programme and implementation criteria.  
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Raffle and Gray6 Definition of Screening (page 37): 
- “Testing of people who either do not have or have not recognised the signs or symptoms of the condition being 
tested for. In other words, they believe themselves to be well in relation to the disease that the screening relates to. 
- Where the stated or implied purpose is to reduce risk for that individual of future ill health in relation to the 
condition being tested for, or to give information about risk that is deemed valuable for that individual even though 
risk cannot be altered. 
- It encompasses the whole system or programme of events necessary to achieve risk reduction. Screening is a 
programme not a test” 6 (p. 37) 
 
In 2007, Hewitson et al. showed that bowel cancer screening could reduce mortality from 
CRC by 16% in a meta-analysis of 4 randomised trials.10 The National Screening Committee 
(NSC) recommended bowel cancer screening using a guaiac faecal occult blood test (gFOBT) 
following a pilot study for men and women aged 50 to 74 in July 2003.11 Currently in England, 
men and women aged 60 to 74 are offered a biennial gFOBT.12 A more recent test called the 
faecal immunochemical test (FIT) has been shown to have superior accuracy than the 
gFOBT.13 14 This test has several other advantages over the gFOBT including the requirement 
of a single stool sample, greater specificity for human haemoglobin and an adjustable 
haemoglobin concentration threshold. The haemoglobin concentration detected by the test 
has also been shown to relate to risk of colorectal cancer,15 and severity of colorectal cancer 
lesions.16 17 As a result the FIT has been recommended for CRC screening by the European 
guidelines for quality assurance in CRC screening and diagnosis in 2010.18 Many countries 
have now adopted FIT screening including Australia, New Zealand, the Netherlands, France, 
Canada, Spain, Italy and the Republic of Ireland.19 20 The US Preventative Services Task Force 
recommend several screening strategies including the FIT for those at average risk aged 50-
75 years.21  
 
A 6 month pilot study of FIT versus the current guaiac FOBT was carried out in April 2014 by 
the NHS Bowel Cancer Screening Programme (BCSP) in England.22 This study found a 
statistically significant greater uptake of screening with the FIT compared to gFOBT (66.4% 
versus 59.3%), and increased cancer and advanced adenoma detection rate. At an 
internationally used threshold of 20µg/g, the FIT positivity was 7.8% compared to the 
equivalent gFOBT positivity of 1.7%. Increasing the threshold to 180 µg/g gave a FIT positivity 
of 1.52%. Due to the improved uptake and higher test positivity when using internationally 
derived thresholds, extra demand would be put on a limited colonoscopy resource. The pilot 
study suggests there would be around 290,000 additional participants a year. This number 
would not be manageable for the current colonoscopy service. To ensure that capacity can 
be met, alternative thresholds for positivity (between 150-180 µg/g) are being investigated. 
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A suggested threshold to match colonoscopy resource and to give a similar number of people 
recalled to gFOBT was 160 µg/g. The NHS BCSP in England plans to adopt the FIT by the end 
of 2018. 
 
In addition to amending the threshold of the FIT, stratified/personalised risk based CRC 
screening could be implemented to improve effective colonoscopy use, test accuracy and 
consequently health outcomes.22-24 Stratified medicine aims to identify patients who would 
have a greater clinical benefit or least harm from a specific treatment.25 A few studies have 
developed risk prediction models which combine the FIT concentration with other risk 
indicators for use in screening referral decisions.15 24 26 27  This approach reserves the 
expensive and invasive colonoscopy resource for those at higher risk as estimated by a risk 
prediction model. By obtaining absolute risk predictions for individuals, those at higher risk 
can be referred on for diagnostic testing and those at lower risk can be placed back into the 
screening pool for continued surveillance every two years. This approach may optimise the 
benefits and harms of screening as well as available resource use.  
 
The risk prediction model development study by Stegeman et al26 combined the FIT result 
with risk indicators collected from a lifestyle questionnaire in a multivariable logistic 
regression model. The model had greater discrimination, with an area under the ROC curve 
of 0.76 than FIT alone (0.69). Test accuracy parameters were estimated with the risk based 
model which had a sensitivity of 40% compared to 32% for the FIT alone (at 93% specificity). 
The study by Tao et al28 combined blood based inflammatory markers with the FIT and 
showed improved discriminatory power when comparing FIT alone (AUC 0.683) to a model 
combining FIT with 3 blood based markers (AUC 0.729). Test accuracy also showed improved 
sensitivity for the multivariable model. 
 
Studies which require additional lab testing or the completion of a questionnaire have been 
shown to decrease screening uptake.29 Electronic Health Records (EHRs) used in screening 
programmes and for healthcare in the UK are a rich resource of routine data and are being 
increasingly utilised in research. The NHS Bowel Cancer Screening Programme (BCSP) use the 
Bowel Cancer Screening System (BCSS) to record information for participants invited to 
screening. Information stored on this system includes invitation dates, whether an individual 
returned a screening kit, the result of the screening test, attendance at a SSP (Specialist 
Screening Practitioner) clinic and colonoscopy or diagnostic test results. Other EHRs include 
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those used by primary care to record diagnoses and symptoms as well as lifestyle factors, 
routine lab tests, drug prescriptions and anthropometrics. The interconnectivity of these 
different health systems in the NHS could be exploited for future research. By using routine 
data available from EHRs, the data are subject to quality assurance standards that improve 
data accuracy and completeness, as well as reducing participant burden. Furthermore, 
prediction models which utilise predictors available in routine care allow for greater 
application of the model in clinical practice.30 
 
The area of risk prediction models or prognosis research compared to intervention studies 
and even diagnostic accuracy studies is an evolving area of research. There is growing 
interest in prediction model studies as reflected in the number of publications in recent 
years.30 31 A prognostic model is described as ‘a formal combination of multiple predictors 
from which risks of a specific end point can be calculated for individual patients’.30 Prediction 
model research encompasses both prognostic models, which estimate the absolute 
probability that a certain outcome will occur within a specific time period in an individual, 
and diagnostic prediction models, which estimate the absolute probability that a certain 
outcome is already present.32 The research in this thesis considers mainly the latter type. 
More guidance to improve research quality in this area has been published in recent years 
with the establishment of a Cochrane Prognosis Methods Group (PMG) 
(http://methods.cochrane.org/prognosis/welcome) and the PROGRESS (PROGnosis 
RESearch Strategy) research group (www.progress-partnership.org). The PROGRESS strategy 
series sets out a framework of 4 interconnected research themes for prognosis research and 
provides evidence to improve current research standards. Several guidelines, checklists and 
quality appraisal tools have been recently published for prognostic and risk prediction 
studies.33-36 These are described in greater detail in the Systematic Review (Chapter 2). 
 
Risk prediction models can be used in a variety of ways in healthcare including for guiding 
referral and treatment decisions as well as follow up strategies, cost effectiveness analyses 
and for shared decision making.30 Although prediction models can provide a risk score, often 
this is used to assign individuals to risk groups and therefore the estimate of absolute 
probability is more accurate. This thesis focuses on producing risk prediction models which 
provide an absolute risk probability for use in decision making. The application of prediction 
models also relates to the shift towards personalised or stratified medicine where treatment 
plans and referral decisions are based on an individual’s covariate (predictor) pattern. Since 
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prognostic and prediction model research, if applied on a population can lead to a change in 
health outcomes, and possibly to the spectrum of diagnosed disease, they can be considered 
a type of health technology assessment.37 38 This is where the crossovers between applying 
a prediction model as a test can occur and is a key consideration of the thesis.  
 
Risk based screening can be implemented at different points within the screening pathway.  
For instance, risk stratification of the target population to decide who should undergo the 
FIT could be performed to identify those at highest risk. This approach is investigated by 
Aniwan et al. using the Asia-Pacific Colorectal Screening System (APCS) as a 
preselection/triage before applying the screening test.39 Alternatively, risk predictors could 
be integrated within the screening algorithm at the time of screening to decide who to refer 
on for colonoscopy.26 Finally post screening surveillance strategies could be tailored by 
individual FIT results.40 41 Timing is an important consideration of the Critical Appraisal and 
Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) checklist, 
‘intended moment of using the model’.33 This thesis focuses upon the combination of risk 
information around the time of the screening test (before colonoscopy) to determine high 
risk individuals to refer on for further diagnostic testing. 
 
Different statistical methods can be used to build a prediction model, the most commonly 
used methods are regression, but other machine learning approaches can also be used such 
as neural networks, support vector machines, classification trees and random forests.36 In 
this thesis, three different statistical methods are used to develop risk prediction models for 
use in bowel cancer screening. Standard statistical methodology in the form of logistic 
regression is initially used to integrate risk predictors with the FIT. This is then extended to a 
machine learning approach; an artificial neural network. The final approach considered is 
time to event analysis (survival analysis) where Cox Regression is implemented as the risk 
prediction model and further parametric models are explored. The ‘Transparent Reporting 
of a multivariable prediction model for Individual Prognosis Or Diagnosis’ (TRIPOD) 
guidelines for developing and reporting a multivariable prediction model are considered 
throughout. Where possible the recommendations and framework of the PROGRESS 
research group have also been implemented. Key themes of the research consider the cross-
overs between risk prediction modelling and diagnostic accuracy research, specifically 
applying a diagnostic risk prediction model as a test and assessing the performance.  
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The studies in this thesis aim to contribute to determining the value of risk adjusted 
colorectal cancer screening using the FIT. 
2.0 Outline of Thesis 
Chapter two is a systematic review to understand whether risk prediction models that 
combine the FIT with other predictors performs better than regular FIT screening for 
colorectal cancer in terms of model performance and test accuracy. This systematic review 
crosses diagnostic accuracy and risk prediction model review boundaries and considers 
aspects and reporting guidelines from both. This crossover between risk prediction and 
diagnostic accuracy is carried forward as one of the main themes of the thesis.  
Chapter three is a risk prediction model development study combining routinely available 
risk factors from the BCSS (the computer system used for the NHS BCSP in England) with the 
FIT result to assess whether model performance and test accuracy are improved. The 
modelling procedure applied in this chapter was logistic regression as a conventional 
approach in statistical methodology commonly used to build risk prediction models. One of 
the major advantages of this approach is the use of routine data requiring no additional data 
collection from participants, which improves data completeness and reduces participant 
burden. Further to this, the outputs of logistic regression are well understood and can be 
applied simply to an external dataset/screening population. 
Chapter four then considers a machine learning approach to developing a risk prediction 
model in the form of a neural network to determine whether this performs better than 
standard statistical methods. This method does not require the strong assumption of 
linearity, as seen with logistic regression, and allows combinations of predictors to be 
combined without underlying knowledge of their interactions or relationship with the output 
variable. The same routine predictors are considered as those investigated in Chapter 3 and 
cross-validation is used to aid comparison. Individualised risk probabilities were produced 
for each patient and compared with the logistic regression risk adjusted FIT model and FIT 
only. The transparency of reporting this machine learning method is focussed upon by 
providing the full risk equation and detailing the model building process. 
Chapter five investigates the use of an electronic primary care database to improve 
colorectal cancer screening referral decisions. Potential predictors from GP databases which 
may enhance a future risk adjusted model were investigated along with the data 
completeness of these predictors. Databases from primary care have a richer level of data 
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which may add a further dimension to a risk based prediction model to improve colorectal 
cancer screening. For instance, data are available on, symptoms, diagnoses, prescriptions, 
laboratory test results, lifestyle parameters and anthropometrics. The anonymised GP record 
database, ‘The Health Improvement Network’ (THIN) was used to extract data for the 
patients of interest and for model development. There are links between GP data and 
screening data, it is possible that further information could be drawn onto the screening 
system to contribute to decision making in screening. A further modelling approach is 
considered in this chapter in the form of survival analysis to predict the diagnosis of 
colorectal cancer within 2 years of the latest FOBT result. Using time to event analysis for 
longitudinal health records is a more efficient use of data than logistic regression since 
outcomes and exposures can occur at multiple time points for each participant. The semi-
parametric Cox-Regression model was used to assess the association of >30 clinical features 
with colorectal cancer and polyps for an average risk screening population. A multivariable 
risk model was then developed using Cox-Regression and extended by considering the model 
fit of parametric models. The baseline survival was estimated for the Cox Regression model 
to give absolute risk probabilities for each individual. 
Chapter six describes the methods used to extract valid data from THIN that was used for 
the analysis in Chapter 5. This included the development of a method to define acceptable 
periods of NHS BCSP notifications for practices receiving electronic results – the Acceptable 
Electronic BCSP (AEB) date. This AEB date was used to derive an average risk BCSP cohort for 
analysis from THIN, for data quality assurance, practice eligibility and to define the patient 
start dates for follow up in Chapter 5. The methods used to derive this date can be applied 
in future colorectal cancer screening studies, other cancer screening programmes or further 
electronic health record databases. In order to extract data for a research study from THIN 
for symptoms and diagnoses, Read code lists specifying the defined diagnosis/symptom need 
to be constructed. For prescriptions, drug code lists are also used to extract this information. 
Methods are presented for selected examples of diagnoses, symptoms and prescriptions. 
The additional health data file which houses data such as laboratory test results is more 
complex and a methods strategy needs to be constructed in order to extract the data of 
interest, in the units of interest and within the acceptable/relevant range. The methods for 
extracting haemoglobin concentration are presented as an example in this chapter. 
All these studies are tied together for the thesis discussion (Chapter Seven) with a summary 
of the findings from each chapter and the corresponding future perspectives in this area of 
research. 
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ABSTRACT  
Objectives 
To systematically review studies that develop or validate risk prediction models which 
combine the faecal immunochemical test (FIT) result with other predictors for colorectal 
cancer screening referral decisions. Predicting the risk of current colorectal cancer using 
diagnostic risk prediction models allows screening programmes to determine which 
individuals are at highest risk for referral to colonoscopy. This approach could potentially 
improve cancer detection rates and allow more effective use of colonoscopy resources. The 
primary objective of the review was to assess model performance as well as test accuracy 
measures where applicable. Secondary objectives included identifying different statistical 
methodologies used to combine predictors in the models (logistic regression, survival 
analysis, machine learning algorithms), types of predictors included (demographic 
characteristics versus lifestyle factors, biomarkers or lab results), how the model would be 
applied in practice and how it is presented for use (equation, nomogram, risk score). 
 
Design 
The following bibliographic databases were searched using a combination of medical 
subject headings, key words and recommended search filters: MEDLINE, EMBASE, Web of 
Science and the Cochrane Library. Clinical trial databases were also searched to identify any 
relevant ongoing studies as well as databases of conference proceedings for any relevant 
unpublished studies. Reference lists of included studies and relevant reviews were 
searched and experts contacted for any additional papers. Two reviewers independently 
sifted titles and abstracts and subsequently full texts using predefined criteria. Data 
extraction was performed by one reviewer and checked by a second reviewer. Recently 
developed methodology and guidance for systematic reviews of risk prediction models 
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were followed. This included using a pilot version of the Prediction study Risk Of Bias 
Assessment Tool (PROBAST). Domains from QUADAS-2 were used for quality assessment if 
the model was applied as a test. The review was primarily concerned with identifying 
diagnostic risk prediction models that allow individualised risk predictions to be obtained. 
Models were considered for inclusion if they combined the FIT, allowed an individualised 
risk prediction and assessed model performance. Test accuracy measures were considered 
additionally if assessed. Primary outcomes were therefore model performance (calibration, 
discrimination) and where applicable test accuracy (sensitivity, specificity). 
 
Results 
The searches identified 5,671 articles for title and abstract sifting after removing duplicate 
references. 54 full text articles were then reviewed for inclusion using predefined criteria. 
Eight studies were included for data extraction and quality assessment. The heterogeneity 
in statistical methodology, predictors included in the models, populations and outcomes 
reported meant a meta-analysis of model performance and test accuracy was not possible 
and so a narrative synthesis was performed. Discrimination ranged from 0.676-0.960 for 
risk adjusted FIT (reported in 6/8 studies) and 0.683-0.902 for FIT only (reported in 4/8 
studies). Calibration using the Hosmer-Lemeshow statistic ranged from 0.276-0.940 for risk 
adjusted FIT (reported in 3/8 studies) and calibration plots were presented in just one 
study. Where test accuracy measures were included (4/8 studies) sensitivity ranged from 
21.9% to 88.0% for risk adjusted FIT at a range of set specificities from 90-97.7%. FIT-only 
sensitivity ranged from 19.7% to 82.0% at the same specificities. Additional metrics 
included net reclassification improvement (reported by 2 studies). Five out of eight studies 
used logistic regression, two further studies used a modified version of logistic regression 
and 1/8 used an accelerated failure time model (survival analysis). Half the included studies 
used some form of internal validation. Predictors used in the models varied from 
demographic characteristics, biomarkers and lab results as well as additional information 
obtained from questionnaires. The most consistently used predictors across the models 
were sex and age. PROBAST identified that all studies were at high risk of bias. For those 
studies which applied the model as a test (4/8), a high risk of bias was identified in 50% 
(8/16) of the domains using QUADAS-2.  
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Conclusions 
Although it could not be tested formally due to the underlying heterogeneity, there is some 
evidence to suggest that including additional factors with the FIT result can improve model 
performance and test accuracy comparing FIT with risk adjusted FIT models. The models 
identified are at a development stage and need further assessment and validation before 
being applied in practice. Lab results and biomarkers tended to give higher discrimination 
values and test accuracy metrics but a significant improvement was also seen when using 
simple routinely available predictors such as age and sex which are more readily available. 
This suggests a reasonable improvement could be achieved using demographic factors 
alone without additional laboratory testing. Electronic Health Records and routine data 
could provide a convenient source of data for model development and validation. Future 
research should incorporate predictors which were consistent across these studies as well 
as predictors in risk prediction models for colorectal cancer without the FIT of which 
systematic reviews have been recently completed. Model development and reporting of 
the studies would benefit from using the TRIPOD guidelines as statistical analysis and 
predictor selection was often rated at high risk of bias using the PROBAST tool. 
Furthermore, external validation and impact studies are required before implementing any 
of the existing models. All the identified studies used standard statistical methodology to 
develop models; machine-learning algorithms have been shown to have similar or superior 
performance and could be assessed for performance alongside logistic regression to 
determine any improved outcomes.  
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1.0 BACKGROUND AND RATIONALE 
1.1 Colorectal Cancer and Screening 
 
Screening for colorectal cancer aims to detect the disease at earlier stages when it is easier 
to treat and cure. A Cochrane systematic review has shown that colorectal cancer 
screening using the faecal occult blood test (FOBT) can reduce the risk of mortality by 16%.1 
Countries worldwide including Australia, The Netherlands, Korea and the UK have 
implemented colorectal cancer screening at national, regional and local levels using either 
the guaiac faecal occult blood test (gFOBT), the faecal immunochemical test (FIT), optical 
colonoscopy or flexible sigmoidoscopy.2 The most commonly used screening tool however 
is the FOBT.3 
 
1.2 The FIT versus the Guaiac Based Test 
 
Both the gFOBT and the FIT detect blood present in faeces as a marker for colorectal cancer 
and advanced adenomas. The more recently developed FIT has been shown to be 
analytically superior to the gFOBT and has been recommended for screening programmes 
worldwide by the 2010 European guidelines for quality assurance in CRC screening and 
diagnosis.4 A systematic review and meta-analysis has shown that the FIT has a sensitivity 
of 87.2% and a specificity of 92.8% for colorectal cancer whereas the guaiac based test has 
a much lower sensitivity at 47.4% and a specificity of 92%.5 The first random comparison 
between the guaiac and immunochemical based tests has also shown that the 
immunochemical test has a significantly higher advanced adenoma and cancer detection 
rate.6 
 
Apart from the improved accuracy of the test, the FIT has several advantages over the 
guaiac based test including ease of use (with only one sample required instead of three), 
improved screening uptake and cancer detection rate,6 7 is more specific for human 
haemoglobin and as such does not require dietary restriction. Perhaps most importantly, 
the test allows quantification of the result giving the amount/concentration of 
haemoglobin present per gram of faeces. This FIT concentration has shown to relate to risk 
and stage of colorectal cancer.8 9  
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1.3 Combining Risk Stratification with the FIT 
 
The haemoglobin concentration provided by the FIT has been shown to be related to the 
risk of CRC, with a higher result indicating a greater risk.  Yen et al.9 have shown that the FIT 
haemoglobin concentration is an independent predictor for colorectal neoplasia risk. The 
concentration has also been related to severity of colorectal cancer lesions.8 10  
 
Risk stratification using prediction models, risk scores and indexes to tailor screening in 
average risk individuals has been investigated.11 12 It has been suggested that the FIT 
concentration can be included in individual risk assessment to improve the effectiveness of 
screening strategies.8 10 13 Stegeman et al.14 suggests that risk factors could be used to 
either target high-risk populations for screening through risk stratification or screening 
could be tailored by calculating risk for individuals. For instance, those who are at greater 
risk can commence screening at a younger age or be screened more regularly. The 
American College of Gastroenterology Guidelines based on a systematic review of the 
literature recommend CRC screening to start at age 45 for African-Americans compared 
with age 50 for other groups.15 The guidelines also support screening heavy smokers and 
those at risk of obesity earlier. 
 
Diagnostic risk prediction models which determine the probability of CRC can be used to 
improve the test accuracy during screening. There is some evidence to suggest that 
combining the FIT with individual risk factors enhances the accuracy of the test. For 
example, a study by Stegeman et al.16 showed that a risk based model improved sensitivity 
from 32% to 40%. Risk factors for CRC can include any predictors which are associated with 
a higher or lower risk of CRC. Risk factors known to increase the likelihood of being 
diagnosed with CRC include, increasing age, male sex, lifestyle factors such as smoking, and 
increased alcohol consumption. Several different biomarkers (proteins, RNA and DNA) for 
CRC have also been identified along with single nucleotide polymorphisms (SNPs) from the 
Colorectal cancer GENeTics (COGENT) study which could be used in risk models.17-19 
 
Why combine the FIT with other factors for this systematic review? 
There are risk prediction models which have been developed and validated for colorectal 
cancer which do not combine the FIT result.20 21 However, the discrimination power of 
models which do not include FIT are likely to be significantly lower. For example, Kaminski 
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et al.21 develop and validate a logistic regression model which includes age, sex, family 
history of colorectal cancer, cigarette smoking and body mass index to predict the presence 
of advanced colorectal neoplasia. The model was well calibrated with moderate 
discriminatory power (AUC ROC 0.62).21  The authors suggest combining predictors such as 
the ones identified in this model with FIT or blood based biomarkers to improve 
discrimination and referral selection. The model by Stegeman et al.16 on the other hand 
which combines the FIT with calcium intake, family history and age had a higher 
discrimination with an AUC of 0.76. 
 
FIT on its own, without other predictors may fail to detect intermittent bleeding or smaller 
lesions which may not bleed. Lab results such as including abnormal blood cell results with 
the FOBT have been shown to improve sensitivity for detecting colorectal cancer.22 
Additionally to this, the FOBT has been shown to be less sensitive in females,23 and it has 
been suggested that sex specific cut off values for the FIT are used in screening 
porgrammes.24 25 This suggests that lab test results as well as demographic factors may help 
to enhance the performance of the FIT. Individual risk prediction is usually low when only 
considering one factor and should integrate several parameters.26 
 
1.4 Why is it important to do this review? 
 
1.4.1 To build on previous models before developing a new one 
 
Before developing a risk prediction model it is best practice to build upon what has already 
been developed previously.27 28 For instance, there may be an internally validated model 
which could be suitable for the target population and the model could be externally 
validated and assessed in an impact study. Before implementing a model in practice it is 
important it has been externally validated and assessed in an impact study to ensure it 
improves decision-making and therefore patient outcomes. Alternatively, predictors which 
are found consistent in previous studies can be considered in future model development 
research. 
 
There is currently an abundance of model development studies, fewer validation studies 
and very few impact studies.29 A systematic review of predictive performance is required to 
determine the models predictive ability in different case mixes, settings, locations and to 
assess whether adjustments can be made to the model.28 The guidance for systematic 
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reviews of therapeutic interventions is well developed with growing guidance for 
systematic reviews of diagnostic test accuracy. Prediction model systematic review 
methodology is still being developed with guidelines, checklists and quality appraisal tools 
being published over the last few years. More recently, methods for meta analyses have 
been considered for example with independent patient data.30 
 
1.4.2 Improved accuracy of the test and cancer detection rates 
 
Despite the relationship between FIT concentration and risk of CRC, screening programmes 
dichotomise the result and refer patients over a certain cutoff for colonoscopy and place 
those under the cutoff back into the screening pool. This wastes potential information 
relating to risk which could be used to personalise screening strategies to improve patient 
outcomes and screening performance. For instance, haemoglobin concentration has been 
found to be affected by participant demographics such as age and sex,13 31-34 supporting 
tailored screening strategies. The study by Stegeman et al.16 showed improved sensitivity 
using a risk based model over the FIT alone from 32% to 40% and an increase in cancer 
detection. 
 
1.4.3 Colonoscopy Capacity 
 
The FIT has recently been piloted in the UK in 40,000 participants,7 and has been 
recommended to replace the guaiac test by the National Screening Committee (NSC) as of 
January 2016.35 The results show that the uptake for the FIT was higher than the guaiac test 
(66.4% versus 59.3%) and the FIT detected more cancers (0.27% versus 0.12%) and 
advanced adenomas (1.73% versus 0.35%).36 Due to an increase in the uptake of the test as 
well as increased test positivity (7.8% at a cutoff of 20μg/g versus 1.7% with the guaiac 
test), the FIT may put additional pressure on already limited colonoscopy capacity.7 For 
instance, Ireland and the Netherlands have recently introduced the FIT for their screening 
programmes and had to alter their screening referral criteria due to an added strain on 
colonoscopy resources.37 38 Future strategies for CRC screening will need to ensure 
positivity thresholds are set appropriately and screening referrals are recommended for 
those at greatest risk to ensure effective colonoscopy use. The NSC have recommended 
research into setting an appropriate threshold as colonoscopy capacity and uptake 
increases.35 Further work from the UK pilot study will investigate different positivity 
thresholds and individualised thresholds according to patient characteristics.36  
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A risk-based approach to screening could offer several advantages including an increased 
detection of early stage cancers and their precursors as well as minimizing the number of 
false positives and negatives. In addition, by identifying people at higher risk instead of 
those at low risk, the use of available resources is optimised.10 11 16 
 
1.5 Related Research and Systematic Reviews  
 
Ma and Ladabaum12 conducted a systematic review of risk prediction models, which could 
be used to personalise CRC screening. This systematic review looked at risk prediction 
models using clinical and demographic predictors. Some of the prediction models included 
sigmoidoscopy and colonoscopy results but not FOBT or FIT results. Usher-Smith et al.39 
carried out a systematic review for risk prediction models which predict the future risk of 
primary colorectal cancer for asymptomatic individuals. The current systematic review 
however proposes to investigate current undiagnosed colorectal cancer to assist with 
colonoscopy referral decision making. A systematic review on risk prediction models for 
colorectal cancer in people with symptoms has also been completed but this review 
focused on models which could be used for patients in primary care.40 This population is 
treated differently to a screening population in terms of risk and the NICE guidelines for 
referral. 
 
The accuracy of faecal immunochemical tests for CRC in asymptomatic, average risk adults 
has been investigated by Lee et al.41 Subgroup analyses were performed on the number of 
FIT samples, cutoff value for a positive FIT test, FIT brand and reference standard. However, 
the review did not look at the effect of risk based testing or the use of risk algorithms on 
diagnostic accuracy. Finally, a systematic review has been carried out to identify 
biomarkers for early colorectal cancer detection and found that combinations of both fecal 
biomarkers and serum biomarkers led to higher test accuracy measures such as sensitivity 
and specificity.42 This review however did not look specifically at risk prediction models or 
consider other predictors.42 
 
An increasing number of studies have been published in this area in recent years. A  
Research Group in the Netherlands are investigating FIT based CRC screening and risk 
stratification. Over the last few years at the World Endoscopy Organization CRC Screening 
meeting, there has been increased research relating to risk based screening. In addition, 
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the UK FIT research team are investigating whether combining routinely available risk 
factors with the FIT improves test accuracy. The USA include in their guidelines risk based 
assessment by subgroups when considering what age to commence screening.15 Ireland 
and Scotland have implemented FIT into their screening programmes. This method could 
also combat the problem of increased pressures on colonoscopy resources and optimise 
the benefits and harms of screening. 
 
The proposed systematic review will be investigating studies which have combined risk 
predictors with the FIT result in a diagnostic risk prediction model and will pilot an early 
version of the recently developed prediction model risk of bias assessment tool (PROBAST) 
to investigate risk of bias and systematic review applicability.43 
 
1.6 Objectives 
Primary Objective 
 
The primary objective was to perform a systematic review to identify risk prediction models 
which combine the FIT result for colorectal cancer screening referral decisions and to 
determine whether they perform better than regular screening using the FIT alone.  
 
Further Objectives  
 
 Identify all risk scoring systems (risk models, scores, clinical decision rules and 
other algorithms) which combine the FIT result for colorectal cancer screening. 
 To determine the characteristics of predictive models (including which predictive 
factors are included in the models or used in the recall algorithm) 
 To identify the important predictors for CRC detection in the prediction models 
 To describe key methodologies used to combine risk factors into the screening 
recall algorithm (e.g. logistic regression, survival analysis, machine learning 
approaches and clinical decision rules etc.) 
 To describe how the models are presented for use (equation, nomogram, risk 
calculator etc.) 
 To assess the model performance of diagnostic predictive models (including the 
performance measures: calibration, discrimination and classification) 
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 To assess test accuracy of the predictive models (including sensitivity and 
specificity at particular cutoffs and the area under the curve of the Receiver 
Operating Characteristic Curve) 
 To determine whether risk prediction models combining the FIT have better test 
accuracy than screening using the FIT alone. 
 If the data permits, to perform a meta-analysis of test accuracy (sensitivity and 
specificity) and model performance (discrimination and calibration) 
 To make recommendations on the use of risk prediction models in screening for 
CRC 
2.0 METHODS 
This review considered risk prediction model studies which combined the FIT result with at 
least one other predictor to produce individualised risk predictions for colorectal 
cancer/adenomas for diagnostic testing referral decisions. The risk models needed to give 
an individualised risk prediction and ideally a measure of absolute risk.  
 
Analysis focused upon risk prediction model performance and was supplemented with test 
accuracy measures. Risk of bias in studies was assessed using criteria from both PROBAST43 
(prediction modelling studies) and QUADAS-244 (in those assessing a test accuracy 
component). A similar approach was undertaken in a previous HTA report where criteria 
relating to prognostic studies as well as diagnostic accuracy studies was used to determine 
the overall quality of the studies.45 
 
Systematic reviews of prognostic and diagnostic risk prediction models is a new and 
evolving area and methods are being developed for these types of reviews.  Exemplar 
reviews have been pursued for prediction model reviews including the protocol by Pace et 
al.46 The Cochrane Prognosis Methods Group established in 2008 are developing 
methodological tools and resources in this area for use in systematic reviews of prediction 
modeling studies.47 Several of these tools were used or piloted within this systematic 
review including the CHecklist for critical Appraisal and data extraction for systematic 
Reviews of prediction Modeling Studies (CHARMS checklist) which was used to form the 
review question for the systematic review as well as for critical appraisal of prediction 
studies and data extraction.27 In addition, an early version of PROBAST was piloted to 
assess the risk of bias of prediction modeling studies and the applicability of the study to 
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the systematic review.43 The full PROBAST assessment tool and the explanation and 
elaboration document will be published in 2018. PRISMA guidelines will be followed to 
report the systematic review.48 
 
2.1 Criteria for considering studies for this review 
The CHARMS checklist was used to guide the review aim, search strategy and inclusion and 
exclusion of studies used in the review across seven different domains (See Table 1).27 Any 
risk prediction model which has combined the FIT result with at least one other predictor 
to determine the risk of CRC was included in this review. For instance, a study may have 
used an individual risk questionnaire and separately combined this information with the FIT 
result to determine who to refer for colonoscopy. 
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Item Comment 
1. Prognostic versus diagnostic prediction model Diagnostic prediction model. The aim is to review models to 
predict current disease status for CRC screening. 
2. Intended scope of the review The scope of the review and intended purpose of the models 
reviewed in it.  
Risk prediction models combining the FIT result to inform 
referral to diagnostic testing 
3. Type of prediction modeling studies 1a – Prediction model development  (ideally with internal 
validation) 
1b – Prediction model external validation (with possible 
updating) 
1c - Prediction model development and external validation 
1d – Developing/validating a model and then applying as a 
test  
1e – Applying the risk prediction model as a test (impact 
study) 
4. Target population to whom the prediction model applies The target population relevant to the review scope. 
Average risk screening population or representative of a 
screening population  
Both men and women aged 40-75 (10% outside screening 
range is acceptable) 
Both organised screening and opportunistic screening. 
5. Outcome to be predicted The outcome of interest to be predicted. 
Specific diagnostic target disease – colorectal neoplasia (CRC 
and advanced adenomas) detected at colonoscopy. 
The model should predict; colorectal cancer, adenoma and 
polyp diagnoses. 
6. Time span of prediction Predicting current disease status in screening for referral to 
colonoscopy 
7. Intended moment of using the model The systematic review may focus on models to be used at a 
specific moment in time. 
- Model to be used around the time of FIT screening to 
identify high risk individuals for further diagnostic testing 
such as colonoscopy 
Table 1: Key items to guide the framing of the review aim, search strategy, and study inclusion and exclusion 
criteria based on the CHARMS checklist. CHARMS: CHecklist for critical Appraisal and data extraction for 
systematic Reviews of prediction Modeling Studies. 
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2.1.1 Selection and Inclusion Criteria 
 
The selection criteria was based on PICOTS (Participants, Intervention, Comparator, 
Outcome, Timing, Setting) which is recommended for use in risk prediction modelling 
studies.27 28 PICOTS is an amended version of PICO which includes a temporal element for 
the moment of using the model.   
 
Participants 
Average risk screening population or representative of a screening population  
Both men and women aged 40-75 (10% outside screening range is acceptable). Screening 
programmes worldwide target individuals within this age range.49 Both organised and 
opportunistic screening will be considered since screening is implemented in different ways 
across countries.  
 
Intervention: Index test combined within a risk prediction model: 
Where the FIT has been combined with other risk factors/predictors in a risk prediction 
model to aid referral decisions to diagnostic testing. 
 
All risk factors/predictors will be investigated including demographic, clinical and lifestyle 
factors. For example, predictors could include age, sex, socioeconomic deprivation, dietary 
factors, physical activity, alcohol consumption, smoking status, previous screening history, 
medication use, BMI, hypertension etc. Genetic markers and biomarkers including DNA 
proteins, messenger RNA and microRNA will also be included. 
 
Comparator Tests: Index Test alone 
Studies may or may not have used FIT as a comparator. FIT alone can be compared either 
applied as a test or applied within a model. FITs of all brands both qualitative 
(positive/negative) and quantitative (provides a concentration of haemoglobin) for the 
detection of CRC and advanced adenomas (AAs). Qualitative FITs are generally used as 
point of care (POC) tests and use a lateral flow immunochromatographic analysis 
technique.2 This type of FIT relies on visual interpretation with the cutoff set by the 
manufacturer. Quantitative FITs on the other hand use an immunoturbidimetry technique 
for analysis.2 This test provides a continuous result and the cutoff can be set to fit local 
contexts taking into account prevalence of disease and colonoscopy resources.  
 
   
 
24 
 
Chapter 2 Chapter two | Systematic Review 
Outcomes (Target condition/reference standard/performance measures) 
Models to predict presence of colorectal cancer, adenomas or polyps. Colorectal advanced 
neoplasia includes both CRC and advanced adenomas. Advanced adenomas have a high risk 
of developing into cancer and are defined by the European Guidelines for Quality 
Assurance in CRC and Screening Diagnosis (2010) as one which is 10mm or over, or 
contains high grade mucosal neoplasia or contains a villous component.50 
 
Where diagnostic accuracy parameters are included, the reference standard can be either: 
a) Colonoscopy for the detection of CRC or advanced adenomas  
b) At least two-year longitudinal follow-up using clinical records (e.g. cancer registries, GP 
records etc. 
 
The primary outcomes for the review will be model performance and test accuracy 
parameters in relation to CRC detection at colonoscopy. For instance, discrimination, 
calibration and classification will be identified for model performance whereas sensitivity, 
specificity, AUC ROC, positive prediction value (PPV) and negative prediction value (NPV) 
will be identified for test accuracy. 
 
Timing   
As a diagnostic prediction model to predict the probability of current disease before a 
reference (gold) standard test that has not yet been performed. 
 
Setting/Role 
Intended role of the model is to determine risk for referral to diagnostic testing or 
colonoscopy in a bowel cancer screening/average risk population setting. 
 
2.1.2 Types of studies included in the review 
 
This review will include studies of any design that develop or validate a risk prediction 
model which combines FIT with other predictors to predict risk of colorectal 
cancer/adenoma diagnosis. Risk prediction modeling studies include: model development 
(ideally with internal validation), model external validation and impact studies. Some 
studies can develop a model and validate it within the same paper. However, the gold 
standard of model development and external validation would usually require a separate 
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dataset to validate and ideally separate research team as there is evidence to suggest 
model performance measures are inflated otherwise.51 The inclusion and exclusion criteria 
for the abstract and title sift as well as the full text review are shown in Table 2 and Table 3 
respectively. 
 
The following categories will be considered in this review: 
1a - Model development (ideally with internal validation)  
1b - Model development with external validation  
1c - External Validation 
1d - Developing/validating a model and then applying as a test  
1e - Applying the risk prediction model as a test (impact study incl. diagnostic accuracy). 
 
2.1.3 Inclusion and Exclusion Criteria for abstract and title sift 
 
Inclusion Criteria 
Screening Test: The risk prediction model includes the FIT result and at least one other predictor 
Model: The risk prediction model can be used to give individualised risk predictions ideally absolute measures of 
risk but relative levels of risk will also be included (e.g. linear predictor or scoring systems) 
Outcome: The outcome of the prediction model is colorectal cancer, adenomas or polyps 
Performance Measures: The study reports model performance parameters (calibration, discrimination and 
classification) or test accuracy parameters (sensitivity, specificity, PPV, NPV or area under the ROC curve) 
Population: The risk prediction model is developed or applied on men and women aged between 40-75 
representing the average risk screening population 
Exclusion Criteria  
Articles in languages other than English 
Case Studies 
Articles published before 1978 
Non-human studies 
Table 2: Inclusion and exclusion criteria for abstract and title sift 
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2.1.4 Inclusion and Exclusion Criteria for Full Text Sort 
Study Design Y/N/U 
Studies of any design that develop, validate, update a diagnostic risk prediction model for colorectal cancer 
which combines FIT with at least one other predictor.  
 
Risk prediction modeling studies for this review include the following categories: 
1a - Model development (ideally with internal validation)  
1b - Model development with external validation  
1c - External Validation 
1d - Developing/validating a model and then applying as a test  
1e - Applying the risk prediction model as a test (impact study incl. diagnostic accuracy). 
 
Note: Studies may develop a model and externally validate it within the same paper. 
 
Model  
Definition of a diagnostic model in this review: Combination of FIT with at least one other predictor to 
predict individualised risk of colorectal cancer/advanced adenomas using a statistical model (can include 
neural networks, logistic regression, survival analysis/Cox Regression or other approaches i.e. a 
multivariable diagnostic study only) 
 
Intended moment of using the model: Can the model be used around the time of FIT screening to identify 
high-risk individuals for referral (further diagnostic testing such as colonoscopy)? i.e. before diagnostic 
testing 
 
Does the model assess more than just the association of predictors with outcome?  
(I.e. Exclude if it is only a logistic regression or Cox regression which is not applied/developed as a risk 
prediction model, it just presents ORs and HRs) 
 
Has the index test (FIT) been combined with at least one other predictor/risk factor* in a diagnostic risk 
prediction model?  
*Predictors could include; age, sex, socioeconomic deprivation, other test results, dietary factors, physical 
activity, alcohol consumption, symptoms, previous screening history, medication use, genetic markers, 
biomarkers, blood results etc 
 
Does the study produce a risk prediction model/scoring system/algorithm using statistical methods such as 
neural networks, logistic regression, survival analysis (Cox Regression), machine learning or other similar 
approaches? 
 
Screening Test (Index Test)  
The test assessed is the Faecal Immunochemical test (FIT) which includes all brands both quantitative 
(provides a concentration of haemoglobin) and qualitative (positive/negative). 
Examples of FIT brands include; OC-Micro/Sensor, OC-Light, Hemeselect, Flexsure OBT, FOB Gold, OC 
Hemodia, FECA-EIA, HM-Jack, Instant-View, Occultech, Ridascreen. 
 
Note: If the test is a guaiac based test, exclude. Brand names include: Haemoccult, Haemoccult II, 
Hemoccult Sensa, Fecatwin, Fecatest. 
 
Reference Standard  
Where diagnostic accuracy parameters are included (including impact studies) is the reference standard 
either:  
-Colonoscopy (small numbers of other diagnostic procedures acceptable as some individuals may not be 
suitable for colonoscopy e.g. CT/flexible sigmoidoscopy) 
-At least two year longitudinal follow up using clinical records (e.g. cancer registries, GP records etc)? 
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Population  
Both men and women aged 40-75 years representative of an average risk screening population 
(mean/average age needs to be over 40 years so participants over 18 can be included/10% outside 
screening range is acceptable) 
 
Note: Symptomatic patients may be included if considered a part of a general screening population sample 
with symptoms used as predictors (Symptoms requiring further investigation suggests the population is 
primary care GP referral two week wait criteria. NICE guidelines list these symptoms.) 
 
Outcome (Target Condition)  
Does the model predict the following outcomes? 
-Advanced neoplasia which can include both CRC and advanced adenomas 
-Colorectal polyps 
 
Performance Measures   
Does the study include model performance parameters, test accuracy parameters, or both? 
 
a) Model performance parameters (calibration, discrimination (also called AUC ROC or c-statistic), 
re-classification) 
b) Test accuracy parameters in relation to CRC detection (sensitivity, specificity, 2x2 data, AUC ROC) 
 
Note: If analytical sensitivity and specificity has been reported (differs to clinical sensitivity), the population 
may not be appropriate for the review (these studies tend to just look at positive samples/random samples) 
 
 
Table 3: Inclusion and Exclusion criteria for full text assessment. If all criteria are ‘Y’ include the study, if there 
are any ‘N’s exclude the study, if there are any ‘U’s then discuss the study. 
 
2.2 Search methods for the identification of studies 
 
A search strategy was developed with the input of an information specialist (SJ) to ensure 
all relevant articles were retrieved from the appropriate databases. As recommended by 
the Cochrane handbook and recent guide to systematic review and meta-analysis of 
prediction model performance,28 the search strategy incorporates the search filters 
suggested by Geering et al.52 to identify diagnostic prediction studies in Medline. This 
strategy includes using the Ingui filter53 in combination with the additional search string 
developed by Geering et al.54 (using the Boolean operator ‘OR’). This was combined with 
the disease of interest (CRC) and terms for the screening test. Further search terms which 
encompassed diagnostic accuracy were also included. See Appendix 1 for the search 
strategies. 
 
The search strategy was developed to maximize sensitivity (number of relevant studies 
identified over the total number of relevant reports on the topic) rather than focusing on 
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precision (number of relevant records identified by a search over the total number of 
records) as recommended by the Cochrane Handbook for DTA Reviews.52  
 
Scoping Searches 
 
Scoping searches were undertaken to determine the types of studies and the volume of 
studies relating to the research aim. Medline, Embase, and Web of Science were used for 
scoping purposes, to formulate a draft search strategy and inclusion/exclusion criteria. 
 
Electronic searches 
 
1. The electronic databases that were searched to identify published studies: 
 
MEDLINE (via Ovid), EMBASE (via OVID), Cochrane Library (Wiley) (including the Cochrane 
Database of Systematic Reviews, the database of abstracts of reviews of effects (DARE) and 
the Health Technology Assessment database) and Thomson Reuters Web of Science using a 
combination of medical subject headings and key words.  
 
The review was restricted to English language and limited to the date from which the first 
FIT was produced in 1978.55 
 
2. To identify any relevant ongoing studies, the following trial registers were searched: 
Clinical trial databases searched will include; Cochrane Central Register of Controlled Trials 
(CENTRAL), ClinicalTrials.gov, UKCRN Portfolio Database; WHO International Clinical Trials 
Registry Platform, ISRCTN. 
 
Searching other resources 
 
Grey Literature 
Conference abstracts have been shown to overestimate the accuracy of a test.56 However, 
since this is a niche field and all the current available evidence is desired for this review, 
authors of relevant conference proceedings were contacted for results or to obtain further 
information. The Zetoc database (The British Library), Science Citation Index and 
Conference Proceedings (Web of Science) were searched for relevant unpublished studies. 
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Reference lists 
All reference lists of included papers and relevant reviews were searched and any 
appropriate papers considered for inclusion. 
 
Correspondence 
Experts were contacted to identify any further papers for review. 
 
Sources of Heterogeneity 
Brand of FIT 
Qualitative (positive/negative) versus Quantitative (haemoglobin concentration FIT) 
Cutoff value selected 
Patient characteristics 
Reference standard 
Number of samples 
Risk factors considered in the model  
Predictive model methodology /statistical methodology 
How the model is applied/presented (e.g. nomogram, risk groups, risk calculators) 
2.3 Data collection and analysis 
 
2.3.1 Selection of studies 
 
After running searches on the above databases all citations were saved to Endnote X7 
Software. Duplicate references were removed at this stage. Two reviewers independently 
screened the titles and abstracts (JC, RC) retrieved from the search against the inclusion 
and exclusion criteria. The full texts of those studies included were then also screened 
independently by two reviewers (JC, KF) and any discrepancies resolved with a third 
reviewer (NP, CS). Reasons for exclusion were recorded. The PRISMA study flow diagram 
depicting the screening process and reasons for exclusion are provided in the results 
section. 
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2.3.2 Data extraction and management 
 
Data on ‘study characteristics’, ‘model characteristics’ and ‘screening test’ characteristics 
were extracted using a pre-specified data extraction table. The data extraction table was 
constructed using the CHARMS checklist,27 previous systematic reviews of prediction 
models including Cochrane Exemplar Reviews,45 the Cochrane Diagnostic Accuracy 
Handbook, the STARD statement 57 and QUADAS-244. One reviewer extracted the data from 
the included studies and a second reviewer checked this information. 
 
Data extraction included the following domains (the full data extraction form can be found 
in Appendix 2): 
 
 Study characteristics (e.g. study design, country, setting) 
 Source of data (e.g. cohort, case control, prospective, retrospective etc) 
 Participants (e.g. inclusion and exclusion criteria, recruitment method and 
participant description) 
 Outcomes to be predicted (e.g. definition and measurement of outcome) 
 Candidate Predictors (E.g. number and type of predictors, definition of predictors 
 Sample Size and Missing Data 
 Model Development (e.g. modeling method (logistic regression, survival analysis, 
machine learning approaches) methods for selecting predictors) 
 Model Performance (e.g. discrimination, calibration and classification measures) 
 Model Evaluation (e.g. internal and external validation) 
 Risk Stratification (How has risk been combined with the FIT and how has risk 
stratification been presented; as a score, as a probability etc) 
 Diagnostic Accuracy Considerations (target disease definition, type and brand of 
FIT, reference standard) 
 Test accuracy (diagnostic accuracy measures such as sensitivity, specificity, area 
under the receiver operating characteristic curve, cutpoint used) 
 Results (presentation of the final multivariable model) 
 Interpretation and discussion (Clinical applicability of the model, strengths, 
limitations etc) 
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2.3.3 Assessment of risk of bias 
 
This systematic review was predominately a risk prediction model review and therefore 
PROBAST was used to assess methodological quality of the risk prediction model 
development and validation studies. Diagnostic accuracy measures if assessed within the 
same paper were considered an add on measure. Where the study considered a test 
accuracy component, QUADAS-2 was used to assess the methodological quality. The 
QUADAS-2 tool was tailored to this review using the FITTER standards58 as guidance 
(Appendix 4). The Cochrane Risk of Bias Tool has been recommended by experts to use for 
model impact studies (comparative or intervention studies for different risk assessment). 
 
An early pilot version of PROBAST43 was used to assess risk of bias and the applicability of 
prediction modeling studies to the systematic review (Mallett et al, personal 
communication). This tool is based and developed from previous tools including the Quality 
in Prognostic Studies (QUIPS) tool,59 and QUADAS-244 as well as from REporting 
recommendations for tumour MARKer prognostic studies (REMARK)60 and Transparent 
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis 
(TRIPOD).61 PROBAST was used independently by two reviewers to assess the quality of the 
diagnostic prediction modeling studies. PROBAST has five key domains which are assessed 
for risk of bias; participation selection, predictors, outcome, sample size and participant 
flow and analysis. The first three domains are also judged for applicability to the systematic 
review question. QUADAS-2 comprises 4 domains which are assessed in terms of risk of 
bias and include; patient selection, index test, reference standard and flow and timing. 
Applicability is also assessed using the first 3 domains.44 
 
Appendix 4 includes an example of the tailored QUADAS-2 tool and key details for the pilot 
version of PROBAST. 
 
2.4 Data synthesis 
 
This review aimed to summarise the evidence of risk prediction models which combine the 
FIT for CRC screening. A narrative synthesis of the evidence was given using the data 
extracted and quality appraisal tools. Results and characteristics of individual studies were 
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presented in tabular displays for study characteristics, model characteristics and screening 
test characteristics in summary of results tables.  
 
Study characteristics included population and setting, outcome measure of the model and 
sample size used for model development.  
 
Model Performance 
Model characteristics included type of predictors used in the model, statistical modeling 
approach, model performance parameters and how the model is presented/applied in 
practice which were summarized in a summary of results table. 
 
If the data permitted and studies evaluated the same prediction model, a meta-analysis of 
calibration and discrimination was planned using DerSimonian and Laird’s random effects 
meta-analysis.62 A random effects model would have been required based on the probable 
methodological and clinical variability of the studies. Statistics which could be pooled to 
measure discrimination included the concordance (c) index, area under the curve and 
discrimination slope.63 For calibration statistics, the O:E statistic, calibration-in-the-large 
and calibration slope can be pooled.63 It is not recommended to pool results from the 
Hosmer-Lemeshow test and from the maximum likelihood as these measures depend on 
sample size.63  
 
Test Accuracy 
 
The screening test characteristics summary of results table included sensitivity, specificity, 
AUC ROC and cut-point used for the test and whether FIT only was used as a comparator. 
Cutoffs of the tests were converted to micrograms of haemoglobin per gram of faeces 
(µg/g) as recommended by the World Endoscopy Organization.64 Test accuracy 
components were considered by four studies. Where risk based FIT was compared to using 
the FIT alone, linked ROC plots were produced where sensitivity and specificity are joined 
by a line in ROC space to show the relative test accuracy in each study. A linked forest plot 
of sensitivity and specificity without summary statistics was presented for only one study 
where it was possible to derive the 2 by 2 data (true positives (TP), true negatives (TN), 
false positives (FP), false negatives (FN)). 
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If the same prediction models were evaluated as tests, a meta-analysis was planned to 
combine estimates of test accuracy including sensitivity and specificity. Due to the 
heterogeneity of studies included in the review in terms of predictors included in the 
models, outcomes, statistical modelling procedure and underlying populations, the data 
did not permit a meta-analysis. 
 
If a common threshold value (predicted probability) was used, results could be used to 
generate the summary sensitivity and specificity of the tests at that threshold. If a similar 
threshold was used in the identified studies then a bivariate model could be used for meta-
analysis to give an average operating point across studies.65 However, it was more likely for 
the threshold value to vary from study to study and therefore an estimation of a summary 
ROC curve would have been more appropriate by fitting a hierarchical SROC model.66 By 
plotting the ROC curve, the accuracy of the test can be compared at a range of different 
thresholds. This would require the same risk prediction model to be investigated in each 
study since this model assumes the underlying ROC curve for each study has the same 
shape but if different predictors are used this would not be the case. 
3.0 RESULTS 
3.1 Search Results 
 
The search produced 8,828 records of which 3,157 were duplicate records identified from 
Endnote and manually. This left 5,671 records to fully screen against the abstract and title 
inclusion/exclusion criteria. 54 articles were subjected to a full screen using the full 
inclusion/exclusion criteria (this included, 37 full text articles and 17 conference abstracts). 
46 articles were excluded based on the following criteria; statistical model (n=19), 
screening test (n=8), population (n=5), study design (n=5). For abstracts, 8 studies had a full 
text article associated and 1 study the author could not provide additional information as 
the results were pending publication. Reasons for exclusion for each study are listed in 
Appendix 3 and the PRISMA study flow chart is shown in Figure 1. 
 
Studies identified by experts (Professor Tom Marshall and Professor Stephen Halloran) 
were also assessed against the pre-defined criteria for the review.67-69 Boursi et al.67 
combined demographic, behavioural and past screening colonoscopy information but did 
not include the FIT. The other study by Kinar et al.69 also combined lab based results with 
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other factors in a decision tree based prediction algorithm but included the guaiac based 
test as opposed to the FIT. Finally, the study by Birks et al.68 investigated validating the 
previous model in a UK setting for primary care.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: PRISMA Study Flowchart 
 
3.2 Summary of included Full Text Articles  
 
Stegeman et al.16 investigated combining the FIT result with a risk questionnaire in CRC 
screening. The data were collected from a randomized screening pilot for using 
colonoscopy as a primary screening tool in the Netherlands. Risk factors selected to be 
included in the questionnaire came from previous analysis of variables for advanced 
neoplasia.14 The final population size for model development was 1112 participants who 
completed both a risk questionnaire and the FIT. The statistical modelling strategy used 
logistic regression with backwards elimination.  
 
El
ig
ib
ili
ty
 
Full text articles assessed for 
eligibility  
(n = 54) 
37 published full text articles 
17 conference abstracts 
In
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Studies included in synthesis  
(n = 8) full text articles 
8 models 
Records identified 
through database 
searching  
(n =8580) 
Sc
re
en
in
g 
Full text articles 
excluded from current 
review 
(n=46) 
 
Statistical model n= 19 (18+1)  
Screening test n= 8 (4 + 4) 
Population n= 5 (3 + 2) 
Study Design n= 5 (4 + 1) 
Has a full text n= 8 (0 + 8) 
Author could not provide 
sufficient detail n=1 (0 +1) 
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Records after duplicates removed 
and then screened 
(n =5671) 
Records excluded on 
basis of title and 
abstract as not meeting 
inclusion criteria  
(n=5619) 
Records excluded not fitting all 
the inclusion criteria 
(n=164) 
Additional records 
identified through 
other sources  
(n = 248) 
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Yen et al.9 combined the FIT with conventional risk factors obtained from a questionnaire 
along with lab results (triglyceride levels). This study used a cohort from Taiwan invited to 
population based screening for colorectal neoplasia (n=54,921) to develop the model and 
another two datasets combined for external geographical validation (n=17,085) (two 
community based integrated screening programmes). This study produced nine models in 
total; one which was conventional risk factors only, another which was FIT adjusted for age 
and a combined model of FIT plus conventional risk factors. Each of these models was 
applied for the three different outcomes investigated: colorectal neoplasia, colorectal 
cancer and colorectal adenoma. Risk equations were presented for each model. 
 
Omata et al.70 combined the FIT result with routine predictors obtained from a general 
health checkup (age, sex, BMI). Data were collected as part of a cross sectional study 
investigating the optimal cut point of FIT in asymptomatic participants in Japan. The final 
sample size was 1085 (70% males) who completed both a FIT and colonoscopy. The 
modelling strategy was non-linear ordinal logistic regression using a three-category status 
of colorectal neoplasms as the dependent variable. The first objective of the study was to 
decide on the optimal cut-off point of the FIT – for this they selected an ideal cut-off value 
of FIT based on a value that maximised the sum of both sensitivity and specificity and 
clinical utility. This approach engineers good performance and not clinical reality. 
 
Auge et al.71 combined demographic characteristics (age and sex) with the OC-Sensor FIT. 
The population was FIT positive asymptomatic men and women from the first round of the 
Barcelona screening Programme (n=3109). A low threshold (20 μg/g) was used for positivity 
which gave a sample population at slightly higher than average risk. Logistic regression is 
used for model development and to delineate 16 risk categories and subsequently 3 risk 
levels based on the positive predictive values from the models. 
 
Kim et al.72 integrates the FIT with fecal Calgranulin B (CALB) and age using logistic 
regression. This study uses cases and controls from a previous study based in Korea where 
Western blot analysis of CALB was performed. Controls were recruited from participants at 
the Health Screening Program at the National Cancer Centre, Korea. Cases and controls 
from another independent patient cohort were also used. The modelling strategy uses a 
development set (81 cases, 51 controls), validation set (94 cases, 100 controls) and 
combined set (132 cases, 151 controls) to produce the overall risk prediction model.  
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Tao et al.73 investigate combining blood based inflammatory markers with the FIT in a 
logistic regression algorithm to compare performance using the area under the curve. Data 
comes from participants recruited from an ongoing prospective screening study in 
Germany where screening colonoscopy is offered, as well as patients from the sub-study 
DACHS + where CRC patients are referred by GPs/gastroenterologists for surgery (enriched 
sample/case-control). The sample size used to produce the model includes 467 participants 
with available blood and stool samples. The study uses logistic regression as a tool to 
combine the blood based inflammatory markers and is mainly concerned with diagnostic 
accuracy over developing a risk prediction model but does provide individualised 
prediction. 
 
Wietan et al.74 combines the FIT with demographic factors (age, gender) using data from an 
organised screening programme in the Netherlands, Rotterdam-Rijnmond. The sample 
population used those with a positive test and successful colonoscopy (n=481). Data is 
combined in a logistic regression analysis to give a predicted probability of advanced 
neoplasia. Predicted probabilities are depicted in a figure with age as a continuous variable. 
The primary aim of this study was to assess how increasing the cutoff concentration for FIT 
and screening age subsequently affects colonoscopy yield, missed lesions and demand. 
 
Karl et al.75 investigated novel biomarkers to improve sensitivity of the detection of CRC 
using stool samples. The RIDASCREEN hemoglobin-haptoglobin FIT is combined with 
biomarkers TIMP-1 and S100A12 using Bayes logistic regression (BLR) as a mathematical 
model. The RIDASCREEN test was one of the FITs considered in recent NICE guidance.76 
Stool samples were obtained from two European multicenter studies in Germany; one of 
which was a preventative screening study at gastroenterology units and the other was used 
to recruit additional CRC patients from surgery units. The sample population comprised 252 
controls, 113 advanced adenomas, 186 colorectal cancers. The main aim of the study was 
to examine the clinical performance of fecal S100A12 and other biomarkers. The study is 
therefore mainly concerned with diagnostic accuracy measures and uses BLR as a method 
to combine the biomarker and FIT results but does use posterior case probabilities to 
define a threshold for positivity (according to a specificity level of 95% or 98%). 
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3.3 Populations and Study Design  
 
Models were developed using data collected from The Netherlands,16 74 Japan,70 Taiwan,9 
Spain,71 Korea,72 and Germany73 75. Study settings included data from population based 
colorectal cancer screening programmes, general health checkups and community based 
integrated screening. Data from case controls included a proportion of data from screening 
based settings. Included studies used a variety of study designs including 
prospective/retrospective cohort studies, cross sectional studies, case controls and 
enriched samples. Table 4 summarises the study characteristics for the included papers. 
 
The outcomes for the final models developed varied in spectrum across the studies from 
advanced adenoma73 to colorectal cancer72 and some considered a combined endpoint 
(e.g. advanced adenomas plus colorectal cancer as colorectal neoplasia)9 16 70 71 74. 
Combined endpoints are often included in screening studies due to the clinical benefit of 
detecting both early stage and later stage disease. Omata et al.70 for instance considered 
significant neoplasia and the combined endpoint significant neoplasia or adenomatous 
polyps within the final Nomogram. Tao et al.73 present model performance results for 
advanced adenoma only, since adding biomarkers to a model with FIT alone made no 
improvement to the detection of colorectal cancer. Karl et al.75 present cross-validated 
results for colorectal cancer but also consider advanced adenomas and colorectal cancer 
separately when assessing a model combining both development and validation sets. 
 
The TRIPOD classification of risk prediction model studies61 was used as well as criteria 
developed for this review specifically (Table 4). Two of the studies are categorized as 
TRIPOD Classification 1b which is development and validation using resampling16 70 
although the methods for Omata et al.70 are unclear. Two other studies use an independent 
dataset but for one of these studies72 the final model presented combines both 
development and validation sets and for the other study the validation set uses new cases 
but the same controls from the development set75. These studies therefore cannot be 
considered a pure external validation study and are classified as a nonrandom split-sample 
development and validation study (TRIPOD Classification: 2b). Furthermore, these two 
studies72 75 present cross validated performance results as well as performance determined 
externally but the final model presented for Kim et al.72 is not internally validated. One of 
the studies was a development and validation study using separate data (TRIPOD 
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Classification: 3).9 The final three studies are classified as development only (TRIPOD 
Classification: 2a) as internal validation is not reported.71 73 74 
 
Four studies also consider applying the risk prediction model as a test and report test 
accuracy measures sensitivity and specificity.16 72 73 75 These studies use FIT only as a 
comparator. 
  
Study Model of 
interest 
TRIPOD 
Classification 
Study Design Country Setting Participant Description Outcome Sample Size for 
Model 
Events 
Stegeman, 
2014 
1d 
 
OC Sensor 
result + 
lifestyle 
questionnaire 
predictors 
1b Data from colonoscopy 
arm of a randomized 
screening trial – 
prospective cohort 
The 
Netherlands 
Population based colorectal 
cancer screening programme 
Asymptomatic men and women 50-75 years old.  
 
Mean age 60.6 (SD 6.2) 543/1112 (49%) female 
Presence of advanced neoplasia 
during colonoscopy 
1112 underwent 
colonoscopy, 
completed a 
questionnaire and 
completed a FIT 
101 (94 advanced 
adenoma and 7 
cancer) 
Yen, 2014 1b 3 Cohort invited to 
population screening 
for colorectal neoplasia 
using FIT – longitudinal 
follow up study 
Taiwan. Keelung 
City for 
development 
dataset. 
Changhua and 
Tainan for 
validation 
dataset 
Community based integrated 
screening 
Subjects aged 40 years or older. 
 
Risk for developing colorectal 
neoplasia (colorectal cancer and 
colorectal adenomas) 
Development: 54,921 
 
Validation: 883 
colorectal cancers, 
2028 adenoma cases 
and 14,174 disease 
free subjects 
Development: 824 
colorectal 
adenoma, 323 
colorectal cancer 
 
Validation: 883 
colorectal cancers, 
2028 adenomas 
Omata, 2011 1a 1b Cross-sectional study of 
asymptomatic Japanese 
individuals undergoing 
a general health check-
up 
Tokyo, Japan General health checkup with a 
proportion of patients 
undergoing colonoscopy 
Asymptomatic patients from the general population.  
 
Mean age 64 years, 756/1085 (70%) male. 
Three category status of 
Colorectal Neoplasms (CRN) – (A) 
No CRN, (B) AP excluding AAP (C) 
SN (significant neoplasia) 
 
AP (colorectal adenomatous 
polyps) 
AAP (advanced colorectal 
adenomatous polyps) 
SN includes AAP and CRC 
(colorectal cancer) 
 
1085 completed full 
colonoscopy and 
QTFIT 
393 cases of AP 
including 69 cases 
of AAP and 8 cases 
of CRC.  
Auge, 2014 1a 1a Retrospective study of a 
series of participants to 
the Barcelona 
colorectal cancer 
screening programme 
Barcelona, 
Spain 
First round of Barcelona 
colorectal cancer screening 
round 
Asymptomatic men and women (50-69 years) 
participating in the Barcelona screening programme 
 
Median age – 60 
43% women (1334/3109) 
57% men (1775/3109) 
Advanced colorectal neoplasia 
(colorectal cancer or high risk 
adenoma) versus non advanced 
colorectal neoplasia 
3109 FIT positive 
participants 
undergoing 
colonoscopy 
1147 high risk 
adenoma 
294 colorectal 
cancer 
Wieten, 2016 1a 1a Data from an organised 
CRC screening 
programme in the 
Netherlands 
The 
Netherlands, 
Rotterdam-
Rijnmond 
First round of CRC Screening 
Programme using the FIT 
Average risk screening population aged 50-74  
 
Median age 61 years, 48% of participants were male. 
Advanced neoplasia (defined as 
CRC and advanced adenomas) 
481 (positive test and 
successful 
colonoscopy) 
164 advanced 
adenoma 
29 CRC 
 
Advanced neoplasia 
= 193 
Tao, 2012 1d 1a Data from participants 
recruited from the BliTz 
study and satellite sub-
study DACHS +  
Enriched sample/case 
control 
Germany The BliTz study is an ongoing 
prospective screening study 
where screening colonoscopy is 
offered. 
The DACHS study is an ongoing 
case-control study focusing on 
the role of colonoscopy in CRC 
prevention. 
Men and women aged 55 and over in Germany from 
BliTz study. Participants from DACH study were CRC 
patients referred by GPs/gastroenterologists for 
surgery.  
These two studies were used to derive three groups 
of participants; those with no neoplasm, advanced 
adenoma, CRC. 
 
Advanced adenoma OR 
colorectal cancer 
 
No colorectal neoplasm (44.4% 
male, mean age 61.9). Advanced 
adenoma (64.3% male, mean age 
65.0). Colorectal cancer (54.8% 
male, mean age 68.1) 
467 Participants with 
available blood and 
stool samples 
183 advanced 
adenoma 
67 colorectal 
cancer 
217 without 
neoplasm 
  
  
Study Model of 
interest 
TRIPOD 
Classification 
Study Design Country Setting Participant Description Outcome Sample Size for 
Model 
Events 
Kim, 2014 1d 2b Case control 
development and 
validation study. 
Subjects divided into 
two independent sets. 
Korea Development dataset – 
patients in which western blot 
analysis was performed on 
samples from 81 patients with 
CRC (and 51 controls) 
Validation dataset – 
independent patient cohort of 
94 cases and 100 control 
subjects. 
Final model uses a 
combination of both datasets 
for model development. 
Cases and controls 
Development – 81 cases (mean age 63.16 (SD 
10.42)), 51 controls (mean age 50.24 (SD 10.12)) 
 
Validation – 94 cases, 100 controls (mean age 62.96 
(SD 11.97)) Combined – 132 cases, 151 controls 
(mean age 49.43 (SD 10.78)). Breakdown by sex not 
given. 
Colorectal cancer Development – 81 
cases, 51 controls  
 
Validation – 94 cases, 
100 controls 
 
Combined – 132 
cases, 151 controls  
 
Development – 81  
 
Validation – 94  
 
Combined – 132  
 
Karl, 2008 1d 2b Case control 
study/enriched study 
with stool samples 
obtained from 2 
European multicenter 
studies. 
Europe (Germany) Study 1 – Preventive 
screening study at 
gastroenterology units 
Study II – Cancer collection 
study at surgery units 
Clinical samples from both multicentre studies were 
compiled: 
- Group A comprised the control cohort 
with 252 patients from study I.  
- Group B comprised the advanced adenoma cohort 
containing 113 patients 
from study I and study II 
-Group C comprised the CRC cohort with 186 CRC 
patients from study I and study II. Cancer patients 
were divided into collective I (no 
FOBT testing or visible blood in stool), and collective 
II (no restrictions applied). 
Colorectal cancer or 
Advanced adenoma 
Development used  
CRC collective I and 
controls. 
 
BLR then applied to 
all samples in 
collective I (n=101) 
(controls n=252) to 
learn a final 
diagnostic rule and 
again its thresholds 
were determined. 
252 controls 
113 advanced 
adenomas 
186 colorectal 
cancers 
 
Table 4: Study Characteristics for the eight included studies. 
 
Tripod classification includes; 1a - Development only, 1b - Development and validation using resampling, 2a - Random split-sample development, 2b – Nonrandom split-sample development 
and validation, 3 – Development and validation using separate data, 4 – Validation study. Model of interest classification for this review includes; 1a  - Model development (ideally with internal 
validation), 1b – Model development with external validation, 1c – External Validation, 1d – Developing/validating a model and then applying as a test, 1e – Applying the risk prediction model 
as a test (impact study incl. diagnostic accuracy). 
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3.4 Predictors 
 
Studies assessed a range of predictors including demographic factors which would have 
been routinely available, novel biomarkers, lab test results and additional lifestyle 
information from questionnaires. There was some overlap with predictors included in the 
models; the most frequently included predictors were age and sex. These factors are most 
likely to be readily available and are well known risk factors for colorectal cancer. Three 
studies assessed purely demographic factors.70 71 74 Table 5 details the included predictors 
for each of the models developed. 
 
Yen et al.9 and Stegeman et al.16 utilized questionnaires in order to gain additional data on 
lifestyle factors and other conditions. This is a richer source of data than the routinely 
available predictors but requires additional data collection. For example, further data on 
smoking habits and alcohol consumption were obtained along with family history of CRC. 
Yen et al.9 also carried out additional lab tests; fasting glucose and lipid profile 
(triglyceride/total cholesterol) in order to obtain further predictors.  
 
Kim et al.72 investigated combining FIT with Calgranulin B (CALB) and age in order to assess 
the incremental benefit of CALB to a prediction model including the FIT. Tao et al.73 and 
Karl et al.75 incorporate novel biomarkers into the prediction models. The studies which 
integrated lab/biomarkers tended to have more of a diagnostic focus. 
 
In terms of how continuous variables were modelled, Stegeman et al.16 treated 
quantitative variables as continuous in the multivariable model. Restricted cubic splines 
were used to evaluate the linearity of predictors which led to the square root of the FIT 
result being used in the multivariable analysis. Lab and biomarkers were in general 
modeled continuously within the relevant studies.72 73 75 For Kim et al.72 CALB is modelled as 
a rank transformed value to accommodate the non-normality, the conversion table is 
supplied within the supplementary material of the paper.  
 
Categorisation of predictors was commonly used. For example, for the models produced by 
Yen et al.9 FIT is treated as an ordinal variable using 10 categories and BMI and triglyceride 
levels are also categorized in the final models. Wieten et al.74 models both age and fecal 
haemoglobin concentration as 10 unit increases. Finally, Auge et al.71 uses quartiles of FIT 
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combined with age and sex (log of FIT is used for graphical representation). Categorisation 
of continuous predictors is not recommended due to the loss of information.61 77 78 
 
The events per predictor (EPP) rule of thumb requiring 10 events per predictor61 79 was met 
by all studies as far as could be identified in terms of predictors reported for multivariable 
inclusion. When assessing the EPP for all considered predictors, Stegeman et al.16 mention 
13 predictors in the methods, results and Table 1 of the paper. Based on the 101 events 
and 13 predictors in this study, this requirement is not quite met with an EPP of 7.77. 
 
3.5 Statistical Analysis 
 
Most of the studies used conventional statistical methods to develop the risk prediction 
model. Logistic regression was used in five out of the eight studies. Two further studies 
used a modified version of logistic regression; for example Karl et al.75 used a Bayesian 
approach to logistic regression and Omata et al.70 used the three-category status of CRN as 
the dependent variable in a nonlinear ordinal logistic regression. The final study by Yen et 
al.9 used survival analysis methods (accelerated failure time models) due to staggered 
invitations to screening. 
 
Predictor selection was not always reported sufficiently in the included studies. Those 
studies which used univariable screening of variables included Auge et al.71 and Wieten et 
al.74 where variables were included if they had a p value of less than 0.05. For Wieten et 
al.74 sex was also included based on clinician’s rationale which reduces some of the data 
driven selection. Studies which use univariable screening can lead to bias in the predictor 
effects because although not significant in isolation, a variable may become significant 
when combined with other factors in a multivariable model. Stegeman et al.14 conducted a 
previous study which assessed the importance of various predictors for colorectal cancer 
and included these predictors in the analysis. Studies which had a test accuracy focus as 
well as a model development focus tended to use all available predictors or test the 
incremental benefit of including an additional parameter. The model was seen as a method 
of combining several biomarkers or an additional lab result for an overall result. 
 
Internal validation methods were used by half of the included studies (4/8). Cross 
validation was used by Kim et al.72 (leave one out cross validation) and Karl et al.75 (100 
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runs in a Monte-Carlo cross-validation) when developing the Bayesian logistic regression to 
estimate results for diagnostic performance. Omata et al.70 assesses the internal validity of 
the model using bootstrapping which showed an optimism of 0.06 but it is not described 
whether this was for model performance measures or for model parameters. Finally, 
Stegeman et al.16 used penalized shrinkage to estimate coefficients and to correct the 
logistic regression model for optimism. Correcting for optimism reduces the overfitting of 
the model so it is more generalizable to new populations. Other studies do not report any 
adjustment for optimism explicitly in the text. 
 
Model building strategies were not always described in enough detail to allow replication 
of the methods. Backwards elimination was used to build a logistic regression model by 
Stegeman et al.16 using a p value of 0.02 as the removal level. Other studies just included 
predictors which were significant at a certain p-value (0.05).9 70 71 73 74  
 
Two studies used a split sample method to develop their model as well as using cross 
validation and applying the model in an ‘independent dataset’. The final model by Kim et 
al.72 presented as a model equation is based on a model produced from combining both 
development and validation datasets. Despite validating the model internally and 
externally, this final model is based on combining both the validation and development 
data samples, rather than using the coefficients from the original developed model either 
adjusted for optimism or recalibrated in the new external dataset. This new model which 
has been developed needs subsequent external validation. A similar approach is taken for 
Karl et al.75 where two models are effectively developed. The first uses 2/3 of the CRC 
Collective I and controls data. Bayes Logistic Regression (BLR) was then applied to all 
samples from Collective I to develop a final diagnostic rule and thresholds determined. This 
final rule was then used to predict test results for the CRC Collective II (authors say in an 
independent patient cohort) and adenomas. The final model developed would need to be 
both internally and externally validated depending on which version is used. 
 
Only one study had a pure external validation dataset which was used to assess 
performance of the model (AUC – discrimination) in a new patient population.9 For model 
development, patients were those invited to population based screening for colorectal 
neoplasia using the FIT in Keelung. The external validation set on the other hand used two 
community based screening programs which included the FIT, in Changhua and Tainan in 
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Taiwan (geographical validation). All the colorectal neoplasia cases and a random sample of 
one-tenth of disease-free subjects were selected for external validation. Although this used 
an external validation dataset, the population is selected in a case control approach with a 
random sample of 1/10 of disease free subjects and all the colorectal neoplasia cases which 
may inflate model performance/test accuracy parameters. A minimum of 100 events are 
recommended in external validation studies.80 
 
Only one study used multiple imputation to account for missing variable data,16 the other 
studies either did not report any missing data or reduced the sample size sufficiently to 
allow for complete results (complete case analysis). Reducing the sample size in this way 
can lead to unreliable associations between predictors and outcomes. 
 
3.6 Model Performance (Discrimination, calibration) 
 
Six of the eight studies reported discrimination measures (AUC ROC) and three out of eight 
reported calibration. Calibration was most often reported as the Hosmer-Lemeshow 
statistic, with one study providing a calibration plot for assessment as well as a histogram 
showing the distribution of risk.16 Discrimination ranged from 0.676-0.960 for risk adjusted 
FIT (reported in 6/8 studies) and 0.683-0.902 for FIT only (reported in 4/8 studies). Lab 
results and biomarkers tended to give higher discrimination values but a significant 
improvement was also seen when using simple routinely available predictors such as age 
and sex which are more readily available. Calibration using Hosmer-Lemeshow ranged from 
0.276-0.940 for risk adjusted FIT (reported in 3/8 studies). The highest calibration was 
reported by Stegeman et al. with the combination of lifestyle and routine data.  
 
Omata et al.70 just reports model fit in terms of whether the likelihood ratio test showed an 
improvement over the model including only FIT (p<0.001). FIT only is compared to risk 
adjusted FIT when reporting discrimination in 4 studies.9 16 72 73 This is also formally tested 
by looking at the difference in the AUC ROC and reporting the p value for Yen et al.9 (not 
significant p=0.62), Kim et al.72 (just significant p=0.049) and Stegeman et al. (significant 
p=0.02). For those studies using FIT or FIT in a model as a comparator, likelihood ratio 
testing is used to determine if the model has a significantly better fit for Stegeman et al.16 
(p<0.001), Omata et al.70 (p<0.001) and Tao et al.73 (p=0.002 for adding one marker, 
p=0.0007 for adding 3 markers).  
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Different levels of model discrimination are achieved depending on whether lab based 
predictors are used, routine demographic data or richer questionnaire data. Stegeman et 
al.16 used a questionnaire to collect additional predictor information and reported an 
increase in the AUC from 0.69 (for FIT only adjusted for age) to 0.76 (significant). Auge et 
al.71 included just age and sex along with the FIT result and had an AUC of 0.676 (95% CI: 
0.657-0.695) with no comparator to FIT-only. Yen et al.9 used questionnaire plus lab 
parameters (AUC of 0.83) and compared this to FIT only (AUC of 0.83) and a model 
containing conventional risk factors only (AUC of 0.66). Tao et al. reported an increase from 
FIT only (AUC 0.683) to FIT plus biomarkers CRP, sCD26 and TIMP-1 (AUC 0.729). Finally, 
Kim et al.72 compared a FIT only model (adjusted for age) with an AUC of 89.52 with a 
model with FIT, age and CALB with an AUC of 92.05 (significant difference in AUC).  
 
Model performance results are summarized in Table 5. 
 
 
 
Study Predictors considered Predictors 
included 
How continuous 
predictors 
modelled 
EPP (events 
per predictor) 
Modelling 
Method 
Predictor 
Selection 
Extra 
Predictor data 
Internal/external 
validation method and 
optimism adjustment 
Discrimination Calibration Other 
performance 
measures 
Risk 
Assessment 
Risk 
Presentation 
Stegeman, 
2014 
Predictors mentioned 
in the methods, 
results and Table 1: 
FIT result, age, calcium 
intake, CRC family 
history, smoking, BMI, 
menopausal status, 
fibre intake, 
aspirin/NSAID use, red 
meat intake, sex, 
alcohol intake, 
physical activity 
FIT result, age, 
calcium intake, 
family history, 
past or current 
smoking 
Restricted cubic 
splines, square 
root of FIT result. 
Quantitative 
variables treated 
as such in the 
multivariable 
model 
For all 
considered 
predictors: 
101/13 = 7.77 
 
For the final 
model: 
101/5 = 20.2 
Logistic 
Regression 
Backwards 
Elimination 0.20 
as removal 
criterion 
FIT plus risk 
questionnaire 
Corrected for optimism 
by penalized shrinkage 
– coefficients are 
estimated with 
penalized maximum 
likelihood the optimal 
penalty factor is 
determined with the 
akaike information 
criterion 
AUC FIT only 
model – 0.69       
AUC Risk model 
– 0.76 
 
Discrimination 
improved 
significantly 
with the risk 
based model 
(p=0.02) 
Hosmer-
Lemeshow 
test p=0.94  
 
Calibration 
plot of the 
risk model 
FIT only model 
(adjusted for age) 
compared to risk 
based FIT 
p<0.001 
goodness-of-fit 
likelihood ratio 
test  
 
NRI 0.054 
p=0.073 
 
5 more cases 
advanced 
adenoma 
detected by 
referring those at 
highest risk 
 
Distribution of 
risk. 
Risk as a 
probability for 
advanced 
neoplasia 
with a 
threshold of 
0.19 
Odds ratios 
presented and 
the risk 
equation is 
used to 
generate 
probabilities. 
Yen, 2014 
(Results 
for the 
model 
predicting 
colorectal 
neoplasia) 
Structured 
questionnaire; dietary 
habits (alcohol, 
smoking), family 
history, and personal 
history of cancer, type 
2 diabetes, 
hypertension, 
cerebrovascular 
disease, 
cardiovascular disease 
(hypertension), BMI. 
Additional lab tests; 
fasting glucose, lipid 
profile 
(triglyceride/total 
cholesterol), FIT result. 
Demographic factors; 
gender 
Gender, FIT 
result, family 
history of CRC, 
diabetes 
mellitus, 
hypertension, 
alcohol 
drinking, 
smoking, BMI, 
triglyceride 
 
FIT and 
Gender also 
assessed. 
FIT is treated as 
an ordinal 
variable with 10 
categories. BMI 
and triglyceride 
also categorized. 
FIT as a 
continuous 
variable is 
assessed but 
model not 
reported. 
Development: 
1147/22 = 
52.14 (for the 
final model) 
 
Validation: 
2911/22 = 
132.32 (for the 
final model) 
Accelerated 
Failure Time 
model 
Predictor 
selection not 
reported – 
includes those 
with a 5% 
significance 
level 
FIT plus fasting 
glucose, lipid 
profile and a 
structured 
questionnaire 
on lifestyle 
External validation: 
 
AUC for the model 
containing only FIT was 
85.6% (95% CI – 84.8-
86.4%) 
 
Conventional risk 
factors only 63.6% (95% 
CI – 62.5-64.7%) 
 
FIT plus conventional 
risk factors 86.1% (95% 
CI – 85.2-86.9%) 
Development:  
AUC for the 
model 
containing only 
FIT was 83.0% 
(95% CI – 81.5-
84.4%) 
 
Conventional 
risk factors only 
65.8% (95% CI – 
64.2-67.4%) 
 
FIT plus 
conventional 
risk factors 
83.5% (95% CI – 
82.1-84.9%) 
- Adding 
conventional risk 
factors to the 
model with FIT 
only did not 
make a 
significant 
contribution 
(p=0.62) (AUC) 
The 
probability of 
having 
incident 
colorectal 
neoplasia. 
Risk equations 
presented. The 
regression 
coefficients 
from the AFT 
models were 
used as the 
clinical weights 
in external 
validation. 
Omata, 
2011 
FIT result, age, BMI 
and sex 
BMI, age, sex, 
FIT 
Nonlinear effect 
was assessed by 
testing linear 
effect for all 
variables – 
method unclear 
For predictors 
in the final 
model 
 
Events per 
predictor for 
SN 
69 AAP + 8 
CRC 
77/4 = 19.25 
Nonlinear 
Ordinal 
Logistic 
Regression 
using three-
category 
status of 
CRN as 
dependent 
variable 
Not reported. In 
unadjusted 
analysis for SN 
there was 
significant 
difference in 
age, sex, BMI 
and QTFIT 
between disease 
categories 
CRN data 
obtained from 
general health 
checkup 
Internal validity of 
prediction model 
investigated by 
bootstrapping. 
Optimism 0.06. 
Further details not 
given. 
 - - Presents 10 
profiles with 
probability of 
adenomatous 
polyp and 
significant 
neoplasia and 
significant 
neoplasia 
Likelihood Ratio 
Prediction of 
SN 
Nomogram for 
predicting AP 
or SN and SN 
 
 
 
SN or AP 
SN = 77 
AP = 393 
(including 69 
cases of AAP) 
470/4 = 117.5 
 
test showed an 
improvement 
over the model 
including only 
QTFIT (p<0.001) 
Auge, 2014 Sex, age, FIT quartiles, 
referral hospital, city 
district and primary 
care centre 
FIT result, age, 
sex 
Log FIT for 
graphic 
representation 
but quartiles of 
FIT used for 
multivariable 
model. 
 
Age is 
categorized into 
2 groups: 
50-59 
60-69 
For all 
considered (6 
variables) 
 
1441/6 = 
240.17 
 
Final model 
 
1441/3 = 
480.33 
Logistic 
regression 
Included 
variables with a 
p value of less 
than 0.05 in the 
multivariable 
model 
FIT plus 
demographic 
characteristics  
No internal 
validation/adjustment 
for optimism 
AUC ROC 0.676 
(95% CI: 0.657-
0.695) 
Hosmer-
Lemeshow 
test 
p=0.312 
- Logistic 
regression 
model was 
used to 
delineate 16 
risk 
categories for 
advanced 
colorectal 
neoplasia 
16 risk 
categories 
associated with 
different 
probabilities for 
advanced 
colorectal 
neoplasia 
 
These 
categories 
were then 
classed into 3 
risk levels 
(arbitrarily) 
with different 
probabilities 
according to 
the 
corresponding 
PPV. 
 
Up to 30% - low 
risk 
31%-50% - 
average risk 
>50% - high risk 
Wieten, 
2016 
Sex, age, 
socioeconomic status, 
FIT concentration 
Age, gender, 
FIT 
Age (per 10 year 
increase) 
Fecal Hb 
Concentration 
(per 10 µg Hb/g 
increase) 
For all 
considered 
variables 
(parameters) 
193/5 = 38.6 
 
For final 
model 
 
193/3 = 64.33 
Logistic 
regression 
Univariable 
screening 
(p<0.05) plus 
clinicians 
rationale 
FIT plus 
demographic 
characteristics 
No internal 
validation/adjustment 
for optimism 
- Hosmer-
Lemeshow 
goodness 
of fit: 
p=0.276 
- Predicted 
probability of 
having AN per 
screenee who 
had a positive 
FIT and 
subsequent 
colonoscopy 
Predicted 
probabilities of 
having AN per 
screenee were 
depicted in a 
figure with age 
as a continuous 
variable 
Tao, 2012 C-reactive protein 
(CRP), serum CD26 
(sCD26), complement 
C3a anaphylatoxin, 
tissue inhibitor of 
metalloproteinases I 
(TIMP-1) – measured 
by ELISA tests and FIT 
and guaiac FOBT also 
FIT, CRP, 
sCD26 and 
TIMP-1 
Assumption 
modeled 
continuously 
blood markers as 
(ng ml-1) and FIT 
concentration as 
µg Hb/g. 
For all 
considered 
predictors 
(advanced 
adenoma 
results) 
 
183/5 = 36.6 
 
Logistic 
regression 
Included 
predictors 
whose levels 
showed 
statistically 
significant 
differences in 
CRC cases 
versus 
FIT plus blood 
based 
inflammatory 
markers (lab 
results) 
No internal 
validation/adjustment 
for optimism 
FIT plus TIMP-1 
AUC = 0.710 
 
FIT plus CRP, 
sCD26 and 
TIMP-1 
AUC = 0.729 
 
FIT only  
- (Advanced 
adenoma) Model 
fit was 
significantly 
improved adding 
TIMP-1 to FIT 
result (p=0.002) 
or all three 
markers (FIT, 
Predicted 
probability of 
advanced 
adenoma 
Model not 
presented 
 
 
 
performed. Final model 
185/4 = 46.25 
 
 
participants free 
of neoplasms 
AUC = 0.683 CRP, sCD26 and 
TIMP-1) 
(p=0.0007) using 
likelihood ratio 
tests 
Kim, 2014 Fecal CALB 
(calgranulin B), FOBT, 
age 
Fecal CALB, 
FOBT, age 
CALB is a rank 
transformed 
value (conversion 
table supplied in 
supplementary 
material). Their 
rank was used in 
to accommodate 
the non-
normality. 
Assume FOBT 
and age are 
continuously 
modeled from 
risk equation 
Development:  
 
81/3 = 27 
 
Validation:  
 
94/3 = 31.33 
 
Combined 
development: 
132/3 = 44 
 
Logistic 
regression 
The aim of the 
paper was to 
assess the 
incremental 
benefit of CALB 
to a prediction 
model including 
FOBT. The 
model was also 
adjusted for age 
due to 
imbalances 
between CRC 
patients and 
controls in both 
the sets 
FIT plus CALB 
(lab result) 
Internal validation - 
LOOCV (leave-one-out 
cross validation)  
 
External validation 
using an independent 
set (non-random split 
sample development 
and validation) 
 
Final model presented 
combines both 
development set and 
validation set. 
 
Model (age + FIT)  
AUC – 0.9017 
Partial AUC – 0.0699  
 
Model (age + FIT + 
CALB) 
AUC – 0.9282 
Partial AUC – 0.0748 
 
Development 
dataset: 
Model (age + 
FIT)  
AUC – 89.52 
Partial AUC – 
6.65 
Model (age + FIT 
+ CALB) 
AUC – 92.05 
Partial AUC  - 
7.02 
Development 
LOOCV dataset: 
Model (age + 
FIT)  
AUC – 87.78 
Partial AUC – 
5.62 
Model (age + FIT 
+ CALB) 
AUC – 89.81 
Partial AUC – 
5.70 
Validation 
dataset: 
Model (age + 
FIT)  
AUC – 90.65 
Partial AUC – 
7.34  
Model (age + FIT 
+ CALB) 
AUC – 92.74 
Partial AUC – 
7.71 
- For the 
development 
dataset. 
 
Reclassification 
improvement 
p-value of RI in 
CRC patients and 
controls from the 
model using 
FOBT adjusted 
for age 0.0013 
and for the full 
model 0.0173.  
P-value of NRI 
was 0.0001. 
 
Difference in AUC 
ROC for 
incremental 
benefit of CALB 
p-value 0.0499 
 
 
Predicted 
probability of 
CRC. 
 
Cut point is at 
a specificity 
closest to 
90% 
Risk equation 
for the model 
combining both 
datasets is 
presented 
Karl, 2008 Hemoglobin, 
Hemoglobin-
haptoglobin, S100A12, 
TIMP-1, Calprotectin, 
CEA 
Model 
Combination 
1: 
Hemoglobin-
haptoglobin, 
S100A12 
 
Model 
Combination 
2: 
Hemoglobin-
haptoglobin, 
Continuous  Collective 1 
(n=101 CRC) 
Controls 
(n=252) 
 
2/3s used for 
development. 
 
0.66*101 = 
67.33 
 
68/6 = 11.33 
Bayes 
Logistic 
Regression 
Six marker 
candidates were 
evaluated alone 
or in 
combination for 
the detection of 
CRC in stool 
samples using 
BLR. BLR 
‘selected’ the 
combinations. 
FIT plus 
biomarkers 
Results of BLR were 
evaluated by 100 runs 
in a Monte-Carlo cross-
validation design 
applied on CRC 
collective I and controls. 
 
Using CRC collective II 
they validated the 
results in an 
independent patient 
cohort. 
AUC 0.95 for 
S100A12 alone 
to 0.96 for 
marker 
combinations 
(Haemoglobin-
Haptoglobin plis 
S100A12), 
(Haemoglobin-
Haptoglobin 
plus S100A12 
plus TIMP-1) 
- - A 
threshold on 
the estimated 
posterior case 
probabilities 
was 
determined 
on the 
controls of 
the training 
set to achieve 
an 
Model not 
presented 
 
 
 
S100A12, 
TIMP-1 
 
(all considered 
predictors) 
apparent 
specificity of 
95% or 98% 
for the 
multivariable 
diagnostic 
rule. BLR then 
was applied 
to all samples 
in collective I 
to 
learn a final 
diagnostic 
rule and again 
its thresholds 
were 
determined. 
 
Table 5: Model Characteristics for the eight included studies. BLR = Bayesian logistic regression. 
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3.7 Other Performance Measures (Net Reclassification Improvement) 
 
Two studies reported classification related parameters.16 72 For Net Reclassification 
Improvement (NRI), reclassification tables are produced separately for both participants 
with events, and those without events and then the correct movement in categories is 
quantified. For example, an improvement in reclassification occurs when participants with 
the outcome are re-classified into higher risk groups (move upwards) or when a participant 
without the outcome moves into lower risk groups (downwards).81 This reclassification 
metric allows insight into the added value of predictors to a model.82 
 
The NRI for the FIT only compared to risk based FIT was 0.054 with a p value of 0.073.16 
Five more cases of advanced adenoma were detected by referring those at highest risk. For 
Kim et al.72 the p value for the NRI was 0.0001 when comparing the incremental benefit of 
calgranulin b to a model with just FIT adjusted for age, indicating a significant improvement 
in reclassification. 
 
3.8 Individualised Risk Prediction: Presentation and Application 
 
Only two studies published the overall risk equation for use in other populations.9 72 The 
model presented by Kim et al.72 was based on combining both the development and 
validation sets and would therefore need internal/external validation to assess its 
performance in another patient population. Yen et al.9 provided model equations for all 
nine models produced, including the parameterisation of the baseline hazard. The same 
weights from these models are then applied in the external validation assessment.  One 
study presents the risk model as a nomogram, which needs external validation.70 When a 
nomogram is presented it is likely to not use the full version of regression coefficients for 
probability assessment. Three studies present the odds ratios for the multivariable model 
but the intercept would be required for the full prediction model if converting odds ratios 
to weight parameters.16 71 74 
 
Auge et al.71 uses the model with FIT result, age and sex to produce probabilities for 
advanced colorectal neoplasia. The probabilities were used to delineate 16 risk categories 
and 3 risk levels arbitrarily based on corresponding PPVs. Up to 30% PPV is assigned as low 
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risk, 31-50% is assigned as average risk and over 50% is high risk. The authors suggest these 
categories could be used to prioritise individuals for colonoscopy. 
3.9 Test Accuracy  
 
Four of the studies included an assessment of the risk prediction model applied as a test 
and report the sensitivity at a set specificity or recall rate using the same level achieved by 
the FIT/FOBT.16 72 73 75 Sensitivity ranged from 21.9% to 88% for risk adjusted FIT at a range 
of set specificities from 90-97.7%. FIT only sensitivity ranged from 19.7% to 82% at 
specificities from 90-97.7%. The highest sensitivities were seen in studies combining further 
lab test results including calgranulin B, S100A12 and TIMP-1. The relative improvement in 
sensitivity from FIT only to risk-adjusted was similar for a study combining questionnaire 
data (32% to 40%, an 8% increase). Outcomes for these models were advanced adenoma,73 
advanced colorectal neoplasia,16 and colorectal cancer72 75. 
 
The sensitivity of risk-adjusted FIT (the model including FIT with other predictors) along 
with FIT only is plotted in ROC space for these 4 studies in Figure 2. Risk-adjusted FIT has a 
higher sensitivity at similar specificity for all these studies. Stegeman et al.16 set the recall 
rate the same (same specificity as FIT only) giving a risk threshold of 0.19; this is then used 
to define TPs, TNs, FPs, FNs. This is the only study which reports the 2 by 2 data required 
for assessment of test accuracy (See Forest Plot, Figure 3). 
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Figure 2: Sensitivity and Specificity plotted in ROC space for the studies which applied the risk prediction model 
as a test. These studies compare the test accuracy of the model to FIT only. Outcomes differ between the studies 
(Stegeman 2014 advanced neoplasia), (Karl 2008 colorectal cancer results using the cross-validated model at 
95% specificity), (Kim 2014 colorectal cancer results using the model combining both development and 
validation sets), (Tao 2012 advanced adenoma). 
 
Figure 3: Forest plot of sensitivity and specificity for Stegeman et al. Other studies did not report or it was not 
possible to derive 2 by 2 data.
  
Author 
Year 
Type and Brand of FIT Threshold Reference Standard 2 by 2 Sensitivity (95% CI) Specificity 
(95% CI) 
AUC ROC PPV/NPV 
Stegeman, 2014 OC Sensor 50 ng/ml 
10 µg Hb/g 
Colonoscopy FIT plus risk - 
TP (41), TN 
(950), FN 
(60), FP (61) 
 
FIT only - TP 
(36), TN 
(945), FN 
(65), FP (66) 
40% - risk based model, 32% for FIT only 93% 
specificity for 
FIT only and 
FIT plus risk. 
AUC of FIT only model - 0.69 
AUC of Risk based model - 0.76 
(AUCs significantly different 
p=0.02) 
FIT plus risk - 
40.2% (PPV); 
94.1% (NPV). 
 
FIT only -      
35.3% (PPV);               
93.6% (NPV) 
 
(calculated) 
Yen, 2014 
(Results for the model 
predicting colorectal 
neoplasia) 
OC-Sensor (Eiken) 100ng/ml 
20 µg Hb/g 
Colonoscopy following 
referral for screen detected 
cancers or linkage to the 
Cancer Registry 
- - - Development: 83.5% (95% CI: 
82.1%, 84.9%) 
 
External Validation: 86.1% 
(95% CI: 85.2%, 86.9%) 
- 
Omata, 2011 OC-Micro Instrument (Eiken 
Chemical Co., Tokyo, Japan) 
For AP: 25ng/ml 
For SN: 25ng/ml 
For CRC: 50ng/ml 
Colonoscopy and 
pathological findings of 
biopsy specimens 
No results for 
the risk 
prediction 
model 
applied as a 
test. 
- - - - 
Auge, 2014 OC-SENSOR DIANA 20 µg Hb/g Colonoscopy - - - AUC ROC 0.676 (95% CI: 0.657-
0.695) 
Risk categories 
created using 
PPV. Low risk 
(30%>), average 
risk (31-50%) and 
high risk (>50%) 
Wieten, 2016 OC-sensor Micro analyser 10 µg Hb/g Colonoscopy No results for 
the risk 
prediction 
model 
applied as a 
test. 
- - - - 
Tao, 2012 (results for 
advanced adenoma) 
RIDASCREEN Haemoglobin Sensitivities were calculated 
at cutoff points yielding the 
level of specificity observed 
for gFOBT (97.7%) (the test 
applied at the time in 
Germany) – 24 µg Hb/g 
Colonoscopy - Sensitivity 21.3% for TIMP plus FIT 
 
Sensitivity 21.9% for CRP, sCD26 and TIMP-1) plus FIT 
 
Sensitivity FIT alone 19.7% 
 
All at cutoff points yielding 97.7% specificity 
97.7% 
Specificity 
FIT plus TIMP-1 AUC = 0.710 
 
FIT plus CRP, sCD26 and TIMP-
1 
AUC = 0.729 
 
FIT only  
AUC = 0.683 
 
- 
Kim, 2014 OC Sensor kit Analytical cut off positivity = 
100ng Hb/ml 
 
20 µg Hb/g 
 
Sensitivity at a specificity 
closest to 90% 
CRC diagnosed by 
colonoscopy and 
histopathology 
- Development dataset: 
Model (age + FIT)  
-Sensitivity – 75.31% 
-Specificity – 90.2% 
Model (age + FIT + CALB) 
-Sensitivity – 83.95% 
-Specificity – 90.2% 
Development LOOCV dataset: 
Model (age + FIT)  
90% 
Specificity 
Development dataset: 
Model (age + FIT)  
AUC – 89.52 
Partial AUC – 6.65 
Model (age + FIT + CALB) 
AUC – 92.05 
Partial AUC  - 7.02 
Development LOOCV dataset: 
Model (age + FIT)  
- 
  
-Sensitivity – 75.31% 
-Specificity – 90.2% 
Model (age + FIT + CALB) 
-Sensitivity – 82.72% 
-Specificity – 90.2% 
Validation dataset: 
Model (age + FIT)  
-Sensitivity – 79.79% 
-Specificity – 90% 
Model (age + FIT + CALB) 
-Sensitivity – 79.79% 
-Specificity – 79.79% 
 
Final model presented combines both development 
set and validation set. 
Model (age + FIT)  
-Sensitivity – 77.71% 
-Specificity – 90.07% 
Model (age + FIT + CALB) 
-Sensitivity – 80.57% 
-Specificity – 90.07% 
 
AUC – 87.78 
Partial AUC – 5.62 
Model (age + FIT + CALB) 
AUC – 89.81 
Partial AUC – 5.70 
Validation dataset: 
Model (age + FIT)  
AUC – 90.65 
Partial AUC – 7.34  
Model (age + FIT + CALB) 
AUC – 92.74 
Partial AUC – 7.71 
 
Final model presented 
combines both development 
set and validation set. 
Model (age + FIT)  
AUC – 0.9017 
Partial AUC – 0.0699  
 
Model (age + FIT + CALB) 
AUC – 0.9282 
Partial AUC – 0.0748 
 
 
Karl, 2008 Hemoglobin-haptoglobin 
(RIDASCREEN Hemoglobin- 
Haptoglobin) 
A threshold on the estimated 
posterior case probabilities 
was determined on the 
controls of the training set to 
achieve an apparent 
specificity of 95% or 98% for 
the multivariable diagnostic 
rule. BLR then was applied to 
all samples in collective I to 
learn a final diagnostic rule 
and again its thresholds were 
determined. 
Study 1: Colonoscopy 
Study 2: Diagnosis of CRC 
confirmed by pathologic 
staging of each patient 
- Sensitivity at a specificity of 95% 
 
Median sensitivities from cross validation CRC 
collective I. 
 
-Hemoglobin-Haptoglobin: 82% 
-S100A12 + hemoglobin-haptoglobin: 88%  
-S100A12 + hemoglobin-haptoglobin + TIMP-1: 88% 
 
Sensitivity at a specificity of 98% 
-Hemoglobin-Haptoglobin: 73% 
-S100A12 + hemoglobin-haptoglobin: 79%  
-S100A12 + hemoglobin-haptoglobin + TIMP-1: 82% 
 
Median sensitivities from CRC collective II 
 
-Hemoglobin-Haptoglobin: 85% 
-S100A12 + hemoglobin-haptoglobin: 88%  
-S100A12 + hemoglobin-haptoglobin + TIMP-1: 88% 
 
Sensitivity at a specificity of 98% 
-Hemoglobin-Haptoglobin: 78% 
-S100A12 + hemoglobin-haptoglobin: 82%  
-S100A12 + hemoglobin-haptoglobin + TIMP-1: 86% 
 
 
Sensitivity at 
a preset 
specificity of 
95% and 98% 
investigated. 
 
0.95 for S100A12 alone to 0.96 
for marker combinations  
 
(Haemoglobin-Haptoglobin 
plus S100A12), (Haemoglobin-
Haptoglobin plus S100A12 plus 
TIMP-1) 
- 
Table 6: Test Characteristics for the eight included studies. 
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3.10 Risk of Bias 
3.10.1 PROBAST 
 
The risk of bias of the models in the included studies was assessed using an early version of 
PROBAST for both model development and model validation (Table 7). In the context of 
risk prediction models, risk of bias assesses the extent of unbiased estimates of model 
performance for intended use and target population. This tool considers the following 
domains: Study participants, predictors, outcome, sample size and missing data and 
statistical analysis. The applicability assessments are related to the first three of these 
domains.  
 
All studies had an ‘overall judgement’ rated as a ‘high risk’ of bias (Figure 4). The two 
domains with the greatest concerns included ‘statistical analysis’ where 90% of models 
(9/10) had a high risk of bias and ‘sample size and missing data’ where 60% of models 
(6/10) had a high risk of bias and the remaining 40% (4/10) had an unclear risk of bias. For 
statistical analysis of prediction models, the methods were not often adequately reported, 
there was a lack of internal validation among model development studies and there was 
rarely an adjustment for optimism. Further to this, only one study could be considered as 
using external validation to assess the model,9 and in this case it was a case-control 
validation sample which may bias model performance results. Stegeman et al.16 was 
considered the most methodologically sound study in terms of statistical analysis which 
was rated as a low risk of bias (Table 7). The model was developed using penalised 
shrinkage methods and model development was fully reported. 
 
Often due to the nature of screening studies, sample size and missing data were either at 
high risk of bias or not enough information was provided to make an assessment. Sample 
populations in screening studies also tend to have limited populations/reduced sample size 
based on screening test and reference standard uptake. Further to this, the included 
studies have the added constraint of additional predictor information to collect which may 
not always be completed by all individuals. This would be less of a problem for routine 
demographic data compared to additional lab test results. Stegeman et al.16 was the only 
study which used multiple imputation for missing predictor data, other studies just used a 
complete case analysis. 
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Half of the studies had a high concern regarding applicability (extent to which the model 
matches the review question). This was mostly down to the case-control design or enriched 
sample population.72 73 75 Karl et al.75 and Tao et al.73 used data from two different sample 
populations. The timing of predictors and outcomes differed for the two sample 
populations as well as the level of underlying risk. Omata et al.70 used a sample population 
which was 70% male and some individuals had a history of CRN putting them at higher risk.  
 
 
 
  
Study 
RISK OF BIAS APPLICABILITY CONCERNS USABILITY 
STUDY 
PARTICIPANTS 
PREDICTORS OUTCOME 
SAMPLE 
SIZE & 
MISSING 
DATA 
STATISTICAL 
ANALYSIS 
OVERALL 
JUDGEMENT 
OF BIAS 
STUDY 
PARTICIPANTS 
PREDICTORS OUTCOME 
OVERALL 
JUDGEMENT 
OF 
APPLICABILITY 
USABILITY 
OF THE 
MODEL 
 
Stegeman, 2014 
          
N 
 
Yen, 2014 (Development) 
          
N 
 
Yen, 2014 (Validation) 
          
N 
Omata, 2011 
          
N 
Auge, 2014 
          
N 
Wieten, 2016 
          
N 
Tao, 2012 
          
N 
Kim, 2014 (Development) 
          
N 
Kim, 2014 (Validation) 
          
N 
Karl, 2008 
          
N 
              
           
                                                                                           Low Risk      High Risk    Unclear Risk 
 
Table 7: Tabular display of PROBAST assessments for the eight included studies. 
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Figure 4: Graphical summary of PROBAST assessments for all included studies. Top – displays the proportion of 
studies with low, high or unclear Risk of Bias, Bottom – displays the proportion of studies with low, high or 
unclear concerns regarding applicability 
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3.10.2 QUADAS-2 
 
Four of the studies also assessed the diagnostic accuracy of the model and reported test 
accuracy measures of sensitivity, specificity as well as the AUC ROC (interchangeable with 
model performance). A tailored QUADAS-2 assessment was carried out for this purpose 
and is summarized in Table 8. 
 
‘Flow and timing’ and ‘patient selection’ was rated as high risk of bias for 3 out of the 4 
studies for similar reasons identified by PROBAST (Figure 5). These reasons included the 
nature of screening studies in relation to uptake of the screening test and reference 
standard, case control study designs or enriched sample populations. The index test was 
also rated as high risk of bias for half the studies (when applying the model as the test). 
This was due to the timing of predictor collection for some participants being after 
colonoscopy for stool samples.73 75 With regard to applicability there are again similar 
issues with patient selection as identified by PROBAST along with the timing of predictor 
collection for the index tests. The review question is assessing studies where the FIT and 
predictor information are assessed before colonoscopy. 
 
Study 
RISK OF BIAS APPLICABILITY CONCERNS 
PATIENT 
SELECTION 
INDEX 
TEST 
REFERENCE 
STANDARD 
FLOW 
AND 
TIMING 
PATIENT 
SELECTION 
INDEX 
TEST 
REFERENCE 
STANDARD 
Stegeman, 
2014        
Tao, 2012   ?     
Kim, 2014    ?         
Karl, 2008        
 
 
      
   Low Risk High Risk    ?  Unclear Risk  
Table 8: Tabular display of QUADAS-2 Assessments for the 4 studies including a test accuracy component 
Finally, the role of the sponsor for Karl et al.75 could also be considered at high risk of bias 
since the study aims to identify new screening markers and combinations to determine if 
sensitivity can be improved and all authors are employees of Roche Diagnostics GmbH who 
funded the study. This could bias test accuracy measures by assessing a cutpoint which 
provides good performance.  
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Figure 5: Graphical summary of QUADAS-2 assessments for the 4 studies including a test accuracy component. 
Top – displays the proportion of studies with low, high or unclear Risk of Bias, Bottom – displays the proportion 
of studies with low, high or unclear concerns regarding applicability.  
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4.0 DISCUSSION 
4.1 Statement of principal findings 
 
In this systematic review of risk prediction models which combine the FIT result for 
colorectal cancer screening referral decisions, eight full text studies were identified which 
develop independent risk prediction models. Predictors used in the models included 
demographic characteristics, biomarkers and lab results as well as additional information 
obtained from questionnaires. The most consistently used predictors across the models 
were sex and age, possibly due to their availability and known association with colorectal 
cancer.  
 
A meta-analysis of risk prediction model performance and test accuracy was not possible 
due to the underlying heterogeneity between studies and so a narrative synthesis was 
performed using summary of results tables. Discrimination assessed as the AUC ROC 
ranged from 0.676-0.960 for risk adjusted FIT (reported in 6/8 studies) and 0.683-0.902 for 
FIT only (reported in 4/8 studies). Lab results and biomarkers tended to give higher 
discrimination values but a significant improvement was also seen when using simple 
routinely available predictors such as age and sex. High performing models also included 
lifestyle information such as smoking and alcohol consumption as well as family history of 
cancer. Lab test results associated with greater model performance included TIMP-1, CEA, 
sCD26 and calgranulin B. Further evidence is required to confirm which biomarkers and 
other predictors should be included in a risk based screening model for FIT. 
 
Calibration using the Hosmer-Lemeshow statistic ranged from 0.276-0.940 for risk-adjusted 
FIT (reported in 3/8 studies) and calibration plots were presented in just one study. The 
highest calibration was reported by Stegeman et al. This may be a reflection of the more 
rigorous model development procedure used by this study to generate more accurate 
predictions/results. 
 
Where test accuracy measures were included (4/8 studies) sensitivity ranged from 21.9% to 
88% for risk adjusted FIT at a range of set specificities from 90-97.7%. FIT-only sensitivity 
ranged from 19.7% to 82% at the same specificities stated previously. The highest 
sensitivities were seen in studies combining further laboratory test results including 
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calgranulin B, S100A12 and TIMP-1. The relative improvement in sensitivity from FIT only to 
risk-adjusted was just as much for a study combining questionnaire data (32% to 40%, an 
8% increase). Studies focusing more on test accuracy metrics often showed higher 
sensitivity for FIT only (and risk-adjusted) due to study design and quality. Studies which 
had a test accuracy focus as well as a model development focus tended to use all available 
predictors or test the incremental benefit of including an additional parameter. The model 
was seen as a method of combining several biomarkers or an additional lab result for an 
overall test result. 
 
Most studies used standard statistical methodologies to build the risk prediction model; 
5/8 studies used logistic regression, two further studies used a modified version of logistic 
regression and 1/8 used accelerated failure time models (survival analysis). Half of the 
studies considered some form of internal validation. Model building strategies were not 
always described in enough detail to allow replication of the methods. 
 
Risk prediction models were either presented as the full equation, a Nomogram or by 
creating risk categories. Two of the 8 studies present the full risk equation, although for 
one of these studies this would need subsequent internal and external validation. The risk-
based categories produced by one of the studies was based on the probabilities from the 
logistic regression equation and then the subsequent PPV to assign three risk categories. 
Many of the studies just present the odds ratios only with no intercept or baseline hazard 
parameterization. 
 
Domains marked consistently at a high risk of bias using PROBAST included ‘statistical 
analysis’ where 90% of studies had a high risk of bias and ‘sample size and missing data’ 
where 60% of studies had a high risk of bias. For statistical analysis of prediction models, 
the methods were not often adequately reported, there was a lack of internal validation 
among model development studies and there was rarely an adjustment for optimism. 
Statistical methodology was rated as low risk of bias for just one of the studies.16 Half of the 
studies had a high concern regarding applicability. This was usually down to the case-
control design or enriched sample populations. 
 
For studies which had a test accuracy component, the QUADAS-2 tool further identified the 
‘index test’ domain as being at high risk of bias for three out of the four studies. This was 
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due to the timing of predictor collection for some participants being after colonoscopy for 
stool samples.  
 
4.2 Strengths and weaknesses of the study 
 
This systematic review summarises all the available evidence of risk prediction models 
which combine the FIT result for colorectal cancer screening referral decisions. Searches 
included grey literature as well as ongoing study searches to capture all available evidence. 
In addition, the review uses recently developed and published tools for risk prediction 
models: CHARMS, TRIPOD and a piloted early version of PROBAST.27 61 
 
A limitation of the review is that a quantitative synthesis could not be performed due to 
the underlying heterogeneity. However, the review finds some evidence for improved 
model performance and test accuracy using a risk-adjusted approach. Further to this, case 
control/enriched sample studies are included in this review which can inflate test accuracy 
and bias model performance. Useful information however can be obtained from these 
studies regarding potential predictors, how the models are presented for application and 
statistical modelling procedures. 
 
Sample populations in screening studies also tend to have limited populations/reduced 
sample size based on screening test and reference standard uptake. Included studies have 
the added constraint of additional predictor information to collect which may not always 
be completed by all individuals. The applicability of the models therefore needs to be 
inspected for use in an average risk screening population, if the study for instance only 
includes responders to screening and those with a positive FIT. The use of these models 
however could be as a further triage if an individual has a positive FIT to decide on 
colonoscopy resource use.  
 
Studies reporting test accuracy parameters had more of a diagnostic accuracy focus over 
model performance and therefore did not focus fully on model development reporting and 
often did not fully report the methods used to combine FIT with other biomarkers.  
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4.3 Strengths and weaknesses in relation to other studies 
 
The conclusions relating to reporting and issues in statistical methodology are similar in this 
review compared to those found in other recent risk prediction reviews.83 84 Improved 
reporting of risk prediction studies is likely to correlate with the publication of risk 
prediction model guidelines such as TRIPOD (published in 2015).61 A systematic review 
which synthesized models which predict future risk of colorectal cancer identified a 
discrimination range of between 0.71 to 0.78 compared to the wider range reported by this 
review of between 0.676 to 0.960. This is likely due to the differences in outcome 
definitions, statistical methodologies and since this included apparent performance as well 
as cross validated and external performance. 
 
This review did not include all possible methods of combining FIT with other risk predictors, 
the focus was on risk prediction models. The FIT can be combined sequentially, at different 
time points and in different populations (negative versus positive test results only) or the 
predicted risk considered for surveillance strategies. A model for predicting advanced 
colorectal neoplasia in FIT negative people only was recently developed with an intended 
use of prioritising patients for colonoscopy.85 For example, some studies considered using a 
scoring system as a triage (The Asia-Pacific Colorectal Screening score) and then applying 
the FIT separately.86 87 The current review however focused on risk prediction models which 
combined all the information within one model/package. The timing of the risk prediction 
model would be around the time of the FIT to determine participants who are at highest 
risk of colorectal cancer for colonoscopy referral. 
 
Furthermore, other studies which use risk prediction models focus on symptomatic 
populations only and these types of studies were excluded from this review.88 The NHS 
Bowel Cancer Screening Programme treats symptomatic and screening participants 
separately using different computer systems and referral criteria which is why these 
models were not included in this review. In addition, risk prediction models for CRC in 
symptomatic patients has been considered in a recently published systematic review.40 
 
There are many risk prediction models which consider routine predictors only and do not 
combine the FIT result.20 21 89 These were not included as this research investigated the 
added value of modifying the screening test with further factors in more of a personalised 
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screening approach. These models also tend to have lower discrimination on their own 
when not including the FIT. 
 
4.4 Practical Implications 
 
From the studies included in this review there is some evidence to suggest risk adjusted FIT 
performs better than FIT only. Both demographic characteristics as well as lab test results 
showed an improved performance in discrimination and test accuracy parameters. 
Demographic characteristics such as age, sex and other socioeconomic data such as IMD 
and BMI are likely to be readily available on GP records or screening systems requiring no 
additional data collection. Lab tests although they improve sensitivity are subject to 
additional issues such as cost as well as uptake/completion by the target population. If 
blood tests are taken for general health checkups then this sort of lab data could be used 
as another source of predictor information. Ideally this would be made available in 
electronic health records. 
 
Based on PROBAST assessment, none of the models were considered as usable in the 
target population and screening context. This was mainly due to a lack of external 
validation and lack of reporting the final model and statistical methodology. Yen et al.9 was 
the only model which used external validation but this study used a case control participant 
selection strategy for this purpose. 
 
Application of models could be at the screening programme level and use in-built risk 
calculators within the screening systems to decide on whether someone is risk positive. 
Furthermore, risk information can be presented to potentially help informed decision 
making and increase uptake of the reference standard as well as the screening test.90 91 If 
an individual has a lack of perceived risk this can affect uptake. 
 
4.5 Future research 
 
Predictors which were most commonly included in the final models included demographic 
characteristics age and sex and so these predictors should be considered for inclusion in 
future model development studies. Routinely available predictors are available from most 
   
 
 
66 
 
Chapter 2 Chapter two | Systematic Review 
screening programme IT systems such as the BCSS in the NHS. These factors could be 
investigated without requiring additional data collection in a model development study.  
 
With the recent publication of the TRIPOD guidelines, future risk prediction modelling 
studies should consider these criteria when developing a new model and for reporting. This 
will help to improve the quality of the study, provide reproducibility of the model 
development process and allow the model to be validated externally or applied in an 
impact study. 
 
Experts identified two studies which use machine learning approaches including decision 
trees with cross validation techniques.68 69 This model included the guaiac FOBT and various 
lab parameters and showed that in comparison to gFOBT alone the number of CRC cases 
increased from 170 to 365 (AUC of 0.82) demonstrating that such an approach could 
improve the performance of other screening tests. In addition, the model can detect CRC 
throughout the colon, which is a feature the authors argue could complement screening 
tests such as the FOBT which show less sensitivity for right hand sided CRC compared to 
left sided.69 92 No studies identified in this review applied machine learning approaches to 
model development. This approach warrants further investigation and comparison to more 
conventional methods such as logistic regression. 
 
The studies which applied the model as a test to estimate diagnostic accuracy parameters 
in future studies should consider the patient flow and timing of the prediction model 
application. This can be achieved by avoiding a case-control study design which has been 
shown to bias test accuracy measures. Prospective study designs where all eligible patients 
are subjected to the index test (in this case the risk prediction model) as well as the 
reference standard compared to the FIT used on its own (as a comparator of standard 
care). This will determine the added benefit of using a risk adjusted approach to screening.  
5.0 CONCLUSIONS AND RECOMMENDATIONS 
Although it could not be formally tested in a meta-analysis due to the underlying 
heterogeneity in studies (outcomes, statistical methodology, populations, FITs and 
reported outcomes), there is some evidence to suggest that including additional factors 
with the FIT result can improve model performance and test accuracy for those studies 
using FIT only as a comparator to risk adjusted FIT. Improvement is seen in studies using 
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both lab based predictors as well as those including routine demographic data or richer 
questionnaire data. The latter predictors require no additional expensive lab based testing. 
Due to the limited number of studies, further evidence would be required to validate this 
improvement.  
 
The majority of models which were identified in this review have several limitations in 
terms of statistical methodology for model development or with the sample 
size/population used for analysis. None of the models were considered currently usable in 
the target population in a screening based context. With the recent publication of the 
TRIPOD guidelines, future risk prediction modelling studies should consider these criteria 
when developing a new model and reporting the study in order to improve the quality of 
the study, provide reproducibility of the model development process and so the model can 
be validated externally or applied in an impact study. The model equation needs to be 
provided for this purpose including the intercept or a parameterisation of the baseline 
hazard if applying a survival analysis model.   
 
Future research should focus on considering routine data which does not require additional 
data collection and is more likely to be complete to determine whether these predictors 
improve model performance and test accuracy. In addition, age and sex were factors 
consistently included in the final models and these should be considered in future model 
development studies along with consistent predictors identified in systematic reviews of 
risk prediction models which do not include the FIT. Machine learning methods have been 
used for similar studies and this could be a potential avenue to explore alongside more 
traditional statistical methods. 
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7.0 APPENDICES  
Appendix 1: Search Strategies 
 
A.1.1 Medline (Ovid) Search Strategy 24/02/2016 
 
# Searches Results 
1 Validat$.mp. or Predict$.ti. or Rule$.mp. or (Predict$ and (Outcome$ or Risk$ or Model$)).mp. 
or ((History or Variable$ or Criteria or Scor$ or Characteristic$ or Finding$ or Factor$) and 
(Predict$ or Model$ or Decision$ or Identif$ or Prognos$)).mp. or (Decision$.mp. and ((Model$ 
or Clinical$).mp. or exp Logistic Models/)) or (Prognostic and (History or Variable$ or Criteria or 
Scor$ or Characteristic$ or Finding$ or Factor$ or Model$)).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
3,006,838 
2 "Stratification".mp. or exp "ROC Curve"/ or "Discrimination".mp. or "Discriminate".mp. or "c-
statistic".mp. or "c statistic".mp. or "Area under the curve".mp. or "AUC".mp. or 
"Calibration".mp. or "Indices".mp. or "Algorithm".mp. or "Multivariable".mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
527240 
3 exp "Sensitivity and Specificity"/ or exp "Predictive Value of Tests"/ or sensitiv$.ti,ab. or 
specifici$.ti,ab. or accurac$.ti,ab. or "detection rate$".ti,ab. or "likelihood ratio$".ti,ab. or "false 
positive$".ti,ab. or "false negative$".ti,ab. or "predictive value$".ti,ab. 
1641487 
4 1 or 2 or 3 4382693 
5 exp Colorectal Neoplasms/ 161083 
6 CRC.ti,ab. 13466 
7 ((cancer$ or neoplas$ or tumor$ or tumour$ or adenoma$ or adeno?carcinom$ or 
adenocarcinoma$ or polyp$) adj3 (colorectal$ or colon or rectal or rectum or bowel)).ti,ab. 
128146 
8 
exp "Adenomatous Polyps"/ 
6999 
9 "advanced adenoma".ti,ab. 321 
10 
5 or 6 or 7 or 8 or 9 
189583 
11 exp Occult Blood/ or exp Immunochemistry/ or ("fecal immunochemical" or "faecal 
immunochemical" or "fecal occult blood" or "faecal occult blood" or "FIT" or fobt$ or fob$ or 
ifobt or qnFIT or qlFIT or QTFIT or immunochemi$).ti,ab. or "OC-Micro".mp. or "OC Micro".mp. 
or "OC-Sensor".mp. or "OC Sensor".mp. or "OC-Hemodia".mp. or "OC Hemodia".mp. or "OC-
363615 
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Light".mp. or "OC Light".mp. or HemeSelect.mp. or FlexSure.mp. or MagStream.mp. or "Instant-
view".mp. or "Instant View".mp. or Hemoccult.mp. or Immocare.mp. or Monohaem.mp. or 
Hemosure.mp. or Ocultech.mp. or Quickvue.mp. or Clearview.mp. or Hemoquant.mp. or "Hema 
screen".mp. or "Hema-screen".mp. or Innovacon.mp. or Aimstep.mp. or Magstream.mp. or 
Immudia.mp. 
12 exp Early Detection of Cancer/ or exp mass screening/ or exp population surveillance/ or 
screen$.ti,ab. or (early adj3 detect$).ti,ab. or test$.ti,ab. 
2626867 
13 4 and 10 and 11 and 12 3037 
14 limit 12 to (humans and yr="1978 -Current") 3009 
 
A.1.2 Embase classic + Embase search strategy 24/02/2016 via OVID 
 
# Searches Results 
1 predict$.ti,ab. or validat$.ti,ab. or index.ti,ab. or model.ti,ab. or scor$.ti,ab. or exp "statistical 
model"/ 
4,415,041 
2 "Stratification".mp. or exp "receiver operating characteristic"/ or "Discrimination".mp. or 
"Discriminate".mp. or "c-statistic".mp. or "c statistic".mp. or "Area under the curve".mp. or 
"AUC".mp. or "Calibration".mp. or "Indices".mp. or "Algorithm".mp. or "Multivariable".mp. 
937201 
3 exp "sensitivity and specificity"/ or exp "predictive value"/ or sensitiv$.ti,ab. or specifici$.ti,ab. 
or accurac$.ti,ab. or "detection rate$".ti,ab. or "likelihood ratio$".ti,ab. or "false positive$".ti,ab. 
or "false negative$".ti,ab. or "predictive value$".ti,ab. 
2062939 
4 1 or 2 or 3 6259870 
5 exp colorectal tumour/ or exp colorectal cancer/ or exp colorectal adenoma/ or exp colorectal 
carcinoma/ 
132960 
6 CRC.ti,ab. 26574 
7 ((cancer$ or neoplas$ or tumor$ or tumour$ or adenoma$ or adeno?carcinom$ or 
adenocarcinoma$ or polyp$) adj3 (colorectal$ or colon or rectal or rectum or bowel)).ti,ab. 
200970 
8 exp "adenomatous polyp"/ 7975 
9 "advanced adenoma".ti,ab. 837 
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10 5 or 6 or 7 or 8 or 9 243748 
11 exp occult blood test/ or exp immunochemistry/ or ("fecal immunochemical" or "faecal 
immunochemical" or "fecal occult blood" or "faecal occult blood" or "FIT" or fobt$ or fob$ or 
ifobt or qnFIT or qlFIT or QTFIT or immunochemi$).ti,ab. or "OC-Micro".mp. or "OC Micro".mp. 
or "OC-Sensor".mp. or "OC Sensor".mp. or "OC-Hemodia".mp. or "OC Hemodia".mp. or "OC-
Light".mp. or "OC Light".mp. or HemeSelect.mp. or FlexSure.mp. or MagStream.mp. or "Instant-
view".mp. or "Instant View".mp. or Hemoccult.mp. or Immocare.mp. or Monohaem.mp. or 
Hemosure.mp. or Ocultech.mp. or Quickvue.mp. or Clearview.mp. or Hemoquant.mp. or "Hema 
screen".mp. or "Hema-screen".mp. or Innovacon.mp. or Aimstep.mp. or Magstream.mp. or 
Immudia.mp. 
822038 
12 exp screening/ or exp screening test/ or exp mass screening/ or exp population surveillance/ or 
screen$.ti,ab. or (early adj3 detect$).ti,ab. or test$.ti,ab. 
4212903 
13 4 and 10 and 11 and 12 3725 
14 limit 12 to (humans and yr="1978 -Current") 3272 
 
A.1.3 Cochrane Wiley Search 01/03/2016 
# Searches Results 
1 
predict*:ti,ab or validat*:ti,ab or index:ti,ab or model:ti,ab or scor*:ti,ab  212929 
2 
MeSH descriptor: [Models, Statistical] explode all trees 15259 
3 MeSH descriptor: [Risk Assessment] explode all trees 8672 
4 stratification or discrimination or discriminate or "c-statistic" or "c statistic" or "area under the 
curve" or "AUC" or calibration or indices or algorithm or multivariable  42164 
5 MeSH descriptor: [ROC Curve] explode all trees 1288 
6 sensitiv*:ti,ab or specifici*:ti,ab or accurac*:ti,ab or "detection rate*":ti,ab or "likelihood 
ratio*":ti,ab or "false positive*":ti,ab or "false negative*":ti,ab or "predictive value*":ti,ab  48337 
7 MeSH descriptor: [Sensitivity and Specificity] explode all trees 17833 
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8 
MeSH descriptor: [Predictive Value of Tests] explode all trees 7035 
9 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)  282324 
10 
MeSH descriptor: [Colorectal Neoplasms] explode all trees 6053 
11 CRC  1334 
12 ((cancer* or neoplasm* or tumor* or tumour* or adenoma* or adeno?carcinom* or 
adenocarcinoma* or polyp*) near/3 (colorectal* or colon or rectal or rectum or bowel))  11210 
13 MeSH descriptor: [Adenomatous Polyps] explode all trees 175 
14 advanced adenoma  69 
15 (#10 or #11 or #12 or #13 or #14)  11865 
16 MeSH descriptor: [Occult Blood] explode all trees 480 
17 MeSH descriptor: [Immunochemistry] explode all trees 1282 
18 fecal immunochemical:ti,ab or "faecal immunochemical":ti,ab or "fecal occult blood":ti,ab or 
"faecal occult blood":ti,ab or "FIT":ti,ab or fobt*:ti,ab or fob*:ti,ab or ifobt:ti,ab or qnFIT:ti,ab or 
qlFIT:ti,ab or QTFIT:ti,ab or immunochemi*:ti,ab  3807 
19 OC-Micro or "OC Micro" or "OC-Sensor" or "OC Sensor" or "OC-Hemodia" or "OC Hemodia" or 
"OC-Light" or "OC Light" or HemeSelect or FlexSure or MagStream or "Instant-view" or "Instant 
View" or Hemoccult or Immocare or Monohaem or Hemosure or Ocultech or Quickvue or 
Clearview or Hemoquant or "Hema screen" or "Hema-screen" or Innovacon or Aimstep or 
Magstream or Immudia  151 
20 (#16 or #17 or #18 or #19)  5295 
21 MeSH descriptor: [Mass Screening] explode all trees 5443 
22 MeSH descriptor: [Early Detection of Cancer] explode all trees 814 
23 MeSH descriptor: [Population Surveillance] explode all trees 709 
24 screen*:ti,ab or (early near/3 detect*):ti,ab or test*:ti,ab  178913 
25 (#21 or #22 or #23 or #24)  180201 
26 (#9 and #15 and #20 and #25)  321 
27 (#9 and #15 and #20 and #25) * Publication Year from 1978 to 2016 321 
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A.1.4 Web of Science Core Collection minus Arts and Humanities 01/03/2016 
# Searches Results 
1 (TS=(predict* OR validat* OR index OR scor* OR (model* SAME statistical) OR (model* SAME 
(predict* OR decision*)) OR "risk assessment" OR stratification OR discrimination OR 
discriminate OR "c-statistic" OR "c statistic" OR "area under the curve" OR "AUC" OR calibration 
OR indices OR algorithm OR multivariable OR "ROC curve" OR "receiver operating 
characteristic")) 5,888,571 
 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=1978-2016 
 
2 (TS=(sensitiv* OR specifici* OR accurac* OR "detection rate*" OR "likelihood ratio*" OR "false 
positive*" OR "false negative*" OR "predictive value*")) AND LANGUAGE: (English) 2,519,996 
 Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=1978-2016  
3 #2 OR #1 7,578,356 
 Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=1978-2016  
4 (TS=((cancer* OR neoplasm* OR tumor* OR tumour* OR adenoma* OR adeno?carcinom* OR 
adenocarcinoma* OR polyp*) NEAR/3 (colorectal* OR colon OR rectal OR rectum OR bowel))) 
AND LANGUAGE: (English) 207,090 
 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=1978-2016 
 
5 (TS=("advanced adenoma" OR "adenomatous polyps" OR CRC)) 20,473 
 
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=1978-2016 
 
6 #5 OR #4 211,507 
 Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=1978-2016  
7 (TS=("occult blood test" OR immunochemistry OR "fecal immunochemical" OR "faecal 
immunochemical" OR "fecal occult blood" OR "faecal occult blood" OR "FIT" OR fobt* OR fob* 
OR ifobt OR qnFIT OR qlFIT OR QTFIT OR immunochemi* OR "OC-Micro" OR "OC Micro" OR "OC-
Sensor" OR "OC Sensor" OR "OC-Hemodia" OR "OC Hemodia" OR "OC-Light" OR "OC Light" OR 
HemeSelect OR FlexSure OR MagStream OR "Instant-view" OR "Instant View" OR Hemoccult OR 248,953 
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Immocare OR Monohaem OR Hemosure OR Ocultech OR Quickvue OR Clearview OR Hemoquant 
OR "Hema screen" OR "Hema-screen" OR Innovacon OR Aimstep OR Magstream OR Immudia)) 
AND LANGUAGE: (English) 
 Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=1978-2016  
8 (TS=(screen* or (early NEAR/3 detect*) or test* or surveillance)) AND LANGUAGE: (English) 4,369,037 
 Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=1978-2016  
9 #8 AND #7 AND #6 AND #3 1,978 
 Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH, ESCI Timespan=1978-2016  
 
 
Appendix 2: Data Extraction Form based on the CHARMS Checklist. 
 
Domain Key items to extract 
1. Study Characteristics/Design - Author 
- Year 
- Describe the study design, whether cohort, case control, diagnostic 
accuracy study etc 
- Country 
- Setting 
2. Source of Data - Source of data (e.g. cohort, case-control, randomized trial participants, or 
registry data) 
3. Participants - Participant eligibility and recruitment method (e.g. consecutive 
participants, location, number of centres, setting, inclusion and exclusion 
criteria) 
- Participant description (e.g. females aged between 60-74 participating in a 
screening programme) 
- Study dates 
- Mean/median age and ethnicity 
4. Outcomes to be predicted - Definition and method for measurement of outcome 
- Was the same outcome definition (and method for measurement) used in 
all patients? 
- Type of outcome (single or combined endpoints) 
- Was the outcome assessed without knowledge of the candidate predictors 
(i.e. blinded)? 
- Were candidate predictors part of the outcome (e.g. in panel or consensus 
diagnosis)? 
- Diagnosis at colonoscopy or follow up? 
- Cancer detection rate if applicable 
5. Candidate predictors/risk factors (or 
index tests) 
- Number and type of predictors (e.g. demographics, patient history, 
physical examination, additional testing, disease characteristics) 
- Definition and method for measurement of candidate predictors 
- Timing of predictor measurement (e.g. at patient presentation, at 
diagnosis, at treatment initiation) 
- Were predictors assessed blinded for outcome, and for each other (if 
relevant)? 
- Handling of predictors in the modeling (e.g. continuous, linear, non-linear 
transformations or categorized) 
-Corresponding adjusted and unadjusted odd ratios etc with measures of 
uncertainty (95% confidence interval and P values)  
6. Sample Size - Number of participants and number of outcomes/events 
- Number of outcomes/events in relation to the number of candidate 
predictors (events per variable) 
7. Missing data - Number of participants with any missing value (include predictor and 
outcomes) 
- Number of predictors with missing data for each predictor 
- Handling of missing data (e.g. complete case analysis, imputation or other 
methods) 
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8. Model Development - Modelling method (e.g. logistic, survival, neural networks or machine 
learning techniques) 
- Modelling assumptions satisfied 
- Method for selection of predictors for inclusion in multivariable modeling 
(e.g. all candidate predictors, pre-selection based on unadjusted association 
with the outcome) 
- Method for selection of predictors during multivariable modeling (e.g. full 
model approach, backward or forward selection) and criteria used (e.g. p-
value, Akaike Information Criterion) 
- Shrinkage of predictor weights or regression coefficients (e.g. no 
shrinkage, uniform shrinkage, penalized estimation) 
- The corresponding relative risks, odds ratios or hazard ratios (adjusted and 
unadjusted) with estimates of uncertainty for the predictors included (95% 
confidence intervals/P values) 
9. Model Performance - Calibration (calibration plot, calibration slope, Hosmer-Lemeshow test) 
and Discrimination (C-statistic, D-statistic, log-rank) measures with 
confidence intervals. 
- Classification measures (e.g. sensitivity, specificity, predictive values, net 
reclassification improvement, integrated discrimination improvement) and 
whether a priori cut points were used 
10. Model Evaluation  - Method used for testing model performance: development dataset only 
(random split of data, resampling methods, e.g. bootstrap or cross-
validation, none) or separate external validation (e.g. temporal, 
geographical, different setting, different investigators) 
- In case of poor validation, whether model was adjusted or updated (e.g. 
intercept recalibrated, predictor effects adjusted, or new predictors added) 
11. Risk Stratification - How is risk stratification combined with the FIT? 
What method has been used to combine risk stratification with the FIT? 
(E.g. Modellling: unvariable analysis, multivariable analysis (including 
logistic regression and time-to-event analysis), nomograms, artificial neural 
networks, decision trees) 
Or another method? 
 
- How is risk assessed? 
Is risk assessed using a score, using risk tiers/categories, as a probability 
etc? 
 
- When is risk assessment carried out?  
Before/after the index and reference tests? (recall bias) 
 
12. Diagnostic Accuracy Considerations -Target disease definition 
-Type and brand of FIT (qualitative FIT or quantitative FIT, OC-Sensor, OC-
Micro etc) 
-Reference Standard and rationale (e.g. Colonoscopy or follow up?) 
- Number of FIT samples 
-Prevalence of Colorectal cancer or advanced adenomas in the study 
- Number of participants enrolled for the study 
- Number of participants for whom results are available 
- Methods and timing of index test  
- Methods and timing of reference standard 
13. Test accuracy - 2 x 2 data 
-Sensitivity 
-Specificity 
-AUC ROC  
-Cutpoint and reason for cutpoint 
-(if presented) True positives, false positives, true negatives and false 
negatives 
-Positive and negative predictive values 
-Positive and negative diagnostic likelihood ratios 
-The CRC and advanced adenoma detection rate (representing the benefits 
of screening) 
-(If included) NNTScope (representing the harms of screening) 
-Number of missing, indeterminate, intermediate and uninterpretable test 
results. 
14. Results - Final and other multivariable models (e.g. basic, extended, simplified) 
presented, including predictor weights or regression coefficients, intercept, 
baseline survival, model performance measures (with standard errors or 
confidence intervals) 
- Any alternative presentation of the final prediction models e.g. sum score, 
nomogram, score chart, predictions for specific risk subgroups with 
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performance 
- Comparison of the distribution of predictors (including missing data) for 
development and validation datasets 
15. Interpretation and Discussion - Interpretation of presented models (confirmatory, i.e. model useful for 
practice versus exploratory i.e. more research needed) 
- The clinical applicability of study findings 
- Comparison with other studies, discussion of generalizability, strengths 
and limitations 
 
Appendix 3: Exclusion of Studies 
 
# Full Text 
 Article Reason for Exclusion 
1 Aniwan, S., et al. (2015). "A combination of 
clinical risk stratification and fecal 
immunochemical test results to prioritize 
colonoscopy screening in asymptomatic 
participants." Gastrointestinal endoscopy 81(3): 
719-727. 
Model 
The study just looks at prevalence (and sensitivity/specificity) 
in 4 different groups based on the combination of the FIT 
result and APCS score. They are not combining this 
information in a risk prediction model for individualised risk 
prediction. 
2 Cai, S. R., et al. (2011). "Performance of a 
colorectal cancer screening protocol in an 
economically and medically underserved 
population." Cancer Prevention Research 4(10): 
1572-1579. 
Model 
Does not combine the questionnaire and FIT into a prediction 
model for individualised predictions. 
3 Calistri, D., et al. (2010). "Fecal DNA for 
noninvasive diagnosis of colorectal cancer in 
immunochemical fecal occult blood test-positive 
individuals." Cancer Epidemiology, Biomarkers & 
Prevention 19(10): 2647-2654. 
Model 
Discussed with 3rd reviewer (NP) - the model underlying the 
nomogram is unclear. It is not strictly a model development 
study.  
 
Model performance parameters not reported. 
4 Cha, J. M., et al. (2012). "First-degree relatives of 
colorectal cancer patients are likely to show 
advanced colorectal neoplasia despite a negative 
fecal immunochemical test." Digestion 86(4): 
283-287. 
Model 
FIT result is not included as dependent variable in the logistic 
regression. 
The outcome is defined as 'colorectal cancer despite a 
negative FIT result'. 
5 Chang, L. C., et al. (2014) Metabolic syndrome 
and smoking may justify earlier colorectal cancer 
screening in men. Gastrointestinal endoscopy 
79, 961-969 DOI: 10.1016/j.gie.2013.11.035 
Model 
 
Model does not give individual risk, no details about 
probability, just looks at adjusted odds ratios. 
 
Exclude based on population and performance measures. 
6 Chen, H. S. and S. M. Sheen-Chen (2002). 
"Influence of age and gender on surveillance for 
colorectal tumors in low-risk asymptomatic 
population." Anticancer Research 22(1A): 399-
403. 
Model 
Not a risk prediction model development study 
FOBT is probably guaiac 
7 Chen, L. S., et al. (2011). "Baseline faecal occult 
blood concentration as a predictor of incident 
colorectal neoplasia: longitudinal follow-up of a 
Taiwanese population-based colorectal cancer 
screening cohort." Lancet Oncology 12(6): 551-
558. 
Model 
Not producing individualised risk just looking at associations 
in a multivariable model. 
Timing considered in the model does not match review 
question. 
8 Chiang, T. H., et al. (2014). "Difference in 
performance of fecal immunochemical tests 
with the same hemoglobin cutoff concentration 
in a nationwide colorectal cancer screening 
program." Gastroenterology 147(6): 1317-1326. 
Model 
Compares the outcomes between two different types of FIT. 
Looking at the difference in performance between two FITs 
'Adjusting for' other factors 
Not an individualised risk prediction model 
9 Garcia, M., et al. (2015). "Fecal hemoglobin 
concentration as a measure of risk to tailor 
colorectal cancer screening: are we there yet?" 
European Journal of Cancer Prevention 24(4): 
321-327. 
Model 
Logistic regression model just looked at associations not 
individualised risk 
10 Imperiale, T. F., et al. (2014). "Multitarget stool 
DNA testing for colorectal-cancer screening." N 
Engl J Med 370(14): 1287-1297. 
Model (creating a panel test) 
The algorithm used for this study consists of three parts to 
obtain an overall score; a logistic score which combines all of 
the DNA and Hb results, a Sum of Scores which incorporates 
the Logistic Score and individual marker scores and a 
Composite score (Sum of Scores is subjected to an 
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exponential equation). The multi-target stool DNA test 
provides a dichotomous positive or negative result. No other 
information is provided.  
 
The logistic score is not used as the final risk prediction 
model, the result of this is used to calculate a Sum of Scores 
then a Composite Score – and this Composite Score is then 
designated positive/negative. 
 
In addition, the hemoglobin component of the multi-target 
sDNA Test is not a commercially available FIT. 
 
The main aim of the study is to determine the performance 
characteristics of the DNA test in the detection of CRC. 
11 KIM, N. H., KWON, M. J., KIM, H. Y., LEE, T., 
JEONG, S. H., PARK, D. I., CHOI, K. & JUNG, Y. S. 
2016. Fecal hemoglobin concentration is useful 
for risk stratification of advanced colorectal 
neoplasia. Dig Liver Dis, 48, 667-72. 
Model 
Model investigates risk in terms of odds ratios but not 
individualised risk. This needs to go one step further as it is 
not a risk prediction model. 
12 Lidgard, G. P., et al. (2013). "Clinical 
performance of an automated stool DNA assay 
for detection of colorectal neoplasia." Clin 
Gastroenterol Hepatol 11(10): 1313-1318. 
Model 
The aim of the study is to optimise an automated sDNA assay 
and evaluate its clinical performance. Part of this process is 
combining DNA markers and hemoglobin component in a 
logistic regression algorithm – but determining the overall 
output from this algorithm involves two other components as 
described in the supplementary material in the study by 
Imperiale et al. 2014. 
 
‘The individual results are used in combination to develop a 
logistic regression algorithm which generated a dichotomous 
patient result’ 
 
Test – The hemoglobin component of the multi-target sDNA 
test is not a commercially available FIT. 
  
13 Park, M. J., et al. (2012). "A comparison of 
qualitative and quantitative fecal 
immunochemical tests in the Korean national 
colorectal cancer screening program." 
Scandinavian Journal of Gastroenterology 47(4): 
461-466. 
Model 
Combines FIT type in the model not the FIT result. Not 
developing a model for individualised risk prediction just 
looking at positivity rates. 
14 Qin, M., et al. (2015). "Risk factors for colorectal 
neoplasms based on colonoscopy and 
pathological diagnoses of Chinese citizens: a 
multicenter, case-control study." International 
Journal of Colorectal Disease 30(3): 353-361. 
Model 
Model does not give individualised predictions. It just looks at 
ORs/associations. 
 
Population is patients from hospitals. 
Does not state which FOBT is used. 
15 Rengucci, C., et al. (2014). "Improved stool DNA 
integrity method for early colorectal cancer 
diagnosis." Cancer Epidemiology Biomarkers and 
Prevention 23(11): 2553-2560. 
Model 
Not strictly a risk prediction model development study. 
 
Does not report any model performance/test parameters for 
the combination. 
 
Tested whether FL-DNA assay could improve diagnostic 
accuracy. 
 
Could argue Bayesian method. This was discussed with a third 
author (NP) who agreed this is not strictly a model 
development study and the methods are not clear. 
16 Wild, N., et al. (2010). "A combination of serum 
markers for the early detection of colorectal 
cancer." Clinical Cancer Research 16(24): 6111-
6121. 
Model 
Does combine FIT with serum markers but just looks at 
diagnostic accuracy. 
 
The aim is not to develop a risk prediction model with 
individualised risk prediction. 
17 Wong, M. C. S., et al. (2014). "Should prior FIT 
results be incorporated as an additional variable 
to estimate risk of colorectal neoplasia? A 
prospective study of 5,813 screening 
colonoscopies." PLoS ONE 
Model 
Not individualised risk prediction model, just investigates 
associations. 
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18 Zheng, S., et al. (2003). "Cluster randomization 
trial of sequence mass screening for colorectal 
cancer." Diseases of the Colon and Rectum 
46(1): 51-58. 
Model 
 
FOBT result does not contribute to ADV score but is used to 
decide on which risk group. 
 
Not individualised risk prediction combining FIT with risk 
factor detail in a statistical model 
 
Flexible sigmoidoscopy used as diagnostic tool only small 
numbers of colonoscopy for a specific protocol. 
 
The associated paper which assesses the risk assessment is in 
Chinese. 
19 Parente, F., et al. (2012). "A combination of 
faecal tests for the detection of colon cancer: a 
new strategy for an appropriate selection of 
referrals to colonoscopy? A prospective 
multicentre Italian study." European Journal of 
Gastroenterology & Hepatology 24(10): 1145-
1152. 
Population -  
Population is all symptomatic and symptoms are not included 
in the model 
There is also no model it uses a ‘if one positive' rule between 
the tests 
20 Rodriguez-Alonso, L., et al. (2015). "An urgent 
referral strategy for symptomatic patients with 
suspected colorectal cancer based on a 
quantitative immunochemical faecal occult 
blood test." Digestive and Liver Disease 47(9): 
797-804. 
Population 
Model for primary care use. 
 
Population is primary care for urgent referral. 
21 Sanders, A. D., et al. (2013). "A novel pathway 
for investigation of colorectal symptoms with 
colonoscopy or computed tomography 
colonography." New Zealand Medical Journal 
126(1382): 45-57. 
Population 
Not known whether the FOBT is FIT or not - probably guaiac 
as its not specified. 
Symptomatic population only in primary care 
This study assesses a whole pathway, the scoring system is 
just a part of it. 
22 Brazer, S. R., et al. (1991). "USING ORDINAL 
LOGISTIC-REGRESSION TO ESTIMATE THE 
LIKELIHOOD OF COLORECTAL NEOPLASIA." 
Journal of Clinical Epidemiology 44(11): 1263-
1270. 
Screening Test 
Guaiac based test referenced in the text also reference 22 in 
the text relates to a guaiac test 
23 Griffiths, E. K. and D. V. Schapira (1991). "Serum 
ferritin and stool occult blood and colon cancer 
screening." Cancer Detection & Prevention 
15(4): 303-305. 
Screening Test 
Seracult guaiac test 
24 Kaminski, M. F., et al. (2014). "A score to 
estimate the likelihood of detecting advanced 
colorectal neoplasia at colonoscopy." Gut 63(7): 
1112-1119. 
Screening Test 
Does not combine FIT within the prediction model. 
25 Sequist, T. D., et al. (2011). "Electronic Patient 
Messages to Promote Colorectal Cancer 
Screening A Randomized Controlled Trial." 
Archives of Internal Medicine 171(7): 636-641. 
Screening Test 
 
The personalised model /scoring system behind/underlying 
this study does not combine FIT. 
 
Not a risk prediction modelling study design. 
 
Study looks at uptake, not test or model performance 
 
May have applicability issues as they look at patients overdue 
for colorectal cancer screening who are at higher risk 
26 Bosch, L. J., et al. (2012). "DNA methylation of 
phosphatase and actin regulator 3 detects 
colorectal cancer in stool and complements FIT." 
Cancer Prevention Research 5(3): 464-472. 
Study Design  
Not a model development study- just combines the positive 
result of one test with the positive result of another. 
Referral subjects – uses just stool samples 
Does not produce individualised risk predictions 
27 Brenner, H., et al. (2014). "Reduced risk of 
colorectal cancer up to 10 years after screening, 
surveillance, or diagnostic colonoscopy." 
Gastroenterology 146(3): 709-717. 
Study Design 
The authors investigated specific associations of CRC risk with 
previous colonoscopy conducted for various indications which 
does not match the review question. 
Guaiac based test 
The population had various indications, including primary 
screening, surveillance after a preceding colonoscopy, follow-
up of positive FOBT result, or specific symptoms. 
28 Cubiella, J., et al. (2014). "Diagnostic accuracy of Study Design 
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fecal immunochemical test in average- and 
familial-risk colorectal cancer screening." United 
European Gastroenterology Journal 2(6): 522-
529. 
Issues with study design. 
29 Huang, W., et al. (2014). "Cost-effectiveness of 
colorectal cancer screening protocols in urban 
Chinese populations." PLoS ONE [Electronic 
Resource] 9(10): e109150. 
Study Design 
Study design looks at cost effectiveness, not a prediction 
modelling study.  
FOBT is probably guaiac too as it is not explicitly specified. 
 Abstracts 
 Article Reason for Exclusion 
1 Sassatelli, R., et al. (2014). "Repeated fit 
screening: The influence of subject's 
characteristics and screening history on the 
positive predictive value and neoplasia yield." 
Gastroenterology 1): S410-S411. 
Model 
Does not mention a statistical model. 
PPV and DR are the outcomes 
Discrimination or calibration not mentioned 
2 Ardizzoia, A., et al. (2011). "A combination of 
fecal tests for the detection of colon cancer: A 
new strategy for appropriate prioritization of 
referrals to colonscopy-A prospective Italian 
study." Journal of Clinical Oncology. Conference: 
ASCO Annual Meeting 29(15 SUPPL. 1). 
Population 
Includes those with abdominal symptoms and it is uncertain 
whether/how they combine the predictors/tests.  
It is uncertain whether individualised predictions are 
determined. 
3 Guery, E., et al. (2015). "Performance of a blood 
methylated mutitarget DNA test (colohybritest) 
for the diagnosis of colorectal (CRC) cancer: A 
transversal study on 878 individuals." 
Gastroenterology 1): S745. 
Population 
The population is considered at high risk by including 
symptomatic patients as well as those with a positive gFOBT. 
Blood test is adjusted for age, positive FIT, symptoms family 
history. Does not mention individualised risk prediction. 
4 Boursi, S. B., et al. (2015). "Impact of a risk 
model based on routine lab results on colorectal 
cancer screening in average risk population." 
Journal of Clinical Oncology. Conference 33(15 
SUPPL. 1). 
Screening Test 
FIT is not included in the model 
5 Castiglione, G., et al. (1986). "THE PREDICTIVE 
VALUE OF HEMOCCULT AND AN ANAMNESTIC 
QUESTIONNAIRE FOR THE EARLY DETECTION OF 
COLORECTAL-CANCER IN SELF SELECTED 
PATIENTS." Digestive Diseases and Sciences 
31(10): S462-S462. 
Screening Test 
Hemoccult is Guaiac test. 
Page 460, abstract 1837 
6 Imperiale, T., et al. (2013). "Risk for advanced 
colorectal neoplasia in asymptomatic adults is 
effectively stratified by phenotypic features." 
American Journal of Gastroenterology 108: 
S646. 
Screening Test 
Does not mention FIT in the model. 
Associated with a full text: 
Imperiale, T. F., et al. (2015). "Derivation and Validation of a 
Scoring System to Stratify Risk for Advanced Colorectal 
Neoplasia in Asymptomatic Adults: A Cross-sectional Study." 
Ann Intern Med 163(5): 339-346. 
7 Imperiale, T., et al. (2014). "A scoring system for 
predicting the risk of advanced proximal 
neoplasia in asymptomatic adults." American 
Journal of Gastroenterology 109: S600. 
Screening Test 
Does not mention FIT in the model. 
Associated with a full text 
8 * Ladabaum, U., et al. (2015). "Potential 
effectiveness and cost-effectiveness of tailoring 
screening to predicted colorectal cancer risk." 
Gastroenterology 1): S1. 
Study Design 
Author was contacted for further information. The study was 
a hypothetical modelling exercise which did not apply to the 
review. 
9 Aniwan, S., et al. (2013). "Clinical risk score and 
fecal immunochemical testing are helpful to 
prioritize the patients for colon cancer screening 
by colonoscopy." Gastroenterology 1): S578. 
Full Text Associated 
Although different numbers probably a follow on study with 
different risk groups defined too. 
  
They are not combining the information in a risk prediction 
model for individualised risk prediction.  
10 Auge, J. M. (2014). "Practical experience of the 
fecal hemoglobin immunochemical test in a 
colorectal cancer screening program." 
Anticancer Research 34 (10): 5821. 
Full Text Associated 
The risk component is associated with a full text 
11 Auge, J. M. (2014). "Fit and colonoscopy. 
Competition and cooperation." Tumor Biology 
35: S17. 
Full Text Associated 
The risk component is associated with a full text 
12 Kim, N., et al. (2015). "Fecal hemoglobin 
concentration is useful for risk stratification of 
advanced colorectal neoplasia." Journal of 
Gastroenterology and Hepatology (Australia) 30: 
94-95. 
Full Text Associated 
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13 Lidgard, G. P., et al. (2012). "An optimised multi-
marker stool test for colorectal cancer screening: 
Initial clinical appraisal." Gastroenterology 1): 
S770. 
Full Text Associated 
14 Lidgard, G. P., et al. (2012). "An optimised 
molecular stool test for colorectal cancer 
screening: Evaluation of an automated analytic 
platform and logistic algorithm." Cancer 
Prevention Research. Conference: 11th Annual 
AACR International Conference on Frontiers in 
Cancer Prevention Research Anaheim, CA United 
States. Conference Start 5(11 SUPPL. 1). 
Full Text Associated 
 
15 Wieten, E., et al. (2015). "Positive predictive 
value increases with age in a FIT-based 
colorectal cancer screening program." 
Gastroenterology 1): S760. 
Full Text Associated which is included as a final text. 
16 Wild, N., et al. (2010). "Early detection of 
colorectal cancer applying a combination of 
serum markers." Cancer Research. Conference: 
101st Annual Meeting of the American 
Association for Cancer Research, AACR 70(8 
SUPPL. 1). 
Full Text Associated 
17 *Bosch, L. J. W., et al. (2015). "Advanced 
neoplasia detection in colorectal cancer 
screening using multiple stool DNA markers and 
haemoglobin." Journal of Pathology 237: S14. 
Author could not supply further detail due to impending 
publication of results. 
 
The FIT was however combined in a statistical model with the 
sDNA panel. 
 
*contacted author for additional information  
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Appendix 4: Assessment of Methodological Quality 
 
A.4.1 QUADAS-2 Tailored Tool: Risk of bias and applicability judgements 
 
QUADAS-2: Systematic review of risk prediction models combining the FIT result for Colorectal 
Cancer screening 
 
First author surname and year of publication: Stegeman 2014 
 
Name of first reviewer: Jennifer Cooper Name of second reviewer: Karoline Freeman 
Phase 1: State the review question: 
Patients (setting, intended use of index test, presentation, prior testing): Both men and women aged 
40-75 years representative of an average risk screening population (mean/average age needs to be 
over 40 years so participants over 18 can be included/10% outside screening range is acceptable) 
Index test(s): Where the FIT has been combined with other risk factors/predictors in a risk prediction 
 model/risk scoring system (e.g. risk model, score or clinical decision rule) This may or may not be 
 compared to using FIT alone  
Reference standard and target condition: Where diagnostic accuracy parameters are included, the  
reference standard can be either; colonoscopy or at least two years of follow up using clinical records  
(cancer registries, GP records etc). Small numbers of other diagnostic procedures acceptable as some 
individuals may not be suitable for colonoscopy e.g. CT/flexible sigmoidoscopy). The target condition 
is advanced neoplasia which includes both colorectal cancer and advanced adenomas as well as 
colorectal polyps. 
 
Phase 2: Draw a flow diagram for the primary study  
 
 
 
 
 
   
 
 
87 
 
Chapter 2 Chapter two | Systematic Review 
Phase 3: Risk of bias and applicability judgments 
QUADAS-2 is structured so that 4 key domains are each rated in terms of the risk of bias 
and the concern regarding applicability to the research question (as defined above). Each 
key domain has a set of signalling questions to help reach the judgements regarding bias 
and applicability. For each section, one ‘NO’ = High Risk of bias.  
DOMAIN 1: PATIENT SELECTION 
A. Risk of Bias  
Describe methods of patient selection: 
Data collected from randomized screening trial in the Netherlands (COCOS study) 
6600 asymptomatic men and women 50-75 years of age randomly selected and invited for 
colonoscopy 
All those who underwent colonoscopy were asked to complete risk questionnaire and a FIT 
Exclusions – those who have had colonic exam in the last 5 years, those in colonoscopy 
surveillance programme, those with a life expectancy of less than 5 years. 
+ Was a consecutive or random sample of patients enrolled? Yes/No/Unclear 
 
 Yes: If a study has enrolled all consecutive or a random sample of eligible patients with 
suspected disease 
 No: If a study makes inappropriate exclusions or studies which enrol patients with known 
disease status. 
 Unclear: when insufficient data are reported to decide. 
+ Was a case-control design avoided? Yes/No/Unclear 
 Yes: if a case–control design was avoided (nested case-control study have less bias) 
 No: if a case–control design was used and data on predictors collected after the diagnosis was 
made. Case-control studies create spectrum bias which can overestimate the accuracy of a 
test. Recall bias can also be a problem but if a study uses data collected on predictors before 
the diagnosis was made (i.e. GP records) then this can be minimised. 
 Unclear: when insufficient data are reported to decide. 
+ Did the study avoid inappropriate exclusions? Yes/No/Unclear 
 Yes: if a study avoided inappropriate exclusions. (Acceptable exclusions could be 
comorbidities, if a patient had been previously diagnosed with CRC or if they were on a 
colonoscopy surveillance programme as an example)  
 No: if a study made inappropriate exclusions.  
 Unclear: when insufficient data are reported to decide. 
Could the selection of patients have introduced bias? 
If all signaling questions for a domain are answered ‘yes’ 
there is a low risk of bias, if any signaling question is 
answered ‘no’ this indicates a high level of bias. 
RISK: LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability 
Describe included patients (prior testing, presentation, intended use of index test and setting): 
 
6600 asymptomatic men and women 50-75 years of age randomly selected and invited for 
colonoscopy as part of the COCOS randomized screening trial in the Netherlands. 1426 agreed to 
undergo colonoscopy, 1236/1426 completed the questionnaire and 1112 also completed the FIT. 
Intended use of the risk prediction model combining FIT is pre-selection for colonoscopy in a 
screening programme setting. 
Is there concern that the included patients do not match 
the review question? 
 
CONCERN: LOW/HIGH/UNCLEAR 
 High concern: if the study population cannot be considered an adult average risk screening 
population (men and women aged 40-75), if individuals are known to have high risk genetic 
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syndromes such as familial adenomatous polyposis (FAP) or Lynch syndrome. Hospitalised 
patients or symptomatic patients only would also be at higher risk and would indicate high 
concern of applicability issues. 
 Low concern: if the study population can be considered an adult average risk screening 
population (men and women aged 40-75) 
 Unclear: when insufficient data are reported to decide.  
  
DOMAIN 2: INDEX TEST(S) 
If more than one index test was used, please complete for each test.  
The FIT and risk prediction model that has been applied as a test need to be considered in this section. 
A. Risk of Bias  
1 - Describe the index test and how it was conducted and interpreted: 
2 - Describe how the risk factor information is collected (before or after index/reference standard, 
by questionnaire/routine electronic data/chart review etc) 
3 – Impact study considers the model outcome (probability/risk score); model development 
considers predictor information including the FIT. 
 
The OC-Sensor FIT test was conducted before colonoscopy was carried out (one sample). A 
threshold of 50 ng/ml was used to compare the sensitivity of the risk model at a specificity of 93%. 
Risk factor information was collected via a questionnaire which was handed out to the participants 
in the waiting room before colonoscopy (therefore patients have not changed responses according 
to the results – recall bias). 
+ Were the index test results (predictors including FIT/probability or 
risk score) interpreted without knowledge of the results of the 
reference standard? (Test review bias) 
 
Yes as FIT and questionnaire completed before colonoscopy 
Yes/No/Unclear 
 Yes: If the analysts are blinded (masked) to the results of the reference investigation and 
other clinical information (knowledge of additional clinical information is clinical review bias) 
(colonoscopy/two year follow up/small numbers of alternative investigations) 
 No: if the FIT result or risk model was interpreted with knowledge of the reference standard 
(colonoscopy/two year follow up)  
 Unclear: when insufficient data are reported to decide. 
+ Was risk information obtained around the time of the FIT result but 
before the reference standard (or previously recorded on clinical 
records)? I.e. avoiding retrospective data collection? (Recall bias) This 
includes if more than one lab test incorporated. 
Yes/No/Unclear 
 Yes: If retrospective data collection is avoided or obtained after the reference standard 
 No: If retrospective risk information collected, or any lab tests performed after the reference 
standard  
 Unclear: when insufficient data are reported to decide 
+ Is the brand/type of FIT used described?  Yes/No/Unclear 
 Yes: if the study mentioned the brand/type of FIT i.e. whether qualitative or quantitative. 
(Ideally name of specimen collection device and supplier given) 
 No: if the study does not describe the brand/type of FIT 
 Unclear: when insufficient data are reported to decide. 
+If a threshold was used, was it pre-specified? 
 
Used 10 µg Hb/g of faeces as this was the anticipated cut off for the 
Dutch screening programme i.e. it was not reverse engineered to 
give positive results. 
Yes/No/Unclear 
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 Yes: if the study indicates what threshold of the FIT is used for a positive test result or sets 
the sensitivity/referral rate/probability threshold the same if comparing a risk scoring system 
incorporating the FIT with the FIT alone. The threshold considered needs to be within the 
range used by a screening programme; 20 µg Hb/g of faeces is commonly used as a cutoff for 
the OC-Sensor test as an example. Published studies have considered thresholds around 10-
180 µg Hb/g. 
 No: if the study does not pre-specify a threshold or selects a threshold solely to maximise 
performance.  
 Unclear: when insufficient data are reported to decide. 
  + Details of faecal collection method (sampling technique and 
number of samples if applicable) provided. 
 
One sample but the sampling technique is not reported. 
Yes/No/Unclear 
 Yes: if the study indicates the sampling technique 
 No: if the study does not indicate the sampling technique 
 Unclear: when insufficient data are reported to decide. 
+ Was the FIT return time up to 10 days only or was the test 
repeated if past this date? (This could give false negative results)1 
Yes/No/Unclear 
 Yes: if the study indicates that the FIT result is returned within 10 days of the test/excludes 
those after this time period or repeats the test.  
 No: if the study includes the FIT result if returned within 10 days of the test/includes those 
results after this time period or doesn’t repeat the test 
 Unclear: when insufficient data are reported to decide. 
+ Time and storage of collection devices from specimen collection to 
analysis, including time and temperature (median and range) 
indicated? 
Yes/No/Unclear 
 Yes: if the study indicates the time and storage of collection devices from specimen collection 
to analysis 
 No: if the study does not include the time and storage of collection devices from specimen 
collection to analysis 
 Unclear: when insufficient data are reported to decide. 
Could the conduct or interpretation of the index test have 
introduced bias?  
The first 4 signaling questions are the most important for risk prediction 
models. If these 4 are Yes then low risk of bias. 
 
The first four signaling questions are Yes. 
RISK: LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability 
Is there concern that the index test, its conduct, or interpretation 
differ from the review question? 
 
Quantitative FIT OC Sensor and risk questionnaire (used to develop 
the risk prediction model) are performed before colonoscopy. 
  
 
CONCERN: 
LOW/HIGH/UNCLEAR 
 
                                                                
 
1 van Roon, A. H., et al. (2012). "Are fecal immunochemical test characteristics influenced by sample return time? A 
population-based colorectal cancer screening trial." Am J Gastroenterol 107(1): 99-107. 
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 High Concern: If there are variations in test technology, execution or interpretation which 
would affect diagnostic accuracy 
 Low Concern: If test methods are those specified in the review question (i.e. qualitative or 
quantitative FIT) 
 Unclear: when insufficient data are reported to decide. 
 
DOMAIN 3: REFERENCE STANDARD 
A. Risk of Bias 
Describe the reference standard and how it was conducted and interpreted: 
 
Colonoscopies were performed using the standard quality aspects defined by the American Society 
for Gastrointestinal Endoscopy. Colonoscopy was performed after the risk questionnaire and FIT. The 
most advanced lesion per patient was used. Advanced neoplasia was defined as at least one CRC or 
advanced adenoma: adenoma of 10 mm or larger, ≥25% villous histology or high grade dysplasia. CRC 
and advanced adenoma were reported separately. All included participants had a colonoscopy. 
+ Were reference standard results interpreted without 
knowledge of the results of the index test? (Diagnostic 
review bias) 
Yes/No/Unclear 
 Yes: if colonoscopy is carried out without knowledge of the FIT result/other clinical 
information (clinical review bias) – more difficult to meet this criteria in screening studies as 
usually positive results are referred on for colonoscopy. 
 No: if colonoscopy is carried out with knowledge of the FIT result/risk model result 
 Unclear: if insufficient information is provided to decide. 
+ Is the reference standard likely to correctly identify CRC? Yes/No/Unclear 
 Yes: if the reference standard was colonoscopy (considered the gold standard) or two year 
follow up. Small numbers of other diagnostic tests such as CT/Flexible Sigmoidoscopy are 
acceptable if the patient is not suitable for colonoscopy – these need to be noted as a large 
proportion will bias results. 
 No: if the reference standard was not was colonoscopy (considered the gold standard) or two 
year follow up.  
 Unclear: when insufficient data are reported to decide. 
+ Has the study avoided introducing partial or differential 
verification bias? Partial verification bias is particularly an 
issue for screening studies whereby only those with positive 
results are referred for diagnostic testing.2 
Yes/No/Unclear 
 Yes: If all study subjects who have had an index test have also received the reference standard 
(colonoscopy) or if there is at least two years of follow up (or verification bias is corrected 
using mathematical correction methods). Ideally all patients should have the same reference 
standard (e.g. just colonoscopy) but this is often not the case in screening studies. 
 No: If not all study subjects who have had an index test have also received the reference 
standard (colonoscopy), or if there is not at least two years follow up (or mathematical 
correction has not been applied). Bias will also be present if a different reference standard is 
used like flexible sigmoidoscopy in different groups of people. 
 Unclear: when insufficient data are reported to decide. 
Could the reference standard, its conduct, or its interpretation 
have introduced bias? RISK: LOW/HIGH/UNCLEAR 
                                                                
 
2 de Groot, J. A. H., et al. (2011). "Verification problems in diagnostic accuracy studies: consequences and solutions." BMJ 343. 
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B. Concerns regarding applicability 
Is there concern that the target condition as defined by the reference standard does not match the 
review question?  
 
                                                                                                                              CONCERN: LOW/HIGH/UNCLEAR 
 High: If the target condition that the reference standard defines differs from the target 
condition (colorectal cancer, advanced adenoma, colorectal polyps) in the review question. 
 Low: if the target condition that the reference standard defines does not differ from the target 
condition (colorectal cancer, advanced adenoma, colorectal polyps) in the review question. 
 Unclear: when insufficient data are reported to decide. 
 
 
DOMAIN 4: FLOW AND TIMING 
A. Risk of Bias  
 
Describe any patients who did not receive the index test(s) and/or reference standard or who were 
excluded from the 2x2 table (refer to flow diagram): 
 
In total 6600 persons were invited for primary colonoscopy screening, of which 1426 (22%) agreed to 
undergo colonoscopy. In this group, 1236 (87%) individuals completed the questionnaire and 1112 
(90%) of them also completed the FIT test. 
 
+Was there an appropriate interval between index test  
(predictors and FIT/probability or risk score) and reference 
standard? 
 
FIT completed before the colonoscopy along with the 
questionnaire. 
Yes/No/Unclear 
 Yes: if there is an appropriate interval between FIT and colonoscopy. Abnormal tests are 
offered an appointment with a SSP clinic within 14 days and a colonoscopy appointment is 
made within two weeks (under 6-8 weeks could be considered a reasonable time interval for a 
chronic condition.3 
 No: if there is not an appropriate interval between FIT and colonoscopy 
 Unclear: when insufficient data are reported to decide. 
+ Did all patients receive a reference standard? 
 
Out of the original people invited 1426 had colonoscopy. 
All patients who had a FIT would have had a colonoscopy. 
Yes/No/Unclear 
 Yes: if all patients received a reference standard (colonoscopy/two year follow up). 
 No: if all patients did not receive a reference standard (colonoscopy/two year follow up). 
 Unclear: when insufficient data are reported to decide. 
+ Did all patients receive the same reference standard? Yes/No/Unclear 
 
 Yes: if the reference standard was the same (colonoscopy/two year follow up).  A systematic 
review by Lee et al.4 shows that the sensitivity estimates vary when using colonoscopy on FIT 
negative patients (0.71) compared with a two year follow up (0.87) so if there is a mix this 
                                                                
 
3 Logan, R. F., et al. (2012). "Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million 
tests." Gut 61(10): 1439-1446. 
 
4 Lee, J. K., et al. (2014). "Accuracy of Fecal Immunochemical Tests for Colorectal CancerSystematic Review and Meta-
analysis." Annals of Internal Medicine 160(3): 171-181. 
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needs to be considered in assessing risk of bias. 
 No: if the reference standard was not the same (colonoscopy/two year follow up).   
 Unclear: when insufficient data are reported to decide. 
+ Were all patients included in the analysis? 
(all patients who were recruited into the study should be 
included in the analysis) 
Yes/No/Unclear 
 Yes: if all participants were included i.e. if 2 by 2 data is presented, the number of patients 
enrolled should not differ from the number included in the 2 by 2 tables. Those who drop out 
from having follow up tests may be at higher risk due to lifestyle factors, comorbidities, or if 
they are not appropriate for further diagnostic tests. 
 No: if participants were excluded.  
 Unclear: when insufficient data are reported to decide. 
Could the patient flow have introduced bias? 
All those enrolled were not included in the final analysis. Not all 
participants completed both a FIT and questionnaire. 
Those who agreed to have a colonoscopy are more likely to be 
healthy – the healthy screenee effect which could potentially 
reduce sensitivity. 
RISK: LOW/HIGH/UNCLEAR 
 
 
DOMAIN 5: ROLE OF SPONSOR 
A. Risk of Bias 
+ Did the funding source/sponsor play no role in design of 
study, interpretation of results and publication? 
 
‘…funded by The Netherlands Organization for Health 
Research and Development of the Dutch Ministry of 
Health… The sponsor was not involved in the study.’ 
Yes/No/Unclear 
 
Could the funding source have introduced bias? 
                    
                                                                                                                              RISK: LOW/HIGH/UNCLEAR 
 
 High: If the FIT manufacturer as an example have played a role in the design of the study, 
interpretation of results and publication. 
 Low: if the funding source/sponsor have not played a role in the design of the study, 
interpretation of results or publication. 
 Unclear: when insufficient data are reported to decide. 
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A.4.2 PROBAST: Risk of bias and applicability judgements 
(Prediction model study Risk of Bias Assessment Tool) 
 
An early version of PROBAST was piloted but not reproduced in this thesis since the 
finalised tool will be published in 2018. 
 
PROBAST assesses risk of bias and applicability of studies evaluating a multivariable 
diagnostic or prognostic prediction model. The tool is used for studies which develop a 
model or externally validate a model.  
 
There are 5 key domains including: Participant Selection, Predictors, Outcome, Sample Size 
and Participant Flow and Statistical Analysis. Signalling questions are rated as ‘Yes’, 
‘Probably Yes’, ‘Probably No’, ‘No’ or ‘No Information’. Each domain is then subsequently 
rated as ‘high’, ‘low’ or ‘unclear’ risk of bias. An overall judgement is rated for each model 
along with the usability of the model. The first three domains listed above are also assessed 
for applicability to the review question. 
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Risk-adjusted Colorectal Cancer Screening Using the FIT and 
Routine Screening Data: Development of a Risk Prediction Model 
 
 
Chapter based on the following published paper: Cooper, J. A., et al. (2018). "Risk-adjusted 
colorectal cancer screening using the FIT and routine screening data: development of a risk 
prediction model." Br J Cancer 118(2): 285-293. 
ABSTRACT  
Objectives: The fecal immunochemical test (FIT) has recently been recommended to 
replace the guaiac fecal occult blood test in the NHS Bowel Cancer Screening Programme. 
Increased uptake and positivity of the FIT will put added strain on limited colonoscopy 
services. There is evidence to suggest that combining risk indicators such as age, sex and 
other lifestyle factors with the FIT improves test accuracy and may help to guide more 
efficient colonoscopy use. This study aimed to develop a risk prediction model combining 
routinely available predictors from the Bowel Cancer Screening System with the FIT to 
determine whether model performance and test accuracy are improved in a representative 
sample of the English screening population. 
  
Design: Data for this study were collected during the six-month FIT pilot study for the NHS 
Bowel Cancer Screening Programme. Of the people invited to complete a FIT kit, 27,066 
individuals aged 59-75 adequately participated. Multivariable analysis used those with a 
positive FIT (≥20 μg/g) and with a diagnostic colonoscopy outcome (n=1810). Stepwise 
backwards elimination was used to build a logistic regression model using FIT result, age, 
sex and previous screening history. Model outcome was either cancer or advanced 
adenoma (high-risk adenoma or intermediate-risk adenoma) detected at colonoscopy. 
Model performance was assessed using discrimination and calibration and test accuracy 
was investigated using sensitivity, specificity and receiver operating characteristic (ROC) 
curves. 
 
Results: Of the sample used for multivariable analysis (n=1810), 549 cancers and advanced 
adenomas were detected (30.3%). Discrimination improved from 0.628 with FIT only to 
0.659 for the risk-adjusted model (p=0.01). The calibration of the risk-adjusted model was 
0.898 using the Hosmer-Lemeshow statistic compared with 0.481 for FIT only. The 
sensitivity improved from 30.78% (FIT only) to 33.15% (risk-adjusted model) at similar 
specificity using a threshold of 160 μg/g which is the anticipated threshold for the NHS 
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Bowel Cancer Screening Programme. The risk-adjusted screening algorithm detected 13 
more advanced adenomas and the same number of cancers compared to FIT-only at a 
threshold of 160 μg Hb/g faeces. The risk model mainly improved detection in men, but 
also more than halved the number of false positive results for women. When analysing the 
detection rates by subgroup, there was a reduction in the detection rate for female first 
time invitees. The detection rate for male previous non-responders more than doubled 
(16.98% to 37.11%). 
 
Conclusions: Risk-adjusted screening using routinely available predictors on the BCSS 
enhanced both model performance and test accuracy. This could lead to more appropriate 
referrals whereby those at greatest risk are sent for a follow up colonoscopy. Further 
investigation is required relating to the greater cancer/advanced adenoma detection in 
males compared with females and the acceptability of this difference to the population and 
the screening programme. Future research should investigate additional predictors 
available from the Bowel Cancer Screening System, particularly relating to screening 
history, as well as other modelling approaches including machine learning methods. 
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1.0 INTRODUCTION 
 
The previous chapter reported a systematic review of risk prediction models which 
combine the FIT result with other risk predictors for colorectal cancer screening referral 
decisions. There was some evidence to suggest that including additional factors with the 
FIT result can improve model performance and test accuracy when comparing FIT only to a 
risk based FIT model. Both lab based predictors and routine data (e.g. age, sex, BMI) lead to 
an improvement in discrimination as well as test accuracy. The advantages of using routine 
data only are that no further testing is required and it often has a high percentage of 
completeness. The Bowel Cancer Screening System (BCSS) used in the NHS stores detailed 
information for all participants invited to screening in an electronic health record format. 
This data source was investigated as a potential method to enhance the performance of 
the FIT. 
 
In England, a 6-month comparative pilot study was initiated by the NHS BCSP in April 2014 
to assess uptake and acceptability, as well as diagnostic performance of FIT.1 The FIT pilot 
using the OC-Sensor/DIANA Eiken Chemical Co., Tokyo, Japan (FIT) found an improved 
uptake (66.4% versus 59.3%) and increased cancer detection rate using FIT compared to 
the gFOBT.  Due to this increased uptake of the test and higher positivity, additional strain 
could be expected on colonoscopy services. The pilot results suggest an additional 290,000 
people would be screened each year when replacing the current test with the FIT, leading 
to further referrals for colonoscopy.1 Furthermore, those who participate in earlier 
screening rounds have been shown to be more likely to continue participating in later 
rounds.2 3 One paper reports that England has had a 20% increase in colonoscopy capacity 
over the last 5 years, with a current rate of 360,000 examinations performed each year.4 A 
range of thresholds are currently being investigated for the FIT between 150 and 180 μg 
Hb/g faeces to keep the referral rates similar to current colonoscopy service use.1 5 
 
Another approach which could improve effective colonoscopy use, test accuracy and 
consequently health outcomes is risk based colorectal cancer screening.1 6 7 A few studies 
have developed risk prediction models which combine the FIT concentration with other risk 
indicators for use in screening referral decisions.7-13 For example, Stegeman et al8 in the 
Netherlands combined the FIT with risk indicators obtained from a lifestyle questionnaire in 
a logistic regression model. Sex, age, calcium intake, smoking status, family history and the 
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FIT result were retained in the final model which had improved sensitivity (40% versus 32% 
for FIT alone) at a 93% specificity.8 The Netherlands is currently in the process of 
implementing a pragmatic integrated trial of risk-adjusted FIT with outcome diagnostic 
yield.14 Other studies have investigated combining blood based inflammatory markers with 
the FIT which improved discrimination from 0.683 to 0.729 (AUC ROC),11 or integrating 
demographic characteristics to categorise risk into 16 different subgroups.7 The Asia-Pacific 
Screening Scoring System which includes age, sex, smoking and family history was 
combined in an algorithm with FIT to triage participants for colonoscopy based on whether 
they were at low, medium or high risk.15 
 
The studies described hitherto required additional testing or lifestyle questionnaires to 
obtain predictor information for the model. Sending additional documents such as 
questionnaires has been shown to significantly reduce screening uptake.16 A more efficient 
approach would be to utilise screening data that are routinely available as an electronic 
record. This would reduce participant burden and enhance data completeness for use 
within a prediction model. As far as can be identified, the present study is the first to adopt 
this pragmatic approach in a population-based screening programme and to combine risk 
indicators with the FIT in an English screening population. Following the transition to the 
FIT for the NHS BCSP, application of this approach could improve test accuracy and enable 
more efficient use of limited and expensive colonoscopy resources. 
 
The aim of this study was to develop a risk prediction model which integrates routinely 
available predictors from the NHS BCSS with the quantitative FIT result to determine 
whether model performance and test accuracy are improved in an English screening 
population. 
 
2.0 METHODS 
Since this study both develops a risk prediction model and assesses test accuracy, the 
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or 
Diagnosis (TRIPOD) and Standards for Reporting of Diagnostic Accuracy Studies (STARD) 
statements have been followed for reporting.17 18 In addition, Steyerberg’s checklist (Table 
1) for developing valid prediction models was considered for data management and 
analysis to ensure that an internally valid prediction model was produced.19 
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Step Specific Issues 
General Considerations  
Research question Aim: predictors/prediction? 
Intended application Clinical practice/research? 
Outcome Clinically relevant? 
Predictors Reliable measurement? 
Comprehensiveness 
Study Design Retrospective/prospective? 
Cohort; case-control 
Statistical Model Appropriate for research question and type of outcome? 
Sample Size Sufficient for aim? 
Seven Modelling Steps  
Data Inspection  Missing values 
Coding of Predictors Continuous predictors 
Combining categorical predictors 
Restrictions on candidate predictors 
Model Specification Appropriate selection of main effects? 
Assessment of assumptions (distributional, linearity, and 
additivity) 
Model Estimation Shrinkage included? 
Model Performance Appropriate statistical measures used? 
Clinical usefulness considered? 
Model Validation Internal validation, including model specification and 
estimation? 
External Validation? 
Model Presentation Format appropriate for audience? 
Validity  
Internal: Overfitting Sufficient attempts to limit and correct for overfitting? 
External: Generalizability Predictions valid for plausibly related populations? 
Table 1: Steyerberg’s checklist for developing valid prediction models.19 
 
2.1 Study population and data source  
 
The NHS BCSP performed a comparative study to determine the acceptability and accuracy 
of the FIT compared with the gFOBT.1 The study involved two out of the five regional 
screening hubs in England; (i) the Midlands and North West Hub and (ii) the Southern Hub. 
Between 7th April and 10th October 2014, 1,126,087 individuals were invited to complete a 
gFOBT, with 667,945 adequately screened (i.e. those with a definitive positive or negative 
result), and 40,930 individuals were invited to complete a FIT (one out of 28 screening 
invitations), with 27,167 adequately screened. The pilot analysed data from participants 
aged 59 to 75 years old. The FIT pilot study is discussed in further detail elsewhere.1  
 
This analysis is limited to complete cases (i.e. those with complete data records) and those 
who had a FIT result of 20 μg Hb/g faeces and above (n=1810) as this was the cutoff chosen 
for test positivity during the pilot and ensured participants had a definitive diagnosis at 
colonoscopy. Twenty μg Hb/g faeces was the threshold chosen for test positivity for the 
pilot. Since this threshold was set low, it enabled different thresholds to be examined up to 
180 μg Hb/g faeces and their corresponding effects on positivity and clinical outcomes. This 
approach also enables investigation of a risk-adjusted approach by comparing relative 
performance between FIT only and FIT combined with risk factors. 
  
 
99 
  
Chapter 3 Chapter three | Risk Prediction Model Combining the FIT and Routine Screening Data 
 
The data for the FIT pilot and this study were recorded on the BCSS which contains routine 
information on the screening pathway for participants. These data were anonymised and 
provided by the Health and Social Care Information Centre (HSCIC) – now NHS Digital - 
through the Office for Data Release (ODR). Data were extracted by NHS Digital on the 10th 
March 2016. 
 
All participants who received an invitation during the study period were included (7 April 
2014 to 10 October 2014). For the sample population analysed, FIT kits were distributed 
between 15th April 2014 and 19th November 2014. Completed kits were received at the lab 
between 22nd April 2014 and 5th March 2015 and examined between 25th April 2014 and 9th 
March 2015. 
 
2.2 Ethical Approval 
 
Ethical approval was obtained from the University of Warwick Biomedical and Scientific 
Research Ethics Committee (BSREC) (Reference Number REGO-2015-1575). The Bowel 
Cancer Screening Research Committee also approved the study protocol (ID152). The data 
were anonymised and provided by NHS Digital through the Office for Data Release 
(ODR1516_045). The approval letters along with the System Level Security Policy followed 
for this project are provided in Appendix 1 and Appendix 2 respectively. 
 
2.3 Routinely available predictors 
 
The routinely available predictors recorded on the BCSS which were investigated in this 
study were age, sex, Index of Multiple Deprivation (IMD) score and previous screening 
history (i.e. whether someone was a previous non-responder/responder to screening). Age 
at the start of the screening episode for the pilot was used for the analysis. Social 
Deprivation was measured using the IMD score, which is derived using the English Indices 
of Deprivation 2010 based on 38 separate indicators in seven domains.20 The IMD is 
calculated for every Lower Super Output Area (LSOA) in England and can be ranked to give 
the IMD rank. There are 32,482 LSOA in the UK, which are small areas based on postcode 
and consisting of approximately 1500 people.20 IMD score was supplied by NHS Digital 
based on the participant’s postcode of residence.  
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2.4 FIT Concentration (Index test) 
 
The OC-SENSOR FIT (Eiken Chemical Co. Ltd., Japan, supplied by Mast Diagnostics, UK) was 
used along with the OC-SENSOR Diana analyser. The FIT units were converted from ng 
Hb/ml buffer to μg Hb/g faeces as recommended by the World Endoscopy Organisation 
and experts, to aid comparison between studies.21 The OC-SENSOR deposits 10mg of faeces 
into 2.0mL of buffer. Units in nanograms of haemoglobin per ml of buffer can be converted 
to μg haemoglobin per g faeces by multiplying the concentration by 2 and dividing by 10 for 
certain FITs (100ng haemoglobin per mL of buffer is equal to 20 μg Hb/g faeces).21 FIT kits 
were sent by post for participants to complete at home and returned by mail to the 
screening hubs.  
 
2.5 Colonoscopy (Diagnostic test) 
 
Participants with a positive test result were offered a specialist screening practitioner 
appointment and referred for a colonoscopy assessment within 14 days of this 
appointment (alternative investigations were arranged if the colonoscopy was 
inappropriate or fails first time round e.g. CT scan or flexible sigmoidoscopy).22 
Colonoscopies were performed using the quality assurance guidelines for colonoscopy 
published by the NHS Cancer Screening Programmes.23 
 
The NHS BCSS uses an algorithm to record the diagnosis of an individual based on the 
guidelines for colorectal cancer screening and surveillance (Table 2). A low risk adenoma is 
indicated by the presence of 1 or 2 small adenomas less than 1cm in diameter. An 
intermediate risk adenoma is indicated by the presence of 3 or 4 small adenomas or at 
least one which is ≥1cm in diameter. A high risk adenoma is indicated by the presence of ≥5 
adenomas or ≥3 adenomas where at least one is ≥1cm in diameter.24  
 
Adenoma Type Definition 
Low Risk Adenoma The presence of 1 or 2 small adenomas which 
are less than 1cm in diameter 
Intermediate Risk Adenoma The presence of 3 or 4 small adenomas or at 
least one which is ≥1cm in diameter 
High Risk Adenoma The presence of ≥5 adenomas or ≥3 adenomas 
where at least one is ≥1cm in diameter 
Table 2: Definition of adenomas used by the NHS Bowel Cancer Screening System based on the guidelines for 
colorectal cancer screening and surveillance. 
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2.6 Model Outcome 
 
The binary model outcome was colorectal cancer or advanced adenoma detected at 
colonoscopy after a positive FIT referral. Advanced adenomas were those classified as 
either high risk or intermediate risk, since these have potential, if left untreated, to develop 
into bowel cancer, particularly as age increases.25 26 Detection of these adenomas is a key 
health outcome of the NHS bowel cancer screening programme (NHSBCSP).22 In addition, 
the NHS BCSP carries out surveillance of patients with high or intermediate risk adenomas 
which have been detected at previous screening rounds.22 24 
 
For modelling purposes, colorectal cancer or advanced adenoma was coded as a single 
binary outcome variable (i.e. yes = 1 or no = 0). Where there was more than one diagnostic 
outcome recorded for an individual, the ‘greatest risk’ scenario was used giving one 
diagnostic outcome per individual. 
 
2.7 Statistical analysis 
 
All data were analysed in RStudio Version 0.99.903 (driven by R version 3.3.1) on a 
Windows 7 computer.27 Additional packages were also loaded from The Comprehensive R 
Archive Network (CRAN; https://cran.r-project.org/).28-34 Two models were tested using 
logistic regression, with a binary response variable of cancer status; (i) FIT concentration 
only as a predictor and (ii) FIT concentration and routine data. The R scripts used to 
develop and assess the performance of the models are provided in Appendix 3. 
2.7.1 Model Development 
 
Routinely available risk factors from the database were selected based on previous studies7 
8 and the information available from the data extract provided. Initial evaluation of 
routinely collected predictor variables and their association with colorectal cancer and 
advanced adenomas was undertaken using univariable logistic regression. 
 
Typically, univariable screening of predictors which are over a pre-defined p-value is not 
recommended,35 therefore when developing the risk model all variables were considered 
for inclusion. The risk-adjusted model was built by adding all the routinely available risk 
factors into a single multivariable logistic regression model and then using backwards 
elimination to remove non-significant variables with a p-value greater than 0.1 as 
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determined through likelihood ratio testing. Backwards elimination is generally preferred 
to stepwise forwards selection as the latter is more likely to exclude predictors involved in 
suppressor effects.36 The z statistic was used to assess the significance of estimated model 
coefficients; this follows a normal distribution and indicates whether the coefficient is 
significantly different from 0.36 All possible pairwise interactions were also investigated. 
 
Models developed using this methodology often perform poorly when used on new data; 
i.e. different data from that which was used for model development.37 38 Models are over-
fitted to the particular data used for model development and thus do not generalise well to 
new settings.37 One way to address this issue is to divide the data into training and 
validation datasets, the former being used for model building and the latter for model 
performance testing. When data are limited, a more efficient procedure is to use cross-
validation39 as an internal validation method. Cross-validation involves partitioning the data 
sample into distinct subsets, performing the analysis on one subset (training data), and 
validating the analysis on the other subset (validation data). Multiple runs of cross-
validation are performed using random partitions of the data, which are then averaged 
over the runs. Ten-fold cross-validation was used during model development; the data 
were divided 10 times into 10 randomly selected subsets of approximately equal size and 
90% of the data were used for model building (training data) and predictions were made on 
the remaining 10% of the data. Bootstrapping (10,000 replications) was used to construct 
confidence intervals for the model coefficients and to estimate bias. The confidence 
intervals reflect our true confidence in the value calculated from the data alone.38 
 
All continuous variables were kept as such (i.e. not dichotomised or categorised) as 
recommended by previous research and the TRIPOD guidelines (age, FIT concentration, 
IMD score).37 40-42 Age was not formally significant in the final model but was retained as it 
was found to be a consistent significant predictor in the models identified in Chapter 2 
(along with sex).7 8 43 The log of the FIT concentration was used for analysis as this was 
found to give improved model performance and better fitted linearity. Screening history 
was coded as a factor (either a previous responder, previous non-responder or first-time 
invitee). This was determined using two variables recorded on the BCSS; sequence number 
(EPISODE_SEQUENCE_NUMBER) and type of episode (PREVALENT_INCIDENT). Sex on the 
BCSS was treated as a factor with two levels: male or female.  
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2.7.2 Model Performance 
 
Model performance was assessed using calibration and discrimination. Calibration assesses 
the agreement between the observed outcomes and the predictions.44 This was 
determined using the Hosmer-Lemeshow statistic where a small p-value indicates that the 
model does not predict accurately.45 The observations can be split into a different number 
of groups based on their predicted probabilities and this can affect the corresponding 
result of the Hosmer-Lemeshow statistic.46  Therefore, group splits between 5 and 15 were 
investigated.  A calibration plot of predicted risk versus observed risk was plotted for 
deciles of participants where points close to the line of equality indicates good 
calibration.19  
 
Discrimination is the ability of a model or test to distinguish between those with and 
without the outcome (cancer status) or those at high risk versus those at low risk.44 This 
was assessed using the c-statistic, which is also referred to the AUC (area under the curve) 
of the Receiver Operating Characteristic (ROC) curve. 
 
The two models (risk-adjusted model and FIT only model) were compared using the 
likelihood ratio test (which quantifies changes in the model residual deviance). Overall 
model fit for the logistic regression models was assessed using pseudo R2 measures 
including Nagelkerke’s R2. Ordinary Least Squares regression uses the standard R2 measure 
to assess goodness of fit (how well the model fits the data) by comparing the null to the 
fitted model but there is not an equivalent measure for assessing logistic regression. 
Therefore, several pseudo R2 measures have been proposed.  These measures usually range 
from 0 to 1 with higher values indicating a better model fit. Cox and Snell’s R2  assesses the 
improvement of the full model over the intercept model. Since this statistic cannot reach 
the maximum value of one, Nagelkerke introduced an amendment so the possible value 
can extend to one.47 
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2.7.3 Test Accuracy of the Risk Model 
 
The ROC curves were plotted for the risk-adjusted FIT model and FIT only to compare test 
accuracy across different thresholds. A ROC test was performed to analyse the difference 
between the AUC for both models using bootstrapping.  
 
Two by two tables were then produced to determine the sensitivity and specificity for a 
threshold of 160μg Hb/g faeces and the equivalent risk threshold for the risk-adjusted 
model. This threshold was selected based on previous work from the FIT pilot,1 as well as 
discussions regarding colonoscopy capacity by stakeholders. A threshold of 150 μg Hb/g 
faeces gave a similar positivity rate to the gFOBT and 180 μg Hb/g faeces a similar referral 
rate.1 5 A threshold of between 150 μg Hb/g faeces and 180 μg Hb/g faeces will be adopted 
by the NHS Bowel Cancer Screening programme and adjusted as appropriate in order to 
ensure adequate colonoscopy capacity.  
 
The predictiveness curve, which plots the distribution of risk, has been proposed by Pepe et 
al.48 as an alternative plot which allows both the assessment of the fit of the model and the 
clinical utility when applied to the population. It is argued that the predictiveness curve can 
give additional information about risk-threshold which is not typically provided by the ROC 
curve. A histogram of risk probabilities can display similar information however this 
involves defining risk intervals/bins whereas the predictiveness curves shows the 
proportions of patients over risk thresholds.48 
 
To plot a prediction curve, estimated risk for each individual is calculated from the logistic 
regression model and ordered from highest to lowest, this is plotted against risk percentile 
of the sample population. The predictiveness curve will be plotted for both the risk-
adjusted model and the model for FIT only for comparison. 
 
2.7.4 Additional predictors and their effect on FIT positivity 
 
The effect of sample return time, ambient temperature, sex and age on FIT positivity at a 
threshold of 160 μg Hb/g faeces was investigated in unvariable logistic regression. The 
sample population for this analysis was those who had adequately participated with a 
definitive FIT result of positive or negative (n=27,066). At 160 μg Hb/g faeces, 26,614 
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participants had a negative result and 452 had a positive result and there were 14,305 
females (52.85%) and 12,761 males. 
 
Sample Return Time 
Sample return time can affect FIT screening outcomes due to the degradation of 
haemoglobin present in the sample, leading to false negative results.49 The manufacturer 
Eiken Chemical Co., Ltd state that the stability of Haemoglobin for the OC-SENSOR should 
last up to 14 days if the ambient temperature is between 2 and 10 ˚C or up to 7 days if 
stored at room temperature. The time taken from sample (F_SAMPLE_DATE) to laboratory 
receipt (DATE_KIT_LOGGED) was investigated using the corresponding dates recorded on 
the BCSS.  
 
Ambient Temperature 
Ambient temperature has been shown to affect the positivity rate of the FIT.50-53 Ambient 
temperature that the FIT was exposed to once the sample had been completed was 
estimated by determining the median time from sample date (F_SAMPLE_DATE) to when 
the FIT was received at the lab (DATE_KIT_LOGGED) (2 days). This gives a day for the 
sample, day in the post and a day for receipt at the lab so it was assumed the FIT would be 
exposed to ambient temperature for 3 days. The daily maximum temperature across these 
days for each participant was then determined and this variable was named ‘maximum 
mean temperature’. This is a similar method to that of Daley et al.51 who investigated the 
effect of ambient temperature on positivity rate. 
 
Temperature data were obtained from the UK Met Office, providing data for each weather 
station in the UK.54 Data were downloaded as CSV files from 
http://datamarket.azure.com/dataset/datagovuk/metofficeweatheropendata. This dataset 
it provided to data.gov.uk by the UK Met Office and is hosted by Windows Azure 
Datamarket. The Church Lawford station (site code 3544) was the nearest station to the 
Midlands hub and Farnborough weather station (site code 3768) was the nearest weather 
station to the Southern hub. These stations were used as a regional estimate for every 
participant within the region. 
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2.8 Reproducing the Dataset 
 
Data were provided by NHS Digital as separate dataframes: Subjects, Episodes, Testkits, 
Colonoscopy Assessment, Diagnostic and Polyps. These dataframes were cleaned and 
merged for the analysis as appropriate. A data schematic, and how the data were merged 
for analysis, is given in Figure 1 below. 
 
  
 
 
Figure 1: Data schematic and linkage across dataframes for the FIT pilot data extract provided from NHS Digital 
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The ‘Subject’ dataframe was merged with the ‘Testkit’ dataframe and subsetted to FIT tests 
only (n=40,930). The FIT kit results were then limited to normal/abnormal which removed 
the results which were classed as ‘spoilt’. Individuals with multiple test kits were limited to 
the most recent result giving a one to one relationship for subject and test kit. The 
‘Episodes’ dataframe was then merged with this dataset to obtain the 
LATEST_EVENT_DESC_CLOSED field which was used to determine the definitive outcome 
for an individual. This final dataset was then limited to those individuals who adequately 
participated (those who returned the FIT kit and have a definitive result) (n=27,066). To 
investigate the demographics of those with an abnormal test kit the dataset was limited to 
those with a FIT result of ≥20 μg Hb/g faeces (n=2117) this sample population was also 
used for univariable analysis. For multivariable analysis and model building, complete cases 
were used which limited the sample size to n=1810.  
 
The LATEST_EVENT_DESC_CLOSED variable in combination with the ‘Diagnostic’ 
dataframes when needed was used to provide the definitive diagnosis. This field gives the 
latest status of that episode when it is closed. Where there was just a description and not a 
diagnostic outcome (e.g. Hand over into Symptomatic Care) the ‘Colonoscopy Assessment’, 
‘Diagnostic’ and ‘Polyps’ dataframes were investigated for each individual to determine the 
diagnostic outcome. Where there was more than one diagnostic outcome recorded for an 
individual, the ‘greatest risk’ scenario was used. Where a diagnostic appointment was 
made and an individual did not attend, this was classified as ‘Not attended’ and where an 
appointment was cancelled the outcome was classified as ‘Cancelled’ (See Appendix 4 to 
see how individuals were classified). The possible outcome categories for an individual 
were: Subject Discharge (Normal), Abnormal, Low-risk Adenoma, Normal (No 
Abnormalities Found), Intermediate-risk Adenoma, High-risk Adenoma, Cancer, Cancelled 
and Not Attended. 
 
2.9 Estimation of Test Accuracy Measures for a Population with Negative FIT 
Results 
 
 
Since the data provided from the BCSS does not provide follow up information and 
diagnoses for those with negative screening test results, exploratory analyses were 
conducted to provide estimates of test accuracy measures for the FIT used in this sample 
population. Two approaches were used to calculate estimates of test accuracy. Firstly, the 
ratio of interval cancers to screen detected cancers for FIT was obtained from a recent 
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systematic review55 and applied to the study data to populate a 2 by 2 table. The 
prevalence of colorectal cancer/polyps from the dataset extracted from GP records for a 
screening population in Chapter 5 was also used as a comparison. Lastly, a logit model was 
used to extrapolate the proportion of cancers/advanced adenomas for those with a 
screening test of <20 μg/g and this data was used to populate a 2 by 2 table for the study 
dataset. 
3.0 RESULTS 
3.1 Study Population 
 
From the total of 40,930 individuals who were sent a FIT kit, 27,066 (66.13%) adequately 
participated (those who had a definitive positive or negative result) and from this 2,117 
(7.82%) had a FIT result of ≥20 μg Hb/g faeces which was classed as positive.  From this 
group, 1818 (85.88%) had a definitive outcome recorded (i.e. not ‘cancelled’ or ‘not 
attended’).  This is a similar proportion of those undergoing further investigation as 
reported in other studies.56 Where a diagnostic appointment was made and an individual 
did not attend, this was classified as ‘Not attended’ and where an appointment was 
cancelled the outcome was classified as ‘Cancelled’ (Appendix 5). Eight records were 
missing IMD and so a final population of 1810 participants were used for multiple logistic 
regression analysis (Figure 2 for study flow diagram). The mean age of this group was 66.54 
years (See Table 3 for outcome by age and sex). The FIT result ranged from 20 μg Hb/g 
faeces to 20,854 μg Hb/g faeces (other studies have reported similarly high results7), with a 
median result of 55.6 μg Hb/g faeces. There were 912 individuals served by the Midlands 
hub and 898 by the Southern hub.  
 
Seventy-three cancers, 214 high risk adenomas, 262 intermediate risk adenomas and 466 
low risk adenomas were detected in the study group. This gave 549 cases with a positive 
outcome (cancer and advanced adenomas) and 1261 participants with a negative outcome. 
The FIT concentration increased relative to the severity of the outcome (Figure 3) i.e. a 
normal result had the lowest FIT concentrations on average compared to cancers having 
the highest FIT results on average.  
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Figure 2: Study flow diagram for the FIT data  
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Diagnostic outcome by age and sex (n=1810) 
Diagnostic 
outcome 
Age Category Female Age Category Male 
 ≤60 61-65 66-70 71-75 Total ≤60 61-65 66-70 71-75 Total 
Abnormal                           29  
(10.3%) 
90 
(31.9%) 
93 
(33%.0%) 
70 
(24.8%) 
282 
(100%) 
28 
(11.2%) 
86 
(34.5%) 
85 
(34.1%) 
50 
(20.1%) 
249 
(100%) 
Cancer                              2  
(8.7%) 
5 
(21.7%) 
6 
(26.1%) 
10 
(43.5%) 
23 
(100%) 
4 
(8.0%) 
15 
(30.0%) 
21 
(42.0%) 
10 
(20.0%) 
50 
(100%) 
High risk 
Adenoma  
7  
(10.1%) 
12 
(17.4%) 
27 
(39.1%) 
23 
(33.3%) 
69 
(100%) 
17 
(11.7%) 
37 
(25.5%) 
58 
(40.0%) 
33 
(22.8%) 
145 
(100%) 
Intermediate risk 
Adenoma 
13  
(13.1%) 
23 
(23.2%) 
45 
(45.5%) 
18 
(18.2%) 
99 
(100%) 
20 
(12.3%) 
53 
(32.5%) 
52 
(31.9%) 
38 
(23.3%) 
163 
(100%) 
Low risk Adenoma  18  
(8.9%) 
67 
(33.0%) 
73 
(36.0%) 
45 
(22.17%) 
203 
(100%) 
33 
(12.5%) 
84 
(31.9%) 
90 
(34.2%) 
56 
(21.3%) 
263 
(100%) 
Normal (No 
Abnormalities 
Found)  
23  
(16.0%) 
45 
(45.5%) 
57 
(39.6%) 
19 
(13.19%) 
144 
(100%) 
13 
(10.8%) 
39 
(32.5%) 
36 
(30.0%) 
32 
(26.7%) 
120 
(100%) 
Total 92 
(11.2%) 
242 
(29.5%) 
301 
(36.7%) 
185 
(22.6%) 
820 
(100%) 
115 
(11.6%) 
314 
(31.7%) 
342 
(34.5%) 
219 
(22.1%) 
990 
(100%) 
Table 3: Diagnostic outcome by age and sex for included participants who adequately participated, had a FIT 
≥20 μg Hb/g faeces and with a definitive outcome (n=1810) 
 
 
 
Figure 3: Boxplots of FIT concentration ordered by median for each diagnostic outcome from a normal 
diagnostic test to the detection of CRC (n=1810). Line is the median, box is the interquartile range, whiskers give 
1.5 times the interquartile range and observations outside of this are plotted individually. 
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3.2 Univariable Logistic Regression (n=2116) 
 
The association of the routine risk indicators with the detection of colorectal cancer and 
advanced adenomas at colonoscopy are given below using the population who had a FIT 
result ≥20 μg/g to utilize all available data (n=2116). Risk indicators found to be significant 
(p value <0.05) in univariable analysis included the FIT result, sex and previous response to 
screening. The odds of a male being diagnosed at colonoscopy with cancer or advanced 
adenoma was 1.88 times higher compared to females (OR 1.88, 95% CI: 1.53-2.31). A 
previous non-responder to screening was 2.7 times more likely of having the outcome 
diagnosed at colonoscopy compared to a first time screenee at baseline (OR 2.7, 95% CI: 
1.77-4.17). 
 
Variable P-value Odds Ratio (95% CI) Missing (n) 
Log of FIT result 0.00 1.46 (1.33-1.60) 298 observations 
deleted  
due to missingness 
Age (at episode start) (continuous) 0.06 1.02 (0.999-1.05) 298 
Male (female as base) 0.00 1.88 (1.53-2.31) 298 
IMD Score  0.53 0.997 (0.99-1.00) 306 
Rank of IMD Score 0.27 1.00 (0.99-1.00) 306 
PREVIOUS RESPONSE TO SCREENING    
First Time invitee - - 298 
Previous non-responder (compared to first 
time screenee at baseline) 
0.00 2.70 (1.77-4.17) 298 
Previous responder (compared to first time 
screenee at baseline) 
0.03 1.50 (1.05-2.19) 298 
Southern hub (compared to Midlands at 
baseline) 
0.64 1.05 (0.86-1.28) 298 
 
Table 4: Univariable logistic regression of BCSS routine data with colorectal cancer/advanced adenoma detected 
at colonoscopy.  
 
3.3 Multivariable Logistic Regression (n=1810) 
 
The logistic regression model with FIT only is given in Table 5. Complete cases were used 
for multiple logistic regression analysis (n=1810). Backwards elimination with cross 
validation was used to build a multivariable logistic regression model (Table 6). The p-
values for the likelihood ratio test were analysed to determine whether a variable should 
be dropped from the model using cross-validation. Risk indicators found to be significant 
and retained in the model with a p value of <0.1 were the FIT result, sex and previous 
screening history. The full risk equation is given below in Equation 1. 
 
The odds of colorectal cancer and advanced adenoma increase as the FIT result increases 
(OR: 1.434, CI: 1.309 – 1.573), for males (OR: 1.749, CI: 1.415 – 2.166) and for previous non-
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responders (OR: 2.271, CI: 1.422 – 3.667). Age was not found to have a statistically 
significant influence on whether cancer was detected, but was retained in the model due 
to clinical importance and it was found to be a significant predictor in the literature and 
Chapter 2 (OR: 1.020, CI: 0.889 – 2.112).7 8 43 All possible pairwise interactions were 
investigated due to the small number of predictors retained, none of which were significant 
at the 5% level.  
 
Statistical power calculations for reliable predictions frequently consider the rule of thumb 
of 10 events per variable (EPV) as demonstrated in two simulation studies.19 57 58 The events 
per variable/parameter for this model were 91.5 (549 events/5 parameters plus 1 for the 
parameter representing the constant). This result satisfies the rule and suggests that there 
are enough EPVs to accurately estimate the coefficients in the logistic regression model. 
Prediction models with EPVs below ten can be overfitted to the data. 
 
 
Coefficients  Estimate  Std. Error Bootstrapped 
coefficient 
bias 
Bootstrapped 
standard error 
Pr (>|z|) OR 95% CI 
Intercept -2.487 
 
0.212 -0.005 0.217 <0.001  0.083  
(0.055 – 0.126) 
log(FIT Result +1) 0.374 0.046 0.001 0.048 <0.001  1.454 (1.329 – 
1.592) 
Null deviance – 2221.4 on 1809 degrees of freedom Residual deviance – 2153.6 on 1808 degrees of freedom AIC – 2157.6 
Number of Fisher Scoring Iterations  - 4  
Table 5: FIT only Logistic Regression Model 
 
Coefficients  Estimate  Std. Error Bootstrapped 
coefficient 
bias 
Bootstrapped 
std. error 
Pr (>|z|) OR 95% CI 
Intercept -4.439 
 
0.934 -2.167e-02  0.949 
 
<0.001 0.012  
(0.002 – 0.073) 
log(FIT Result +1) 0.360 
 
0.047 1.963e-03 0.049 
 
<0.001 1.434  
(1.309 – 1.573) 
Age at episode start 0.020 
 
0.015 6.691e-05 0.015 
 
0.171 1.020  
(0.991-1.050) 
Sex (male) 0.559 
 
0.109 1.360e-03 0.108 
 
<0.001 1.749  
(1.415-2.166) 
First Time Invitee 0.000 - - - - - 
Previous non 
responder (compared 
to first time screen) 
0.820 0.241 3.818e-03 0.245 
 
0.001 2.271  
(1.422-3.667) 
Previous responder 
(compared to first time 
screen) 
0.308 
 
0.220 6.516e-03 0.220 
 
0.162 1.361  
(0.889 – 2.112) 
Null deviance – 2221.4 on 1809 degrees of freedom     Residual deviance – 2103.0 on 1804 degrees of freedom 
AIC – 2115 Number of Fisher Scoring Iterations – 4       Nagelkerke’s R2  - 0.09 (risk-adjusted model) and 0.05 (FIT only) 
Events per variable/parameter - 91.5 (549 events/5 parameters plus 1 for the parameter representing the constant)    
Table 6: Multiple Logistic Regression Model (FIT combined with risk indicators) 
  
  
 
114 
  
Chapter 3 Chapter three | Risk Prediction Model Combining the FIT and Routine Screening Data 
Risk Equation:  
 
 
logit(𝑝(𝑥)) = log (
𝑝(𝑥)
1 − 𝑝(𝑥)
) = 𝑎 +  𝛽𝑋1 +  𝛽𝑋2 + ⋯ 
 
𝑝 =  
𝑒𝑎+ 𝛽𝑋1+ 𝛽𝑋2+⋯
1 +  𝑒𝑎+ 𝛽𝑋1+ 𝛽𝑋2+⋯
 
 
𝑝 =probability  
𝑎 =constant 
𝛽 =coefficient predictor variable  
 
𝒑 =  
𝒆−𝟒.𝟒𝟒+ 𝟎.𝟑𝟔𝟎𝑿𝟏+ 𝟎.𝟎𝟐𝑿𝟐+ 𝟎.𝟓𝟔𝑿𝟑 + 𝟎.𝟖𝟐𝑿𝟒 + 𝟎.𝟑𝟏𝑿𝟓
𝟏 +  𝒆−𝟒.𝟒𝟒+ 𝟎.𝟑𝟔𝟎𝑿𝟏+ 𝟎.𝟎𝟐𝑿𝟐+ 𝟎.𝟓𝟔𝑿𝟑 + 𝟎.𝟖𝟐𝑿𝟒 + 𝟎.𝟑𝟏𝑿𝟓
 
 
𝑝 =probability  
𝑎 =constant 
𝛽 =coefficient predictor variable  
𝑥1 = log(FIT Result +1) 
𝑥2 =Age at episode start 
𝑥3 =Sex (male) 
𝑥4 = Previous non responder (compared to first time screen) 
𝑥5 = Previous responder (compared to first time screen) 
 
 
Equation 1: Risk equation for the multivariable model combining FIT with other risk predictors. 
 
3.4 Overall Model FIT 
 
The deviance for the FIT only model was 2153.6 on 1808 degrees of freedom (cross 
validated deviance 2157.8), the risk adjusted model improved this measure giving a value 
of 2103.0 on 1804 degrees of freedom (cross validated deviance 2113.995). The likelihood 
ratio test was used to compare the goodness of fit of the nested models by assessing the 
difference in deviance. The risk-adjusted model had a significantly better fit compared to 
FIT only: χ²(4) = 50.57, p<0.001).  
 
The overall model fit for the logistic regression models was also assessed using pseudo R2 
measures (Table 7). Cox and Snell’s R2  assesses the improvement of the full model over the 
intercept model and gives a value of 0.037 for the FIT only model compared to 0.063 for 
the risk-adjusted model. Nagelkerke’s R2 was 0.090 for the risk adjusted model compared 
with 0.052 for the FIT only model. 
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Pseudo R2 FIT only Model Risk adjusted Model 
McFadden      0.031  0.053        
Adj.McFadden         0.028 0.047  
Cox.Snell        0.037  0.063  
Nagelkerke 0.052  0.090  
McKelvey.Zavoina            0.049  0.090  
Effron             0.038  0.065  
Count 0.696            0.701             
Adj.Count               -0.004  0.015  
AIC     2157.6 2115.0                    
Corrected.AIC 2157.6 2115.1 
 
Table 7: Pseudo R2 measures for the multivariable logistic regression model (FIT combined with risk indicators) 
 
3.5 Calibration 
 
Calibration assesses the agreement between the observed and expected risk. The 
calibration plots of observed risk against predicted risk are given for both models in Figure 
4 where the study group is split into deciles according to their predicted probabilities. The 
Hosmer-Lemeshow goodness of fit test is used to assess calibration. The calibration for the 
risk-adjusted model was 0.898 versus 0.481 for the FIT (Table 8 and Table 9). Small p-
values and points which are far from the line of equality in the calibration plot indicate a 
poor fit. A well calibrated model has predictions around the 45 degree line on the 
calibration plot with a slope close to 1 and intercept close to 0. Since the number of group 
splits for the predicted probabilities can affect the corresponding Hosmer and Lemeshow p 
values, group divisions between 5-15 and their p-values are presented in Appendix 6. The 
slope/gradient of the FIT only model based on the calibration plot was 1.005x and for the 
risk-adjusted model 1.028x. The closer the calibration slope to 1, the better the fit of the 
model. 
 
Figure 4: Calibration plot of observed risk versus predicted risk for FIT only (left) and risk-adjusted FIT models 
(right). 
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Model 2 risk 
adjusted 
Calibration 
Total Mean of the predicted 
probabilities  
Mean of the 
observed 
probabilities 
Predicted 
number of cases 
Observed 
number of cases 
[0.105,0.171)    181 0.150    0.160      27.18        29 
[0.171,0.194)    181 0.182    0.155      32.97        28 
[0.194,0.227)    181 0.210    0.199      37.97        36 
[0.227,0.260)    181 0.244    0.254      44.24        46 
[0.260,0.285)    181 0.274    0.254      49.55        46 
[0.285,0.313) 181 0.299    0.326      54.17        59 
[0.313,0.346)    181 0.329    0.320      59.51        58 
[0.346,0.392)    181 0.369    0.403      66.84        73 
[0.392,0.462) 181 0.423    0.403      76.59        73 
[0.462,0.843]    181 0.552    0.558      99.98       101 
Chi squared – 3.52 degrees of freedom – 8  p value - 0.8977 
Table 8: Observed versus expected risk for the Hosmer-Lemeshow goodness of fit test using deciles of risk for the 
risk-adjusted model 
Model 1 FIT only 
Calibration 
Total Mean of the predicted 
probabilities  
Mean of the 
observed 
probabilities 
Predicted 
number of 
cases 
Observed 
number of cases 
[0.206,0.219) 184 0.213    0.196      39.15        36 
[0.219,0.233)    182 0.225    0.203      41.04        37 
[0.233,0.245)    177 0.239    0.215      42.30        38 
[0.245,0.259) 185 0.252    0.227      46.60        42 
[0.259,0.274)    181 0.267    0.271      48.37        49 
[0.274,0.294) 177 0.283    0.271      50.12        48 
[0.294,0.320)    181 0.306    0.370      55.38        67 
[0.320,0.363)    181 0.339    0.376      61.40        68 
[0.363,0.434)    181 0.393    0.414      71.15        75 
[0.434,0.775]    181 0.517    0.492      93.49        89 
Chi squared – 7.53 degrees of freedom – 8 p value - 0.4807 
Table 9: Observed versus expected risk for the Hosmer-Lemeshow goodness of fit test using deciles of risk for the 
FIT only model 
 
3.6 Discrimination 
 
Discrimination was measured by assessing the area under the ROC curve. This measure 
determines how well the model can discriminate between those with and those without 
the outcome of interest. The ROC curves for both models are presented below. The AUC 
for the FIT only model was 0.63 (95% CI: 0.60 - 0.66) compared to 0.66 for the risk-adjusted 
model indicating improved discrimination (95% CI: 0.63 - 0.69). A ROC test using 10,000 
bootstrap iterations shows that the AUCs are significantly different (D = -2.7601, p-value = 
0.006).  
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3.7 Predictiveness Curve 
 
The predictiveness curve for the risk-adjusted model is presented in Figure 5. The 
predictiveness curve integrates two statistical approaches to model evaluation; modelling 
the risk of disease and classification performance. This is achieved by displaying 
information on both classification and predictiveness within one plot. A risk threshold of 
0.389 using the risk-adjusted model is equivalent to a FIT cut-off of 160 μg/g (setting the 
recall rate the same). With a risk probability of 0.389, around 21% of patients in the cohort 
have risk probabilities at or above this threshold using the risk-adjusted model. For FIT only 
on the other hand around 18% have risk probabilities above this threshold. The plot 
summarizes the distribution and range of risk probabilities from the model and from FIT 
only. A reference line can be included at 0.30, which represents the prevalence of disease 
in the sample, to correspond to a predictiveness curve for an uninformative risk model 
(assigning subjects at the same risk).48  
 
 
Figure 5: Predictiveness curves for the FIT only model and Risk adjusted model 
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3.8 Test Accuracy  
 
Test accuracy is presented in a 2 by 2 table for a threshold of 160 μg/g in Table 10. At all 
investigated thresholds (30-180 μg Hb/g faeces), the sensitivity and specificity of risk 
adjusted FIT is greater than FIT alone (see Table 11).  Individuals were sorted by predicted 
probability and the number of referrals kept the same between using the FIT alone and 
using risk adjusted FIT. For instance, for a FIT cut-off of 160 μg/g, 375 individuals had a 
positive result and for an equivalent threshold of risk (predicted probability of 0.389) 375 
individuals would also be referred when applying the logistic regression model. At this 
threshold, the FIT has a sensitivity of 30.78% versus 33.15% for the risk-adjusted model and 
a specificity of 83.66% versus 84.69%. The ROC curves are given for both models in Figure 6 
which displays the sensitivity and specificity pairs for all available thresholds. 
 
The risk-adjusted model for this sample population leads to the detection of 13 additional 
advanced adenomas and the same number of cancers (17 more high risk adenomas, 4 
fewer intermediate risk adenomas) when compared to the FIT only at an equivalent 
threshold of 160 μg/g. The severity profiles of the detected lesions are shown in Table 10 
(further thresholds are presented in Chapter 4). The risk-adjusted model therefore 
improves the diagnostic yield of high-risk adenomas. At the same time, there is a reduction 
in the number of false positives and negatives as well as an increase in the number of true 
negatives.   
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2 by 2 table for FIT only and the risk-adjusted logistic regression model 
160 μg Hb/g faeces  
Threshold 
Diagnostic Positive Diagnostic Negative 
Total 
FIT Risk-adjusted FIT Risk-adjusted 
FIT/Risk Positive 
169 182 206 193 
375 
37 - Cancer 37 - Cancer 70 - Abnormal 69 - Abnormal 
66 - High Risk 
Adenoma 
83- High Risk Adenoma 
92 - Low Risk 
Adenoma 
81 - Low Risk 
Adenoma 
66 - Intermediate 
Risk Adenoma 
62 - Intermediate Risk 
Adenoma 
44 - Normal (No 
Abnormalities 
Found) 
43 - Normal (No 
Abnormalities 
Found) 
FIT/Risk Negative 
380 367 1055 1068 
1435 
36 - Cancer 36 - Cancer 396 - Abnormal 397 - Abnormal 
148 - High Risk 
Adenoma 
131 - High Risk 
Adenoma 
439 - Low Risk 
Adenoma 
450 - Low Risk 
Adenoma 
196 - Intermediate 
Risk Adenoma 
200 - Intermediate Risk 
Adenoma 
220 - Normal (No 
Abnormalities 
Found) 
221 - Normal (No 
Abnormalities 
Found) 
Total 549 1261 1810 
FIT only: Sensitivity 30.78%, Specificity 83.66%, PPV 45.07%, NPV 73.52%, FIT positivity 20.72%, Cancer Detection Rate 9.34% 
Risk adjusted: Sensitivity 33.15%, Specificity 84.69%, PPV 48.53%, NPV 74.42%, FIT positivity 20.72%, Cancer Detection Rate 10.60% 
Table 10: 2 by 2 table for FIT only and the risk-adjusted logistic regression model. A threshold of 160 μg Hb/g 
faeces was used for the FIT which is equivalent to a risk threshold of 0.389 for the risk-adjusted model. Profiles 
of outcome severity are also given. 
  
  
 
120 
  
Chapter 3 Chapter three | Risk Prediction Model Combining the FIT and Routine Screening Data 
Clinical sensitivity and specificity pairs for FIT thresholds between 30 and 180 μg Hb/g faeces and the corresponding risk 
thresholds. 
Model FIT (μg Hb/g faeces)/ 
Risk Threshold (probability) 
Sensitivity (%) Specificity (%) 
FIT only 
Risk-adjusted LR 
30.00 
0.191 
88.34 
90.35 
22.20 
23.08 
FIT only 
Risk-adjusted LR 
40.00 
0.242 
76.68 
80.15 
38.94 
40.44 
FIT only 
Risk-adjusted LR 
50.00 
0.272 
69.03 
70.86 
50.04 
50.83 
FIT only 
Risk-adjusted LR 
60.00 
0.295 
60.66 
62.48 
59.24 
60.03 
FIT only 
Risk-adjusted LR 
70.00 
0.310 
55.19 
57.19 
64.63 
65.42 
FIT only 
Risk-adjusted LR 
80.00 
0.321 
51.18 
52.64 
69.31 
69.94 
FIT only 
Risk-adjusted LR 
90.00 
0.336 
45.72 
48.63 
72.56 
73.83 
FIT only 
Risk-adjusted LR 
100.00 
0.346 
42.44 
44.99 
75.26 
76.37 
FIT only 
Risk-adjusted LR 
110.00 
0.356 
40.07 
42.99 
77.08 
78.35 
FIT only 
Risk-adjusted LR 
120.00 
0.362 
38.07 
40.26 
78.59 
79.54 
FIT only 
Risk-adjusted LR 
130.00 
0.371 
34.79 
37.89 
80.33 
81.68 
FIT only 
Risk-adjusted LR 
140.00 
0.379 
33.70 
36.25 
81.60 
82.71 
FIT only 
Risk-adjusted LR 
150.00 
0.383 
32.42 
35.15 
82.39 
83.58 
FIT only 
Risk-adjusted LR 
160.00 
0.389 
30.78 
33.15 
83.66 
84.69 
FIT only 
Risk-adjusted LR 
170.00 
0.392 
29.87 
31.69 
84.30 
85.09 
FIT only 
Risk-adjusted LRs 
180.00 
0.399 
28.60 
30.05 
85.57 
86.20 
Table 11: Clinical sensitivity and specificity pairs for FIT thresholds between 30 and 180 μg Hb/g faeces and the 
corresponding risk thresholds for the logistic regression model. 
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AUC (95% CI) for the Risk-adjusted Logistic Regression Model:  0.659 (0.632  -  0.686) 
AUC (95% CI) for the FIT only:  0.628 (0.600  -  0.656) 
 
Figure 6: ROC curves for FIT only compared to risk-adjusted FIT 
 
3.9 Test Accuracy for Subgroups 
 
Presenting the results by sex, Table 12 shows the risk model at 160 μg/g recalls more men 
and fewer women, increases detection in men but decreases detection in women in 
comparison to the FIT result alone. The FIT result alone recalled 225 men (115 TP – true 
positives, 110 FP – false positives) of which 115 had cancer or advanced adenoma (51.11%), 
and 150 women (54 TP, 96 FP) where 54 (36%) had cancer or advanced adenoma. The 
logistic regression model recalled 314 men (156 TP, 158 FP) of which 156 (49.68%) had 
cancer or advanced adenoma, and 61 women (26 TP, 35 FP) where 26 (42.62%) had cancer 
or advanced adenoma. Detection rates by screening history and sex subgroup are shown in 
Table 13. There is a reduction in the detection rate for female first time invitees and the 
detection rate for male previous non-responders more than doubled (16.98% to 37.11%). 
   
2 by 2 table for FIT only and the risk-adjusted logistic regression model split by sex. 
  Diagnostic Positive Diagnostic Negative   
160 μg Hb/g faeces 
  FIT only Risk-adjusted 
 
FIT only Risk-adjusted Total 
Threshold 
    Male Female Male Female   Male Female Male Female 
375 
  Total 115 54 156 26 Total 110 96 158 35 
FIT/Risk Positive Cancer 27 10 29 8 Low Risk Adenoma 41 29 60 9 
  High risk Adenoma 45 21 72 11 Abnormal 51 41 66 15 
  
Intermediate risk 
Adenoma 
43 23 55 7 
Normal (No 
Abnormalities Found) 
18 26 32 11 
    Male Female Male Female 
 
Male Female Male Female 
1435 
  Total 243 137 202 165 Total 522 533 474 594 
FIT/Risk Negative Cancer 23 13 21 15 Low Risk Adenoma 222 174 203 194 
  High risk Adenoma 100 48 73 58 Abnormal 198 241 183 267 
  
Intermediate risk 
Adenoma 
120 76 108 92 
Normal (No 
Abnormalities Found) 
102 118 88 133 
Total 549 1261 1810 
Table 12: 2 by 2 table for FIT only and the risk-adjusted logistic regression model split by sex. A threshold of 160 μg Hb/g faeces was used for the FIT which is equivalent to a risk 
threshold of 0.389 for the risk-adjusted model. Profiles of outcome severity are also given. 
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Cancer/advanced adenoma detection rate by screening history and sex subgroup 
 FIT Only Risk Model 
Subgroup TP FP FN TN Cancer/Advanced 
Adenoma  
Detection Rate (%) 
TP FP FN TN Cancer/Advanced 
Adenoma  
Detection Rate (%) 
Female First Time 
Invitee 
4 10 12 64 4.44 0 1 16 73 0.00 
Male First Time 
Invitee 
12 14 13 61 12.00 5 6 20 69 5.00 
Female Non 
Responder 
14 10 18 49 15.38 14 12 18 47 15.38 
Male Non 
Responder 
27 15 47 70 16.98 59 63 15 22 37.11 
Female Responder 36 76 107 420 5.63 12 22 131 474 1.88 
Male Responder 76 81 183 391 10.40 92 89 167 383 12.59 
TP – True Positive; FP – False Positive; FN- False Negative; TN – True Negative  
Table 13: Cancer/advanced adenoma detection rate by screening history and sex subgroup (Threshold 160 μg 
Hb/g) for the FIT only and risk-adjusted model. 
3.10 Additional Predictors and their effect on FIT positivity 
 
For the sample population that had adequately participated with a definitive FIT result of 
positive or negative (n=27,066) there were 498 missing results for sample return time and 
mean maximum temperature. This is most likely due to the participant not filling out the 
sample date on the FIT kit properly. This was a relatively low number of individuals so these 
were excluded from the unvariable analysis. 26,614 participants had a negative result and 
452 had a positive result and there were 14,305 females (52.85%) and 12,761 males. The 
mean return time was 2.14 days (SD: 1.26) and the mean maximum ambient temperature 
was 18.92°C (SD: 3.64) (boxplots for these variables are provided in Appendix 7). Time 
series plots for mean maximum temperatures are shown for both the Midlands and 
Southern hubs in Figure 7 and Figure 8. 
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Figure 7: Time series plot showing the mean maximum temperature recorded each day for the Midlands Hub 
from April 2014 to July 2015. 
 
Figure 8: Time series plot showing the mean maximum temperature recorded each day for the Southern Hub 
from April 2014 to July 2015. 
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Univariable logistic regression at a threshold of 160 μg Hb/g faeces (Table 14) shows that 
sample return time is statistically significant and associated with a positive FIT result. As 
sample return time increases by 1 day, the odds of FIT positivity increases by 0.105. This 
result was still statistically significant when adjusting for sex, previous screening history and 
age (p=0.003). Sex was significant, even after adjusting for screening history and age 
(p<0.001). IMD was still significant after adjusting for sex, previous screening history and 
age (p<0.001). Conversely, the ambient temperature that FIT is exposed to was not 
statistically significant. The screening hub becomes no longer significant when adjusting for 
IMD, Sex and age (p=0.326) as these factors would explain underlying differences in the 
populations served by the hubs. 
 
Variable P-value Odds Ratio (95% CI) Missing (n) 
Sample Return Time <0.001 1.10 (1.04-1.17) 498 observations deleted  
due to missingness 
Ambient Mean Maximum Temperature 0.467 0.99 (0.96-1.02) 498  
Sex (males compared to females at 
baseline) 
<0.001 1.84 (1.52-2.24) 0 
Age 0.016 1.03 (1.01-1.05) 0 
First Time invitee - - 298 
Previous non-responder (compared to 
first time screenee at baseline) 
<0.001 2.55 (1.79-3.68) 0 
Previous responder (compared to first 
time screenee at baseline) 
0.09 1.31 (0.97-1.80) 0 
IMD Score <0.001 1.01 (1.01-1.02) 200  
Screening Hub (southern hub compared to 
midlands at baseline) 
0.037 0.82 (0.68-0.99) 0 
Table 14: Univariable logistic regression results for a threshold of 160 μg/g. 
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3.11 Estimation of Test Accuracy Measures for a Population with a Negative FIT 
Result 
 
 
This section describes exploratory analyses to provide estimates of test accuracy measures 
for the FIT used in this sample population (in particular the NPV). Ideally, to determine 
unbiased diagnostic accuracy measures, all individuals who are screened should be tested 
with a diagnostic reference standard. This is a common limitation for population based 
screening studies which have large sample populations but do not offer diagnostic testing 
to individuals below a screening test cutoff (in this case 20 μg Hb/g faeces) due to cost 
effectiveness. This leads to partial verification bias where there is selectively missing data 
on disease outcome causing biased estimates of test accuracy.59 A sample population with 
a screening test of 20 μg Hb/g faeces and above will result in a population at higher risk of 
having colorectal cancer detected, potentially inflating test accuracy measures such as the 
sensitivity.   
 
Alternatively, two year follow up data can be used for those with a negative screening test 
result, linking screening data to the cancer registry. This too comes with its limitations due 
to the different reference standards used for diagnosis (colonoscopy versus two year follow 
up) leading to differential verification bias.59 Screening for instance is more likely to identify 
slow growing disease compared to those which present symptomatically (length time 
bias).60 
 
An additional consideration when investigating false negative results or interval cancers are 
the different definitions of interval cancers which may be used in each study. Screening 
programmes often define interval cancers as those missed at colonoscopy and by the 
screening test.61 Interval cancers can be considered different to a false negative screening 
result which is defined at the time of colonoscopy (a shorter term outcome).  
 
Two approaches were considered to estimate test accuracy for the sample population;  
(i) Modelling the available data to extrapolate the proportion of cancers for those with a 
screening test of less than 20 μg Hb/g faeces and (ii) Examining data available in the 
literature. 
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Examining the Literature 
A recent systematic review by Wieten et al.55 identified that the incidence rate for 
colorectal interval cancers is lower when using the FIT (20 interval cancers per 100,000 
person years) compared to the guaiac based test (34 interval cancers per 100,000 person 
years).  The findings suggest that for each interval cancer missed by the FIT, 2.6 screen 
detected colorectal cancers are diagnosed, whereas for the gFOBT the ratio is 1 to 1.2. 
Based on these figures, the following 2 by 2 table can be estimated using the data from this 
study, whereby screen detected cancers have a ratio of 2.6 to 1 interval cancer (Table 15).  
 
The ratio may be underestimated because it did not include advanced adenomas in 
addition to cancers but provides a reasonable estimate for these data. The sensitivity found 
from this estimate was 0.72 along with a specificity of 0.95 which matches reasonably 
closely the pooled estimate 0.79 (95% CI, 0.69 to 0.86) from the systematic review of faecal 
immunochemical test accuracy by Lee et al.62 The PPV was 0.30 which is specific to the 
prevalence of the sample population and the NPV was estimated as 0.99. The prevalence of 
colorectal cancer and advanced adenomas in the study was 2.84% based on these 
estimated values.  
 Positive Diagnostic 
Result 
Negative Diagnostic 
Result 
Total 
FIT positive 
> 20 μg/g 
549 1261 1810 
FIT negative 
< 20 μg/g 
212 24,737 24949 
Total 761 25,998 26,759 
Sensitivity: 0.72%, Specificity: 0.95%, PPV: 0.30, NPV: 0.99, Sample prevalence: 2.84%, FIT positivity 6.76%. 
Excluded: Those with positive test result (>20 μg/g) but with no diagnostic outcome (27,066 – 307 = 26,759).  
This will most likely underestimate the number of true positive results. 
Table 15: 2 by 2 table using estimated interval cancer ratios from the literature,55 and applying to the data 
obtained from this study. 
In a randomised population based screening study in the Netherlands, where everyone 
obtained a colonoscopy regardless of FIT result, the sensitivity was 31% (95% CI: 23-40) and 
specificity 97% (95% CI: 96-98) for advanced neoplasia. The PPV for advanced adenoma 
was 52% (95% CI: 40-64) and NPV 93% (95% CI: 91-94), both these measures are 
dependent on the prevalence in the sample population. The FIT positivity was 6% using a 
cut-off of 20 μg/g and sample prevalence for advanced neoplasia was 9% and for CRC 0.6%. 
The prevalence appears higher since the population tested in this study were screening 
naïve, whereas the FIT pilot data includes a mix of individuals who have had a different 
number of screening rounds. As screening rounds continue, the prevalence in advanced 
neoplasia will drop over time.  As a comparator, the Office for National Statistics data for 
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adults aged 60-74 in England in 2016 gave 0.997% for newly diagnosed cases of colorectal 
cancer.63 A study in Scotland looking at interval cancers 2 years after the last negative FIT 
result (80μg/g used as the threshold) had 31 interval cancers out of 30,893 participants 
with a definitive test result and 30 screen detected cancers giving a sample prevalence of 
0.197%.64  
 
Using the data obtained for a screening cohort extracted from GP records investigated in 
Chapter 5 can provide an additional comparison. Table 16 below shows a 2 by 2 table of 
colorectal cancer or polyp diagnosis by guaiac faecal occult blood test result for 
participants with 2 years of follow up. This data provides an overall estimate for the 
prevalence of cancer/polyps in an average risk screening population which is 3.55%. This 
estimate is higher than the previous estimated sample population prevalence (2.84%) and 
is presumably due to the inclusion of colorectal polyps as a diagnosis which can reflect less 
severe disease. The sensitivity and specificity are specific to the guaiac based test and 
match systematic review estimates reasonably closely (0.47 sensitivity, 0.92 specificity).65 
 
gFOBT result 
Cancer /Polyp 
Diagnosis Positive 
Cancer /Polyp 
Diagnosis Negative Total 
Positive 
220 colorectal cancers 
329 polyps 
=549 
1,084 1633 
Negative 
226 colorectal cancers 
297 polyps 
=523 
28,031 28,554 
Total 1072 29,115 30,187 
Sensitivity: 0.51, Specificity: 0.96, PPV: 0.34, NPV: 0.98, Sample prevalence: 3.55%, gFOBT positivity 5.41%. 
N=30,187 
Table 16: 2 by 2 table of colorectal cancer/polyp diagnosis by guaiac faecal occult blood test result for 
participants with 2 years of follow up (data from the study reported in Chapter 5). 
 
By applying the prevalence estimate of cancer/polyps to the FIT data in the current chapter 
(3.55%-2.05% = 1.50% remaining) the following results are obtained; Sensitivity 0.58, 
specificity 0.95, PPV 0.30, NPV 0.95. The NPV could be potentially underestimated due to 
the inclusion of colorectal polyps as a diagnostic outcome. This approach may also 
underestimate the sensitivity of the faecal immunochemical test (0.58) as the ratio of 
screen detected to interval cancers is based on gFOBT data. 
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 Positive Diagnostic 
Result 
Negative Diagnostic 
Result 
Total 
FIT positive 
> 20 μg/g 
549 1,261 1810 
FIT negative 
< 20 μg/g 
402 24,547 24,949 
Total 951 25,808 26,759 
Sensitivity: 0.58, Specificity: 0.95, PPV: 0.30, NPV: 0.98, Sample prevalence: 3.55%, FIT positivity 6.76%. 
Excluded: Those with positive test result (>20 μg/g) but with no diagnostic outcome (27,066 – 307 = 26,759).  
This will likely underestimate the number of true positive results. 
Table 17: 2 by 2 table estimating the number of false negative and true negative results using the sample 
prevalence obtained from Table 16. 
 
Modelling the available data to estimate the proportion of cancers for those with a result 
of less than 20 μg/g 
 
A model predicting cancer/advanced adenoma for those with a result of 20 μg/g or over 
could be used to extrapolate the expected proportion of those with undiagnosed 
cancer/advanced adenoma for a result of under 20 μg/g. Several assumptions would need 
to be made to produce such an estimate and different model types (e.g. logit, probit etc) 
could be investigated to determine which model has the best fit to the nature of the data.  
 
To illustrate such an approach, a logit model was fitted to the FIT result to predict a 
cancer/advanced adenoma outcome for those with a result of 20 μg/g or over. This sample 
population which has both a FIT result and outcome (n=1810) was split into deciles based 
on the FIT result and the logit model was fit over the top and illustrated in Figure 9. From 
this plot, the proportion of those with potential undiagnosed cancer/advanced adenomas 
for varying FIT results can be estimated. Alternatively the underlying model equation can 
be used to calculate more accurate figures. 
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Figure 9: Log of the FIT result plus 1 plotted against the estimated proportion of those with cancer based on the 
logit model developed using participant data with a FIT result of 20 μg/g and over with a diagnostic outcome 
and extrapolated for FIT results less than 20 μg/g (cancer here includes both advanced adenomas and colorectal 
cancers). 
 
To estimate the proportion of those with a FIT result of less than 20 μg/g who might have 
undiagnosed cancer/advanced adenoma, the proportion of people with a certain FIT result 
(between 1 to 19) out of those with a result of less than 20 μg/g (n=24,930) was multiplied 
by the probability of cancer/advanced adenoma based on the logit model fitted to the 
n=1810 population (Table 18). This gave an expected proportion of 3.5%. This may be an 
overestimate due to the probabilities being higher than anticipated based on this model. In 
addition, this model which used a small proportion of the total population (n=1810) is 
being used to predict outcomes for a larger sample population. The subsample used to 
build the model was at higher risk which can have repercussions for extrapolating 
predictions at lower test results.  
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 FIT 
Result 
(μg/g) 
p(x) Probability of 
cancer/advanced 
adenoma for this test 
result* 
Frequency of 
individuals with 
this FIT result 
Total sample 
population 
with a result 
of  
<20 μg/g 
f(x) Proportion of 
individuals with this FIT 
result out of the total 
number of those with a 
result of <20 μg/g 
 f(x)p(x) 
0 0.0000 15404 24,930 0.6179 0.0000 
1 0.0782 2718 24,930 0.1090 0.0085 
2 0.0866 1739 24,930 0.0698 0.0060 
3 0.0920 1098 24,930 0.0440 0.0041 
4 0.0959 761 24,930 0.0305 0.0029 
5 0.0991 552 24,930 0.0221 0.0022 
6 0.1017 492 24,930 0.0197 0.0020 
7 0.1040 330 24,930 0.0132 0.0014 
8 0.1061 278 24,930 0.0112 0.0012 
9 0.1079 225 24,930 0.0090 0.0010 
10 0.1095 219 24,930 0.0088 0.0010 
11 0.1110 148 24,930 0.0059 0.0007 
12 0.1124 142 24,930 0.0057 0.0006 
13 0.1137 226 24,930 0.0091 0.0010 
14 0.1149 179 24,930 0.0072 0.0008 
15 0.1161 129 24,930 0.0052 0.0006 
16 0.1171 99 24,930 0.0040 0.0005 
17 0.1181 75 24,930 0.0030 0.0004 
18 0.1191 70 24,930 0.0028 0.0003 
19 0.1200 46 24,930 0.0018 0.0002 
*Probabilities based on the following logit model: 
logit(𝑝(𝑥)) = log (
𝑝(𝑥)
1 − 𝑝(𝑥)
) = −2.467 +  0.371 ∗ log (𝐹𝐼𝑇 𝑟𝑒𝑠𝑢𝑙𝑡) 
 
Σ f(x)p(x): 0.0354 
 
Table 18: Estimation of the proportion of those with cancer or advanced adenoma with a FIT result of less than 
20 μg/g. The logit model used to produce the estimated probabilities is given below the table. An assumption of 
a FIT result of 0 μg/g having a probability of 0 was made to obtain this estimation and discrete FIT values were 
used by rounding to the nearest whole number. 
An assumption in this case was made that a result of ‘0’ would provide a probability of zero 
for colorectal cancer/advanced adenomas whereas in reality this would not always be the 
case. For instance, there are adenomas which may bleed intermittently or have 
undetectable amounts of bleeding, leading to false negative results. In addition, to 
calculate an estimate, discrete FIT results were used by rounding to the nearest whole 
number; whereas data provided gave up to one decimal place. Based on these 
approximations, a NPV of 0.96 has been calculated for this test, which is similar to the 
values estimated and reported previously (Table 19). 
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A potentially smaller ratio of false negative to true negative results based on the literature 
would be expected and so 0.96 could be considered an underestimate. The sensitivity of 
the test is also much lower than the other estimates due to this higher number of false 
negative results (0.39). Other methods could be used to estimate proportions for 
continuous test results. By repeating the analysis for Log(FIT+1) the proportion of people 
estimated with cancer/advanced adenoma with a FIT result below 20μg/g increases to 
8.4%. This is due to the large number of individuals with a result of 0μg/g (15,404) which is 
a much greater overestimate.  
 
This exploratory analysis suggests further models could be investigated which may fit the 
lower tail end of the data better to provide more accurate predictions for extrapolation. 
 
 Positive Diagnostic 
Result 
Negative Diagnostic 
Result 
Total 
FIT positive 
> 20 μg/g 
549 1261 1,810 
FIT negative 
< 20 μg/g 
874 24075 24,949 
Total 1,423 25,336 26,759 
Sensitivity: 0.39, Specificity: 0.95, PPV: 0.30, NPV: 0.96, Sample prevalence: 5.32%, FIT positivity 6.76%. 
Excluded: Those with positive test result (>20 μg/g) but with no diagnostic outcome (27,066 – 307 = 26,759).  
This will likely underestimate the number of true positive results. 
Table 19: 2 by 2 table using the FIT data combined with logit model estimates for a FIT result of less than 20μg/g 
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4.0 DISCUSSION 
4.1 Statement of principal findings 
 
This study has demonstrated that including routinely available risk predictors in the 
screening algorithm alongside the FIT improved both model performance and test 
accuracy.  At a threshold of 160μg Hb/g faeces, sensitivity improved from 30.78% to 
33.15% using a risk adjusted model compared to FIT alone (setting the number of recalls 
the same/the same specificity). Furthermore, the risk-adjusted model for this sample 
population (threshold of 160μg Hb/g faeces) leads to the detection of 13 additional 
advanced adenomas and the same number of cancers (17 more high risk adenomas, 4 less 
intermediate risk adenomas) using FIT only as the comparator. Improvement was therefore 
seen in the number of high-risk adenomas detected by the risk-adjusted model.  
 
Based on the results from these data, for every 1,000,000 people invited to screening, it 
can be estimated that 318 additional advanced adenomas (4,447/1,000,000) would be 
detected compared to FIT only (4,129/1,000,000). Although this approach would require 
external validation, the figures give the relative performance of this risk-based approach. 
The algorithm mainly improves detection in men compared to women.  
 
A higher positive FIT rate (160μg/g) was independently associated with age, males, 
previous non-responders to screening, IMD score and sample return time (p<0.05). There 
was a negative association with the Southern compared to the Midlands hub (p=0.04) and 
ambient temperature was not significantly associated with a positive result (p=0.47). High 
temperature has been shown to be associated with reduced positivity.52 
 
4.2 Strengths and weaknesses of the study 
 
The main strength of the study was the quality of the data; the data were collected for the 
FIT pilot comparative study which was implemented within a live screening programme. In 
addition, routine data were used to develop the risk prediction model meaning no 
additional data collection was required, reducing costs and the burden on the screened 
participants. This approach also makes it feasible to implement risk-adjusted screening in 
practice by using data direct from the BCSS. The test thresholds analysed were those which 
were identified in the FIT pilot as having a similar positivity or referral rate to the gFOBT to 
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ensure adequate colonoscopy capacity. The TRIPOD guidelines were followed when 
developing and reporting the model to improve the quality of the study. 
 
Limitations of the study include the lack of follow up data for participants with a result of 
<20 μg Hb/g faeces as interval cancers are not recorded on the BCSS. Ideally, follow up data 
for participants sent the FIT would be obtained from cancer registries (National Cancer 
Intelligence Network, or Office for National Statistics data linked through NHS number). A 
follow up period of two years would allow the clinical identification of existing cancers. Not 
all individuals had a diagnostic result if they cancelled or did not attend the appointment 
and this could cause potential selection bias if non-healthy participants tend to not have 
follow up colonoscopy. The pattern of attendance for diagnostic investigation seen in this 
study is however similar to that seen in the screening programme in general.56 This 
approach can lead to partial verification bias and inflated test accuracy measures.59 66 
However, the results provided in this study give the relative performance of a risk-adjusted 
approach versus a regular screening approach. Multiple imputation can be used for missing 
predictor information but in the current study only 8 IMD scores were missing. 
 
The selection bias in this study by only including those with a FIT result of ≥20 μg Hb/g 
faeces (as they have outcome data) has implications on making predictions for those with 
FIT results of less than 20 μg/g and subsequent model performance and test accuracy. The 
highly selected population affects external validation of the prediction model and therefore 
generalizability and accuracy. There are a greater proportion of participants at higher risk 
and with the outcome compared to a complete general risk screening population. Since the 
case mix is of higher risk in this model development study if applied to another population 
(with outcomes for all FIT results) the model would most likely need to be recalibrated. This 
can be achieved by adjusting regression coefficients by an adjustment factor e.g. 
calibration slope or by adjusting the intercept since there will be a difference in the sample 
prevalence from this model development study to a validation study using all cut-off 
ranges. The difference in case mix (in this case outcome prevalence) can affect the 
predictor-outcome associations and therefore when applied in a different sample this will 
affect model accuracy.37 67 
 
The current model can estimate for FIT results less than 20 μg/g but the parameter 
estimates would be less precise as there is a greater degree of uncertainty around the 
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predicted probabilities for these individuals. Eligibility criteria and the study flow diagram 
are reported fully in this study to allow assessment of the applicability or generalizability of 
this model and its predictions in another dataset. Future research should investigate 
further predictors from the BCSS and obtain follow up data for those with a result <20 μg/g 
to improve generalizability. 
 
Since not all participants have a reference standard in this study, this introduces partial 
verification bias. This is a common form of bias in screening studies as identified in the 
systematic review reported in Chapter 2, since the participant flow only tests those with a 
positive screening test result. Furthermore, the dataset used for this study uses routine 
data which is not specifically collected for research purposes. When assessing test accuracy 
characteristics, the sensitivity of the FIT and risk adjusted FIT would most likely be 
overestimated using these cut-offs (30 to 180) due to an underestimate of false negative 
results. The appropriate denominator to calculate sensitivity and specificity would ideally 
use all participants who adequately participated in FIT screening (27,066). By using a 
selected subsample of participants with results of ≥20 μg/g, presumably since these 
individuals are at higher risk of cancer/advanced adenomas being detected, the severity of 
disease detected would also be greater.18 68 This may in turn inflate test accuracy 
parameters (higher sensitivity). In addition, by using this ‘complete-case’ approach, there is 
a reduction in sample size which can lead to reduced precision; bias is also introduced since 
not having a colonoscopy is associated with the risk of having colorectal cancer. As such the 
generalizability of these test accuracy measures can only be compared for those studies 
which assess test accuracy in those with a FIT result of ≥20 μg Hb/g. 
 
Efforts were made in Section 3.11 to estimate test accuracy measures for those with a 
result of <20 μg/g by comparing with literature estimates, data from Chapter 5 and using a 
modelling approach to extrapolate the proportion of undiagnosed cancers/advanced 
adenomas. These approaches are crude estimates and should be compared to using follow 
up data and cancer registries for individuals with a negative result (although this too comes 
with differential verification bias due to different reference standards).  Other methods to 
correct for partial and differential verification bias could be considered.59 
  
Part of the increase in detection for the FIT in the pilot was due to increased uptake of this 
test compared with the gFOBT (66.4% vs 59.3%);69 this study assumes the same uptake 
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seen with the pilot. In subsequent FIT screening rounds, there could however be a change 
in the uptake whereby non-responders to gFOBT are more likely to respond to the FIT, 
whereas non-responders to FIT may be less likely to respond to the next FIT. This could 
affect future detection rates and subsequently model performance. However, data from 
four rounds of a biennial FIT screening programme in the Netherlands showed that uptake 
increased from 60 to 63%, the same could be expected with this new test.70 In addition, 
future iterations of the risk-based model could take into account more detailed previous 
screening episode factors which have been found to be predictive of uptake.69 
 
As identified in the previous chapter for the systematic review, a common limitation of 
screening studies is the flow of participants due to uptake of the index test and then 
subsequent uptake of the reference standard. The final dataset includes those who 
adequately participated i.e. returned a FIT with a definitive positive or negative result and 
then those who subsequently went on to have the reference standard test. This can have 
two possible effects on the population. Individuals who participate in screening are likely to 
be at lower risk, due to the healthy screenee effect, compared to those who do not return 
a FIT. The same may be true for uptake of the reference standard but conversely this also 
includes the effect of elderly people and people with comorbidities who may not be 
recommended to undergo colonoscopy and who are often at higher risk. This can have an 
effect on the underlying case mix seen in the study.  
 
4.3 Strengths and weaknesses in relation to other studies 
 
Other studies which have investigated the added value of risk factors combined with the 
FIT have shown an improvement in model and test accuracy parameters as identified in the 
previous chapter. A study in the Netherlands developed a multivariable prediction model 
which combined the following risk factors: total calcium intake, family history, age and FIT 
result (OC-Sensor).8 The risk-adjusted model had similar calibration and discrimination to 
the model developed in this study despite using different predictors. The AUC ROC 
improved from 0.69 to 0.76 when including the additional predictors compared with an 
improvement reported in this study of 0.63 to 0.66. The smaller increase seen in the 
current study compared to the model by Stegeman et al. is most likely due to the richer 
predictor data included in the model which came from a lifestyle questionnaire. The 
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questionnaire would however require a response and additional time from a participant 
whereas this study sought to use routine data.  
 
In addition, sex of a participant was investigated in this study combining questionnaire data 
but was found to not be significant in the multivariable model. This suggests that the 
variance explained by sex was explained by another variable in the model by Stegeman et 
al.71. Previous studies have however suggested that male sex is associated with increased 
risk of CRC.72 73 74 For instance, Kolligs et al. found that men had an odds ratio of 1.95 for 
advanced neoplasia (1.91-2.00) when compared with females.74 This odds ratio is 
comparable to the odds ratio calculated for this study; adjusted 1.75 (1.413-2.17) and 
unadjusted 1.88 (1.53-2.31). Sex also has also been shown to affect the positivity of the test 
and as such is an important predictor to be included within the model.75 
 
Stratification of risk using a logistic regression model combining age and sex with the FIT 
result has been investigated by Auge et al.7 Colorectal cancer risk was stratified into 16 
categories, these risk categories were then classified into 3 risk levels based on the positive 
predictive value. The authors suggest that this stratified approach could be used to 
prioritize higher risk individuals for colonoscopy examination. By categorizing risk however 
individual information is lost as the probabilities become standardized for all individuals in 
one group.37 The current study gives an absolute risk prediction for each individual, 
providing a personalized and more accurate approach to screening. The discrimination of 
this model including routine predictors only was 0.68 (95% CI: 0.66-0.70) which is similar to 
what is reported in the current study 0.66 (95% CI: 0.63 - 0.69). 
 
Deprivation has been shown to relate to the faecal haemoglobin concentration and has 
consequently been suggested to be included in risk scoring systems.76 Although IMD score 
showed a decreased risk as the value increases (OR 0.997 95% CI: 0.99-1.00) this result was 
not significant in univariable analysis (p-value = 0.53) and was dropped from the 
multivariable model during stepwise selection. This study used data from two screening 
hubs, it may be the case that inclusion of data from other hubs across England could 
produce a significant result. 
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4.4 Practical Implications 
 
This study utilised the data recorded routinely on the BCSS to develop a risk prediction 
model to ensure, as far as possible, that it could be implemented in practice without 
additional data collection. There are more data fields present on the screening system 
which could be investigated or combined for inclusion in the screening algorithm, 
particularly relating to screening history. The logistic regression risk adjusted model 
provides the absolute risk prediction (as a probability) for each individual and this can be 
used to make clinical decisions regarding screening referral by setting an appropriate ‘risk 
threshold’.  
 
Based on the results of this study, a risk-adjusted approach could be implemented at the 
point of screening to decide which participants are at greatest risk for more targeted 
colonoscopy referral. Further predictors exist on the BCSS which could be used to 
investigate a model which provides greater discrimination and corresponding test accuracy. 
This model would then need external validation in a new dataset to confirm study findings 
and to determine if similar performance is achieved. An impact study could then be used to 
assess using a risk-adjusted algorithm on screening outcomes. 
 
4.5 Future research 
 
Although the model improves when adding additional risk indicators to the screening 
algorithm, model performance metrics including Nagelkerke’s R2, AUC and the deviance 
suggest that the prediction of cancer/advanced adenomas at colonoscopy is not fully 
captured by the predictors used in the model. A similar AUC is achieved compared to 
models using routine data only identified in the systematic review reported in the previous 
chapter.77 Future research could include the investigation of additional predictors from the 
BCSS database or obtaining richer data from questionnaires and electronic health records 
to improve predictive performance.  
 
Additional predictors from the BCSS could include the introduction of the once only flexible 
sigmoidoscopy at age 55, since this will provide a protective effect for a number of years.78 
If an individual has had a previous negative colonoscopy this has also been shown to 
reduce risk.79 Previous FIT results could be implemented in the algorithm and monitored 
over time as it has been shown that the Hb concentration relates to the detection of 
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adenomas and CRC in future screening rounds.80 To make use of previous gFOBTs, the 
number of positive spots (or spot positivity %) could also be investigated whilst 
transitioning over to the FIT.81 Lifestyle factors have been shown to have a significant effect 
on the risk of CRC (diet, alcohol, physical inactivity and being overweight).82 Whilst the 
latter information is not currently included on the BCSS other sources such as electronic 
health records or questionnaires could be used to obtain this information.  
 
The inclusion of more complex predictor information available from lifestyle questionnaires 
and from electronic health records may be better captured using machine learning 
algorithms. An alternative model to conventional logistic regression which could possibly 
perform better, might be a feed-forward artificial neural network (ANN). This model is 
highly flexible and, unlike logistic regression, does not require the strong assumption of 
linearity for combinations of variables and thus allows more complex nonlinear 
relationships to be included between predictors and the response variable in prediction 
models.83  
Once the FIT is implemented in the NHS BCSP at the end of 2018, this risk-adjusted 
approach could be investigated in a similar way using the routine screening data once 
sufficient follow up data is available also enabling a more accurate risk positivity threshold 
to be derived. The algorithm led to greater detection in males compared to females which 
depending on screening programme aims will need greater investigation if a risk based 
approach is implemented in the future (e.g. using separate models for each sex). The 
acceptability of this difference to the population could also be examined. For instance, the 
screening programme may want to consider separate models for men and women. The 
detection rate in first time screenees also decreases with a risk-based approach for both 
males and females whilst doubles for male previous non-responders. Likewise the 
detection rate seen between responders/non responders/first time invitees will need 
consideration in future risk models by dissecting previous screening history in greater 
detail. 
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5.0 CONCLUSIONS 
This research has investigated a risk-based approach to colorectal cancer screening by 
combining the FIT with routinely available predictors from the BCSS in a logistic regression 
model. This approach demonstrated an improvement in both model performance and test 
accuracy of the FIT when compared to using the FIT only. As the NHS BCSP prepares to 
transition to the FIT, these initial investigations have shown that further exploration of the 
BCSS for additional predictors which could be included in the algorithm may help to 
improve test accuracy and colonoscopy use.  
 
Machine learning algorithms were identified as a potential avenue to explore in the 
previous chapter. Before embarking on further exploration of routine predictors, which 
may improve the discrimination of the risk adjusted model, a neural network will be 
investigated using the same dataset to determine if this improves model performance and 
test accuracy further without additional data collection. A neural network may allow more 
complex associations to be modelled and has been shown to have similar if not higher 
performance than logistic regression.84-86 The use of more complex predictors and their 
associations from routine health records may be better captured with a machine learning 
algorithm. 
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7.0 APPENDICES 
Appendix 1: Ethical and Research Approval Letters 
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Appendix 2: System Level Security Policy for this Research 
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Appendix 3: R scripts used for model development and to assess performance 
 
#Logistic Regression Modelling# 
# ------------------------------------------------------------------------------------------------------------------------- 
# Read Data in for modelling 
ccFIT20 <- read.csv("FITroutine.csv") 
 
FIT <- read.csv("FIT.AllRecords.csv") 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Developing Risk Prediction Model - Stepwise Regression and Cross-Validation 
 
#Load the Mass library 
library(MASS) 
 
#Load cross validation functions (see bottom of script) 
 
source("CVfunction.R") 
ccFIT20 <- data.frame(ccFIT20, CANCERAA = ccFIT20$Binary.outcome) 
 
#Summarise a baseline model 
base.mod <- glm(CANCERAA ~ 1, data = ccFIT20 ,family=binomial(link="logit")) 
summary(base.mod) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
# ------------------------------------------------------------------------------------------------------------------------- 
#Model Fitting 
#Backwards Elimination Stepwise 
 
###1 Start with full model 
 
cclog.mod.3 <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + IMD_SCORE + 
prev.incident, data = ccFIT20, family=binomial(link="logit")) 
 
summary(cclog.mod.3) 
 
drop1(cclog.mod.3, test = "LRT") 
 
#suggests IMD_SCORE should be removed, run cross validation 
 
cv.logreg(mod = cclog.mod.3, nreps = 10, seedno = 253636) 
 
#Gives coefficient estimates and associated confidence intervals 
exp(cclog.mod.3$coefficients) 
exp(confint(cclog.mod.3)) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
###2 Removing IMD as a variable as least significant as signified by p-value 
 
cclog.mod.3 <- glm(Binary.outcome ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident, 
data = ccFIT20, family=binomial(link="logit")) 
 
summary(cclog.mod.3) 
 
drop1(cclog.mod.3, test = "Chisq") 
 
cv.logreg(mod = cclog.mod.3, nreps = 10, seedno = 253636) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
###3 Remove age 
 
cclog.mod.3 <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + GENDER + prev.incident, data = ccFIT20, 
family=binomial(link="logit")) 
 
summary(cclog.mod.3) 
 
drop1(cclog.mod.3, test = "Chisq") 
 
cv.logreg(mod = cclog.mod.3, nreps = 10, seedno = 253636) 
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#All remaining variables significant 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#For completeness: 
###4 Remove previous screening history (prev.incident) 
 
cclog.mod.3 <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + GENDER, data = ccFIT20, family=binomial(link="logit")) 
 
summary(cclog.mod.3) 
 
drop1(cclog.mod.3, test = "Chisq") 
 
cv.logreg(mod = cclog.mod.3, nreps = 10, seedno = 253636) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
###5 Remove Gender (sex) 
 
cclog.mod.3 <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1), data = ccFIT20, family=binomial(link="logit")) 
 
summary(cclog.mod.3) 
 
drop1(cclog.mod.3, test = "Chisq") 
 
cv.logreg(mod = cclog.mod.3, nreps = 10, seedno = 253636) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
###6 Remove FIT 
 
cclog.mod.3 <- glm(CANCERAA ~ 1, data = ccFIT20, family=binomial(link="logit")) 
 
summary(cclog.mod.3) 
 
drop1(cclog.mod.3, test = "Chisq") 
 
cv.logreg(mod = cclog.mod.3, nreps = 10, seedno = 253636) 
 
 
 
#Previous screening history, gender and FIT only to be retained. 
#Force age back into model due to clinical significance. 
# ------------------------------------------------------------------------------------------------------------------------- 
#########Final Model#########  
 
#Force age back into the model due to clinical signficance, systematic review and literature associations 
 
cclog.mod.2 <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident, data 
= ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.2) 
exp(cclog.mod.2$coefficients) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Investigating possible interactions 
# ------------------------------------------------------------------------------------------------------------------------- 
# Interactions 
#1 Gender and Age Interaction 
cclog.mod.I <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident + 
(AGE_AT_EPISODE_START*GENDER), data = ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.I) 
exp(cclog.mod.I$coefficients) 
 
#Gender and Age Interaction not significant - could cross validate/bootstrap to see if it changes the result 
 
source("CVANNFunctions.R") 
 
cv.logreg(mod = cclog.mod.I, nreps = 10, seedno = 253636) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
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#2. Gender + FIT 
 
cclog.mod.I <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident + 
((log(TRANS_FIT_KIT_RESULT + 1))*GENDER), data = ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.I) 
exp(cclog.mod.I$coefficients) 
 
 
cv.logreg(mod = cclog.mod.I, nreps = 10, seedno = 253636) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#3. GENDER+ prev.incident 
cclog.mod.I <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident + 
(prev.incident*GENDER), data = ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.I) 
exp(cclog.mod.I$coefficients) 
 
 
cv.logreg(mod = cclog.mod.I, nreps = 10, seedno = 253636) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
 
 
#4. FIT+age 
 
cclog.mod.I <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident + 
((log(TRANS_FIT_KIT_RESULT + 1))*AGE_AT_EPISODE_START), data = ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.I) 
exp(cclog.mod.I$coefficients) 
 
 
cv.logreg(mod = cclog.mod.I, nreps = 10, seedno = 253636) 
# ------------------------------------------------------------------------------------------------------------------------- 
#5. FIT+ prev.incident 
 
cclog.mod.I <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident + 
((log(TRANS_FIT_KIT_RESULT + 1))*prev.incident), data = ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.I) 
exp(cclog.mod.I$coefficients) 
 
 
cv.logreg(mod = cclog.mod.I, nreps = 10, seedno = 253636) 
# ------------------------------------------------------------------------------------------------------------------------- 
#6. AGE + prev.incident 
 
cclog.mod.I <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident + 
(AGE_AT_EPISODE_START*prev.incident), data = ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.I) 
exp(cclog.mod.I$coefficients) 
 
 
cv.logreg(mod = cclog.mod.I, nreps = 10, seedno = 253636) 
 
###No interactions significant at the p=0.05 significance level 
# ------------------------------------------------------------------------------------------------------------------------- 
# ------------------------------------------------------------------------------------------------------------------------- 
#Cross-validation 
#Cross validate the model for final cross validated deviance measure 
 
cv.logreg(mod = cclog.mod.2, nreps = 10, seedno = 253636) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
# ------------------------------------------------------------------------------------------------------------------------- 
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#For reporting bootstrapped coefficient bias and confidence intervals 
 
library("boot") 
 
logit.bootstrap <- function(data, indices) { 
   
  d <- data[indices, ] 
  fit <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident, data = d, 
family = "binomial") 
   
  return(coef(fit)) 
} 
 
# Set seed to replicate results 
set.seed(12345)  
 
logit.boot <- boot(data=ccFIT20, statistic=logit.bootstrap, R=10000) # 10'000 samples 
 
logit.boot 
 
plot(logit.boot) 
 
 
boot.ci(logit.boot, type = "basic", index=1) #intercept 
boot.ci(logit.boot, type = "basic", index=2) #FIT result 
boot.ci(logit.boot, type = "basic", index=3) # Age 
boot.ci(logit.boot, type = "basic", index=4) #Gender 
 
# ------------------------------------------------------------------------------------------------------------------------- 
# ------------------------------------------------------------------------------------------------------------------------- 
#Performance Measures: 
 
###Compare models by finding the difference in the deviance statistics which is chi-square distributed### 
 
anova(cclog.mod.1, cclog.mod.2, test = "LRT") 
 
#FIT only model 
cclog.mod.1 <- glm(CANCERAA~ log(TRANS_FIT_KIT_RESULT+1), ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.1) 
exp(cclog.mod.1$coefficients) 
exp(confint(cclog.mod.1, level=0.95)) 
 
#FIT plus risk model 
cclog.mod.2 <- glm(CANCERAA ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident, data 
= ccFIT20, family=binomial(link="logit")) 
 
summary(cclog.mod.2) 
exp(cclog.mod.2$coefficients) 
exp(confint(cclog.mod.2, level=0.95)) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Calibration plot 
 
install.packages("PredictABEL") 
library("PredictABEL") 
# ------------------------------------------------------------------------------------------------------------------------- 
#Calibration Plot (for the risk adjusted model) 
 
cOutcome <- 13 #the column with the outcome in your dataset 
predRisk <- predRisk(cclog.mod.2) 
# specify range of x-axis and y-axis 
rangeaxis <- c(0,1) 
# specify number of groups for Hosmer-Lemeshow test 
groups <- 10 
 
cal <- plotCalibration(data=ccFIT20, cOutcome=cOutcome, predRisk=predRisk, groups=groups, rangeaxis=rangeaxis) 
 
#Return observed versus expected probability table and p value for Hosmer-Lemeshow goodness of fit test 
cal 
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#-------------------------------------------------------------------------------------------------------------------------- 
#Another way to determine Hosmer Lemeshow statistic 
install.packages("ResourceSelection") 
library("ResourceSelection") 
 
hl <-hoslem.test(ccFIT20$CANCERAA, fitted(cclog.mod.2), g=10) 
hl 
 
#loop to give results for different group splits 
 
for (i in 5:15) { 
  print(hoslem.test(ccFIT20$CANCERAA, fitted(cclog.mod.2), g=i)$p.value) 
}   
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Predictiveness curve 
 
# obtain predicted risks 
predRisk1 <- predRisk(cclog.mod.1) 
predRisk2 <- predRisk(cclog.mod.2) 
# specify range of y-axis 
rangeyaxis <- c(0,1) 
# specify labels of the predictiveness curves 
labels <- c("FIT only", "Risk adjusted") 
 
# produce predictiveness curves 
plotPredictivenessCurve(predrisk=cbind(predRisk1,predRisk2),rangeyaxis=rangeyaxis, labels=labels) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
# ------------------------------------------------------------------------------------------------------------------------- 
#Plotting ROC curve 
#Install pROC packages 
install.packages("pROC") 
library("pROC") 
 
# ------------------------------------------------------------------------------------------------------------------------- 
# ------------------------------------------------------------------------------------------------------------------------- 
#1st ROC just TRANSFIT 
 
#Predicted probabilities for the two models 
#FIT only model 
ccFIT20$Predictp1 <- predict(cclog.mod.1, ccFIT20, type = "response") 
#Risk adjusted model 
ccFIT20$Predictp2 <- predict(cclog.mod.2, ccFIT20, type = "response") 
 
#1st ROC curve for FIT only 
roccurve1 <- roc(ccFIT20$CANCERAA ~ ccFIT20$Predictp1) 
#Return AUC 
roccurve1 
 
#Alternatively for 95% CI:  
auc(ccFIT20$CANCERAA, ccFIT20$TRANS_FIT_KIT_RESULT) 
ci.auc(ccFIT20$CANCERAA, ccFIT20$TRANS_FIT_KIT_RESULT, conf.level=0.95, method="delong") 
 
#Return AUC CI 
ci.auc(roccurve1, conf.level=0.95, method="delong") 
ci.auc(roccurve1, conf.level=0.95, method="bootstrap", boot.n = 10000) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#2nd ROC curve for Risk adjusted 
 
roccurve2 <- roc(ccFIT20$CANCERAA ~ ccFIT20$Predictp2) 
 
#Return AUC 
roccurve2 
 
#Return AUC CI 
ci.auc(roccurve2, conf.level=0.95, method="delong") 
ci.auc(roccurve2, conf.level=0.95, method="bootstrap", boot.n = 10000) 
# ------------------------------------------------------------------------------------------------------------------------- 
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#Combine in a ROC plot 
 
#ROC for risk adjusted model 
roccurve2 <- plot.roc(ccFIT20$CANCERAA, ccFIT20$Predictp2) 
 
#Add ROC for FIT only 
roccurve1 <- plot.roc(ccFIT20$CANCERAA, ccFIT20$Predictp1, add=TRUE, col="red", lty=3) 
 
#Add legend 
legend("right", legend = c("Risk-adjusted LR","FIT only"), lty=c(1, 3), col=c("black","red")) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
# ------------------------------------------------------------------------------------------------------------------------- 
#ROC test - to test for significant difference between ROC curves 
 
roc.test(roccurve1, roccurve2) 
 
# The latter used Delong's test. To use bootstrap test: 
roc.test(roccurve1, roccurve2, method="bootstrap", boot.n=10000) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
# ------------------------------------------------------------------------------------------------------------------------- 
#Cross validation functions used for modelling: 
#CVfunction.R 
 
# false and true positive rate 
ft.pr <- function(mod, thresh = 0.5){ 
  S <- predict(mod, type = "response") 
  Ps <- (S > thresh) * 1 
  obs.dat <- as.integer(mod$fitted.values + residuals(mod, type = "response")) 
  FP <- sum((Ps == 1) * (obs.dat == 0)) / sum(obs.dat == 0) 
  TP <- sum((Ps == 1) * (obs.dat == 1)) / sum(obs.dat == 1) 
  vect <- c(FP, TP) 
  names(vect) <- c("FPR", "TPR") 
  return(vect) 
} 
# ft.pr(mod = logreg.mod, thresh = 0.5) 
 
# area under curve 
auc.roc <- function(mod, resol = 0.001){ 
  result <- sapply(seq(0, 1, resol), ft.pr, mod = mod) 
  span <- dim(result)[2] - 1 
  est.auc <- 0 
  for(i in 1:span){ 
    bx.height <- as.numeric((result["TPR", i] + result["TPR", i + 1])/2) 
    bx.width <- as.numeric(abs(result["FPR", i] - result["FPR", i + 1])) 
    est.auc <- est.auc + bx.width * bx.height 
  } 
  return(est.auc) 
} 
# auc.roc(mod = logreg.mod) 
 
 
# cv false and true positive rate 
cvft.pr <- function(obs, pred, thresh = 0.5){ 
  Ps <- (pred > thresh) * 1 
  obs.dat <- obs 
  FP <- sum((Ps == 1) * (obs.dat == 0)) / sum(obs.dat == 0) 
  TP <- sum((Ps == 1) * (obs.dat == 1)) / sum(obs.dat == 1) 
  vect <- c(FP, TP) 
  names(vect) <- c("FPR", "TPR") 
  return(vect) 
} 
 
 
# cv area under curve 
cvauc.roc <- function(obs, pred, resol = 0.001){ 
  result <- sapply(seq(0, 1, resol), cvft.pr, obs = obs, pred = pred) 
  span <- dim(result)[2] - 1 
  est.auc <- 0 
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  for(i in 1:span){ 
    bx.height <- as.numeric((result["TPR", i] + result["TPR", i + 1])/2) 
    bx.width <- as.numeric(abs(result["FPR", i] - result["FPR", i + 1])) 
    est.auc <- est.auc + bx.width * bx.height 
  } 
  return(est.auc) 
} 
 
# cv 
cv.logreg <- function(mod, nfold = 10, nreps = 10, seedno = 1234, sig = 4){ 
   
  # set-up model 
  set.seed(seedno) 
  logn <- function(x){if(x == 0){0} else {log(x)}} 
  mod.terms <- attr(mod$terms, "term.labels") 
  mauc.cv <- mauc <- res.df <- mdev.cv <- mdev <- vector(length = length(mod.terms) + 1) 
  resp.loc <- as.numeric(attr(terms(mod), "response")) 
  resp.var <- attr(attr(attr(mod$model, "terms"), "dataClasses"), "names")[resp.loc] 
  m.dat <- eval(mod$call[["data"]]) 
   
  # nreps of nfold cv 
  mod.set <- 1:length(mod.terms) 
  for(i in 0:length(mod.terms)){ 
    ii <- i + 1 
    pred.cv <- vector(length = dim(m.dat)[1]) 
    text.form <- paste(paste(resp.var," ~ ", sep = ""), paste(mod.terms[mod.set != i], collapse = " + "), sep = "") 
    mod.form <- as.formula(text.form) 
    n.mod <- update(mod, formula =  mod.form) 
    mdev[ii] <- n.mod$deviance 
    res.df[ii] <- n.mod$df.residual 
    mauc[ii] <- auc.roc(mod = n.mod) 
    for (k in 1:nreps){ 
      rand <- sample(nfold, dim(m.dat)[1], replace = T) 
      for (j in sort(unique(rand))) { 
        mod.cv <- update(mod, formula = mod.form, data = m.dat[rand != j,]) 
        pred.cv[rand == j] <- pred.cv[rand == j] + predict(mod.cv, m.dat[rand == j,], type = "response") 
      } 
    } 
    obs.dat <- as.integer(mod$fitted.values + residuals(mod, type = "response")) 
    pred.cv <- pred.cv / nreps 
    mdev.cv[ii] <- 2 * sum(obs.dat * sapply(obs.dat/pred.cv, logn) + (1 - obs.dat) * sapply((1 - obs.dat)/(1 - pred.cv), logn)) 
     
    mauc.cv[ii] <- cvauc.roc(obs = obs.dat, pred = pred.cv) 
  } 
   
  # lrt 
  mod.terms <- c("Full", mod.terms) 
  lrt <- mdev[2:length(mdev)] - mdev[1]  
  lrt.cv <- mdev.cv[2:length(mdev.cv)] - mdev.cv[1] 
  df <- res.df[2:length(res.df)] - res.df[1] 
   
  # summary data frames 
  mod.sum <- data.frame(mod.terms = mod.terms, res.df = res.df, df = c(NA, df), mdev = round(mdev, sig),  
                        lrt = round(c(NA, lrt), sig)) 
  p.value <- pchisq(lrt, df, lower.tail = FALSE) 
  raw.out <- data.frame(mod.sum, p.value = round(c(NA, p.value), sig), mauc = round(mauc, sig)) 
  cvmod.sum <- data.frame(mod.terms = mod.terms, res.df = res.df, df = c(NA, df), mdev.cv = round(mdev.cv, sig),  
                          lrt.cv = round(c(NA, lrt.cv), sig)) 
  p.value <- pchisq(lrt.cv, df, lower.tail = FALSE) 
  cv.out <- data.frame(cvmod.sum, p.value = round(c(NA, p.value), sig), mauc.cv = round(mauc.cv, sig)) 
   
  
 # output 
  list(cv = cv.out, raw = raw.out) 
   
} 
 
# cv.logreg(mod = logreg.mod, nreps = 10, seedno = 253636) 
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Appendix 4: Tables of Results for the FIT Participants Adequately Screened 
(n=27,066) 
 
Latest Event Description (closed episode) Number of Participants 
Subject Discharge Sent (Normal)  24750  
 
Abnormal  
 
528 
Low-risk Adenoma  
 
464   
Normal (No Abnormalities Found)  
 
266       
Intermediate-risk Adenoma  
 
227 
GP Discharge Sent (Normal)  
 
200 
High-risk Adenoma  
 
197 
GP Discharge Sent (No Agreement to Proceed with Diagnostic Tests)  
 
78 
Cancer  
 
74 
GP discharge letter sent (refusal of positive assessment appointment)  
 
53 
Handover into Symptomatic Care - Patient Letter Printed  
 
52 
Letter of Non-agreement to Continue with Investigation sent to GP  
 
29 
GP Discharge Sent (No show for Positive Appointment)  
 
27 
Attended Practitioner clinic  
 
22 
1st Positive Appointment Cancellation Requested (Patient to Reschedule)  
 
15 
GP Discharge Sent (Unsuitable for Diagnostic Tests)  
 
14 
Invited for Diagnostic Test  
 
13 
 
Close Screening Episode via Interrupt  
 
7 
Waiting for Clinician Review  
 
7 
Decision not to Continue with Diagnostic Test  
 
6 
Waiting Decision to Proceed with Diagnostic Test  4 
 
2nd Positive Appointment Cancellation Requested (Patient to Reschedule)  
 
3 
Handover into Symptomatic Care, Patient Unfit, GP Letter Printed  
 
3 
Suitable for Endoscopic Test  3 
1st Positive Appointment Cancellation Requested (Screening Centre)  
 
2 
1st Positive Appointment Non-attendance Sent (Patient)  
 
2 
DNA Diagnostic Test  
 
2 
N/A  
 
2 
Not Suitable for Diagnostic Tests  
 
2 
Patient Discharge Sent (Unsuitable for Diagnostic Tests )  
 
2 
Patient Refused Positive Appointment  
 
2 
1st Positive Appointment Booked  1 
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1st Positive Appointment Cancellation Sent (Patient to Consider)  
 
1 
Cancel Diagnostic Test  
 
1 
GP Discharge Letter Printed - No Patient Contact  
 
1 
GP Discharge letter sent (Discharge by Screening centre) 1 
Post-investigation Appointment Invitation Letter Printed  
 
1 
Post-investigation Appointment NOT Required - Result Letter Created  
 
1 
Post-investigation Contact Made  1 
 
Reminder of Retest Kit Sent (Technical Fail)  
 
1 
Suitable for Radiological Test  1 
  
Total – 27,066  
Table A.4.1: Recorded outcomes for participants based on the latest event description 
field. 
 
Outcome Numbers for 
Southern 
Numbers for 
Midland 
Total 
Abnormal 260 273 533 
Cancelled 13 22 35 
Cancer 39 35 74 
High-risk Adenoma  111 103 214 
Intermediate-risk Adenoma 128 135 263 
Low-risk Adenoma 226 242 468 
Normal (No Abnormalities Found) 138 128 266 
Not Attended 121 142 263 
Subject Discharge Sent (Normal) 13629 11321 24950 
        
Total 14665 12401 27066 
 
Detection rate for cancer Southern 0.266 
Detection rate midlands 0.282 
Overall cancer detection 0.273 
Overall advanced adenoma + Cancers 2.036 
Overall advanced adenoma (HR and IR 
adenoma) 
1.762 
Overall all neoplasms (Cancer + HR + IR + LR 
Adenoma) 
3.765 
Number attended colonoscopy/diagnostic 
test. Those with abnormal, cancer, HR, IR, LR, 
Normal 
1818 
Table A.4.2: Outcomes for participants reclassified into definitive groups and cancer 
detection rates. 
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Appendix 5: Comparison of population with diagnostic follow up versus without. 
 
 
Missing diagnostic follow up (n=299) 
(264 did not attend the appointment 
35 people cancelled) 
Not missing diagnostic follow up 
(n=1818) 
% Female 39.13 45.27 
Mean age 67.33 66.55 
Median age 67.00 67.00 
Median IMD 17.46 14.64 
Mean IMD 21.52 19.31 
Median FIT 64.00 55.60 
% first time invitee 10.37 10.45 
% previous non responders 20.74 13.81 
% of previous responder 68.90 75.80 
Table A.5.1: Demographics of those missing diagnostic follow up versus those with 
diagnostic outcomes 
 
Appendix 6: Hosmer-Lemeshow Statistics for Different Group Splits 
 
Number of groups P value for the Hosmer and Lemeshow goodness of fit 
test 
5 0.906 
6 0.716 
7 0.611 
8 0.802 
9 0.793 
10 0.898 
11 0.647 
12 0.806 
13 0.989 
14 0.798  
15 0.940 
Table A.6.1: Hosmer-Lemeshow goodness of fit test p-values for different group splits for 
the risk adjusted model 
 
Number of groups P value for the Hosmer and Lemeshow goodness of fit 
test 
5 0.100 
6 0.395 
7 0.304 
8 0.191 
9 0.504 
10 0.481 
11 0.328 
12 0.536 
13 0.329 
14 0.047 
15 0.166 
Table A.6.2: Hosmer-Lemeshow goodness of fit test for different group splits for the FIT 
only model 
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Appendix 7: Boxplots for Sample Return Time and Mean Maximum Temperature 
 
 
 
 
 
Mean: 2.14, Median: 2.00, SD: 1.26, Max: 34.00, Min: 0.00  Mean: 18.92, Median: 19.43, SD: 3.64, Max. 27.20, Min. 2.53
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Development of a Risk Prediction Model for Colorectal Cancer 
Screening using an Artificial Neural Network 
 
 
Chapter based on the following published paper: Cooper, J. A., et al. (2018). "Risk-adjusted 
colorectal cancer screening using the FIT and routine screening data: development of a risk 
prediction model." Br J Cancer 118(2): 285-293. 
ABSTRACT  
Objectives: Although logistic regression is typically used in medical research for 
classification and prediction modelling, other statistical methods exist which could provide 
better model performance and therefore clinical outcomes. The methodology for logistic 
regression is well developed and the regression coefficients can provide a form of clinical 
interpretation hence the popularity in employing this method in research. There is however 
evidence to suggest that other machine learning algorithms such as: decision trees, k-
nearest neighbours, artificial neural networks (ANNs) and support vector machines could 
outperform this conventional method in certain contexts. ANNs tend to have a lower 
generalization error compared to these other methods and is the next most commonly 
employed method in the literature. Compared to support vector machines, the ANN 
provides an absolute risk probability which can be used for individual risk estimates. The 
real advantage of ANNs over their more standard statistical counterpart are their flexibility 
and ability to model complex nonlinear relationships between dependent and independent 
variables. The previous chapter investigated developing a risk prediction model which 
combined the FIT with routine screening data using logistic regression. The aim of this 
study was to investigate whether an ANN using the same data improved model 
performance and test accuracy further when compared to the equivalent logistic 
regression model. 
 
Design: The same data as the previous chapter (six-month pilot study) were used to train 
an artificial neural network for risk predictions. This comprised those with a positive FIT 
(≥20 μg/g) and with a diagnostic colonoscopy outcome (n=1810). A feed forward ANN was 
developed using a back-propagation algorithm, which attempts to minimize the mean 
square error for the dataset, with cross-validation. The same risk factors as the previous 
chapter were investigated for model inclusion (age, sex, Index of Multiple Deprivation 
score and previous screening history). Network complexity was investigated by assessing 
weight decay values between 0.01 and 0.1, the number of hidden unit nodes and through 
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pruning network connections by dropping weights with the lowest magnitude and 
assessing the change in cross-validated deviance. These methods also improve the 
generalization of the model in other datasets. Data were normalized before model fitting 
to improve model performance. Discriminatory power and calibration of the ANN was 
compared to the logistic regression model using the AUC ROC, Hosmer-Lemeshow statistic 
and by plotting calibration curves. To compare test accuracy between the logistic 
regression model and neural network, the ROC curves were plotted and a ROC test was 
performed to determine if the difference was significant. Sensitivity and specificity were 
compared at a cutpoint which corresponded to 160 μg Hb/g faeces. Results were also 
broken down by both outcome severity and sex. Patient profiles are presented for 10 
individuals with risk probabilities obtained from the ANN, logistic regression model 
reported in the previous chapter and the FIT result only. 
 
Results: Standardizing the variables for the model led to lower cross validated deviances. A 
matrix was produced which assessed different numbers of hidden layer nodes, variables 
and weight decay parameters through cross validation. A network with 5 input nodes, 3 
hidden layer nodes and 1 output node using a weight decay of 0 and 22 weights gave the 
lowest cross validated deviance and was selected to develop further. A weight decay of 
0.01 gave the lowest sum of squared errors and was used in the final model. Network 
pruning investigations resulted in removing 4 connections to give a lower cross-validated 
deviance (2077.694) with 18 network weights. The AUC for the Neural Network was 0.69 
compared with 0.66 for the logistic regression model. A ROC test confirmed this difference 
was significantly different (p<0.001). Calibration for the ANN assessed using the Hosmer-
Lemeshow statistic gave a similar result (0.8924) to the risk adjusted logistic regression 
model (0.8977) indicating good model fit. At a threshold of 160 μg/g which is the 
anticipated NHS BCSP cutpoint; the ANN has a sensitivity of 35.15% and a specificity of 
85.57% compared to a sensitivity of 33.15% and specificity of 84.69% for the equivalent 
logistic regression model. Compared with the risk-adjusted logistic regression model, 11 
additional advanced adenomas were detected (13 more high risk adenomas, 2 less 
intermediate adenomas). 
 
Conclusions: Although it is often argued that neural networks are more difficult to 
interpret and are often likened to a ‘black box’ this study shows the promise of machine 
learning algorithms for use in screening decisions and clinical practice. Both the logistic 
  
 
 
171 
 
Chapter 4 Chapter four | Artificial Neural Network Risk Prediction Model 
regression and neural network models can give the absolute risk for each individual and 
this can be used for screening referral decisions by setting an appropriate ‘risk threshold’. 
This neural network uses a logistic activation function and the corresponding risk equation 
can be provided for external validation and use in screening practice. With the shift to 
larger and more complex electronic health data, machine-learning algorithms may be 
better placed to deal with larger amounts of data and non-linear associations when 
compared with conventional models such as logistic regression. 
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1.0 INTRODUCTION 
The previous chapter developed a risk prediction model which combined the FIT with 
routine screening data using logistic regression. This model and approach was shown to 
outperform using the screening test (FIT) on its own in terms of model performance 
parameters (discrimination and calibration) and test accuracy (sensitivity and specificity at 
the same number of referrals, at a range of thresholds). Although the standard modelling 
methodology, logistic regression may not be the optimal statistical methodology in the 
setting described here. While the resultant model parameters are easy to interpret, this 
method is limited in many ways, principally by the linearity of the parameters on the scale 
of the linear predictor (log-odds ratio). An alternative, and possibly better performing 
model, might be a feed-forward artificial neural network (ANN). This model is highly 
flexible and, unlike logistic regression, does not require the strong assumption of linearity 
for combinations of variables and thus allows the inclusion of more complex nonlinear 
relationships between predictors and the response variable into the prediction model.1  
 
1.1 Risk Prediction Models and Machine Learning Algorithms 
 
Clinical prediction rules can be used to assist clinicians in making decisions relating to 
patient care.2 This involves the combination of predictors such as patient characteristics 
and test results in order to estimate the probability of an outcome or the most effective 
intervention. A model with good performance is one where the probabilities identified 
from the model match the observed outcomes. Examples of risk prediction models 
(diagnostic and prognostic) applied in public health and clinical practice include, the 
Framingham risk equation for cardiovascular disease (used to identify those at high risk of 
cardiovascular disease)3 and the Gail Breast Cancer prediction model (used to predict 
whether a woman will develop breast cancer over a certain time interval)4. More recently, 
risk-scoring systems to automatically identify symptomatic colorectal cancer for referral in 
primary care have been developed using electronic health records and subsequently tested 
in a clinical setting.5 6 Hippisley-Cox and Coupland (2012) have also developed an algorithm 
to predict the absolute risk of colorectal cancer in primary care, to facilitate referral and 
early diagnosis.7 
 
Typically in medical research, logistic regression is used for classification and predicting 
binary outcomes. The methodology is well developed and the regression coefficients can 
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provide a form of clinical interpretation.8 There are however further methods which can be 
used for classification purposes including machine learning algorithms such as; decision 
trees, k-nearest neighbours (white-box models where model parameters can be 
determined along with logistic regression), neural networks and support vector machines 
(so called black-box models)9 which may perform better than conventional methods. Data 
classification can give just a dichotomous outcome (support vector machine), or an 
approximation of the probability of an outcome or ‘class membership’.  
 
By dichotomizing risk into classes, individual information is lost as probabilities are 
standardized for all individuals within one group.10 Whilst support vector machines assign a 
dichotomous outcome result; logistic regression, ANNs, k-nearest neighbors and decision 
trees give a probability of class membership but vary in their approximation method.9 
Disadvantages of the k-nearest neighbors algorithm is in defining case neighborhood which 
is often performed through trial and error, decision trees split continuous variables which is 
also not recommended as information is lost at each stage. In general, the performance of 
neural networks and logistic regression models are better than decision trees and k-nearest 
neighbors.9 Support vector machines have been shown to have similar performance but are 
not implemented as routinely in statistical software.11 12 In medicine, neural networks and 
logistic regression are the most commonly used models which appears to be due to their 
lower generalization error and ease of model development compared to other models such 
as support vector machines.9 This is reflected by the number of publications indexed in 
Medline for these different types of model: 28,500 for logistic regression, 8500 for neural 
networks, 1300 indexes for k-nearest neighbors, 1100 for decision trees, and 100 for 
support vector machines.12   
 
1.2 Description of Artificial Neural Networks 
 
ANNs are a type of machine learning algorithm which can be considered analogous to the 
structure and function of biological neurones or the human brain. ANNs consist of a 
number of interconnected nodes whereby knowledge is obtained through a learning and 
adaptation process (from a training dataset) and stored as connection weights between 
nodes.13 14 Input nodes have the values of predictor variables and are connected to hidden 
layer nodes through connection weights (which can be considered analogous to the β 
coefficients in a regression model). Connection weights are most often optimized using a 
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back-propagation algorithm where the variables for an observation are used to determine 
predicted output and any difference between predicted output and known output is 
calculated as an error and back-propagated through the network, this is repeated until 
overall error is minimized.1 The hidden layer allows the network to calculate intermediate 
values and allows non-linear relationships to be modelled between the predictors and 
outcome. Each node in this layer is then connected to the output node/s. Bias nodes can 
also connect to the hidden layer or output nodes and can be considered analogous to the 
intercept parameter in logistic regression.  Once the network has been trained it can be 
used for classification or pattern recognition in a validation dataset. A diagram of a neural 
network is shown in Figure 1. 
 
 
 
Figure 1: A Feed Forward Neural Network with 5 input nodes (predictors), one hidden layer (with 3 nodes) and 3 
output nodes. It is also possible to have connections direct from inputs to outputs (skip-layer connections). The 
circles are ‘nodes’ and the lines are connection weights.15 
 
1.3 Comparison of ANNs with Logistic Regression 
 
ANNs can be seen as an extension of logistic regression since an ANN with no hidden layer 
is the same as the equivalent logistic regression model.1 16 Advantages of ANNs include the 
ability to model complex nonlinear relationships between dependent and independent 
variables as well as encompassing all interactions between the variables.17 Using a logistic 
regression model for these types of relationships would require further modelling, for 
example, including an interaction term or taking the log of a continuous variable in order 
for it to better match linearity. In addition, ANNs require no assumptions about the shape 
of the underlying probability distribution,18 meaning risk factors can be included without a 
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known consideration of their association with the outcome or interactions they may have 
with other variables.  
 
On the other hand, ANNs are more likely to be over-fitted to the data compared with 
logistic regression where the model complexity can be considered lower. There are 
however several approaches that can be taken during model development to limit this 
including pruning the network, adding a weight decay term and ‘early stopping’ whereby 
model fitting is stopped before the maximum likelihood estimate is found.9  
 
ANNs are often considered a ‘black box’ and interpretation is seen as more complex than a 
standard linear model.17 19 Logistic regression also offers the advantage of being able to 
identify possible causal relationships between predictor variable and outcome by providing 
β coefficients and odds ratios. 1 Furthermore, during model development, variables which 
are not strongly associated with the outcome can be dropped creating a more 
parsimonious model. The methodologies for ANN model development are not as 
formalized, researchers must investigate different training parameters and network 
architecture to develop the best fitting model.18 
 
1.4 Literature Review of Logistic Regression versus ANNs for Medical Datasets  
 
Recent artificial neural networks and other machine learning algorithms have been 
developed for many clinical areas including cardiovascular prediction,20 21 breast cancer 
image recognition and risk calculation,22 23 lung cancer,24 25 prostate cancer diagnosis,26 
stroke,27 psychiatric disorders 28 diabetic retinopathy29 30 as well as in bioinformatics and 
laboratory medicine31 32. The most recent neural network developed for use in predicting 
advanced colorectal neoplasia to tailor screening had greater performance than the 
standard logistic regression model (AUC: 0.721 (95% CI: 0.680-0.762) versus 0.817 (95% CI: 
0.789-0.847)) and a more complex deep learning network with additional parameters had 
even greater performance (AUC: 0.860 (95% CI: 0.837-0.883)).33 Artificial neural network 
algorithms have been developed since the 1980s and applied for image recognition in the 
1990s.34 Citations relating to machine learning in health have increased tenfold from 2007-
2017 compared to those published up to 2006.32 It has been suggested that machine 
learning and artificial intelligence will soon bring a ‘paradigm shift’ to medical practice.27 32 
35 
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A review by Sargent17 compared the performance of ANNs with regression models for 
medium-large datasets of medical studies (more than 200 participants). Methods to 
compare predictive accuracy between the two models was mainly the use of the area 
under the receiver operating characteristic curve (AUC ROC). In 10 out of 28 studies (36%) 
the ANN outperformed regression, whereas the ANN was outperformed by regression in 4 
cases (14%). In the remaining 14 cases (50%) the methods had similar performances. For 
the largest 8 studies, the methods tied for 7 cases, with regression having the highest 
performance for the remaining study. The author suggests that both methods should be 
explored and used in a complementary manner.17 
 
Another review assessed the methodology of 72 papers which compared ANNs with logistic 
regression for medical datasets.9 The papers were analysed and rated against several 
criteria including, dataset size, model parameter selection procedure and performance 
measures. The model building procedure was reported more often for logistic regression as 
expected due to the implementation of stepwise methods in software packages. When 
comparing the discrimination of the models, performance was similar, however the more 
flexible ANNs outperformed logistic regression in more studies. Lisboa and Taktak36 
conducted a systematic review to determine the clinical benefit of ANNs used for decision 
support in cancer. The number of clinical trials and randomized controlled trials utilizing 
ANNs has increased in recent years from 1 to 38.36 Out of 27 trials identified in the 
systematic review, 21 showed an increased healthcare benefit. In the remaining 6 studies 
ANNs performed as well as more traditional statistical methods. 
 
Ahmed37 carried out a review of ANNs for the diagnosis and survival prediction for colon 
cancer. The review found that the application of ANNs improved colon cancer classification 
and survival prediction when compared to more conventional statistical methods but 
suggest that care must be exercised when reporting or using such models to enhance the 
confidence in reliability of the data. Other ANNs which have been investigated for 
colorectal cancer include the use of a model to predict distant metastasis. Comparing the 
LR model to the ANN in this setting revealed that the accuracy was greater for the ANN 
(measured through the AUC ROC), 0.81 versus 0.78.38 The data for this study were however 
split into a train and test dataset for the ANN which is thought to be an inefficient form of 
internal validation as it does not use all the available data to build the model.39  
 
  
 
 
177 
 
Chapter 4 Chapter four | Artificial Neural Network Risk Prediction Model 
The systematic review reported in Chapter 2 identified that machine learning algorithms 
have not been previously developed which combine the FIT with other risk factors for 
colorectal cancer screening. Other systematic reviews of risk prediction models for 
colorectal cancer have been carried out for both asymptomatic and symptomatic 
individuals.40 41 A recent systematic review of risk prediction models which allow the 
identification of people at higher risk of colorectal cancer with symptoms was performed 
by Williams et al. (2016).41 For study selection, the risk prediction model had to include one 
or more individual risk factors (including symptoms) for undiagnosed colorectal cancer. The 
review identified 18 papers (15 models) for inclusion; 9 for primary care and 6 for 
secondary care. Four of these studies required questionnaires or interviews to obtain data 
on risk factors and 11 needed the input of a health-care worker. Four models included the 
guaiac based FOBT within the model (BB Equation and CAPER score).5 42-44 None of these 
models were designed specifically to be used as part of a screening programme but were 
instead developed for primary care case finding for urgent referral. Furthermore, the 
models which included FOBT all used logistic regression for model development. Clinical 
utility of a risk model was only assessed by one study using a risk score developed by 
Hamilton et al.45 
 
A review of risk prediction models for identifying the future risk of colorectal cancer in 
asymptomatic individuals was carried out by Usher-Smith et al.46 Forty papers describing 52 
risk models and 6 external validation studies were included for analysis. Six of the risk 
models included variables only available in routine medical records whereas the majority 
(n=32) utilized a questionnaire for data. Of the models using routine data for advanced 
colorectal neoplasia, the best performing logistic regression model was used for selecting 
individuals for a primary screening test of colonoscopy and included age, gender and BMI 
(AUC ROC, 0.65).40 No models identified in this review used machine learning algorithms. 
 
1.5 Potential Barriers to the Implementation of Neural Networks and Other 
Machine Learning Algorithms to Healthcare 
 
 
Although there have been many studies which have developed machine learning 
algorithms for a clinical application, few have been implemented in practice. This is in spite 
of the potential for increased diagnostic accuracy and model performance and the fewer 
data assumptions required for these approaches. Medical statisticians are often wary 
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about the application of machine learning approaches.47 Medicine also lags behind other 
industries, which have implemented machine learning approaches widely.48 49 Several 
recent articles have discussed potential obstacles to the wider adoption and clinical 
application of these approaches in healthcare.32 50-53 
 
Some of the reasons discussed by Cabitza et al.51 include deskilling clinicians and other 
healthcare workers by reliance on automated software, intrinsic uncertainty of medical 
data, the clinical context not being represented by the models and the black box nature of 
these algorithms.51 An example of deskilling provided was computer-aided detection for 
breast cancer screening whereby the sensitivity of readers decreased by 14% when CAD 
prompts were provided.54 The authors conclude that before the adoption of machine 
learning algorithms, evidence is required for improved patient outcomes and acceptability 
to patients and clinicians along with the performance metrics.51  
 
Several responses have been published to this article discussing that the problems of using 
machine learning in practice are similar to those found in the introduction of other new 
technologies.50 Other responses argue that overreliance on automated technology would 
be due to lack of methodological transparency and that research should focus on making 
these methods more accessible to healthcare users.55 Lasko et al.56 infer that negative 
consequences of applying machine learning approaches can be due to the misapplication of 
these methods in healthcare and suggest the need for trained medical data scientists with 
an understanding of both medicine and computer science.  
 
A frequently cited reason for machine learning models not being implemented is their 
‘black box’ nature. Users of the models are unable to interpret outputs for clinical 
meaning.51 57 Although models such as neural networks can provide greater accuracy for 
certain clinical scenarios, clinical interpretability of models could be improved using 
different methods such as visualisation tools (e.g. Garson’s algorithm to show relative 
importance of variables).51 The addition of clinicians trained in data science who can 
contribute to model development has also been suggested as a solution to this current 
issue. 35 56 
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A further reason for the slower progression of machine learning into practice over more 
standard statistical models is the nature of the data used for these algorithms. Machine 
learning not only uses standard clinical data but can also use data from images, genetic 
data or even employ natural language processing.27 These algorithms are also often 
developed using large electronic health records. The data used for these models can 
therefore be much larger, more complex and diverse, making the algorithms more difficult 
to validate (where the same predictors are required) and to employ as a holistic approach 
in computer software (e.g. for a diagnosis).  
 
Machine learning algorithms have also been described as ‘data hungry’ - which refers to 
predictive performance in relation to sample size.35 58 Simulation studies comparing the 
performance of support vector machines and neural networks with standard approaches 
(logistic regression) found that these models may need 10 times as many events per 
variable for smaller optimism and stable discrimination measures.59 In order to perform 
optimally, machine learning systems also need to be trained regularly which requires a 
continuous supply of data for model improvement.27 The complexity of data from diverse 
sources and the difficulty in implementing or validating another researcher’s algorithm has 
therefore hindered progress in the implementation of these approaches in practice. 
 
Frank E Harrell Jr. has written a number of recent articles on the topic of machine learning 
and the potential issues in applying these models in medical research.60 For example, 
Harrell discusses that researchers often employ machine learning in large electronic health 
records whereby bias in the healthcare system can be ‘perpetuated’ for future medical 
decisions.60 Another obstacle against implementation is a lack of regulatory standards to 
assess the effectiveness and safety of ‘artificial intelligence systems’. This has been 
improved in the US recently with the FDA providing guidance to evaluate these systems.27  
 
A series of recent articles discuss the theory and application of probability estimation using 
machine learning.47 57 58 61-63 Issues of using machine learning approaches over regression 
models include the need for updating the model in a new clinical context (e.g. secondary 
versus primary care) or in a different population with varying case mix (e.g. geographical 
differences). Updating the model for regression involves adjusting the model intercept and 
is commonly performed. However, it is uncertain and unknown how recalibration of the 
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model would be performed for a machine learning algorithm,58 62 a feature which could be 
deemed essential for validation and applying in clinical practice. 
 
Kruppa et al.63 and Steyerberg et al.58 also discuss the frequently cited issue of 
interpretability of the model to a clinical audience and whether a clinician will trust a 
‘noninterpretable machine’. Logistic regression provides interpretable parameter estimates 
and odds ratios can be reported to assess association with a particular outcome. Variable 
Importance Measures (VIMs) can be provided for Random Forest Models and allow 
variables to be ranked by their importance but the magnitude of the estimates have no 
underlying meaning.63 Garson’s algorithm for neural networks also ranks relative 
importance but provides no further clinical interpretation.64 Further research into methods 
for interpretability need to be undertaken to improve acceptance of these approaches for 
use in practice. Increasing use of web-based or computer based risk calculators can 
facilitate the use of these more complex models.58 
 
Machine learning approaches can have numerous benefits including statistical consistency 
of outcome probabilities and extensive flexibility.63 However, model tuning is also more 
complex with more tuning options adding an additional layer of complexity and making 
comparison of different models problematic.62 The benefits of the flexibility of these 
models also comes with the problem of a lack of standardization for model development 
and for use in practice.  The methodology for model tuning is not fully developed for 
artificial neural networks. More modern methods have been developed for logistic 
regression models to provide additional flexibility including multivariable fractional 
polynomials, restricted cubic splines and shrinkage approaches.58 62 Steyerberg et al.58 
suggest that machine learning will have a supplementary role but will not replace standard 
statistical methodology.  
 
Computational transportability is another issue of applying machine learning models in 
practice.47 This involves the ‘transport and exchange of computer programs allowing 
prediction’ between the model developers and for those who apply or validate the 
model.47 Logistic regression for instance is easy to ‘transport’ since the probabilities are 
straightforward to obtain with minimal computer software requirements and beta 
coefficient estimates along with the intercept can be provided for reporting the model. 
Machine learning algorithms however can often only be applied to their own data if 
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researchers have the corresponding software objects particularly with models such as 
Random Forests.47 Changes in the software could also affect the application of these 
machine learning models; applying the same models in different software can also yield 
different results complicating external validation.47 
 
Along the pathway of assessing whether a model is fit for practice, a model development 
study should be followed by external validation studies in either temporal or geographically 
different datasets and ideally by other research teams to reduce bias. Once externally 
validated, a model impact study can assess the effect on patient outcomes and provide 
confidence in the model results and performance before being implemented in practice.65-
68 There are many model development studies, fewer external validation studies and very 
few model impact studies.10 External validation of machine learning algorithms by other 
researchers is much scarcer than those assessing standard statistical techniques. Along 
with computational transportability as discussed above, this is most likely due to the 
underlying model being more complex and therefore the model equation is less likely to be 
provided in published model development studies. TRIPOD guidelines focus mainly upon 
regression techniques, additional guidance would be required for the unique issues 
encountered by machine learning techniques. 
 
1.6 Rationale 
 
As far as can be identified there are no studies which have developed an ANN for use in 
screening referral decisions for colorectal cancer. The studies identified above which have 
included a screening test result were either developed for case finding in primary care, 
employed the dichotomous gFOBT or used logistic regression to develop the risk prediction 
model. There is some evidence to suggest ANNs outperform logistic regression in certain 
scenarios within medical studies and it has been suggested that both methods should be 
employed in a complementary manner. Other machine learning methods could be 
considered for developing a risk prediction model within the context of colorectal cancer 
screening referrals. However, ANNs and logistic regression are the methods most 
commonly employed in the medical literature. Drawbacks of other methods such as 
decision trees include the splitting of continuous variables which results in the loss of 
information at each stage. The performance of ANNs and logistic regression models have 
been shown to be generally greater than decision trees and k-nearest neighbors. Support 
vector machines on the other hand assign a dichotomous outcome which results again in 
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the loss of information in terms of absolute risk prediction and individualized probability 
for a patient. The real advantage of ANNs are in their flexibility and ability to model 
complex nonlinear relationships between dependent and independent variables. 
 
Reporting and methodology is less well defined for ANNs and so care must be exercised 
when developing an ANN so performance measures can be understood fully. The main 
criticism is that they are considered a ‘black box’ and that interpretation of network 
weights is much more difficult than interpreting the coefficient estimates in a logistic 
regression model. However, weight saliency (the relative importance of weights) can be 
used, not only for optimizing network structure and performance, but also for giving some 
intuition about which inputs contribute most to the accuracy of the network predictions. 
 
The aim of this study was to investigate whether developing an ANN which combines FIT 
with other routine screening data available on the BCSS improves model performance and 
test accuracy further for an average risk English screening population when compared to 
the equivalent logistic regression model. 
2.0 METHODS 
A similar approach to model development was taken to the logistic regression model to aid 
comparability. The TRIPOD guidelines and STARD statement were used when reporting this 
study and to form the data analysis plan.10 69  
 
A multi-layer perception model which has an input layer, a hidden layer and an output 
layer was compared to the logistic regression model that was developed in the previous 
chapter (which combined age, sex, previous screening history and the FIT result). Model 
fitting proceeded in a similar fashion to that described previously for the logistic regression 
model using cross-validation, allowing performance to be compared directly. 
 
2.1 Study population and data source  
 
This study used the same data as the model development study discussed in the previous 
chapter. Briefly, these data were collected for the NHS BCSP comparative study which 
compared the acceptability and accuracy of the FIT compared to the gFOBT.70 Data for the 
FIT only were used where 40,930 individuals were invited to complete a test (one out of 
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every 28 screening invitations) and 27,167 were adequately screened. This analysis used 
complete cases and those who had a FIT result of 20 μg Hb/g faeces and above (n=1810). 
Twenty μg Hb/g faeces was chosen as the cutoff for test positivity during the pilot study 
and therefore these participants would have been referred on for colonoscopy for a 
definitive diagnosis.  
 
2.2 Routinely Available Predictors and Test Results 
 
The candidate predictors investigated to be included in the model were the same as the 
predictors investigated in the previous study. These included age, sex, IMD score and 
previous screening history (i.e. whether someone was a previous non-responder/responder 
to screening). These variables were coded in the same way for the model and used the 
equivalent definitions. The screening test investigated was the OC-SENSOR FIT (Eiken 
Chemical Co. Ltd., Japan, supplied by Mast Diagnostics, UK) along with the OC-SENSOR 
Diana analyser. The FIT units were converted from ng Hb/ml buffer to μg Hb/g faeces as 
recommended by the World Endoscopy Organisation.71 Those participants with a positive 
result were referred on for colonoscopy assessment within 14 days of an appointment with 
a specialist screening practitioner. Alternative investigations were arranged if the 
colonoscopy was inappropriate for a patient or if the test failed first time round e.g. CT 
scan or flexible sigmoidoscopy.72 
 
2.3 Model Outcome 
 
The model outcome was colorectal cancer or advanced adenoma detected at colonoscopy 
after a positive FIT referral. Advanced adenomas were those classified as either high-risk or 
intermediate risk, since these have potential to develop into bowel cancer if untreated, 
particularly as age increases. 73 74 
 
2.4 Statistical Analysis 
 
The FIT pilot data provided by the HSCIC through the Office for Data Release (ODR) were 
analysed in RStudio Version 0.99.903 (driven by R version 3.3.1) on a Windows 7 
computer.75 Additional packages were also loaded from The Comprehensive R Archive 
Network (CRAN; https://cran.r-project.org/).76-82 For neural network development, the 
package ‘nnet’ developed by Ripley79 was loaded and used for analysis purposes. Although 
this package is limited to one hidden layer there is evidence to suggest that additional 
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layers do not significantly improve the performance of the model,15 83 and that most 
functions encountered in medicine can be modelled using a Perceptron with one hidden 
layer.18 Furthermore, the more variables and the more complex the model, the greater the 
computational time which with large datasets can also lead to convergence problems. 
‘Neuralnettools’ was a package used for neural network visualization and for further 
analysis.80 The R scripts used to develop the neural network and assess the performance of 
the models is provided in Appendix 1. 
 
A feed forward ANN was developed using a back-propagation algorithm. Back propagation 
is a learning mechanism which attempts to minimize the mean square error for the 
dataset.18 This is achieved by comparing the output of the network based on the input 
variables with the true output and then this error is propagated backwards through the 
network adjusting connection weights appropriately to reduce mean square error.18 There 
are multiple training algorithms which could be used for neural network development, 
however most medical studies have utilized this particular algorithm.1 A logistic activation 
function acts on the weights connecting the input nodes (in our case the predictor 
variables) to the hidden layers, which are then linked to the outputs by an output 
activation function, which for this binary outcome of colorectal cancer/advanced adenoma 
status is also logistic. Different activation functions also exist including linear functions and 
hyperbolic tangent functions; if the output is continuous a linear function for the output 
node can be selected.1 The output ranges from 0 to 1 based on the network prediction of 
the outcome. The non-linearity added by the activation function allows much more general 
and flexible relationships to be formulated between inputs and outputs. The weights in the 
ANN model are analogous to parameters in the logistic regression model, but because the 
relationship between inputs and outputs is more complex they cannot be interpreted in 
isolation in the same simple manner as in a logistic regression model. A multi-layer ANN 
model with an input layer (consisting of the same predictors as the logistic regression 
model), a single hidden layer and an output layer with a single node was compared to the 
logistic regression model.  
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2.4.1 Model Development 
 
Model fitting proceeded in a similar fashion to that described for the logistic regression 
model using cross-validation, allowing performance to be compared directly.84 The same 
risk factors (age, sex, IMD score and previous screening history) investigated for model 
inclusion were included in developing the neural network regardless of whether they were 
found to be significant in the logistic regression model. 
 
Data Normalisation 
 
The data were normalized before model fitting as this has been shown to improve the 
performance of the network.1 Scaling the data in this way, prevents premature saturation 
of hidden nodes and stops larger numbers overriding smaller ones.83 The continuous 
variables were standardised using Gaussian normalization (subtracting the mean and 
dividing by the standard deviation) and compared to models which did not use 
standardisation. By normalising the weights, the weight decay parameter became less 
important and influential in the model.  
 
Network Architecture 
 
Unlike logistic regression where the methods for model development are fully developed, 
neural networks are not routinely used in medicine and so methods are by necessity more 
individualised for each study and require more experimentation.18 Network complexity can 
be manipulated by changing the weight decay parameter, changing the number of hidden 
unit nodes and cutting out network connections/links (pruning).15 A matrix was produced 
which determined the ten fold cross validated deviance, at varying weight decays, routine 
predictors and number of hidden nodes (the more hidden layer nodes the more complex 
the model) in order to determine the optimal (most parsimonious) neural network model 
architecture. 
 
Neural networks can also be over-trained (over-fitted) to the data, therefore a penalty 
term can be applied during model optimisation E + λC(f), where E is the fit criterion to 
minimize during network model fitting, ‘C’ is a penalty on the roughness of the continuous 
function ‘f’ and ‘λ’ is the weight decay.14 15 In addition, the maximum number of iterations 
can be set at an appropriate level and the network ‘pruned’ to drop any unnecessary 
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connections. Reducing complexity in this way enables improved generalisation of the 
model which would be needed when applying it in external populations.85 The optimum 
model determined from the cross validated deviance was further refined by investigating 
different weight decay values and by pruning weight connections based on absolute 
magnitude. The maximum number of iterations was selected which allowed the models to 
converge (500). 
 
Ripley suggests the use of weight decay (λ) values between 0.01 – 0.1 for the entropy fit,14 
higher values of weight decay do however improve the stability of the model. Weight decay 
helps to smooth the model output through regularization, limiting the magnitude of the 
weights and can be considered analogous to shrinkage in logistic regression.9 Models 
without weight decays are more sensitive to changes when weights are dropped; the 
weight decay level between 0 and 1 was investigated to give the lowest SSE (sum of 
squared errors/model residuals). 
 
The model was ‘pruned’ by dropping out weights with the lowest magnitude and assessing 
the change in cross-validated deviance. Pruning is described by Ripley as a method ‘used 
for removing parts of trees and networks with the aim of increasing generalization’15. By 
removing weight connections within the neural network, the degrees of freedom decrease 
increasing generalization. A plot of cross-validated deviance against the number of weight 
connections was produced to assess this.  
 
2.4.2 Model Performance 
 
Discrimination and calibration of the ANN were compared to the logistic regression model 
using the AUC ROC, Hosmer-Lemeshow statistic and by plotting calibration curves.86 
Discrimination assesses the ability of the model to distinguish between those at high risk of 
colorectal cancer/advanced adenoma versus those at low risk.  
 
The Hosmer-Lemeshow test determines if there are significant differences between 
observed and expected numbers using a chi squared test.87 For this test, observations were 
split into a different number of risk based groups (between 5 to 15) as this can affect the 
corresponding result of the Hosmer-Lemeshow statistic.88  
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2.4.3 Test Accuracy of the Risk Model 
 
To assess test accuracy, the ROC curves of ANN and risk-adjusted logistic regression models 
were compared. As a baseline comparator, the FIT only model (equivalent to just using FIT 
as a test) was also displayed on the ROC curve. A ROC test to compare the AUC ROC 
between both the models was performed using Delong’s method and bootstrapping. 
Delong’s method compares the AUCs of two or more correlated ROC curves which are 
constructed from tests/models performed on the same individuals and takes into account 
the correlated nature of the data.89 
 
To assess the sensitivity and specificity of the ANN at specific thresholds, 2 by 2 tables were 
produced for a threshold of 160μg Hb/g faeces (and the equivalent risk threshold) as 
investigated for the logistic regression model in the previous chapter. The NHS Bowel 
Cancer Screening Programme plans to adopt a threshold of 160 μg Hb/g faeces and Wales 
150 μg Hb/g faeces. Results are also presented for internationally used lower thresholds 
30-50 μg/g 90 and also for 80 μg/g which is the cutpoint which Scotland plans to adopt 
(Stephen Halloran, personal communication).  
 
Results were broken down by both outcome severity (CRC, high-risk adenoma, 
intermediate risk adenoma, low-risk adenoma, abnormal and normal (no abnormalities 
found)) and sex (male and female) for the ANN and logistic regression models using the FIT 
only as baseline for comparability.  
 
2.4.4 Clinical Utility 
  
The predictiveness curve has been proposed by Pepe et al.,91 as an alternative plot which 
allows both the assessment of the fit of the model and the clinical utility when applied to 
the population. It is argued that the predictiveness curve can give additional information 
about risk-threshold which is not typically provided by the ROC curve. The predictiveness 
curve was plotted for the ANN and LR model to aid comparison. 
 
Patient profiles for 10 individuals are presented with the corresponding probabilities of 
cancer/advanced adenoma being detected at colonoscopy estimated from the ANN, 
logistic regression (LR) model and FIT result only. The profiles allow a more detailed 
investigation into which variables may push an individual over a referral threshold. To 
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complement this, a plot using Garson’s algorithm to show the relative importance of each 
variable is presented for the ANN.64 This approach enables interpretation of neural network 
connection weights which is seen as a drawback of ANNs when compared to odds ratios for 
logistic regression.  
3.0 RESULTS 
3.1 Study Population 
  
Participants with a FIT result of ≥20 μg/g and a definitive diagnostic outcome were used to 
develop the ANN (n=1810; 549 cases, 1261 with a negative/low risk outcome). The mean 
age was 66.54 years and 45.3% of participants were females. See Chapter 3 for more detail 
on the study population. 
 
3.2 ANN Model Development 
 
3.2.1 Standardisation 
 
The continuous variables were standardised using Gaussian normalization and compared to 
models which did not use standardisation. By having no hidden layer, the ANN is equivalent 
to the logistic regression model as seen in the cross-validated deviances which are the 
same for a standardized neural network and logistic regression model (Table 1). The neural 
network with standardised variables was more efficient and produced lower cross-
validated deviances (signifying better fit) when compared to the model with 
unstandardized continuous variables as found in previous research (see Table 1). 
 
Model Type Standardised 
continuous variables? 
Deviance Cross-validated 
Deviance 
Neural Network  
(5-0-1) 
No Inf 2308.924 
Neural Network  
(5-0-1) 
Yes 2103.021 2114.95 
Logistic Regression risk-adjusted model No 2103.000 2113.995 
Logistic Regression risk-adjusted model Yes 2103.000 2113.995 
Logistic Regression 
FIT only model 
No 2153.6 2157.825 
Table 1: Comparing a standardized ANN (5-0-1) with a non-standardized ANN and the risk-adjusted logistic 
regression model. The 5-0-1 ANN has 5 input nodes, no hidden layer and one output node with a logistic output 
function. An infinite value is seen with the neural network as the starting seed/point used may not allow the 
model to converge within the number of iterations set for the model 
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3.2.2 Number of hidden nodes 
 
A matrix was produced which assessed different numbers of hidden layer nodes, variables 
and weight decay parameters and the effects on the cross validated deviance. A network 
with 5 input nodes, 3 hidden layer nodes and 1 output node using a weight decay of 0 and 
22 weights gave the lowest cross validated deviance and was selected to develop further. 
The 5 input nodes included the same variables as in the final logistic regression model; FIT, 
age, sex, previous screening history (as two nodes since this variable is treated as a factor). 
The architecture of this neural network is shown below in Figure 2, the weight connection 
values for each node is included in Appendix 2. 
 
 
 
Cross Validated Deviance (2103.04) Deviance (2048.25) E (1024.12), Penalty (0), E.crit (1024.12) 
 
Figure 2: Architecture of the feed forward 5-3-1 neural network with 22 weights, 500 iterations and 0 weight 
decay. Neural network plotted using nnet and the neuralnetworktools packages in R. Positive connection 
weights are represented with black lines, negative connections are represented with grey lines. 
 
  
Node Label 
I1 Input Node 1 – Standardised FIT result (continuous) 
I2 Input Node 2 – Standardised age (continuous) 
I3 Input Node 3 – Sex (Factor Male compared to Female) 
I4 Input Node 4 – Previous non responder compared with a first time screen (Factor) 
I5 Input Node 5 – Previous responder compared with a first time screen (Factor) 
H1 Hidden Layer Node 1 
H2 Hidden Layer Node 2 
H3 Hidden Layer Node 3 
B1 Bias Node 1 
B2 Bias Node 2 
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3.2.3 Weight Decay 
 
Different values of the weight decay parameter affect the sum of squared errors (SSE), 
mean squared error (MSE) and the cross-validated deviance. Table 2 reveals a weight decay 
of 0.01 has the smallest SSE (346.0445) when investigating weight decay values between 
0.0 to 0.5. The smallest cross-validated deviance from this range is obtained using a weight 
decay of 0.001 (2100.892). 
 
Weight Decay SSE MSE Cross Validated 
Deviance 
E Penalty E.Crit 
0.0001 347.060 0.192 2103.719 1025.033 0.833 1025.866 
0.001 348.023 0.192 2100.892 1027.890 1.684 1029.574 
0.01 346.038 0.191 2103.489 1023.470 3.175 1026.646 
0.1 350.959 0.194 2107.905 1035.979 4.078 1040.056 
0.2 351.486 0.194 2106.162 1037.336 6.060 1043.396 
0.3 352.005 0.194 2104.963 1038.673 7.474 1046.147 
0.4 352.663 0.195 2104.912 1040.304 8.062 1048.367 
0.5 353.135 0.195 2104.899 1041.407 8.847 1050.254 
Table 2: Changes in weight decay on SSE, MSE, cross validated deviance for a 5-3-1 neural network model. 
 
Investigating values of the weight decay parameter between 0.0 and 1.0 (in 0.0001 
increments) the lowest SSE (346.06) is achieved from a weight decay of 0.0102 (Figure 3). 
Looking at a more restricted range of weight decay values (0.0001 and 0.1), a weight decay 
of 0.0092 gives the lowest SSE (345.97). Based on these investigations, a weight decay of 
0.01 was used for the final model. 
 
Figure 3: Investigating the effect of changing the weight decay parameter value on the sum of squared errors of 
the neural network model for weight decay values between 0.0-1.0 (left figure) and then from a more restricted 
range between 0.0001 and 0.1 (right figure). 
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3.2.4 Network Pruning 
 
Removing different combinations of weight connections was investigated, small 
magnitudes were removed and the effect on the resultant cross-validated deviance 
analysed (see Figure 4 and Table 3). The model with the lowest cross validated deviance 
(2077.694) was one which removed the following connections; i3->h1, i1->h2, i3->h3, i4-
>h3. 
 
Figure 4: Change in cross-validated deviance as weight connections are dropped from the neural network model.  
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Number of 
Weights 
Cross 
Validated 
Deviance 
Weight connection 
removed 
Deviance E Penalty E.crit 
22 2103.489 Full model 2046.940 1023.470 3.175 1026.646 
21 2083.051 Connection 8 2046.991 1023.496 3.154 1026.649 
20 2081.277 Connection 4,8 2047.205 1023.603 3.267 1026.869 
19 2081.100 Connection 16,4,8 2048.226 1024.113 3.051 1027.164 
18 2077.694 Connection 17, 16, 4, 
8 
2048.520 1024.260 2.925 1027.185 
17 2081.610 Connection 
19,17,16,4,8 
2052.037 1026.019 2.355 1028.374 
16 2080.341 Connection 
13,19,17,16,4,8 
2052.881 1026.441 2.458 1028.899 
15 2089.588 Connection 2, 
13,19,17,16,4,8 
2059.705 1029.852 2.118 1031.970 
14 2087.297 Connection 15, 2, 
13,19,17,16,4,8 
2063.545 1031.772 2.561 1034.333 
13 2085.811 Connection 18, 15, 2, 
13,19,17,16,4,8 
2063.864 1031.932 2.642 1034.574 
12 2092.438 Connection 10, 18, 
15, 2, 13,19,17,16,4,8 
2076.493 1038.247 3.879 1042.126 
11 2092.681 Connection 6, 10, 18, 
15, 2, 13,19,17,16,4,8 
2076.603 1038.302 3.853 1042.155 
10 2091.677 Connection 1, 6, 10, 
18, 15, 2, 
13,19,17,16,4,8 
2076.158 1038.079 4.104 1042.184 
9 2086.436 Connection 12, 1, 6, 
10, 18, 15, 2, 
13,19,17,16,4,8 
2076.173 1038.086 4.098 1042.184 
8 2088.516 Connection 5, 12, 1, 6, 
10, 18, 15, 2, 
13,19,17,16,4,8 
2079.737 1039.869 3.884 1043.752 
7 2105.806 Connection 20, 5, 12, 
1, 6, 10, 18, 15, 2, 
13,19,17,16,4,8 
2094.461 1047.231 4.431 1051.661 
Table 3: The order and effect of removing different weight connection values from the ANN on cross validated 
deviance. 
3.2.5 Refined ANN Final Model 
 
The final model which is compared to the risk adjusted logistic regression model is 
presented in Figure 5 below (and Table 4 for weight connection values). This feed forward 
ANN has 5 input nodes, 3 hidden layer nodes and 1 output node along with two bias nodes 
providing the added flexibility of the model. The weight decay parameter value was 0.01 
and after pruning, the number of network weights was 18. This final refined model was 
used to assess model performance and test accuracy. The full model equation is given 
below in Equation 1. 
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Figure 5: Feed forward 5-3-1 neural network with 18 weights and a weight decay of 0.01. The log of the FIT 
result and age were normalised before modelling with the neural network. 
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Node Formula Weight Connection Value 
b->h1 α1 -3.69 
i1->h1 x1w1 -0.23 
i2->h1 x2w3 -2.12 
i3->h1 / 0.00 
i4->h1 x4w7 3.42 
i5->h1 x5w9 3.50 
b->h2 α2 -3.39 
i1->h2 / 0.00 
i2->h2 x2w4 -0.87 
i3->h2 x3w6 0.35 
i4->h2 x4w8 2.11 
i5->h2 x5w10 1.72 
b->h3 α3 1.06 
i1->h3 x1w2 -5.62 
i2->h3 x2w5 3.30 
i3->h3 / 0.00 
i4->h3 / 0.00 
i5->h3 x5w11 -5.72 
b->o β1 -0.60 
h1->o v1 -5.11 
h2->o v2 11.25 
h3->o v3 -1.07 
Table 4: Weight connection values for the final 5-3-1 neural network model with 18 weights and a weight decay 
of 0.01. 
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Probability of colorectal cancer/advanced adenomas being detected at colonoscopy: 
𝑝 =  
𝑒𝑜1
1 +  𝑒𝑜1
 
Where: 
𝑜1 = 𝑣1h1 +  𝑣2h2 +  𝑣3h3 + 𝛽1 
 
h1 =  
𝑒𝛼1+ ∑ 𝑤𝑖𝑥𝑖
1 +  𝑒𝛼1+ ∑ 𝑤𝑖𝑥𝑖
 
h2 =  
𝑒𝛼2+ ∑ 𝑤𝑖𝑥𝑖
1 +  𝑒𝛼2+ ∑ 𝑤𝑖𝑥𝑖
 
h3 =  
𝑒𝛼3+ ∑ 𝑤𝑖𝑥𝑖
1 +  𝑒𝛼3+ ∑ 𝑤𝑖𝑥𝑖
 
 
Applying the final neural network model: 
𝑝 =  
𝑒𝑜1
1 +  𝑒𝑜1
 
Where: 
𝑜1 = (−5.11)h1 + (11.25)h2 + (−1.07)h3 + (−0.60) 
 
h1 =  
𝑒−3.69+(−0.23)𝑥1+(−2.12)𝑥2 +3.42𝑥4+3.50𝑥5 
1 +  𝑒−3.69+(−0.23)𝑥1+(−2.12)𝑥2 +3.42𝑥4+3.50𝑥5 
 
 
h2 =  
𝑒−3.39+(−0.87)𝑥2+0.35𝑥3+2.11𝑥4+1.72𝑥5
1 +  𝑒−3.39+(−0.87)𝑥2+0.35𝑥3+2.11𝑥4+1.72𝑥5
 
 
h3 =  
𝑒1.06+(−5.62)𝑥1+3.30𝑥2+(−5.72)𝑥5
1 +  𝑒1.06+(−5.62)𝑥1+3.30𝑥2+(−5.72)𝑥5
 
𝑝 = Probability; 𝑜1 = Output 1; 𝑎1 = Bias node 1 to hidden layer 1 weight value; 𝑎2 = Bias node 1 to hidden layer 2 
weight value; 𝑎3 = Bias node 1 to hidden layer 3 weight value; 𝛽1 = Bias node 2 to output weight value; 𝑥1 =  
Standardised log(FIT Result +1); 𝑥2 = Standardised Age at episode start; 𝑥3 = Sex (male compared to female at baseline); 
𝑥4 = Previous non responder (compared to first time screen); 𝑥5 = Previous responder (compared to first time screen); 
h1 = Hidden layer node 1 intermediate output; h2 = Hidden layer node 2 intermediate output; h3 = Hidden layer node 3 
intermediate output; 𝑣1 = Hidden layer 1 to output 1 weight value; 𝑣2 = Hidden layer 2 to output 1 weight value; v3 = 
Hidden layer 3 to output 1 weight value. 
Equation 1: Equation for the risk scores/probabilities obtained from the final 5-3-1 neural network with 18 
weights and a weight decay of 0.01. The log of the FIT result and age were normalised before modelling with the 
neural network. When applying the neural network in new data, the FIT result and age need to be standardised 
using the standard deviation and mean parameters defined in the training dataset (Age; SD =4.22 , Mean= 
66.54 Log of FIT; SD = 1.10 , Mean = 4.35). 
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3.3 Model Performance 
 
Discrimination 
The AUC for the ANN was 0.69 (0.66-0.71) compared with 0.66 (95% CI: 0.63-0.69) for the 
logistic regression model. A ROC test using bootstrapping with 10,000 iterations shows that 
the AUC is statistically significantly different (D = -3.5057, p-value = 0.0005). This was 
validated using Delong’s method89 (Z = -3.5134, p-value = 0.0004). A ROC curve of the ANN 
compared to the risk adjusted logistic regression model with FIT only at baseline is given in 
Figure 6. 
 
 
Figure 6: ROC curves for the final artificial neural network model compared to the risk-adjusted logistic 
regression model and FIT only. AUC (95% CI) for the Neural Network Model:  0.686 (0.659  -  0.712); AUC (95% 
CI) for the Risk-adjusted Logistic Regression Model:  0.659 (0.632  -  0.686); AUC (95% CI) for the FIT only:  0.628 
(0.600  -  0.656). 
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Calibration 
Calibration for the ANN assessed using the Hosmer-Lemeshow statistic gives a similar result 
(0.892) to the risk adjusted logistic regression model (0.898) indicating good model fit (See 
Figure 7 for calibration plots).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Calibration plots for the refined neural network y = 1.0033x (left) and the logistic regression model 
reported in the previous chapter. 
As the number of group divisions used for the Hosmer-Lemeshow test effects the 
corresponding p-value, different group splits were investigated (5 to 15). On average the 
calibration was higher with the ANN across different risk group divisions compared with the 
risk-adjusted logistic regression model (See Appendix 3 for results). 
3.4 Test Accuracy 
 
A two by two table is presented below for the ANN, risk-adjusted logistic regression model 
and FIT only, using a threshold of 160 μg/g and equivalent risk thresholds (Table 5). Two by 
two tables were produced for thresholds between 30 to 180 μg/g (Appendix 4). At all 
thresholds, the sensitivity and specificity were greater for the ANN when compared with 
the logistic regression model (see Table 6). Focusing on a threshold of 160 μg/g which is 
the anticipated NHS BCSP cutpoint; the ANN has a sensitivity of 35.15% and a specificity of 
85.57% compared to a sensitivity of 33.15% and specificity of 84.69% for the equivalent 
logistic regression model. 
Applying the neural network at a threshold of 160 μg/g led to 24 more advanced adenomas 
being detected and the same number of cancers (30 more high risk adenomas and 6 less 
intermediate adenomas) compared with FIT only. Compared with the risk-adjusted logistic 
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regression model, 11 additional advanced adenomas were detected (13 more high risk 
adenomas, 2 less intermediate adenomas). The neural network therefore improved the 
diagnostic yield of high-risk adenomas as seen with the logistic regression model. 
2 by 2 table for the neural network, the risk-adjusted logistic regression model and FIT only 
160 μg Hb/g
 faeces  
Threshold 
 
 
 
FIT 
Diagnostic 
Positive 
 
Risk-adjusted 
 
 
 
 
Neural 
Network 
 
 
 
FIT 
Diagnostic 
Negative 
 
Risk-
adjusted 
 
 
 
Neural 
Network 
 
Total 
FIT/Risk 
Positive 
169 
37 - Cancer 
66 - High Risk 
Adenoma 
66 - 
Intermediate 
Risk Adenoma 
 
182 
37 - Cancer 
83- High Risk 
Adenoma 
62 - 
Intermediate 
Risk Adenoma 
 
193 
37 - Cancer 
96 - High Risk 
Adenoma 
60 - 
Intermediate 
Risk Adenoma 
 
206 
70 - Abnormal 
92 - Low Risk 
Adenoma 
44 - Normal (No 
Abnormalities 
Found) 
193 
69 - Abnormal 
81 - Low Risk 
Adenoma 
43 - Normal (No 
Abnormalities 
Found) 
182 
62 - Abnormal 
79 - Low Risk 
Adenoma 
41 - Normal (No 
Abnormalities 
Found) 
375 
FIT/Risk 
Negative 
380 
36 - Cancer 
148 - High 
Risk Adenoma 
196 - 
Intermediate 
Risk Adenoma 
367 
36 - Cancer 
131 - High Risk 
Adenoma 
200 - 
Intermediate 
Risk Adenoma 
356 
36 - Cancer 
118 - High Risk 
Adenoma 
202 - 
Intermediate 
Risk Adenoma 
1055 
396 - Abnormal 
439 - Low Risk 
Adenoma 
220 - Normal 
(No 
Abnormalities 
Found) 
1068 
397 - Abnormal 
450 - Low Risk 
Adenoma 
221 - Normal (No 
Abnormalities 
Found) 
1079 
404 - Abnormal 
452 - Low Risk 
Adenoma 
223 - Normal 
(No 
Abnormalities 
Found) 
1435 
Total  549   1261  1810 
FIT only: Sensitivity 30.78%, Specificity 83.66%, PPV 45.07%, NPV 73.52%, FIT positivity 20.72%, Cancer Detection Rate 9.34% 
Risk adjusted: Sensitivity 33.15%, Specificity 84.69%, PPV 48.53%, NPV 74.42%, FIT positivity 20.72%, Cancer Detection Rate 10.60% 
Neural Network:  Sensitivity 35.15%, Specificity 85.57%, PPV 51.47%, NPV 75.19%, FIT positivity 20.72%, Cancer Detection Rate 10.66% 
Table 5: 2 by 2 table for FIT only, the risk-adjusted logistic regression model and the neural network. A threshold 
of 160 μg Hb/g faeces was used for the FIT which is equivalent to a risk threshold of 0.389 for the risk-adjusted 
model and 0.407 for the neural network. Profiles of outcome severity are also given. An ‘Abnormal’ result relates 
to other diagnoses such as haemorrhoids and inflammatory bowel diseases. 
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Model FIT (μg Hb/g faeces)/ 
Risk Threshold (probability) 
Sensitivity (%) Specificity (%) 
FIT only 
Risk-adjusted LR 
Neural Network 
30.00 
0.191 
0.178 
88.34 
90.35 
91.99 
22.20 
23.08 
23.79 
FIT only 
Risk-adjusted LR 
Neural Network 
40.00 
0.242 
0.232 
76.68 
80.15 
81.24 
38.94 
40.44 
40.92 
FIT only 
Risk-adjusted LR 
Neural Network 
50.00 
0.272 
0.260 
69.03 
70.86 
73.04 
50.04 
50.83 
51.78 
FIT only 
Risk-adjusted LR 
Neural Network 
60.00 
0.295 
0.288 
60.66 
62.48 
65.03 
59.24 
60.03 
61.14 
FIT only 
Risk-adjusted LR 
Neural Network 
70.00 
0.310 
0.311 
55.19 
57.19 
59.02 
64.63 
65.42 
66.30 
FIT only 
Risk-adjusted LR 
Neural Network 
80.00 
0.321 
0.330 
51.18 
52.64 
55.37 
69.31 
69.94 
71.05 
FIT only 
Risk-adjusted LR 
Neural Network 
90.00 
0.336 
0.349 
45.72 
48.63 
51.55 
72.56 
73.83 
75.10 
FIT only 
Risk-adjusted LR 
Neural Network 
100.00 
0.346 
0.358 
42.44 
44.99 
48.63 
75.26 
76.37 
77.95 
FIT only 
Risk-adjusted LR 
Neural Network 
110.00 
0.356 
0.368 
40.07 
42.99 
45.90 
77.08 
78.35 
79.62 
FIT only 
Risk-adjusted LR 
Neural Network 
120.00 
0.362 
0.375 
38.07 
40.26 
43.53 
78.59 
79.54 
80.97 
FIT only 
Risk-adjusted LR 
Neural Network 
130.00 
0.371 
0.387 
34.79 
37.89 
41.35 
80.33 
81.68 
83.19 
FIT only 
Risk-adjusted LR 
Neural Network 
140.00 
0.379 
0.395 
33.70 
36.25 
39.71 
81.60 
82.71 
84.22 
FIT only 
Risk-adjusted LR 
Neural Network 
150.00 
0.383 
0.399 
32.42 
35.15 
37.70 
82.39 
83.58 
84.69 
FIT only 
Risk-adjusted LR 
Neural Network 
160.00 
0.389 
0.407 
30.78 
33.15 
35.15 
83.66 
84.69 
85.57 
FIT only 
Risk-adjusted LR 
Neural Network 
170.00 
0.392 
0.411 
29.87 
31.69 
34.24 
84.30 
85.09 
86.20 
FIT only 
Risk-adjusted LR 
Neural Network 
180.00 
0.399 
0.425 
28.60 
30.05 
32.79 
85.57 
86.20 
87.39 
Table 6: Clinical sensitivity and specificity pairs for FIT thresholds between 30 and 180 μg Hb/g faeces and the 
corresponding risk thresholds. 
 
3.5 Results Presented by Sex 
The two by two tables are broken down further by sex in Table 7 below for a threshold of 
160 μg/g. Further thresholds are presented in Appendix 4 and include results for; 30, 40, 
50, 80, 150, 170 and 180 μg/g. In general, since males are at higher risk, the FIT detects 
more cancers/advanced adenomas in males compared to females. The risk-adjusted logistic 
regression model exacerbates this difference halving the number of females detected with 
high-risk adenomas. The neural network on the other hand levels out this difference in sex 
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by maintaining a similar number of advanced adenomas detected for females compared to 
using the FIT only.  
The FIT result alone recalled 225 men (115 TP, 110 FP) of which 115 had cancer or 
advanced adenoma (51.11%), and 150 women (54 TP, 96 FP) of which 54 (36.00%) had 
cancer or advanced adenoma. The ANN recalled 279 men (146 TP, 133 FP) of which 146 
(52.33%) had cancer or advanced adenoma, and 96 women (47 TP, 49 FP) of which 47 
(48.96%) had cancer or advanced adenoma. The logistic regression model recalled 314 men 
(156 TP, 158 FP) of which 156 (49.68%) had cancer or advanced adenoma, and 61 women 
(26 TP, 35 FP) of which 26 (42.62%) had cancer or advanced adenoma. The ANN therefore 
when compared to the FIT result alone and logistic regression model improves the 
percentage of cancers/advanced adenomas detected in those recalled for further 
diagnostic tests (PPV). In addition, the difference between males and females in terms of 
cancers/advanced adenomas detected in those referred is reduced. 
Both models decrease the number of false negatives for males compared to FIT only, with a 
greater reduction seen with the logistic regression model. Although both models increase 
the number of false negative results for women, this increase is greater with the logistic 
regression model compared to the ANN. For the false positive results, an increase is seen 
with both the logistic regression model and ANN compared with FIT only but a greater 
increase in this number is seen with the logistic regression model. For females on the other 
hand, the number of false positives is approximately halved for both models with a greater 
reduction seen with the logistic regression model.  
For both models, there is an increase in the number of true positive results for males with a 
greater increase seen with the logistic regression model. There is also a decrease in the 
number of true positive results for women in both models but there are a greater number 
of TPs seen for the ANN, comparable to using FIT only. 
The colorectal cancer/advanced adenoma detection rate for each model by screening 
history and sex subgroup is provided in Appendix 5. The ANN increases the cancer 
detection rate in female responders (4.85%) compared to the logistic regression model 
which decreases the cancer detection rate in this subgroup (1.88%) compared to the FIT 
alone (5.63%). When applying a model as a test in this way, it can lead to a change in the 
spectrum of diagnosed disease and in the subgroups where cancer is detected. This is a key 
element of Health Technology Assessment and can be considered relevant within this 
context. 
 
 
 
2 by 2 table for FIT only, the risk-adjusted logistic regression model split by sex. 
        Diagnostic Positive           Diagnostic Negative       
160 μg Hb/g faeces  
Threshold   FIT only 
 
Risk-adjusted (LR) Neural Network   FIT only 
 
Risk-adjusted (LR) Neural Network Total 
    Male Female Male Female Male Female   Male Female Male Female Male Female   
  Total 115 54 156 26 146 47 Total 110 96 158 35 133 49   
FIT/Risk Positive 
Cancer 27 10 29 8 27 10 
Low Risk 
Adenoma 
41 29 60 9 49 13 
 
  
High risk 
Adenoma 
45 21 72 11 71 25 Abnormal 51 41 66 15 59 20 375 
  
Intermediate 
risk Adenoma 
43 23 55 7 48 12 
Normal (No 
Abnormalities 
Found) 
18 26 32 11 25 16 
 
    Male Female Male Female Male Female 
 
Male Female Male Female Male Female 
 
  Total 243 137 202 165 212 144 Total 522 533 474 594 499 580  
FIT/Risk Negative 
Cancer 23 13 21 15 23 13 
Low Risk 
Adenoma 
222 174 203 194 214 190 
 
  
High risk 
Adenoma 
100 48 73 58 74 44 Abnormal 198 241 183 267 190 262 1435 
  
Intermediate 
risk Adenoma 
120 76 108 92 115 87 
Normal (No 
Abnormalities 
Found) 
102 118 88 133 95 128 
  
Total    
549 
      
1261 
   
1810 
Table 7: 2 by 2 table for the neural network model, the risk adjusted logistic regression and FIT only split by sex. A threshold of 160 μg Hb/g faeces was used for the FIT which is equivalent to a 
risk threshold of 0.407 for the neural network and 0.389 for the risk-adjusted model. Profiles of outcome severity are also given. 
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3.6 Predictiveness Curve 
 
The predictiveness curve is presented for FIT only, the logistic regression model and ANN in 
Figure 8. A risk threshold of 0.407 for the ANN and 0.389 for the logistic regression model is 
equivalent to a FIT cut-off of 160 μg Hb/g faeces. The FIT only model assigns greater risk to 
about 35% of participants (for those with predicted risks of around 0.2 and below) 
compared with the ANN and risk adjusted logistic regression model. Conversely the ANN 
assigns around 40% of individuals at higher probability (for those with predicted risks 
above 0.3) than both the LR and FIT only models. This greater difference seen with the ANN 
enhances the discrimination of the model to distinguish between those at higher risk and 
those at lower risk.  
 
Figure 8: Predictiveness curve for the FIT only, logistic regression model (LR) and the artificial neural network 
(ANN). Predicted risk estimated from the different models versus the cumulative percentage of participants.  
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3.7 Patient Profiles for Each Model 
Individual patient profiles with the corresponding risk probabilities for each model are 
presented in Table 8 below. Referral decisions are based on a FIT threshold of 160 μg/g, 
which is equivalent to a risk threshold of 0.407 for the ANN and 0.389 for the LR model. For 
patient number 10 who is male, aged 62, a previous responder to FOBT screening, with a 
FIT result of 245.6 (well over the threshold to be referred using the FIT result alone) and an 
outcome at colonoscopy of ‘Normal’, the ANN assigns a probability of 0.389 which would 
mean that the individual would not be referred for additional diagnostic tests. Conversely, 
both the risk-adjusted logistic regression model and the FIT result alone would refer this 
individual for colonoscopy which carries its own risks. Looking at another example at the 
other end of the spectrum, patient number 9 who is male, aged 60, a previous non-
responder to screening, with a FIT result of 33.4 (well under the threshold to be referred 
using the FIT result alone) and an outcome of ‘high-risk adenoma’, the ANN assigns a 
probability of 0.673 which would mean that this individual would be referred for additional 
tests. On the other hand, the risk-adjusted logistic regression model and the FIT result 
alone would assign this as a negative test result (false negative) which would miss this high 
risk diagnosis. Further examples are presented in the table along with the IMD score for 
reference, although this was not found to be significant in the logistic regression model and 
did not improve cross-validated deviance for the ANN. 
 
Patient 
Profile 
Age Sex FIT 
Result 
Screening 
History 
IMD 
Score 
Outcome ANN 
probability 
LR 
probability 
FIT only 
probability 
1 66 Male 169 Previous 
responder 
48.18 Low-risk 
Adenoma 
0.385 0.401* 0.363* 
2 60 Female 167 First Time 
Screenee 
5.04 Low-risk 
Adenoma 
0.241 0.199 0.362* 
3 62 Male 162.2 Previous 
responder 
16.43 Abnormal 0.376 0.379 0.359* 
4 68 Female 161.4 Previous 
responder 
40.95 Low-risk 
Adenoma 
0.371 0.282 0.359* 
5 71 Female 157.8 Previous 
Responder 
19.35 Cancer 0.453* 0.292 0.357 
6 69 Male 157.4 Previous 
Responder 
9.06 Cancer 0.518* 0.410* 0.356 
7 68 Male 155.6 Previous 
Responder 
51.43 High-risk 
Adenoma 
0.486* 0.404* 0.355 
8 72 Female 154.4 Previous 
Responder 
2.53 Intermediate-
risk Adenoma 
0.449* 0.295 0.355 
9 60 Male 33.4 Previous 
Non 
responder 
7.55 High Risk 
Adenoma 
0.673* 0.358 0.238 
10 62 Male 245.6 Previous 
Responder 
41.72 Normal (No 
abnormalities 
found) 
0.389 0.414* 0.395* 
Table 8: Patient Profiles for 10 individuals with the corresponding probabilities estimated from the artificial 
neural network (ANN) and logistic regression models (LR) and for the FIT result only. A star ‘*’ next to the 
probability indicates that the individual would have been referred based on that model or FIT result using a FIT 
threshold of 160μg/g, which is equivalent to a risk threshold of 0.407 for the ANN and 0.389 for the LR model. 
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The patient profiles give an idea about the relative importance of the variables in the ANN 
model which for the logistic regression model would be provided in the form of beta 
coefficients and corresponding odds ratios. The plot below uses Garson’s algorithm to 
show the relative importance of the input variables for the ANN  
(Figure 9).64 The relative magnitude of the screening history variables ‘previous responder’ 
and ‘previous non-responder’ compared to a first time invitee at baseline has the greatest 
effect on the model outcome, followed by age, FIT result and finally sex. The odds ratios in 
the previous chapter for the logistic regression model suggests that a ‘previous non 
responder’ has the greatest association with the outcome (OR= 2.271, CI: 1.422-3.667). The 
other variables are more difficult to interpret since a one-unit change in a continuous 
variable has an additive effect on the overall odds ratio. 
  
 
Figure 9: Plot using Garson’s algorithm to show the relative importance of the input variables for the ANN. 
  
  
 
 
205 
 
Chapter 4 Chapter four | Artificial Neural Network Risk Prediction Model 
4.0 DISCUSSION 
4.1 Statement of Principal Findings 
 
The optimal ANN used for comparison against the risk-adjusted logistic regression model 
consisted of 5 input nodes, 3 hidden layer nodes and 1 output node. Standardisation of 
continuous variables reduced the cross-validated deviance and allowed for greater 
generalizability. A weight decay of 0.01 was used for the model since this gave the lowest 
SSE (346.04). Removing 4 weight connections (8, 4, 16 and 17) improved the cross-
validated deviance further (2077.694). This finalized model with 18 weights was used for 
comparison. 
The discrimination of the ANN (0.69, CI: 0.66-0.71) was greater than the risk adjusted 
logistic regression model (0.66, CI: 0.63-0.69) and on average calibration was higher with 
the ANN across different group divisions. The sensitivity and specificity of the ANN was 
greater at all thresholds. At 160 μg/g, sensitivity was 35.15% compared to 33.15% for the 
logistic regression model and specificity was 85.57% compared to 84.69%.  
At this threshold, the ANN detected 11 additional advanced adenomas (13 more high risk 
adenomas and 2 fewer intermediate adenomas) compared with the risk-adjusted logistic 
regression model and 24 more advanced adenomas (30 more high risk adenomas and 6 
fewer intermediate adenomas) compared with the FIT alone. Based on the results from 
these data, for every 1,000,000 people invited to screening an estimate of an additional 
586 cancers/advanced adenomas (4,715/1,000,000) would be detected compared to using 
the FIT alone (4,129/1,000,000). 
When investigating the breakdown of referrals by sex in the 2 by 2 tables for a threshold of 
160 μg Hb/g faeces, it was found that cancers and advanced adenomas were being 
detected more in referrals for men than women. The neural network equalized the 
difference in cancers/advanced adenomas detected between men and women seen with 
the logistic regression and FIT only models. At 160 μg Hb/g faeces, compared with FIT only 
the neural network increased the number of high-risk adenomas detected for women 
(cancers stayed the same) and halves the number of false positive results for women. 
Although the neural network recalls fewer women, the PPV is increased compared to the 
other models and is similar between the sexes (men – 52.33%; women – 48.96%). 
At either end of the risk spectrum, the ANN helped to enhance the difference between 
those at low-risk of disease with those at higher risk, which allowed better discrimination 
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capabilities of the model/test. This difference was visually represented in the 
predictiveness curve.  
Garson’s algorithm was used to assess the relative importance of the input variables for the 
ANN. The relative importance was greatest for the screening history variables, ‘previous 
responder’ and ‘previous non-responder’, followed by age, FIT result and sex. The 
screening history variables also had the greatest odds ratio for the logistic regression 
model. 
Examples of patient profiles were presented. One example showed that the ANN assigned 
a lower probability for an individual with a normal outcome at colonoscopy whereas the LR 
model and FIT only would have referred this individual for further unnecessary testing. The 
repercussions of increased false positive results are putting people through unnecessary 
diagnostic tests, which in the case of colonoscopy carries risk of bleeding and perforation of 
the bowel (which can lead to death). There is also a psychological effect for these 
individuals as they may think they have cancer or its precursor.  
Another example of a patient profile is presented whereby they did not meet the referral 
threshold for both the LR and FIT only models but did so for the neural network when they 
had a ‘high risk’ diagnostic outcome. The number of false negative results should be limited 
as far as possible since this has the effect of missing a potential cancer/advanced adenoma 
and relates to the sensitivity of the test 
4.2 Strengths and Weaknesses of the Study 
 
This study used the same dataset as the previous chapter for developing an ANN risk 
prediction model. In addition, the same variables were used for the final model as the risk-
adjusted logistic regression model allowing direct comparisons in terms of model 
performance and test accuracy. As described in the previous chapter, the pilot was 
implemented within a live screening programme providing good quality data for model 
development. 
 
Different approaches were taken to improve the generalization of the model including 
investigating different values of the weight decay parameter which provided the lowest 
SSE, and pruning network connections. By reducing complexity in this way the 
generalization of the model is improved in external populations. Although the network was 
pruned, this was just based on absolute magnitude with the subsequent change in cross-
  
 
 
207 
 
Chapter 4 Chapter four | Artificial Neural Network Risk Prediction Model 
validated deviance monitored as each weight was dropped. Conversely, an optimization 
algorithm which tried every single iteration of weight connection removal could be used. 
For example, more formal methods of pruning weights have been formalised in the 
literature; optimal brain damage, optimal brain surgery and genetic algorithms have been 
applied to subset selection.15 92-95 The optimal brain damage and optimal brain surgery 
methods are variants of the Wald (or likelihood ratio) test. The method used for this study 
however dropped all the small magnitude weights to achieve a model with a significantly 
lower cross-validated deviance compared to the logistic regression model. Furthermore, for 
ANN model development, there are empirical and methodological issues which remain to 
be resolved,1 there are fewer guidelines to be followed within the literature.  
 
Finally, the same limitations to the dataset as described in the previous chapter in relation 
to follow up data and interval cancers not being recorded on BCSS and the participant flow 
have been inherited in this study. 
4.3 Strengths and weaknesses in relation to other studies 
 
As far as can be identified, neural networks have not been developed for use in an average 
risk screening population for screening referral decisions. ANNs have however been 
developed for diagnosis, survival prediction, cancer relapse and distant metastases for 
colorectal cancer.37 96 
As identified in the methodology review by Dreiseitl and Ohno-Machado,9 the model 
building procedure was reported more often in logistic regression based models compared 
with ANNs based on variable selection, parameter selection and over-fitting avoidance. 
This research fully reports the construction of the network architecture and the selection of 
the weight decay parameter value as well as the step by step removal of weights during the 
network pruning to allow the model to be reproduced. The importance of reporting the 
model-building procedure is reflected in the TRIPOD guidelines under item 10b; ‘Specify 
type of model, all model-building procedures (including any predictor selection), and 
methods for internal validation’.97 Many studies only report the model with best 
discrimination which may reflect a model which is over-fitted with over-optimistic model 
performance and therefore has worse performance when applied in external populations. 
Model selection is driven by both the data and clinical context and this needs to be fully 
reported and justified within the study. 
  
 
 
208 
 
Chapter 4 Chapter four | Artificial Neural Network Risk Prediction Model 
4.4 Practical Implications 
 
Although the performance of the neural network was better than the logistic regression 
model, as discussed in the introduction there are several barriers which have hindered the 
widespread practical application of machine learning approaches.32 50-53 This study focused 
on providing a reportable equation which would allow further researchers to assess and 
validate the model and to enhance computational transportability since it could be applied 
in practice with minimal software requirements. To try and open the ‘black box’, this study 
focused on using additional methods to present the relative importance of variables in the 
form of Garson’s algorithm, patient profiles and predictiveness curves to enhance model 
interpretability. External validation and impact studies would however be required to 
assess the effect on patient outcomes and to determine acceptability to patients and 
clinicians. Assessing outcomes such as these will improve clinician ‘trust’ in the use of 
machine learning algorithms. 
Both models  give the absolute risk prediction for each individual and this can be used to 
make clinical decisions regarding screening referral by setting an appropriate ‘risk 
threshold’. The BCSS has capacity within the database to use a risk algorithm for screening 
referral. The model equation is fully reported in this study and could be used for 
subsequent external validation and future impact studies. The methods for assessing 
external validation of neural networks would however need to be further explored but can 
be based on the methods used for a logistic regression validation if using a logistic 
activation and output function. Furthermore, if additional predictors are included in the 
model in the future, non-linear predictors and model interactions may be better captured 
with a neural network or other machine-learning algorithm. 
The FIT detected more cancers/advanced adenomas in males compared to females and this 
difference was exacerbated when applying the risk-adjusted logistic regression model. The 
neural network on the other hand levels out this difference in sex by increasing the number 
of high-risk adenomas detected for women (cancers stay the same) and halving the 
number of false positive results for women (threshold 160 μg Hb/g faeces). Depending on 
the screening programme aims, by referring a greater number of males this may cause 
potential issues in the screening community. A further method to combat this difference in 
the sexes is to consider separate algorithms for males and females.  
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When applying a model as a test in this way, it can lead to a change in the spectrum of 
diagnosed disease and in the subgroups where cancer is detected. This is a key element of 
Health Technology Assessment and requires further investigation in this area. 
4.5 Future Research 
 
The risk based models developed in the current and previous chapters could be refined 
further by utilising additional risk predictors available from the BCSS as described in the 
previous chapter as well as using follow up information once the FIT is rolled out in 2018. 
This refined model could then be assessed in a further dataset using FIT for external 
validation (for instance, Scotland have implemented the FIT, along with the Isle of Man).  
The impact of the risk prediction model could be investigated by recalling an individual if 
either the FIT result alone or the risk-based model suggests cancer could be detected at 
colonoscopy and assessing the corresponding diagnostic accuracy and patient outcomes.  
The BCSS has an inbuilt function of using 1/n data for screening participants. For the pilot, 1 
out of every 28 invitations was assigned a FIT, a similar approach here could be used to 
assess risk adjusted screening or to assign a range of thresholds so data can be retained for 
future analysis. 
Although the performance of the neural network is significantly better than using a logistic 
regression model, another approach to improving discrimination power is to include a 
richer set of predictors. As identified in the previous chapter, further predictors could be 
obtained from the BCSS such as previous FIT results once this screening test is 
implemented in England, as well as colonoscopy and flexible sigmoidoscopy results. 
Alternatively, studies identified in the systematic review suggest that discrimination can be 
improved by incorporating the results of further lab tests,98-100 or lifestyle parameters.101 102 
A study identified from the systematic review which combines both lifestyle information 
with lab based parameters in an accelerated failure time model shows enhanced 
discrimination (ROC AUC: 0.86, 95% CI – 0.85, 0.87).101 Another potential data source for 
richer predictors such as these which may improve discriminatory power includes 
electronic GP records which contain a wide array of information including; symptoms, 
prescriptions, lab test results and lifestyle parameters. The BCSS receives data for its 
screening participants from the NHS Spine103 which houses demographic information 
(name, address, postcode, NHS number, date of birth for those aged 60-74) drawn from GP 
records. There is capacity therefore to draw further information from the spine or from GP 
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records to improve screening referral decisions. Risk prediction studies for colorectal 
cancer screening have suggested the possible use of electronic GP records to provide this 
extra risk information.102 104 
Machine learning approaches have less guidance over more conventional modelling 
techniques such as logistic regression. The TRIPOD guidelines focus mainly on regression 
models but some of the principles are equally valid to machine learning methods. ANNs are 
less well reported compared to logistic regression as found in systematic reviews.17 37 There 
are also empirical and methodological issues which remain to be resolved,1 and fewer 
guidelines in the literature. Therefore future research in prediction modelling should focus 
on guidelines for such models to improve reporting and transparency of results. This may 
also have a corresponding effect on their clinical use in practice. 
5.0 CONCLUSIONS 
Although it is often argued that neural networks are more difficult to interpret and are 
often likened to a ‘black box’ this result shows the promise of machine learning algorithms 
for use in screening decisions and clinical practice. Both the logistic regression and neural 
network can give the absolute risk for each individual and this can be used for screening 
referral decisions by setting an appropriate ‘risk threshold’. With the shift to larger and 
more complex electronic health data, machine-learning algorithms may be better placed to 
deal with larger amounts of data and non-linear associations when compared with 
conventional models such as logistic regression. 
Another approach to improving model performance and discrimination power is to 
consider a richer set of predictors. The BCSS receives data for its participants from the NHS 
Spine which houses demographic information (name, address, postcode, NHS number, 
date of birth for those aged 60-74) drawn from GP records. There is capacity to draw 
further information from the Spine or from GP records to improve screening referral 
decisions. For instance, lab based parameters and lifestyle parameters were shown to 
improve discrimination when combined with FIT in risk prediction models in Chapter 2. A 
study identified from the review combined both lifestyle information and lab results with 
the FIT in an accelerated failure time model showing enhanced discrimination.101 Further to 
this, several studies based on primary care data have investigated predictors which could 
be used in a prediction model for primary care referral.5 105 106 The next chapter will 
investigate the use of an anonymised GP record database (THIN) to define a screening 
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population, determine how complete potential predictors are for this population and to 
develop risk prediction models (using survival analysis methods) for use in screening 
referral decisions by combining richer predictor information. This will help to identify 
potential further predictors which may enhance a risk based screening model. 
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7.0 APPENDICES 
Appendix 1: R scripts used for model development and to assess performance 
 
###Artificial Neural Network### 
# ------------------------------------------------------------------------------------------------------------------------- 
# Read Data in for modelling 
ccFIT20 <- read.csv("FITroutine.csv") 
# ------------------------------------------------------------------------------------------------------------------------- 
#Load package and library for nnet (in base R) and further packages 
install.packages("nnet") 
library(nnet) 
install.packages("NeuralNetTools") 
library("NeuralNetTools") 
install.packages("ggplot2") 
library("ggplot2") 
install.packages("pROC") 
library("pROC") 
# ------------------------------------------------------------------------------------------------------------------------- 
# Standardisation of continuous variables 
 
ccFIT20$stan.FIT <- (log(ccFIT20$TRANS_FIT_KIT_RESULT +1) - mean(log(ccFIT20$TRANS_FIT_KIT_RESULT 
+1)))/sd(log(ccFIT20$TRANS_FIT_KIT_RESULT +1)) 
mean(ccFIT20$stan.FIT) 
 
ccFIT20$stan.FIT2 <- ccFIT20$TRANS_FIT_KIT_RESULT - 
(mean(ccFIT20$TRANS_FIT_KIT_RESULT)/sd(ccFIT20$TRANS_FIT_KIT_RESULT)) 
mean(ccFIT20$stan.FIT2) 
 
 
ccFIT20$stan.age <- (ccFIT20$AGE_AT_EPISODE_START - 
mean(ccFIT20$AGE_AT_EPISODE_START))/sd(ccFIT20$AGE_AT_EPISODE_START) 
mean(ccFIT20$stan.age) 
 
ccFIT20$stan.IMD <- (ccFIT20$IMD_SCORE - mean(ccFIT20$IMD_SCORE))/sd(ccFIT20$IMD_SCORE) 
mean(ccFIT20$stan.IMD) 
# ------------------------------------------------------------------------------------------------------------------------- 
#Set seed for replication of results 
 
set.seed(23456) 
 
neuralnetmod <- nnet(Binary.outcome~stan.FIT + stan.age + GENDER + prev.incident, data=ccFIT20, skip = FALSE, size = 3, 
linout = FALSE, decay = 0.0, entropy = TRUE, maxit = 500) 
 
#Print structure of network 
summary(neuralnetmod) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Repeat the above for different weight decay values, hidden layer nodes to determine cross validated deviance and therefore 
network architecture of best fitting neural network model 
# ------------------------------------------------------------------------------------------------------------------------- 
 
# deviance and weight decay 
nnet.deviance <- function(nnet.fitted){ 
  nnet.obs <- as.integer(nnet.fitted$residuals + nnet.fitted$fitted.values) 
  e.pos <- nnet.obs * log(nnet.obs / nnet.fitted$fitted.values) 
  e.neg <- (1 - nnet.obs) * log((1 - nnet.obs)/(1 - nnet.fitted$fitted.values)) 
  e.all <- rowSums(data.frame(e.pos, e.neg), na.rm = TRUE) 
  E.mod <- sum(e.all) 
  penalty <- sum(nnet.fitted$wts ^ 2) * nnet.fitted$decay 
  list(deviance = 2* E.mod, E = E.mod, penalty = penalty, E.crit = E.mod + penalty) 
} 
nnet.deviance(nnet.fitted = neuralnetmod) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
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# ------------------------------------------------------------------------------------------------------------------------- 
#To determine cross validated deviance using 10 fold cross validation  
 
CVnn <- function(mod, m.dat, nreps=10, verbose = TRUE, seedno = 1234, ...) 
{ 
  pred.cv <- vector(length = dim(m.dat)[1]) 
  set.seed(seedno) 
  for(rep in 1:nreps) { 
    rand <- sample(10, dim(m.dat)[1], replace = TRUE) 
    if (verbose == TRUE){ 
      cat("Replication =",rep,"\n") 
      cat("Randomisation ",rand[1:10],". . .","\n") 
      cat("Size",paste(mod$n, collapse = "-"),"and decay ",mod$decay,"\n") 
    } 
    for (i in sort(unique(rand))) { 
      if(verbose == TRUE){cat("fold ", i, "\n", sep="")} 
      cvmod.nn <- update(mod, data = m.dat[rand != i, ], trace = FALSE) 
      pred.cv[rand == i] <- pred.cv[rand == i] + 
        predict(cvmod.nn, m.dat[rand == i,]) 
    } 
  } 
  nnet.obs <- as.integer(mod$residuals + mod$fitted.values) 
  e.pos <- nnet.obs * log(nnet.obs / (pred.cv / nreps)) 
  e.neg <- (1 - nnet.obs) * log((1 - nnet.obs)/(1 - (pred.cv / nreps))) 
  e.all <- rowSums(data.frame(e.pos, e.neg), na.rm = TRUE) 
  E.mod <- sum(e.all) 
  cv.deviance <- 2 * E.mod 
  return(cv.deviance) 
} 
#Insert neural network model name 
CVnn(mod = neuralnetmod, m.dat = ccFIT20, nreps = 10, seedno = 51234, verbose = FALSE) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#5-3-1 gives lowest cross validated deviance at a decay of 0 and 3 hidden layer nodes 
# ------------------------------------------------------------------------------------------------------------------------- 
#To visualise the ANN 
 
set.seed(23456) 
neuralnetmod <- nnet(Binary.outcome~stan.FIT + stan.age + GENDER + prev.incident, data=ccFIT20, skip = FALSE, size = 3, 
linout = FALSE, decay = 0.0, entropy = TRUE, maxit = 500) 
summary(neuralnetmod) 
plotnet(neuralnetmod, cex_val =0.8) 
 
#For numerical input 
wts <- neuralweights(neuralnetmod) 
struct <- wts$struct 
wts <- unlist(wts$wts) 
# plot 
plotnet(wts, struct = struct) 
# -------------------------------------------------------------------------------------- 
# To obtain predicted probabilties from the ANN 
neuralnetmod$fitted.values 
# ------------------------------------------------------------------------------------------------------------------------- 
####Optimising the selected model### 
# ------------------------------------------------------------------------------------------------------------------------- 
#Determining weight decay 
 
#Investigating different weight decay values and their effect on SSE from 0.0 to 1.0 
 
error = vector("numeric", 100) 
wdecay = seq(0.0, 1.0, length.out=100) 
 
for(i in 1:100) { 
  set.seed(23456) 
  fit <- nnet(Binary.outcome~stan.FIT + stan.age + GENDER + prev.incident, data=ccFIT20, skip = FALSE, size = 3,  
              linout = FALSE, decay = wdecay[i], entropy = TRUE, maxit = 500) 
  error[i] <- sum(fit$residuals^2)  
} 
plot(wdecay, error) 
 
errordecay <- data.frame(wdecay, error) 
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#Find the minimum SSE 
min(errordecay$error) 
 
 
#Investigate different weight decay values and their effect on SSE from 0.0001 to 0.1 
#SSE1 = sum(fitnn1$residuals^2) 
 
error = vector("numeric", 100) 
wdecay = seq(0.0001, 0.1, length.out=100) 
 
 
for(i in 1:100) { 
  set.seed(23456) 
  fit <- nnet(Binary.outcome~stan.FIT + stan.age + GENDER + prev.incident, data=ccFIT20, skip = FALSE, size = 3,  
              linout = FALSE, decay = wdecay[i], entropy = TRUE, maxit = 500) 
  error[i] <- sum(fit$residuals^2)  
} 
plot(wdecay, error) 
 
errordecay <- data.frame(wdecay, error) 
 
#Find the minimum SSE 
min(errordecay$error) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Pruning the ANN 
#For this best fitting model, look at the smallest magnitude for the different weights and drop/set these to 0 
 
#Seed to replicate results 
set.seed(23456) 
#Fit neural network model 
neuralnetmod <- nnet(Binary.outcome~stan.FIT + stan.age + GENDER + prev.incident, data=ccFIT20, skip = FALSE, size = 3,  
                     linout = FALSE, decay = 0.01, entropy = TRUE, maxit = 500) 
 
#Summarize structure of neural network model 
summary(neuralnetmod) 
 
#Set the weights equal to false 'F' or true 'T' depending on whether you are pruning the weight connection. 
pick.weights <- as.logical(c(F, F, T, F, F, F, T, F, T, F, 
                             T, F, F, T, F, F, F, F, F, F, 
                             T, T)) 
 
#Set the chosen weights equal to zero corresponding to the above order 
start.weights <- neuralnetmod$wts 
start.weights[c(8,4,16,17,19,13,2,15,18,10,6,1,12,5,20)] <- 0 
 
#Set seed to replicate results 
set.seed(23456) 
#Run the pruned network 
neuralnetmod <- nnet(Binary.outcome~stan.FIT + stan.age + GENDER + prev.incident, data=ccFIT20, skip = FALSE, size = 3,  
                     linout = FALSE, decay = 0.01, entropy = TRUE, maxit = 500, Wts = start.weights, mask = pick.weights) 
 
#Summarize structure of neural network model 
summary(neuralnetmod) 
#Rerun cross validation function as above to obtain 
#cross validated deviance 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#The best fitting model has 18 weights 
 
#Seed to replicate results 
set.seed(23456) 
#Fit neural network model 
neuralnetmod <- nnet(Binary.outcome~stan.FIT + stan.age + GENDER + prev.incident, data=ccFIT20, skip = FALSE, size = 3,  
                     linout = FALSE, decay = 0.01, entropy = TRUE, maxit = 500) 
#Summarize structure of neural network model 
summary(neuralnetmod) 
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#Set the 22 weights equal to false 'F' or true 'T' depending on whether you are pruning the weight connection. 
pick.weights <- as.logical(c(T, T, T, F, T, T, T, F, T, T, 
                             T, T, T, T, T, F, F, T, T, T, 
                             T, T)) 
 
#Set the chosen weights equal to zero corresponding to the above order 
start.weights <- neuralnetmod$wts 
start.weights[c(8,4,16,17)] <- 0 
 
#Set seed to replicate results 
set.seed(23456) 
#Run the pruned network 
neuralnetmod <- nnet(Binary.outcome~stan.FIT + stan.age + GENDER + prev.incident, data=ccFIT20, skip = FALSE, size = 3,  
                     linout = FALSE, decay = 0.01, entropy = TRUE, maxit = 500, Wts = start.weights, mask = pick.weights) 
 
 
 
#Summarize structure of neural network model 
summary(neuralnetmod) 
#Rerun cross validation function as above to obtain 
#cross validated deviance 
# ------------------------------------------------------------------------------------------------------------------------- 
#Plot to show change in CV deviance as weight connections removed 
 
pruningcvdeviance <- read.csv("pruningcvdeviance.csv") 
pruningcvdeviance$Number.of.Weights<-as.numeric(pruningcvdeviance$Number.of.Weights) 
attach(pruningcvdeviance) 
 
dev.new(width=10, height=10) 
plot(Number.of.Weights,Cross.Validated.Deviance, xlab="Number of Weights", ylab="Cross-Validated Deviance", xlim=c(22, 
6)) 
lines(Number.of.Weights,Cross.Validated.Deviance,col="black") 
axis(1, at=c(22:7), labels= c(22:7))   
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Garsons algorithm to visualise relative importance of variables (for final selected model) 
 
cols <- blues9 
garson(neuralnetmod) + 
  scale_y_continuous('Relative Importance', limits = c(-1, 1)) + 
  scale_fill_gradientn(colours = cols) + 
  scale_colour_gradientn(colours = "black") + 
  theme(text = element_text(size=15), 
        axis.text.x = element_text(angle=45, hjust=1)) + 
  scale_x_discrete(labels=c("Sex","FIT Result","Age","Previous Non-Responder","Previous Responder")) + 
  xlab(NULL) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Performance Measures: 
# ------------------------------------------------------------------------------------------------------------------------- 
#Calibration plot 
 
install.packages("PredictABEL") 
library("PredictABEL") 
# ------------------------------------------------------------------------------------------------------------------------- 
#Calibration Plot (for the neural network model) 
 
cOutcome <- 13 #the column with the outcome in your dataset 
predRisk <- fitted.values(neuralnetmod) 
# specify range of x-axis and y-axis 
rangeaxis <- c(0,1) 
# specify number of groups for Hosmer-Lemeshow test 
groups <- 10 
 
cal <- plotCalibration(data=ccFIT20, cOutcome=cOutcome, predRisk=predRisk, groups=groups, rangeaxis=rangeaxis) 
 
#Return observed versus expected probability table and p value for Hosmer-Lemeshow goodness of fit test 
cal 
 
#-------------------------------------------------------------------------------------------------------------------------- 
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#Another way to determine Hosmer Lemeshow statistic 
 
install.packages("ResourceSelection") 
library("ResourceSelection") 
 
hl <-hoslem.test(ccFIT20$Binary.outcome, fitted.values(neuralnetmod), g=10) 
hl 
 
#loop to give results for different group splits 
 
for (i in 5:15) { 
  print(hoslem.test(ccFIT20$Binary.outcome, fitted.values(neuralnetmod), g=i)$p.value) 
}   
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Predictiveness curve for FIT only, logistic regression and ANN 
# ------------------------------------------------------------------------------------------------------------------------- 
 
#FIT only model 
cclog.mod.1 <- glm(Binary.outcome~ log(TRANS_FIT_KIT_RESULT+1), ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.1) 
 
#FIT plus risk model (logistic regression) 
cclog.mod.2 <- glm(Binary.outcome ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident, 
data = ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.2) 
 
#Neural Network 
neuralnetmod 
summary(neuralnetmod) 
 
#Different methods for predicted probabilities 
 
#predicted probabilities for neural network 
ccFIT20$nnetprobabilities <-fitted.values(neuralnetmod) 
ccFIT20$nnetprobabilities <- as.vector(ccFIT20$nnetprobabilities) 
 
#FIT only 
ccFIT20$fitprobabilities <- predict(cclog.mod.1, ccFIT20, type = "response") 
 
#Predicted probabilities for just the logistic regression model 
ccFIT20$lrprobabilities <- predict(cclog.mod.2, ccFIT20, type = "response") 
 
#Other method: 
 
predRisk1 <- predRisk(cclog.mod.1) 
predRisk2 <- predRisk(cclog.mod.2) 
predRisk3 <- fitted.values(neuralnetmod) 
# ------------------------------------------------------------------------------------------------------------------------- 
# Predictiveness curve 
 
# specify range of y-axis 
rangeyaxis <- c(0,1) 
# specify labels of the predictiveness curves 
labels <- c("Neural Network", "Risk adjusted LR", "FIT only") 
 
 
# produce predictiveness curves 
plotPredictivenessCurve(predrisk=cbind(predRisk3,predRisk2, predRisk1),rangeyaxis=rangeyaxis, labels=labels) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
# ------------------------------------------------------------------------------------------------------------------------- 
#Plotting ROC curve for all three models 
 
#Install pROC packages 
install.packages("pROC") 
library("pROC") 
 
# ------------------------------------------------------------------------------------------------------------------------- 
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# ------------------------------------------------------------------------------------------------------------------------- 
#1st ROC for FIT only 
 
#1st ROC curve for FIT only 
roccurve1 <- roc(ccFIT20$Binary.outcome ~ ccFIT20$fitprobabilities) 
#Return AUC 
roccurve1 
 
#Alternatively for 95% CI:  
auc(ccFIT20$Binary.outcome, ccFIT20$fitprobabilities) 
ci.auc(ccFIT20$Binary.outcome, ccFIT20$fitprobabilities, conf.level=0.95, method="delong") 
 
#Return AUC CI 
ci.auc(roccurve1, conf.level=0.95, method="delong") 
ci.auc(roccurve1, conf.level=0.95, method="bootstrap", boot.n = 10000) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#2nd ROC curve for Risk adjusted 
 
roccurve2 <- roc(ccFIT20$Binary.outcome ~ ccFIT20$lrprobabilities) 
 
#Return AUC 
roccurve2 
 
#Return AUC CI 
ci.auc(roccurve2, conf.level=0.95, method="delong") 
ci.auc(roccurve2, conf.level=0.95, method="bootstrap", boot.n = 10000) 
# ------------------------------------------------------------------------------------------------------------------------- 
#3rd ROC curve for Neural Network 
 
roccurve3 <- roc(ccFIT20$Binary.outcome ~ ccFIT20$nnetprobabilities) 
 
#Return AUC 
roccurve3 
 
#Return AUC CI 
ci.auc(roccurve3, conf.level=0.95, method="delong") 
ci.auc(roccurve3, conf.level=0.95, method="bootstrap", boot.n = 10000) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
 
#Combine all three models in a ROC plot 
 
#ROC for risk adjusted model 
Risk_adjusted_LR <- plot.roc(ccFIT20$Binary.outcome, ccFIT20$lrprobabilities) 
 
#ROC for neural network 
Neural_Network <- plot.roc(ccFIT20$Binary.outcome, ccFIT20$nnetprobabilities, add=TRUE, col="12", lty=2) 
 
#Add ROC for FIT only 
FIT_only <- plot.roc(ccFIT20$Binary.outcome, ccFIT20$fitprobabilities, add=TRUE, col="red", lty=3) 
 
#Add legend 
legend("right", legend = c("Risk-adjusted LR", "Neural Network", "FIT only"), lty=c(1, 2, 3), col=c("black", "12", "red")) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
 
#ROC test - to test for significant difference between neural network and logistic regression 
 
roc.test(roccurve2, roccurve3) 
 
# The latter used Delong's test. To use bootstrap test: 
#Set seed for replicability 
roc.test(roccurve2, roccurve3, method="bootstrap", boot.n=10000) 
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# ------------------------------------------------------------------------------------------------------------------------- 
#Test performance 2 by 2 data 
# ------------------------------------------------------------------------------------------------------------------------- 
#Install dplyr for data manipulation 
 
install.packages("dplyr") 
library("dplyr") 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Produce predicted probabilities for indivduals using all three models 
#FIT only model 
cclog.mod.1 <- glm(Binary.outcome~ log(TRANS_FIT_KIT_RESULT+1), ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.1) 
 
#FIT plus risk model (logistic regression) 
cclog.mod.2 <- glm(Binary.outcome ~ log(TRANS_FIT_KIT_RESULT + 1) + AGE_AT_EPISODE_START + GENDER + prev.incident, 
data = ccFIT20, family=binomial(link="logit")) 
summary(cclog.mod.2) 
 
#Neural Network 
neuralnetmod 
summary(neuralnetmod) 
 
#Different methods for predicted probabilities 
 
#predicted probabilities for neural network 
ccFIT20$nnetprobabilities <-fitted.values(neuralnetmod) 
#To transform into numerical vector 
ccFIT20$nnetprobabilities<- as.vector(ccFIT20$nnetprobabilities) 
#Alternative 
ccFIT20$nnetprobabilities <-as.numeric(fitted.values(neuralnetmod)) 
str(ccFIT20$nnetprobabilities) 
 
#FIT only 
ccFIT20$fitprobabilities <- predict(cclog.mod.1, ccFIT20, type = "response") 
 
#Predicted probabilities for just the logistic regression model 
ccFIT20$lrprobabilities <- predict(cclog.mod.2, ccFIT20, type = "response") 
 
#To give full decimal places create character variable for predicted probabilities 
 
ccFIT20$CHARnnetprob <- as.character(ccFIT20$nnetprobabilities) 
ccFIT20$CHARlrprob <- as.character(ccFIT20$fitprobabilities) 
ccFIT20$CHARfitprob <- as.character(ccFIT20$lrprobabilities) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
# Set up a 160 cutpoint for the FIT 
 
ccFIT20$cutpoint160[ccFIT20$TRANS_FIT_KIT_RESULT>=160] <- "ABNORMAL" 
ccFIT20$cutpoint160[ccFIT20$TRANS_FIT_KIT_RESULT<160] <- "NORMAL" 
 
# Convert the column to a factor variable 
ccFIT20$cutpoint160 <- factor(ccFIT20$cutpoint160) 
 
#Look at the numbers referred for this cutpoint and set the same 
xtabs(~ccFIT20$cutpoint160+ccFIT20$Binary.outcome) 
 
#375 referred 
ccFIT20[375,] 
 
#Arrange by predicted probabilities for the model and refer the same 
  
ccFIT20<- arrange(ccFIT20, desc(nnetprobabilities)) 
 
#Determine the neural network probability cutpoint 
ccFIT20[375,] 
 
#Set this risk probability for a positive or negative test result 
ccFIT20$riskthreshold160[ccFIT20$nnetprobabilities<"0.40719445665783"] <- "NORMAL" 
ccFIT20$riskthreshold160[ccFIT20$nnetprobabilities>="0.40719445665783"] <- "ABNORMAL" 
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#160 risk cutpoint 2 by 2 table 
 
xtabs(~ccFIT20$riskthreshold160+ccFIT20$Binary.outcome) 
 
#160 risk cutpoint 2 by 2 table for sex 
 
xtabs(~ccFIT20$riskthreshold160+ccFIT20$Binary.outcome + ccFIT20$GENDER) 
 
#160 risk cutpoint 2 by 2 table for severity and sex 
 
xtabs(~ccFIT20$riskthreshold160+ccFIT20$Binary.outcome + ccFIT20$GENDER + ccFIT20$OUTCOME) 
 
# ------------------------------------------------------------------------------------------------------------------------- 
#Repeat this process for cutpoints from 30 to 180 and for all three models to populate two by two table 
# ------------------------------------------------------------------------------------------------------------------------- 
#e.g. for logistic regression model 
 
#Arrange by predicted probabilities for the model and refer the same 
 
ccFIT20<- arrange(ccFIT20, desc(lrprobabilities)) 
 
#375 referred 
ccFIT20[375,] 
 
#Assign a 160 risk probability cutpoint 
 
ccFIT20$riskthreshold160[ccFIT20$lrprobabilities<"0.389255384060317"] <- "NORMAL" 
ccFIT20$riskthreshold160[ccFIT20$lrprobabilities>="0.389255384060317"] <- "ABNORMAL" 
 
#160 risk cutpoint 2 by 2 tables 
 
xtabs(~ccFIT20$riskthreshold160+ccFIT20$Binary.outcome) 
xtabs(~ccFIT20$riskthreshold160+ccFIT20$Binary.outcome+ccFIT20$GENDER+ccFIT20$OUTCOME) 
 
 
# ------------------------------------------------------------------------------------------------------------------------- 
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Appendix 2: Weight Connection Values for a 5-3-1 Neural Network 
 
 
Node Weight Connections 
b->h1 -2.76 
i1->h1 -0.11 
i2->h1 -0.87 
i3->h1 0.01 
i4->h1 1.95 
i5->h1 1.93 
b->h2 -2.94 
i1->h2 -0.05 
i2->h2 -0.53 
i3->h2 0.03 
i4->h2 1.24 
i5->h2 1.21 
b->h3 -33.84 
i1->h3 -36.30 
i2->h3 3.41 
i3->h3 19.15 
i4->h3 -48.50 
i5->h3 -25.82 
b->o   -6.25 
h1->o  -69.04 
h2->o 171.40 
h3->o -1.64 
 
Table A.2.1: A feed forward 5-3-1 neural network with 22 weights, 500 iterations and 0 
weight decay. Neural network plotted using nnet and the neuralnetworktools packages in 
R. 
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Appendix 3: Hosmer-Lemeshow goodness of fit test for different splits for the 
ANN 
 
Number of groups P value for the Hosmer and 
Lemeshow test (ANN) 
P value for the Hosmer and Lemeshow 
test (Logistic Regression) 
5 0.993 0.906 
6 0.974 0.716 
7 0.746 0.611 
8 0.955 0.802 
9 0.969 0.793 
10 0.892 0.898 
11 0.978 0.647 
12 0.943 0.806 
13 0.986 0.989 
14 0.959 0.798 
15 0.912 0.940 
Table A.3.1: Hosmer-Lemeshow goodness of fit test for different splits for the ANN 
 
  
Refined ANN 
Calibration 
Total Mean 
predicted 
probability 
Mean 
observed 
probability 
Predicted (n) Observed (n) 
[0.0634,0.146)    181 0.114 0.099 20.56 18 
[0.1464,0.181) 181 0.164 0.171 29.75 31 
[0.1809,0.215)    181 0.199 0.199 36.11 36 
[0.2149,0.248) 181 0.233 0.232 42.10 42 
[0.2476,0.276) 181 0.262 0.260 47.41 47 
[0.2760,0.315) 181 0.295 0.304 53.37 55 
[0.3148,0.359) 181 0.339 0.298 61.34 54 
[0.3588,0.411)    181 0.384 0.431 69.45 78 
[0.4115,0.503) 181 0.456 0.448 82.45 81 
[0.5030,0.820] 181 0.588 0.591 106.49 107 
Chi square – 3.586  df – 8  p value 0.8924 
Table A.3.2: Hosmer lemeshow statistics for the refined neural network 
 
 
  
  
Appendix 4: Two by two tables for FIT only, Risk-adjusted and Neural Network models at thresholds between 30-180 μg/g 
        Diagnostic Positive           Diagnostic Negative       
30 μg Hb/g faeces  
Threshold   FIT only 
 
Risk-adjusted Neural Network   FIT only 
 
Risk-adjusted Neural Network Total 
    Male Female Male Female Male Female   Male Female Male Female Male Female   
  Total 324 161 357 139 353 152 Total 500 481 615 355 586 375   
FIT/Risk Positive 
Cancer 48 21 50 21 50 21 
Low Risk 
Adenoma 
212 161 257 123 247 127 
 
  
High risk 
Adenoma 
127 56 145 55 144 57 Abnormal 198 208 245 152 232 166 1466 
  
Intermediate 
risk 
Adenoma 
149 84 162 63 159 74 
Normal (No 
Abnormalities 
Found) 
90 112 113 80 107 82 
 
    Male Female Male Female Male Female 
 
Male Female Male Female Male Female 
 
  Total 34 30 1 52 5 39 Total 132 148 17 274 46 254  
FIT/Risk Negative 
Cancer 2 2 0 2 0 2 
Low Risk 
Adenoma 
51 42 6 80 16 76 
 
  
High risk 
Adenoma 
18 13 0 14 1 12 Abnormal 51 74 4 130 17 116 344 
  
Intermediate 
risk 
Adenoma 
14 15 1 36 4 25 
Normal (No 
Abnormalities 
Found) 
30 32 7 64 13 62 
  
Total    
549 
      
1261 
   
1810 
Table A.4.1: 2 by 2 table for FIT only, the risk-adjusted logistic regression model and the neural network split by sex. A threshold of 30 μg Hb/g faeces was 
used for the FIT which is equivalent to a risk threshold of 0.191 for the risk-adjusted model and 0.178 for the neural network. Profiles of outcome severity 
are also given. 
  
  
        Diagnostic Positive           Diagnostic Negative       
40 μg Hb/g faeces  
Threshold   FIT only 
 
Risk-adjusted Neural Network   FIT only 
 
Risk-adjusted Neural Network Total 
    Male Female Male Female Male Female   Male Female Male Female Male Female   
  Total 282 139 347 93 343 103 Total 406 364 568 183 543 202   
FIT/Risk Positive 
Cancer 45 20 49 19 48 18 
Low Risk 
Adenoma 
173 120 237 65 229 65 
 
  
High risk 
Adenoma 
115 51 144 37 141 42 Abnormal 157 157 227 78 214 90 1191 
  
Intermediate 
risk 
Adenoma 
122 68 154 37 154 43 
Normal (No 
Abnormalities 
Found) 
76 87 104 40 100 47 
 
    Male Female Male Female Male Female 
 
Male Female Male Female Male Female 
 
  Total 76 52 11 98 15 88 Total 226 265 64 446 89 427  
FIT/Risk Negative 
Cancer 5 3 1 4 2 5 
Low Risk 
Adenoma 
90 83 26 138 34 138 
 
  
High risk 
Adenoma 
30 18 1 32 4 27 Abnormal 92 125 22 204 35 192 619 
  
Intermediate 
risk 
Adenoma 
41 31 9 62 9 56 
Normal (No 
Abnormalities 
Found) 
44 57 16 104 20 97 
  
Total    
549 
      
1261 
   
1810 
Table A.4.2 2 by 2 table for FIT only, the risk-adjusted logistic regression model and the neural network split by sex. A threshold of 40 μg Hb/g faeces was 
used for the FIT which is equivalent to a risk threshold of 0.242 for the risk-adjusted model and 0.232 for the neural network. Profiles of outcome severity 
are also given. 
 
 
 
  
        Diagnostic Positive           Diagnostic Negative       
50 μg Hb/g faeces  
Threshold   FIT only 
 
Risk-adjusted Neural Network   FIT only 
 
Risk-adjusted Neural Network Total 
    Male Female Male Female Male Female   Male Female Male Female Male Female   
  Total 254 125 323 66 307 94 Total 342 288 489 131 455 153   
FIT/Risk Positive 
Cancer 40 19 46 12 42 17 
Low Risk 
Adenoma 
145 97 208 48 194 48 
 
  
High risk 
Adenoma 
104 45 137 25 132 38 Abnormal 140 120 190 52 182 65 1009 
  
Intermediate 
risk 
Adenoma 
110 61 140 29 133 39 
Normal (No 
Abnormalities 
Found) 
57 71 91 31 79 40 
 
    Male Female Male Female Male Female 
 
Male Female Male Female Male Female 
 
  Total 104 66 35 125 51 97 Total 290 341 143 498 177 476  
FIT/Risk Negative 
Cancer 10 4 4 11 8 6 
Low Risk 
Adenoma 
118 106 55 155 69 155 
 
  
High risk 
Adenoma 
41 24 8 44 13 31 Abnormal 109 162 59 230 67 217 801 
  
Intermediate 
risk 
Adenoma 
53 38 23 70 30 60 
Normal (No 
Abnormalities 
Found) 
63 73 29 113 41 104 
  
Total    
549 
      
1261 
   
1810 
Table A.4.3: 2 by 2 table for FIT only, the risk-adjusted logistic regression model and the neural network split by sex. A threshold of 50 μg Hb/g faeces was 
used for the FIT which is equivalent to a risk threshold of 0.272 for the risk-adjusted model and 0.260 for the neural network. Profiles of outcome severity 
are also given. 
  
  
        Diagnostic Positive           Diagnostic Negative       
80 μg Hb/g faeces  
Threshold   FIT only 
 
Risk-adjusted Neural Network   FIT only 
 
Risk-adjusted Neural Network Total 
    Male Female Male Female Male Female   Male Female Male Female Male Female   
  Total 190 91 248 41 233 71 Total 198 189 306 73 273 92   
FIT/Risk Positive 
Cancer 36 17 37 11 38 15 
Low Risk 
Adenoma 
83 65 125 24 107 30 
 
  
High risk 
Adenoma 
72 35 112 17 102 33 Abnormal 81 79 121 32 117 37 
668 
 
(669 for  
neuralnet) 
  
Intermediate 
risk 
Adenoma 
82 39 99 13 93 23 
Normal (No 
Abnormalities 
Found) 
34 45 60 17 49 25 
 
    Male Female Male Female Male Female 
 
Male Female Male Female Male Female 
 
  Total 168 100 110 150 125 120 Total 434 440 326 556 359 537  
FIT/Risk Negative 
Cancer 14 6 13 12 12 8 
Low Risk 
Adenoma 
180 138 138 179 156 173 
 
  
High risk 
Adenoma 
73 34 33 52 43 36 Abnormal 168 203 128 250 132 245 
1142 
 
(1141 for  
neuralnet) 
  
Intermediate 
risk 
Adenoma 
81 60 64 86 70 76 
Normal (No 
Abnormalities 
Found) 
86 99 60 127 71 119 
  
Total    
549 
      
1261 
   
1810 
 
Table A.4.4: 2 by 2 table for FIT only, the risk-adjusted logistic regression model and the neural network split by sex. A threshold of 80 μg Hb/g faeces was 
used for the FIT which is equivalent to a risk threshold of 0.321 for the risk-adjusted model and 0.330 for the neural network. Profiles of outcome severity 
are also given. 
 
  
        Diagnostic Positive           Diagnostic Negative       
150 μg Hb/g faeces  
Threshold   FIT only 
 
Risk-adjusted Neural Network   FIT only 
 
Risk-adjusted Neural Network Total 
    Male Female Male Female Male Female   Male Female Male Female Male Female   
  Total 122 56 163 30 151 56 Total 118 104 172 35 138 55   
FIT/Risk Positive 
Cancer 29 11 30 9 28 10 
Low Risk 
Adenoma 
46 34 67 9 51 15 
 
  
High risk 
Adenoma 
48 21 75 13 72 28 Abnormal 53 44 70 15 60 22 400 
  
Intermediate 
risk 
Adenoma 
45 24 58 8 51 18 
Normal (No 
Abnormalities 
Found) 
19 26 35 11 27 18 
 
    Male Female Male Female Male Female 
 
Male Female Male Female Male Female 
 
  Total 236 135 195 161 207 135 Total 514 525 460 594 494 574  
FIT/Risk Negative 
Cancer 21 12 20 14 22 13 
Low Risk 
Adenoma 
217 169 196 194 212 188 
 
  
High risk 
Adenoma 
97 48 70 56 73 41 Abnormal 196 238 179 267 189 260 1410 
  
Intermediate 
risk 
Adenoma 
118 75 105 91 112 81 
Normal (No 
Abnormalities 
Found) 
101 118 85 133 93 126 
  
Total    
549 
      
1261 
   
1810 
Table A.4.5: 2 by 2 table for FIT only, the risk-adjusted logistic regression model and the neural network split by sex. A threshold of 150 μg Hb/g faeces was 
used for the FIT which is equivalent to a risk threshold of 0.383 for the risk-adjusted model and 0.399 for the neural network. Profiles of outcome severity 
are also given. 
 
 
 
  
        Diagnostic Positive           Diagnostic Negative       
170 μg Hb/g faeces  
Threshold   FIT only 
 
Risk-adjusted Neural Network   FIT only 
 
Risk-adjusted Neural Network Total 
    Male Female Male Female Male Female   Male Female Male Female Male Female   
  Total 112 52 149 25 145 43 Total 105 93 155 33 128 46   
FIT/Risk Positive 
Cancer 27 10 29 7 27 10 
Low Risk 
Adenoma 
37 27 57 9 49 13 
 
  
High risk 
Adenoma 
42 20 69 11 71 23 Abnormal 50 40 66 14 54 18 362 
  
Intermediate 
risk 
Adenoma 
43 22 51 7 47 10 
Normal (No 
Abnormalities 
Found) 
18 26 32 10 25 15 
 
    Male Female Male Female Male Female 
 
Male Female Male Female Male Female 
 
  Total 246 139 209 166 213 148 Total 527 536 477 596 504 583  
FIT/Risk Negative 
Cancer 23 13 21 16 23 13 
Low Risk 
Adenoma 
226 176 206 194 214 190 
 
  
High risk 
Adenoma 
103 49 76 58 74 46 Abnormal 199 242 183 268 195 264 1448 
  
Intermediate 
risk 
Adenoma 
120 77 112 92 116 89 
Normal (No 
Abnormalities 
Found) 
102 118 88 134 95 129 
  
Total    
549 
      
1261 
   
1810 
 
Table A.4.6: 2 by 2 table for FIT only, the risk-adjusted logistic regression model and the neural network split by sex. A threshold of 170 μg Hb/g faeces was 
used for the FIT which is equivalent to a risk threshold of 0.392 for the risk-adjusted model and 0.411 for the neural network. Profiles of outcome severity 
are also given. 
  
  
        Diagnostic Positive           Diagnostic Negative       
180 μg Hb/g faeces  
Threshold   FIT only 
 
Risk-adjusted Neural Network   FIT only 
 
Risk-adjusted Neural Network Total 
    Male Female Male Female Male Female   Male Female Male Female Male Female   
  Total 108 49 142 23 142 38 Total 97 85 145 29 121 38   
FIT/Risk Positive 
Cancer 26 10 29 6 25 9 
Low Risk 
Adenoma 
37 25 53 7 49 9 
 
  
High risk 
Adenoma 
41 17 65 11 71 21 Abnormal 42 37 63 13 50 15 339 
  
Intermediate 
risk 
Adenoma 
41 22 48 6 46 8 
Normal (No 
Abnormalities 
Found) 
18 23 29 9 22 14 
 
    Male Female Male Female Male Female 
 
Male Female Male Female Male Female 
 
  Total 250 142 216 168 216 153 Total 535 544 487 600 511 591  
FIT/Risk Negative 
Cancer 24 13 21 17 25 14 
Low Risk 
Adenoma 
226 178 210 196 214 194 
 
  
High risk 
Adenoma 
104 52 80 58 74 48 Abnormal 207 245 186 269 199 267 1471 
  
Intermediate 
risk 
Adenoma 
122 77 115 93 117 91 
Normal (No 
Abnormalities 
Found) 
102 121 91 135 98 130 
  
Total    
549 
      
1261 
   
1810 
Table A.4.7: 2 by 2 table for FIT only, the risk-adjusted logistic regression model and the neural network split by sex. A threshold of 180 μg Hb/g faeces was 
used for the FIT which is equivalent to a risk threshold of 0.399 for the risk-adjusted model and 0.425 for the neural network. Profiles of outcome severity 
are also given. 
  
  
Appendix 5: Cancer/advanced adenoma detection rate for each model by screening history and sex subgroup 
 
Cancer/advanced adenoma detection rate for each model by screening history and sex subgroup (Threshold 160 μg Hb/g)  
 FIT Only Risk Model Neural Network 
Subgroup TP FP FN TN Cancer/Advanced 
Adenoma  
Detection Rate (%) 
TP FP FN TN Cancer/Advanced 
Adenoma  
Detection Rate (%) 
TP FP FN TN Cancer/Advanced 
Adenoma  
Detection Rate (%) 
Female First Time 
Invitee 
4 10 12 64 4.44 0 1 16 73 0.00 0 0 16 74 0.00 
Male First Time 
Invitee 
12 14 13 61 12.00 5 6 20 69 5.00 4 6 21 69 4.00 
Female Non 
Responder 
14 10 18 49 15.38 14 12 18 47 15.38 16 7 16 52 17.58 
Male Non 
Responder 
27 15 47 70 16.98 59 63 15 22 37.11 47 29 27 56 29.56 
Female Responder 36 76 107 420 5.63 12 22 131 474 1.88 31 42 112 454 4.85 
Male Responder 76 81 183 391 10.40 92 89 167 383 12.59 95 98 164 374 13.00 
TP – True Positive; FP – False Positive; FN- False Negative; TN – True Negative  
Table A.5.1: Cancer/advanced adenoma detection rate for each model by screening history and sex subgroup using a threshold of 160 μg Hb/g for the FIT 
and equivalent risk thresholds for the ANN model and logistic regression model. 
   
 
236 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
Investigating the Use of Routine GP Patient Data to Improve 
Colorectal Cancer Screening Referral Decisions 
 
This research was carried out as part of an NIHR Infrastructure Doctoral Training Exchange 
(IDTE) Award based at the Institute of Applied Health Research at The University of 
Birmingham. IDTE supervisors were Professor Tom Marshall (TM) and Dr Ronan Ryan (RR) 
based in the Health Informatics team, Primary Care Division. 
ABSTRACT 
 
Background: Risk prediction models which incorporate faecal occult blood tests with other 
known colorectal cancer risk factors have demonstrated increased sensitivity compared 
with FOBT alone. One of the barriers for using these prediction models in practice is the 
collection of data from individuals. Databases of electronic patient records from primary 
care have a richer level of data than that available on the bowel cancer screening system 
(BCSS) and include details on, symptoms, diagnoses, prescriptions, laboratory test results, 
socioeconomic status, lifestyle parameters and anthropometrics. These clinical features 
may add a further dimension to a risk based prediction model to improve colorectal cancer 
screening referral decisions. Further information from GP databases could be drawn out 
onto the screening system to contribute to decision making. The aim of the study was to 
determine (i) the availability of GP data for key predictors of colorectal cancer in the 
screening population and (ii) whether this additional information has the potential to be 
used to make more accurate screening referral decisions by developing multivariable risk 
prediction models. 
Methods: The Health Improvement Network (THIN) database of anonymised GP records 
was used to define a screening population by identifying practices which receive electronic 
bowel cancer screening programme notifications in England and for participants aged 60-
74. The positivity (number of positive results out of all FOBT results) of the FOBT in this 
cohort was compared to that in the literature. The availability of predictors was 
investigated by determining the percentage recorded on the database for each variable. 
Univariable analysis using Cox Regression was used to estimate hazard ratios (HR) for >30 
key clinical features of colorectal cancer driven from the literature. Kaplan-Meier estimates 
for time to diagnosis and time to death were plotted for a population with both negative 
and positive FOBTs. These were stratified by test result type and by sex with a log rank test 
determining if there was a statistical difference between these groups. A risk prediction 
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model combining the FOBT with risk predictors was then developed using Cox Regression 
with backwards elimination (p value >0.05 as removal criterion). Multivariable fractional 
polynomial models for continuous variables and interactions were investigated. To 
determine model performance, Harrell’s C statistic and Somers’ D were determined, along 
with plots of the Cox-Snell residuals to determine goodness of fit. Cox Regression 
diagnostics were also investigated by looking at Schoenfeld residual plots and tests of 
proportionality for individual covariates. The baseline hazard was estimated at 2 years 
using a non-parametric survival estimate (Kaplan-Meier). Absolute risk predictions for 
individuals were then estimated. Parametric survival models were investigated to 
determine whether these provided a better fit to the data using the AIC cumulative hazard, 
Kaplan Meier function plots and Cox-Snell residuals. Since the guaiac FOBT sensitivity is 
around 50%, analysis was then repeated for a population with negative FOBT results only 
to determine whether additional factors could be used for screening referral decisions 
despite a negative test result. A Nomogram was produced for this model as an alternative 
method of applying and presenting the risk prediction model. 
Results: The screening cohort derived from THIN gave 292,168 patients across 360 
practices aged 60-74 with a positive or negative FOBT result. The most severe diagnosis 
within 2 years was colorectal cancer for 929 patients and polyps for 1960 patients (2889 
total). Data were generally well recorded, with binary variables (like symptoms) having 
100% recorded completeness, smoking status 99.44% completeness and alcohol 
consumption 78% completeness. The least complete factors included lab results, e.g. 
platelet count, mean cell volume, and haemoglobin at around 45%, and ferritin at 8.59%. 
Univariable Cox Regression identified that screening based factors had the strongest 
association with colorectal cancer/polyps. For example, previous positive FOBT results had 
a HR of 5.032 (CI: 4.184-6.052) and previous polyps diagnosed before the latest FOBT result 
had a HR of 3.182 (CI: 2.768-3.659). The symptom with the highest HR was rectal bleeding 
(HR 3.118 (2.503-3.883)). A Cox regression model was developed for those with a 
positive/negative screening test (n=98,303, 1197 events). The final model included: FOBT 
result, smoking status, whether a patient has a diagnosis of Crohn’s disease, previous 
polyps diagnosed, flatulence, MCV of <80fL compared to a MCV of ≥80fL, alcohol 
consumption in units per week, family history of gastrointestinal cancer, abdominal 
pain/antispasmodic prescription, diarrhoea, sex, age at FOBT and change in bowel habit. 
Significant interactions at the 0.05 p-value level included FOBT result and age and MCV and 
age. The optimism adjusted performance metrics gave a; C statistic of 0.850, c-slope of 
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0.991, D statistic 2.298 and R2 of 0.558. The best fitting parametric model based on the AIC, 
cumulative hazard plots, Kaplan Meier function plots and Cox-Snell residuals was the 
generalised gamma model which uses the accelerated failure time metric. A model 
investigating predicted probabilities for those with just negative results was also developed 
to explore whether factors could be used to determine whether a patient should be 
referred despite a negative result. The final model for those with a negative FOBT only (n = 
95,792, 587 events) contained the following variables: smoking status, whether a patient 
has an irritable bowel syndrome (IBS) diagnosis, previous polyps diagnosed, flatulence, 
weight loss, MCV of <80fL compared to a MCV of ≥80fL, family history of gastrointestinal 
cancer, abdominal pain/antispasmodic prescription, diarrhoea, sex, age at FOBT and 
change in bowel habit. Optimism adjusted performance metrics for this model gave; a C 
statistic of 0.650, c-slope of 0.944, D statistic 0.836 and R2 of 0.144. A nomogram was 
produced for this model as a visual representation. The best fitting parametric model for 
negative results only was the Gompertz model. 
 
Conclusions: This chapter has shown that there are several clinical predictors available 
from GP databases which are associated with colorectal cancer and polyps for an English 
screening population. Furthermore, this research has identified predictors which could be 
considered for inclusion in a future risk adjusted screening model. Most factors 
contributing to the risk based models are well recorded. Laboratory parameters, although 
shown to be associated with colorectal cancer diagnosis, are the least well recorded factors 
from the model. Additional potential predictors which could be considered for inclusion in 
a future risk adjusted model include those which relate to screening history which have a 
strong association with the diagnosis of colorectal cancer/polyps. Predictors which retained 
significance in both multivariable models included demographic factors age and sex, 
lifestyle factor smoking status, lab test factor MCV, family history of gastrointestinal cancer, 
previous polyps diagnosed and the following symptoms: abdominal pain/antispasmodic 
prescription, diarrhoea, flatulence, and change in bowel habit. Additional data could 
potentially be drawn from primary care onto the BCSS if these factors are shown to 
contribute to the assessment of an individual’s risk of colorectal cancer. Similar analyses 
could be carried out with the FIT which is due to be introduced to the English NHS BCSP. 
Although, there would be many issues relating to quality of data, how the data is handled 
by the GP and the use of different GP operating systems in the NHS. Future risk screening 
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models including the identified factors could be used to help make more accurate 
screening referral decisions to improve early detection of colorectal cancer.  
1.0 INTRODUCTION 
 
The previous chapters have investigated the use of routine screening data from the Bowel 
Cancer Screening System (BCSS) along with the Faecal Immunochemical Test (FIT) to 
develop prediction models and aid referral decisions for colorectal cancer based on risk. 
Chapter 3 used standard statistical methodology in the form of logistic regression and 
Chapter 4 extended this to include a machine learning approach in the form of neural 
networks. Although there was a statistically significant improvement in discrimination 
when applying the neural network model, the value of the AUC ROC of the models suggest 
that there is room for improvement in prediction which could be achieved through other 
risk information/participant data. Chapter 2 identified that lifestyle factors and lab results 
could enhance the discriminatory power in some of the included studies.1 Other sources of 
data and individual participant information could therefore be used to add a further 
dimension to a risk based score and improve model performance and test accuracy.  
As health care records are becoming increasingly electronic and more quality assurance 
processes are being implemented to enhance data completeness and accuracy, databases 
of electronic patient records from general practices offer an additional way to make use of 
routinely available information on individuals. GP records have a richer level of data than 
that available from the BCSS and include details on symptoms, diagnoses, prescriptions, 
laboratory test results, socioeconomic status, lifestyle parameters and anthropometrics.  
This chapter investigated the use of an anonymized GP record database (THIN – The Health 
Improvement Network) to determine how complete potential predictors are for this 
population and identified predictors which could be considered for inclusion in a future risk 
adjusted screening model.  
1.1 Primary Care Databases for Research 
 
There are a number of large primary care databases available for medical research in the 
UK; primary amongst these are the Clinical Practice Research Datalink (CRPD) (formerly 
General Practice Research Database - GPRD), The Health Improvement Network (THIN), 
QRESEARCH and the IMS Mediplus system.2 
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The THIN database of anonymised GP records has data for over 587 practices (5.67% 
coverage of UK in 2014) covering more than 12 million patients (including 3.6 million active 
patients).3 THIN provides information on diagnoses, symptoms, prescriptions, laboratory 
tests and lifestyle factors across four standardised data files.4 These include patient files 
(recording information such as age, sex and other demographics), medical records 
(diagnoses and symptoms), therapy records (prescriptions) and additional health data 
(AHD) records (smoking, cholesterol etc). These different file types are linked by a patient 
ID. 
Diagnoses and symptoms are currently recorded as hierarchical Read codes and 
prescriptions are linked to the British National Formulary (BNF) chapter codes. Read codes 
are clinical codes which the GP enters for a patient consultation relating to new diagnoses 
and symptoms. 
1.2 Read Codes from the Bowel Cancer Screening Programme used in Primary 
Care 
 
Relevant Read codes generated for the English BCSP and used as electronic notifications to 
primary care are listed in Table 1. Read codes are used on primary care systems to record 
various symptoms and diagnoses and can be drawn out of databases for analysis. 
Read Code Description 
6866 Bowel cancer screening programme: faecal occult blood result 
6867 Bowel cancer screening programme faecal occult blood testing kit spoilt 
686A Bowel cancer screening programme faecal occult blood test normal 
686B Bowel cancer screening programme faecal occult blood test abnormal 
686C Bowel cancer screening programme faecal occult blood testing incomplete participation 
9Ow2 No response to bowel cancer screening programme invitation 
Table 1: Set of Read codes used by the NHS BCSP to record colorectal cancer screening activity. 
Currently there are no specific Read codes for the FIT, which is likely to be implemented in 
the BCSP in Summer 2018. The current screening test for bowel  cancer is the guaiac based 
FOBT (Hemascreen, Immunostics, New Jersey, USA) which identifies individuals at 
increased risk of cancer by detecting blood from colorectal neoplasia.5 A systematic review 
suggests that the FIT has a sensitivity of 87.2% and a specificity of 92.8% whereas the 
gFOBT has a sensitivity of 47.4% and a specificity of 92%.6 The FIT however is currently not 
routinely used for screening in the UK and current GP records only receive electronic 
notification results for the gFOBT. 
Health systems in the UK are also transitioning over to SNOMED CT clinical terminology and 
so Read codes will eventually cease to be used. As the FIT is implemented in the UK, GP 
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records will begin to obtain more data on the FIT and the approaches used in this chapter 
could be used to investigate prediction models combining this newer test.  
1.3 Links between GP records and the Bowel Cancer Screening system 
 
When patients sign up to a GP practice, their details are uploaded to the NHS Information 
Authority.7 The Spine supports IT infrastructure for health and social care in England and is 
a set of services used by the NHS Care Record Service including the Personal Demographics 
Service (demographic information and NHS number of patients) and Summary Care Record 
(clinical information of a patient).8 The Spine draws out these registration details over-
night. 8 Correspondingly the details of everyone who falls within the age range of screening 
(60-74) is extracted to the BCSS to gain new patient details. The Spine is set to what 
information is drawn from the GP practice and includes name, address and birth date. 
There is scope to draw out additional information from primary care such as laboratory test 
results, other co-morbidities/conditions and lifestyle parameters. A schematic of how the 
BCSS links up with the other data services used within the NHS and Public Health England is 
shown in Figure 1. 
Since 2010, The BCSS has sent results of the FOBT electronically to GP practices who have 
opted for this service using the same system as the Pathology Messaging Implementation 
Programme (PMIP). 9 This is the service also used by pathology labs to send laboratory 
results to primary care. The gFOBT results from screening are sent once daily overnight to 
the GP practices in batches. 
                                        
Figure 1: Data Schematic of the Bowel Cancer Screening System and the links with other data services from Public Health England.  
Data schematic was provided from Suzanne Wright, personal communication, Public Health England, with thanks.
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1.4 Risk Scoring Systems for Colorectal Cancer using Electronic GP Records 
 
One of the barriers identified to using a risk scoring system for screening is the collection of 
data from individuals; this can be facilitated by using routinely available data from 
electronic medical records. Risk prediction studies for colorectal cancer screening have 
suggested the possible use of electronic GP records to provide risk information.10 11 
Electronic GP records have been used to develop the QCancer risk prediction model12 
which has been validated in women13 and men14. This algorithm was derived from the 
QResearch database (incorporating electronic practice records) and takes into account 
both symptoms as predictors and other risk factors to determine an individual’s absolute 
risk of colorectal cancer in a primary care setting. The algorithm was built using Cox’s 
proportional hazards model on a derivation cohort to estimate risk factor coefficients 
(2,351,052 patients) and was tested on a validation cohort of 1,236,601 patients.15 The 
predictors included in the final model were, age, family history, anaemia, rectal bleeding, 
abdominal pain, appetite loss and weight loss. The algorithm for men also included alcohol 
use and change in bowel habit. Both algorithms had good discrimination in the validation 
cohort (0.89 ROC for females and 0.906 for males) and the authors suggest this algorithm 
could be used to prioritise patients at sufficient risk for primary care referral. This model 
has been validated by Collins and Altman12 with an AUC under the ROC curve of 0.91 for 
men and 0.92 for women. 
Several studies have also looked at identifying and quantifying symptoms and diagnostic 
features of CRC.16-21 NICE guidelines for referral, the CAPER scoring system and the Bristol-
Birmingham (BB) equation can be used to identify patients who warrant further tests based 
on their symptoms and other variables.20-22 The Bristol-Birmingham (BB) equation was 
derived using data provided by THIN and included the following variables: constipation, 
diarrhoea, change in bowel habit, abdominal pain, haemoglobin concentration, mean cell 
volume (MCV) and weight loss. The discrimination for the BB equation was 0.83 in the THIN 
dataset and 0.92 in the CAPER dataset. The CREDIBLE research project as an extension from 
this aimed to prospectively identify whether patients met NICE guidelines for referral by 
searching GP records.23  
The models described above were developed for use in a primary care setting to identify 
those at sufficient risk for primary care referral. The current study however aims to develop 
risk prediction models using a BCSP cohort for referral decisions in a screening based 
setting.  
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1.5 Laboratory Parameters and Colorectal Cancer Diagnosis 
 
Lab test results have been shown to relate to colorectal cancer prognosis and diagnosis.24-27 
A recent study using the THIN database and the Maccabi Healthcare Services (an Israeli 
dataset) combined blood measures, sex and age in a machine learning model (random 
forest model) to determine which individuals were at increased risk for colorectal cancer.28 
This model gave an AUC of 0.82.  In addition, by combining the FOBT with the lab results 
and comparing it to the gFOBT alone, the model identified 48% more CRC cases.28 This 
model was validated in a UK population using the CPRD database and gave AUC results 
comparable to the original Israeli model with an AUC of 0.776.29  
Anaemia has been shown to predict colorectal cancer from blood count data present in 
electronic primary healthcare records.25 Boursi et al.30 developed risk prediction models for 
sporadic colorectal cancer using the THIN database. The AUC for a reference model of CRC 
risk factors was 0.58, for lab based only parameters 0.76 and for a model which combined 
both the reference model and lab parameters the AUC was 0.80.  
The addition of lab based parameters based on these studies has shown improved 
predictive capabilities for colorectal cancer in a primary care setting. Studies identified in 
the systematic review reported in Chapter 2, which combine lab test results with the FIT, 
also show increased discriminatory power. A FOBT on its own, without other predictors 
may fail to detect intermittent bleeding or smaller lesions which may not bleed. The 
combination of abnormal blood results with the FOBT have been shown to improve 
sensitivity for detecting colorectal cancer.31 The inclusion of these parameters within an 
algorithm for colorectal cancer screening referral warrants further investigation. 
1.6 Survival Analysis 
 
Time to event analysis or ‘survival analysis’ investigates the time to the occurrence of a 
defined event. This is usually time to death in clinical trials hence the term ‘survival 
analysis’. At the end of the follow up period, not all individuals would have had the index 
event and so time to the event is unknown. This situation is referred to as right censoring 
of the data; the event (if it does occur) must occur to the right of the current or census 
time. For this reason, time to event data are usually skewed to early events and not 
normally distributed requiring specific methods for data analysis.32 The semi-parametric 
Cox proportional hazards (PH) model is the most widely used for survival analysis and 
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estimates hazard ratios which can be used to measure how much a predictor 
increases/decreases the rate of the defined event.33 The proportional hazards condition 
requires that explanatory variables are multiplicatively related to the hazard. The limitation 
of the Cox model is that it does not explicitly estimate the baseline hazard function.  
The Cox model can be extended to provide an estimate for the baseline hazard but other 
parametric models (e.g. Weibull, generalised gamma, exponential models) also exist which 
provide estimates of the hazard and survival function for a combination of predictors. For 
parametric survival models the hazard is assumed to follow a specific statistical 
distribution.34 Parametric proportional hazards models include the Exponential, Weibull 
and Gompertz models which produce hazard ratios like the semi-parametric Cox 
Regression model. Parametric survival models which follow the accelerated failure time 
metric include; Log-logistic, generalised gamma, Weibull and Log normal. The exponential 
of the coefficients produced by these models are time ratios instead of hazard ratios with a 
time ratio of >1 indicating that the predictor extends the time to the event and a time ratio 
of <1 indicating the predictor speeds up the time to the event.34  
Although parametric survival models require the underlying hazard distribution to be 
specified, they are generally more informative than the equivalent Cox Regression model. 
This is because they provide the hazard function and therefore predicted survival 
probabilities for each patient can be derived. They are also more efficient and give more 
precise parameter estimates, provided that the underlying model is ‘true’.34  
Using time to event analysis for longitudinal health records is a more efficient use of data 
than looking at whether an event has occurred or not as seen in logistic regression analysis. 
In a longitudinal study, outcomes and exposures can occur at multiple time points for each 
participant.  
Although studies usually investigate the time between response to treatment and 
recurrence or time from diagnosis to death, other studies have used survival analysis as a 
means for developing risk prediction models for cancer diagnosis.13 14 35 Hippisley-Cox and 
Coupland15 developed and validated a risk prediction algorithm for patients in primary care 
to facilitate early referral.  The time to event used for this study was time to diagnosis of 
colorectal cancer or more specifically “the primary outcome was incident diagnosis of 
colorectal cancer recorded in the next 2 years”15 (p. e29). This can make the model more 
future focused (or prognostic), rather than assessing accuracy at a fixed time point. The 
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paper also states that the Cox model was used to estimate the absolute risk of a patient in 
primary care currently having colorectal cancer. 
1.7 Rationale 
 
Risk prediction models combining predictors from electronic health records have shown 
promise in improving model and test accuracy for colorectal cancer detection. The richer 
data available from a GP record could be used to add a further dimension to a colorectal 
cancer screening model to improve discriminatory power and referral decisions. Lab test 
results available from GP records relate to the detection of colorectal cancer and may 
enhance the performance of risk prediction models as well as FOBTs which have greater 
sensitivity in men, can miss intermittent bleeding of lesions and have variable performance 
for cancers at different sites of the colon. To exploit longitudinal electronic GP data fully, 
different statistical methods in the form of survival analysis are required for censored data.  
The aims of this study were therefore to determine (i) the availability of GP data for key 
predictors of colorectal cancer in the screening population using the THIN database and (ii) 
whether this additional information has the potential to be used to make more accurate 
screening referral decisions by developing multivariable risk prediction models. 
Previous chapters have developed models based on a single time point to assess both 
model performance and test accuracy. This scenario translates well to using logistic 
regression with a binary endpoint at the time of screening. Survival analysis assesses the 
risk of disease over a certain time period (in this instance, diagnosis of colorectal 
cancer/polyps at 2 years). Given the longitudinal nature of the data, survival analysis is the 
most appropriate statistical method. Although this research uses a different modelling 
approach to previous chapters and uses the gFOBT as the screening test, the models can 
help to identify additional predictors which could be added to future risk based models for 
screening referral decisions. In addition, the methods used in this chapter can be applied 
for the FIT screening test when it is implemented in practice along with the specific clinical 
codes. 
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2.0 METHODS 
 
Reporting will adhere to the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement36 and the extended Reporting of studies Conducted 
using Observational Routinely collected Data (RECORD) guidelines37.  
2.1 Study population and data source 
 
This research used the THIN database of anonymised GP records which has data for over 
587 practices (5.67% coverage of UK in 2014) covering more than 12 million patients 
(including 3.6 million active patients).3 THIN provides demographic information such as sex, 
age, Townsend deprivation score, diagnoses, symptoms and prescriptions recorded on GP 
records. The structure of the THIN database and its constituent data file types are 
described in detail in Chapter 6. 
Risk prediction model development studies require large sample sizes in order to 
investigate the effect of a set of potential predictors on the outcome of interest and to 
produce a generalisable and valid model. Apart from the large source of data, further 
advantages of the THIN database are that it is UK wide, generalisable to the UK population 
38 and allows patients to be followed up over time from an index event/date.  
The BCSS currently sends FOBT results electronically to GP practice systems. The 
interconnectivity between GP records and screening records is likely to improve in the near 
future. Consequently, THIN will allow investigations into the predictors/factors which could 
be used to assist with referral decisions in practice.  
THIN was used to identify men and women eligible for screening events for bowel cancer 
aged 60-74 years of age with at least a years worth of health records before being invited 
to take part in the BCSP. Practices are only included if they receive electronic notifications 
from the BCSP. Patients were followed from a year before they took the test (to ensure 
adequate symptomatic information to be identified) up to the point of diagnosis or a 2 year 
follow up to ensure any interval cancers/diagnoses are identified. 
  
   
 
248 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
2.2 Study Design  
 
The study design was an observational cohort covering the period 1st May 2009 to 17th 
January 2017. The period of interest was defined in part by the Acceptable Electronic BCSP 
(AEB) date for each practice as an assurance of data quality. This date is akin to the 
acceptable mortality reporting (AMR), before this date practices may not have routinely 
recorded patient deaths and de-registrations. 39 The purpose of this date was to ensure 
that the BCSP events recorded are those which are automatically sent by the screening 
programme to GP practices. Before electronic BCSP notifications were sent, practices had 
to manually input test results which may lead to biased recording since positive results may 
be more likely to be recorded. The development of the AEB date is reported in Chapter 6.  
 
In brief, the incidence of BCSP FOBT Read codes for people aged 60-74 for each practice in 
England was examined from the additional health data (AHD) file in THIN (where lab results 
are recorded). This revealed a time-point at which the practice started to receive electronic 
notifications from the bowel cancer screening system. The AEB date was evaluated first, 
before identifying the observation period for each patient. Read code lists defining a BCSP 
notification for the English population are given in Table 1.  
 
Eligible THIN practices included those practices with an AEB date and practices based in 
England (due to differences in bowel cancer screening systems and coding for Scotland, 
Northern Ireland and Wales). The eligible time period for each practice was the latest of 
the following; one year after the Vision practice software installation (to ensure the 
computer system was being fully utilised), AEB date (to ensure electronically received FOBT 
results are used for analysis) and AMR – to ensure the practice is routinely recording 
deaths).  
Eligible patients were those aged between 60 and 74 with a BCSP notification during the 
period of interest. This generated a dataset of participants who had been adequately 
screened (with a positive or negative FOBT). For quality assurance, patients without a 
registration date, patflag A or C and regstat of 01, 02, 05, 99 (markers of data quality) were 
removed from the analysis (the THIN Researcher Guide provides more detail4). Patients 
without a Townsend score (based on four variables; unemployment, non-car ownership, 
non-home ownership and household overcrowding) or where the patient start date was 
greater or equal to the end date were also removed. Finally any patients with a previous 
   
 
249 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
CRC diagnosis (before the most recent FOBT) along with any patients with a diagnosis of a 
high risk condition (hereditary nonpolyposis colorectal cancer (HNPCC) or familial 
adenomatous polyposis (FAP)) were excluded from the analysis. Practice and patient 
exclusion/inclusion criteria are shown in Table 2 (greater detail is given in Appendix 2).  
 
Entry into the cohort is defined as the latest of registration date plus one year (e.g. to allow 
symptoms to be recorded), AMR date, AEB date, Vision date plus one year, with a BCSP 
FOBT result. Exit from the cohort was the earliest of date died/left practice and the last 
practice collection date. 
 
Table 2: Practice and patient inclusion and exclusion criteria. 
 
2.3 Sample size 
 
Feasibility data were obtained before applying for ethical approval in order to determine 
the level of BCSP activity recorded on the THIN database (Table 3). In terms of THIN data in 
2013, around 36% of patients who are eligible for the BCSP had some evidence of 
documentation of their participation in the BCSP. At least 50,000 had documentation from 
2010 onwards.  
 
Year Total 
Population 
of Practices 
(pyr) 
1_Normal 
Result 
2_Abnormal 
Result 
3_Uncertain 
Result 
4_Incomplete 
Participation 
5_No 
Response 
Total Proportion 
with 
evidence of 
BCSP activity 
2010 317529.14 5110 143 32 525 3609 9419 0.03 
2011 314967.94 31379 608 1 1090 18078 51156 0.16 
2012 306224.61 46229 733 4 1664 27272 75902 0.25 
2013 279535.13 60760 1005 1 1075 37537 100378 0.36 
Table 3: Count of Patients with Evidence of Screening Programme Activity. In 2013, 89% (307/346) of THIN 
practices in England had some evidence of BCSP activity recorded on their system; this was 74% (270/366) in 
2012, 55% (209/380) in 2011 and 31% (124/393) in 2010.  
  
Practice Criteria Patient Criteria 
Practice Start Date: The latest of AMR, AEB date (acceptable 
electronic BCSP date) – defined by researcher) and Vision 
date plus one year.  
Patient Observation Start: Later of Practice start date, registration date 
plus one year and age 60. 
Practice End Date: The last collection date from each practice Patient Observation End: Earlier of Practice end date, De-registration or 
death and age 74. 
Exclude practices not in England Period of interest Start: Latest FOBT recorded 
Exclude practices where the practice start date is greater 
than or equal to the practice end date 
Period of interest End: Earlier of patient observation end, or diagnosis of 
colorectal cancer/polyp within 2 years (most severe outcome and 
corresponding date used for analysis) 
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Statistical power calculations for survival analysis relate to the number of events.40 Some 
suggest that for reliable predictions, at least 10 events per variable/predictor need to be 
considered for analysis as demonstrated in simulation studies.41-43. More specifically, this is 
the number of cancers/polyps diagnosed per degree of freedom. Categorical variables have 
(n-1) degrees of freedom and continuous variables have one degree of freedom.  
 
The dataset derived for the multivariable modelling analysis had 1,197 colorectal cancer 
and polyp diagnoses (sample population = 98,303) and considered 33 degrees of freedom 
(45 including interactions) giving 36.27 events per variable or 26.6 including interactions. 
For the model with negative FOBTs only, there were 587 events (sample population = 
95,792) and considered 31 degrees of freedom (39 including interactions) giving 18.94 
events per variable or 15.05 including interactions. 
 
2.4 Ethical Approval 
 
Ethical approval was given by the Scientific Review Committee (SRC) administered by IMS 
Health (SRC Reference Number: 16THIN037 Date: 26/05/2016). See Appendix 3. This is an 
independent scientific review committee which can grant ethical approval for a study using 
data from THIN which is pseudonymised and pre-collected. The NHS South-East Multi-
centre Research Ethics Committee approved THIN data collection in 2003 for this 
purpose.44  
2.5 Model Outcome and Index Date 
 
The index date used for survival analysis was the latest BCSP FOBT result electronically sent 
to GP practices. The index date for the FOBT ranged from 13th May 2009 to 5th January 
2017. The outcome was the diagnosis of colorectal cancer/polyps after this index date for a 
maximum follow up of 2 years. Two years was chosen for follow up as this represents one 
screening round in the NHS and existing cancers are likely to be clinically identified within 
this period.15  
 
Colorectal cancer and polyps are defined using the Read code lists developed and supplied 
in Chapter 6. If both polyps and colorectal cancer had been diagnosed within the 2-year 
period of follow up then the most severe outcome was used for analysis. Polyps were 
   
 
251 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
included in the outcome as during screening the aim is to detect early stage lesions before 
they develop into later stage cancers as well as more severe cancers. 
 
2.6 Model Predictors 
 
Predictors included in the analysis were identified from previous studies incorporating 
symptoms and lab test results as well from the systematic review reported in Chapter 2 
and NICE guidelines (see Table 4).18 21 45-47 These predictors were measured at the time of 
entry to the study/up to 365 days before the index date to ensure they were associated 
with the outcome. The full specification of these variables are provided in Appendix 4 and 
the table contents for data extraction and analysis in Appendix 5. For multivariable 
analysis, 29 variables were considered during the modelling process. Rectal bleeding, 
abdominal mass and abnormal rectal examination are considered red flag symptoms and 
the patients would have been referred in the primary care setting so were not included in 
the multivariable analysis.   
Methods to extract AHD variables (often based on Read code lists as well as AHD codes) are 
given in Chapter 6. Drug codes for three types of drug (anti-motility drugs, antispasmodics 
and laxatives) were derived in part using the methods of Dave and Petersen48 and the THIN 
Data Guide for Researchers4. All the variables were recorded before the index date (date of 
FOBT) since at the time of deciding referral, this would be the only information available. 
Anything recorded after this date would not be able to contribute to the risk prediction 
model. 
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Study/Guidelines Included Variables 
NICE Guidelines (NG12) Suspected 
cancer: recognition and referral45 
 
 
 
 
 
 
 
 
 
 
NICE Diagnostic Guidance (DG30) 
Quantitative faecal 
immunochemical tests to guide 
referral for colorectal cancer in 
primary care49 
 
1.3.1 Two week referral for suspected colorectal cancer:45 
1. Adults aged 40≤ with unexplained weight loss and abdominal pain  
2. Adults aged 50≤ with unexplained rectal bleeding  
3. Adults aged 60≤ with: iron-deficiency anaemia or changes in their bowel habit  
4. Tests show occult blood in their faeces 
 
Consider a suspected cancer pathway referral for:45 
1.3.2 Adults with a rectal or abdominal mass 
1.3.3 Adults aged under 50 with rectal bleeding and any of the following: abdominal 
pain change in bowel habit, weight loss, iron-deficiency anaemia. 
1.3.4 This recommendation has been superseded by the one below using FIT DG30.49 
 
In addition, new guidance using quantitative FIT to guide referrals suggest use of FIT in 
people without rectal bleeding who have unexplained symptoms but do not meet the 
criteria for a suspected cancer pathway. A threshold of 10 micrograms of haemoglobin 
per gram of faeces to be used for referral.49 
 
Variables: Abdominal pain, weight loss, change in bowel habit, rectal bleeding, iron-
deficiency anemia, anemia in the absence of iron deficiency, rectal/abdominal mass, 
FOBT, FIT 
Hippisley-Cox and Coupland15 Algorithm for females included: age; family history of gastrointestinal cancer; anaemia; 
rectal bleeding; abdominal pain; appetite loss; and 
weight loss.  
Algorithm for males same as above but includes alcohol use and change in bowel habit. 
Marshall et al.21 Final model included: Constipation, diarrhoea, change in bowel habit, abdominal pain, 
haemoglobin concentration mean cell volume and weight loss. In univariable analysis, 
a positive FOBT, abnormal rectal examination and abdominal mass had a strong 
association with a diagnosis of colorectal cancer. 
Hamilton20 (CAPER Studies) Variables independently associated with colorectal cancer after multivariable analysis 
included: Rectal bleeding, loss of weight, abdominal pain, diarrhoea, constipation 
Hamilton et al.46 Final multivariable analysis – rectal bleeding, change in bowel habit, abdominal pain, 
diarrhea, constipation, weight loss, haemoglobin concentration, mean red cell volume. 
Lab Measurements Hamilton20 Abnormal primary care investigations: Positive FOBT, haemoglobin concentration, 
blood sugar levels 
Lab Measurements Boursi et al.30 Lab based model only: Hematocrit, mcv, neutrophil-lymphocyte ratio, lymphocytes, 
creatinine, BUN 
Multivariable model based on all variables included: Sex, haemoglobin, MCV, white 
blood cells, platelets, NLR, prescription of metformin/oral hypoglycemic medications  
Lab Measurements Marshall et 
al.21 
MCV, haemoglobin concentration 
Lab Measurements, Kinar et al.28  
validated by Birks et al.29 
 
 
Age, sex, blood count data including; Haemoglobin, mean corpuscular haemoglobin, 
haematocrit, platelets, mean cell volume, mean corpuscular haemoglobin 
concentration, red blood cell distribution width, lymphocytes(%), red blood cell count,, 
mean platelet volume, neutrophils(%), neutrophils (number), monocytes (number). 
 
Also investigated combining FOBT result. 
Table 4: Predictors identified from previous risk prediction model studies and NICE guidelines 
Symptoms used for analysis were the latest record prior to the index date (date of latest 
FOBT) within 365 days to ensure that a record is more likely to be associated with the 
outcome (i.e. diagnosis of colorectal cancer/polyp). These symptoms included, abdominal 
pain/antispasmodic drug use, abnormal rectal examination, constipation/laxative, 
diarrhoea/anti-motility drug use, change in bowel habit, flatulence, loss of appetite, rectal 
bleeding/melaena, tiredness, weight loss. These were coded as binary variables. 
As identified in previous studies,21 Drug codes for anti-motility, laxatives and antispasmodic 
prescriptions were used as a proxy for the following symptoms respectively: diarrhoea, 
constipation and abdominal pain. If the hazard ratios were similar in univariable analysis, 
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the corresponding prescription and symptom were combined for multivariable analysis 
which was the case for antispasmodic drugs and abdominal pain. 
Diagnoses or other conditions used for analysis included, venous thromboembolism (which 
includes pulmonary embolism and deep vein thrombosis) up to 365 days prior to the index 
date, ulcerative colitis, IBS, Crohn’s disease if ever recorded (prior to the index date), 
diabetes up to 365 days prior to the index date, polyps and diverticulitis if ever recorded 
before the index date. 
Lab tests/other investigations included; platelet count, haemoglobin concentration, 
ferritin and MCV the latest record up to 365 days prior to the index date. All lab results 
recorded for 2 years prior to the index date were also extracted so they could be 
investigated longitudinally. The percentage difference between the last two recorded 
values before the index date was used to define new variables to analyse individual 
longitudinal trends. An indication of anaemia is incorporated in the haemoglobin 
concentration variable. Thrombocytosis is also captured using platelet count in the AHD 
records. Low ferritin was investigated in the same way, using ferritin levels recorded in the 
AHD records. The latest height, weight, BMI records before the index date were used as 
well as all the records for individuals two years prior to the index date.  
A FOBT performed in primary care up to 365 days prior to the index date was included as a 
potential variable. The BCSP latest FOBT result was extracted for the index date. All 
previous BCSP FOBT results were also extracted in order to have an individual’s screening 
history. Depending on the result, number of previous negative FOBTs and number of 
previous positive FOBTs were defined as additional variables. 
Other factors included, family history of gastrointestinal cancer if ever recorded before the 
index date. The last recorded entry prior to the index date for alcohol consumption, 
smoking status, blood group, Townsend score (a measure of social deprivation) and ethnic 
group. 
A BCSP flexible sigmoidoscopy recording any time before the index date; this is usually a 
one off test at age 55 which has been recently introduced and rolled out in England as part 
of the BCSP. When investigating this further, there were not enough recordings for this test 
available from the dataset so it was dropped from multivariable analysis. 
Ethnic group was not included as a candidate variable as there is evidence to suggest 
currently that the recordings for some groups are not representative of the UK despite the 
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introduction of Quality and Outcomes Framework (QOF) incentives.50 Other factors such as 
alcohol consumption and smoking status have been shown to be well recorded in THIN.51 In 
addition, abnormal rectal examination was removed from model development since there 
were very few records which meant the model did not always converge. This is a red flag 
symptom and the individual would have been referred under the two week referral 
scheme. There were more records after the index date but the recording of this symptom 
would have suggested a procedure had been performed. 
2.7 Statistical Analysis 
 
The following analyses were undertaken: 
i) Estimate of the sensitivity and specificity of the FOBT for colorectal cancer and 
polyps using the derived screening population. 
This helped to determine if the data extracted based on the electronic BCSP 
notifications was valid if it gave similar results to that reported in the literature. 
ii) Univariable analysis (Cox Regression) and analysis of the availability of variables 
in the screening population. 
This analysis assessed the completeness of variables which may be useful in a 
risk based prediction model and identified predictors with a strong 
independent association. 
iii) Kaplan Meier Survival Analysis:  
A) Survival analysis based on time to diagnosis and time to death from a 
positive or negative FOBT (using the whole derived screening cohort); Kaplan-
Meier estimates stratified by FOBT result and sex. 
B)  Survival analysis based on time to diagnosis and time to death for patients 
with a negative FOBT only; Kaplan Meier estimates stratified by sex.  
C)  Survival analysis time to diagnosis and time to death stratified by true 
negatives, true positives, false negatives and false positives for a population 
with either a diagnosis or a minimum of 2 years of follow up information.  
These analyses described and checked the validity of the data extracted for 
analysis and identified predictors which affect survival by comparing the 
survival functions of different groups/covariate patterns. 
iv) Development of a risk prediction model for those with a positive or negative 
FOBT using Cox Regression. 
   
 
255 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
This analysis identified additional predictors from a multivariable model which 
have the potential to be added to a risk based model to make more accurate 
screening referral decisions. 
v) Absolute risk probabilities (survival predictions) were derived using the Cox 
regression model by estimating the baseline survival at 2 years. 
This analysis was performed to determine individual risk probabilities from the 
previous model and determine the distribution of risk in the sample population 
based on the predictors in the multivariable model.  
vi) Assessment of parametric survival models using AIC, cumulative hazard plots, 
Kaplan Meier function plots and Cox-Snell residuals for those with a positive or 
negative FOBT. 
Parametric models were investigated as an extension to Cox Regression to 
determine whether these models gave a better fit to the data and therefore 
more accurate parameter estimates. 
vii) Development of a risk prediction model for those with just a negative FOBT 
using Cox Regression to assess which other predictors could be predictive of 
cancer and warrant referral (false negatives, true negatives).  
This analysis allowed the identification of additional predictors which could be 
used in a screening population with negative results for screening referral 
decisions. 
viii) Absolute risk probabilities (survival predictions) were derived using the Cox 
regression model by estimating the baseline survival at 2 years. 
This analysis was performed to determine individual risk probabilities from the 
previous model and determine the distribution of risk in the sample population 
based on the predictors in the multivariable model.  
ix) Nomogram of the risk prediction model. 
A Nomogram for the model developed in (vii) was produced as an alternative 
method of presenting the risk equation. 
x) Assessment of parametric survival models using AIC, cumulative hazard, 
survival and Cox-Snell residuals for those with a negative FOBT. 
Parametric models were investigated as an extension to Cox Regression to 
determine whether these models gave a better fit to the data and therefore 
more accurate parameter estimates. 
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‘Survival’ when assessing time to diagnosis in these analyses refers to colorectal 
cancer/polyp free survival. ‘Survival’ when assessing time to death refers to overall 
survival. 
2.7.1 Test Accuracy 
 
Using the derived cohort, this analysis was restricted to patients who had either the 
outcome within 2 years or at least 2 years of follow up information after the FOBT (index 
test) n=32,004. Two by two tables were constructed to estimate sensitivity, specificity, PPV 
(positive predictive value) and NPV (negative predictive value) of the FOBT. The diagnostic 
outcome was broken down by colorectal cancer diagnosis or polyp diagnosis – with the 
most severe outcome used for analysis if both were recorded during the time period. 
2.7.2 Univariable Analysis and Data Missingness 
 
Cox regression was used to estimate hazard ratios for all considered predictors. Hazard 
ratios measure how much a predictor increases or decreases the rate of a defined event.33  
The level of complete/missing data was also recorded in order to determine which 
predictors could be included in the multivariable analysis. Ideally, variables which are 
readily available from GP records for the screening population and variables which are 
strong predictors of colorectal cancer/polyps are the most useful for CRC screening 
decisions.  
2.7.3 Kaplan-Meier Estimations – Time to Diagnosis (colorectal cancer/polyp free 
survival) and Time to Death (survival) 
 
Two useful measures for describing survival data are (i) the survivor probability or survivor 
function S(t) and (ii) the hazard h(t).32 In this setting, the survivor probability refers to the 
probability that an individual is free from colorectal cancer/polyp diagnosis for time to 
diagnosis. For time to death the survivor probability refers to the probability that an 
individual survives/is alive. The hazard is the probability that the patient has an event at a 
particular time point. The nonparametric Kaplan-Meier survivor estimate was used for S(t) 
and the Nelson-Aalen estimator for H(t), the cumulative hazard.32 
Kaplan-Meier survivor estimates were used to estimate the probability of survival at 
particular time points for a sample population with positive and negative results and for a 
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sample with just negative results.52 Time to diagnosis was the time from a FOBT result to 
CRC/polyp diagnosis within 2 years. To compare survival between groups of patients, the 
non-parametric log-rank test was used to compare sex and FOBT result. The log-rank test 
compares the groups using the ordering of failure times. Time to death was the time from a 
FOBT result to any cause of death. 
In addition, the colorectal cancer free survival and survival between patients with a true 
positive (TP), true negative (TN), false positive (FP) and false negative (FN) result were 
plotted on a Kaplan-Meier curve and compared using a log-rank test.  
This analysis allowed the data extracted for analysis to be described and checked for 
validity and also identified subgroups which affect colorectal cancer/polyp free survival and 
overall survival. 
2.7.4 Model Development Strategy 
 
Two different models were produced using Cox Regression. The first was for a population 
with both positive and negative FOBT results. The second model was for a population with 
negative FOBT results only to determine whether other factors could be used to decide 
whether a patient should be referred if they have had a negative result. 
The model development strategy was dependent in part on the level of missing data for 
certain predictors. Variables which had >60% missing data were excluded from the analysis 
since the sample size would have been restricted too much keeping the other factors in the 
analyses. This approach was a compromise between including important lab parameters 
and retaining the sample population for model development.  Initial analysis investigated 
the level of missingness for each variable, and the varying ways in which it could be 
recorded (AHD versus Read code versus combined). For example, alcohol consumption 
could be used as a Read code in the medical table or taken from the AHD tables as units per 
week. Where appropriate, the continuous versions of a variable if well recorded, were used 
for model development. For instance, thrombocytosis can be captured using the platelet 
count measured in the AHD table. Colorectal cancer has been shown to be more frequently 
diagnosed in those with thrombocytosis. 27  
The TRIPOD guidelines recommend using a continuous variable rather than dichotomising 
into different groups as this loses additional predictive information.53 However, since 
setting a cut-off for different blood parameters is also clinically meaningful as it can 
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indicate underlying disease, categorised blood measurements were considered for, platelet 
count, ferritin, haemoglobin concentration and mean cell volume. 
Symptoms: Weight loss, abdominal pain combined with antispasmodic prescription, 
constipation, diarrhoea, change in bowel habit, loss of appetite, tiredness, flatulence. 
Lab test results: Haemoglobin category, MCV category, platelet count category. 
Screening Utilisation: Latest FOBT result, previous negative FOBT result from BCSP, 
previous positive FOBT result from BCSP, previous polyp recording before index date, 
Primary Care FOBT. 
Co-morbidities and previous diagnoses: Crohn’s disease diagnosis, ulcerative colitis, 
diabetes, IBS, diverticulitis, venous thromboembolism. 
Demographic Factors: Sex, age at FOBT. 
Lifestyle and anthropometric factors: Smoking status, BMI, alcohol consumption (number 
of units consumed a week). 
Additional Factors: Townsend quintile, family history of gastrointestinal cancer. 
Cox regression using Efron’s method of handling ties54 was used to develop a multivariable 
model. Multivariable fractional polynomials (MFPs) were applied with the methods 
implemented in Stata55 to model non-linear relationships with continuous predictors.55 This 
allows the variable to be kept continuous and allow for some form of non-linearity.56 57 It is 
best practice to assess non-linear functions after adjusting for other predictors in the 
model. Fractional polynomials provide more flexible parameterisation for continuous 
variables compared with regular polynomials by providing a richer class of possible 
functional forms to fit to the data.56  MFPs also give a better fit to real life data, capture 
more complex associations with the outcome and can lead to better risk predictions.56 
The ‘mfp’ function in Stata selects the variables which best predict the outcome, more 
details about the selection algorithm are supplied in the associated Stata ‘mfp’ manual and 
journal articles.55 56 In brief, this method combines backwards elimination with a search for 
the most suitable FP transformation of a continuous predictor. For backwards elimination a 
p-value of 0.05 was used to determine whether to keep a predictor in the model (a variable 
is removed if dropping it from the model causes a nonsignificant increase in the 
deviance).55 P-values for testing between fractional polynomial models was set at 0.05. 
   
 
259 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
Interactions were also assessed using a p value of 0.05. Interactions investigated included 
age and sex, FOBT result and sex, FOBT result and age, MCV and age, MCV and sex, alcohol 
and sex, alcohol and age, smoking and age, smoking and sex as these 
interactions/associations have been found to be significant from the literature. A likelihood 
ratio test was carried out to determine whether the model with interactions provided 
significantly better fit than a model without interactions. When reporting the final model 
the Cox Regression coefficients are provided along with bootstrapped standard errors (100 
replications). 
Since parametric models can be more efficient than the equivalent Cox regression model 
by producing more precise estimates and offering more with post-estimation such as 
predicted survival probabilities, hazard and predicted times, parametric survival models 
were also investigated. Parametric proportional hazards models are the exponential, 
Weibull and Gompertz models. These models have a monotonic hazard function which 
increases or decreases over time whereas the loglogistic, generalised gamma and 
lognormal models have hazard functions with turning points.33 The fit of the parametric 
models were compared using the AIC, cumulative hazard plots (where the cumulative 
hazard is plotted and parametric curves fitted to it), Kaplan Meier Plots (where the Kaplan-
Meier survivor function is compared with the function predicted if the survival times 
followed a particular parametric distribution) and Cox-Snell residuals to determine the 
model with the best fit.   
A summary of the models investigated and the sample population used to derive the 
models is given below in Table 5. 
Model Population  Model 
Positive and Negative FOBT Results  
(n= 98,303) 
Cox Regression 
Parametric Models 
Negative FOBT results only  
(n=95,792) 
Cox Regression 
Parametric Models  
Table 5: Model types investigated for multivariable analysis 
2.7.5 Model Performance 
 
The model performance was assessed using Harrell’s C statistic which takes into account 
the censored nature of survival data.58 59 This is used as a measure of discrimination akin to 
the AUC ROC for the Cox Regression models. Harrell’s C statistic measures the agreement 
of predictions with observed failure order and is the proportion of subject pairs where the 
predictions and outcomes are in agreement. 60 The values range between 0 and 1. Somers’ 
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D rank correlation which is related to Harrell’s C statistic (D=2(C-0.5)) ranges from -1 to 1 
was also reported. 60 61 The D statistic, R2 and adjusted R2 were also determined as further 
measures of discrimination performance. Separation was also visually assessed by plotting 
Kaplan-Meier survival curves for 4 risk groups (where the linear predictor is divided into 4 
groups based on Cox’s method).62 Five or fewer groups have been recommended for this 
purpose.63 64 This also reflects the underlying C statistic, D statistic and R2 values. 
The linear predictor and its distribution was summarised by plotting a histogram of values 
and reporting the corresponding mean and standard deviation. The linear predictor is the 
linear combination of the predictors in the model with their beta coefficients but without 
the intercept or baseline hazard (LP = β1x1 + β2x2 + β3x3…). Analysing the distribution of risk in 
the population is useful when applying the model to another dataset for external validation 
to explain any underlying differences in performance and to assess the usefulness of the 
model.65 66 The spectrum effect relates to the underlying case mix from which the model is 
derived. The performance of tests/models varies among different population subgroups 
and this must be considered when externally validating a model.67 
Optimism of the model was assessed by calculating the heuristic shrinkage factor of Van 
Houwelingen (given by: (chi2 – degrees of freedom)/chi2).68 This shrinkage factor was then 
applied to the linear predictor to generate a shrunken linear predictor adjusted for 
optimism and the corresponding distribution (mean and standard deviation) was also 
reported.  
To adjust performance statistics for optimism, internal validation was performed using 100 
bootstrap replications for the C statistic, c-slope, D statistic and R2 to quantify optimism. 
The optimism was then subtracted from the apparent performance statistics to give 
optimism adjusted values for these performance parameters. The bootstrap uniform 
shrinkage factor was then reported (based on the optimism adjusted c-slope value) as an 
alternative to the heuristic shrinkage estimate. 
Calibration of the models was assessed by plotting a calibration curve of observed 
probability versus expected probability for deciles of risk. This graphical approach also 
allows discrimination to be assessed visually by investigating the spacing between risk 
groups. The calibration slope is reported once adjusted for optimism. 
Differences in performance between parametric models was assessed using the Akaike 
Information Criterion (AIC) 69 and Bayes Information criterion (BIC). 70 The AIC is defined as 
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the deviance (2 times the minus maximised log likelihood) plus 2k where k is the number of 
fitted parameters.33 The BIC is the deviance plus klogn where n is the number of events and 
k is the number of model parameters. Since the AIC and BIC for the Cox model are 
calculated using partial likelihood, the Cox and parametric models could not be directly 
compared using these statistics. 33 The goodness of fit was assessed for the Cox Regression 
and parametric models using Cox-Snell residuals. If the model fits the data well then the 
cumulative hazard of the Cox-Snell residuals should be a straight line at 45 degrees. 60 The 
goodness of fit is assessed by investigating whether the model represents the survival 
patterns of the data adequately.40 Cumulative hazard and survival plots were also used to 
compare the fit of the models. 
2.7.6 Absolute Risk Probabilities 
 
Predicted probabilities of colorectal cancer/polyps were derived for each patient and their 
covariate pattern. The shrunken linear predictor was used to estimate a new baseline 
survival (adjusted for optimism) which was estimated non-parametrically at 2 years. The 
shrunken linear predictor was combined with the baseline survival to generate 
individualised risk predictions. In order to obtain an event probability as opposed to a 
survival probability, the result of this was subtracted from 1 to generate the probability of 
colorectal cancer/polyps being detected over a 2 year period.  
Cox regression is a semi-parametric model and therefore does not give the baseline hazard 
h0(t) or survival S0(t) and so this was estimated using non parametric methods at a 
particular time point.  Non parametric estimation of the baseline survival was obtained 
using a zero covariate value and the methods implemented in Stata. Baseline survival from 
a particular time-point (2 years) can then be obtained from a Kaplan-Meier curve or 
accompanying results. See Equation 1 for the Cox Regression equation to estimate survival 
probabilities. 
 
S(𝑡) = S0(𝑡)
exp⁡(β1X1+β2X2+⋯) 
 
S0 = Baseline survival probability at 2 years 
 
Equation 1: Risk equation for determining corresponding probabilities from the Cox Regression model. 
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Individualised risk predictions can be used for decision making by setting a probability cut 
point of an individual being diagnosed with cancer in the next 2 years (representing a round 
of screening). The risk prediction model can subsequently be validated and applied in a 
screening population as a screening test to determine if there is an improvement in cancer 
detection or sensitivity/specificity. 
The model for the population with negative tests was displayed as a Kattan style 
Nomogram using a Stata Nomogram generator.71 This allows the probability to be 
determined graphically as an alternative to using the risk equation to generate 
probabilities. 
2.7.7 Cox Regression Diagnostics  
 
To test the proportional hazards assumption of the model, Schoenfeld residuals of the 
covariates were examined. For covariates with a p value of less than 0.05 (testing for the 
null hypothesis of a nonzero slope) the scaled Schoenfeld residuals were plotted. A straight 
horizontal line supports that there is not a violation of the proportional hazards 
assumption. Log-log plots were also plotted for these variables to assess proportionality by 
determining whether the lines are roughly parallel. The overall fit was assessed using Cox-
Snell residuals by plotting the Nelson-Aalen cumulative hazard function against Cox-Snell 
residuals and assessing the corresponding fit. If the model fits the data well then the 
cumulative hazard of the Cox-Snell residuals should be a straight 45 degree line which 
reflects an exponential distribution with hazard equal to 1 across time (t).60 
2.7.8 Parametric Survival Models 
 
Parametric models were investigated as an extension to Cox Regression to determine 
whether these types of model gave a better fit to the data and therefore more accurate 
parameter estimates. The generalised gamma, loglogistic and log normal parametric 
models use the accelerated time metric and allow derivation of time ratios which can be 
seen as more interpretable than hazard ratios.34 The Weibull, exponential and Gompertz 
parametric models on the other hand have a proportional-hazards parameterisation. The 
AIC was used to compare the different parametric survival models since the models do not 
require to be nested as with likelihood ratio testing. The fit was investigated further by 
plotting Cox-Snell residuals, Nelson Aalen cumulative hazard plots and Kaplan Meier 
function graphs for the parametric models to assess the fit visually. 
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Calibration and discrimination were reported for the best fitting parametric models 
according to the above investigations (residual plots, Kaplan-Meier function and Nelson 
Aalen cumulative hazard plots as well as the AIC). Harrell’s C-statistic along with the 
Calibration plots were reported for the generalised gamma model (the best fitting model 
for the scenario which included FOBT results) and the Gompertz model (the best fitting 
model for the scenario including participants with negative FOBTs only). The ‘somersd’ 
package available in Stata can determine Harrell’s C and Somers’ D statistics and provide 
confidence intervals.72 This package can be extended for use in parametric models and so 
was also used to determine Harrell’s C statistic for models fitted with ‘streg’. The R2 used in 
this instance was Royston and Sauerbrei’s (2004) R2D measure of explained variation for 
survival models based on their index of discrimination (D).73 The adjusted R2 measure also 
considers the number of covariates in the model. For non-proportional hazards models R2 
for explained variation is not interpretable but can be used as an index of determination.74 
As an extension to the generalised gamma model, a Wald test was performed testing the 
hypothesis that kappa is equal to zero which would have indicated a lognormal model was 
an appropriate model for the dataset.60 75 A Wald test for whether kappa was equal to one 
was also investigated which would suggest a Weibull model would be an adequate model. 
Calibration and discrimination were therefore also reported for these models in the 
scenario which included FOBT results in the model.60 75  
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3.0 RESULTS 
 
3.1 Study Population 
 
3.1.1 Overall Screening Cohort Derived from THIN 
 
The study flow diagram is shown in Figure 2. The screening cohort defined from the THIN 
database gave 292,168 patients across 360 practices aged 60-74 with a positive or negative 
FOBT result. The cohort was 53.26% female, with a mean age of 66.43. Practices were 
restricted to England and those which receive electronic BCSP notifications. Those with 
high-risk conditions (e.g. familial adenomatous polyposis) were also excluded from the 
analysis. 
The primary outcome investigated was both colorectal cancer and polyps combined. The 
most severe diagnosis within 2 years was colorectal cancer for 929 patients and polyps for 
1960 patients (2889 total) (See Table 6). The number of patients who died during the 2 
year follow up from the index test was 3169. The number who died without a time 
restriction (I.e. until the end of data collection) was 3,842. 
 Colorectal Cancer Polyp Diagnosis not recorded 
Most severe diagnosis within 
2 years of index test 
929 1960 289,279 
Most severe diagnosis to the 
end of follow up from the 
index test 
1024 2158 288,986 
Number of CRC within 2 
years of index test 
929 - 291,239 
Number of Polyps within 2 
years of index test 
2131 - 290,037 
Number of CRC to the end of 
follow up from the index test 
1024 - 291,144 
Number of Polyps to the end 
of follow up from the index 
test 
2341 - 289,827 
Table 6: Diagnostic outcomes within a 2 year follow up period and until the end of follow up for the cohort. 
3.1.2 Test Accuracy Population 
 
For test accuracy purposes, only those participants with a diagnosis within two years or 
with two year follow up were investigated (n = 32,004). For this population, there were 
2,610 positive FOBTs and 29,394 negative FOBTs (positivity 8.16%). Participants were 
51.46% female with a mean age of 66.08 years. There were 2889 colorectal cancers and 
advanced adenomas and 765 deaths. 
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3.1.3 Participants with Positive and Negative FOBTs 
 
For multivariable analysis, complete cases of participants with the variables of interest 
were included (n=98,336). For this population, the mean age was 66.97 years and 50.04% 
were female. There were 2,511 abnormal FOBT results and 95,825 normal FOBT results. 
The number of cancers and polyps detected in this population were 350 and 847 
respectively. After setting the data up for survival analysis, 33 observations occurred on 
entry and so 98303 observations remained with 1197 events and 38,005,604 person years. 
The factors which limited the sample size for this investigation were the laboratory results; 
Hb concentration, platelet count and MCV. The cancer/polyp detection rate for those with 
a laboratory record (for all three results) was around 1.19% and those without 0.83% 
(Pearson’s chi-squared p=<0.001) (Table 7). 
 Haemoglobin Concentration MCV Platelet Count 
 Without 
Record 
With Record Without 
Record 
With Record Without 
Record 
With Record 
Cancer/Polyp 1345 1544 1,352 1,537 1,349 1,540 
No Cancer/Polyp 160,784 128,495 161,293 127,986 161,091 128,188 
Cancer Detection Rate 
(%) 
0.830 1.187 0.831 
 
1.187 
 
0.830 
 
1.187 
Table 7: Cancer detection rates for participants with and without laboratory results (haemoglobin 
concentration, MCV and platelet count). 
Participants with Negative FOBT Population (complete cases n=95,825): Patients with just 
negative FOBT results recorded as their latest screening test result were investigated in 
order to determine whether additional predictors could be used for referral decisions. The 
sensitivity of the FOBT could be improved by adding these additional literature-driven 
factors. For this population there were 144 cancers and 443 polyps diagnosed, 50.32% 
were male and the mean age was 66.97. After setting the data up for survival analysis, 33 
observations occurred on entry and so 95,792 observations remained with 587 events and 
37,154,249.5 total analysis time at risk and under observation. 
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THIN Database 
744 practices 
16,458,973 patients 
 
Restrict practices to England 
497 practices 
12,063,499 patients 
 
Restrict if AEB date is missing (i.e. the practice does not receive electronic 
screening notifications) 
361 practices 
9,208,166 patients 
Restrict if Registration date is missing in patient records 
9,208,166 patients 
Patient does not have a patflag A or C 
7,796,029 
Patient record does not have a regstat of 01, 02, 05, 99 
7,796,029 
Restrict patients if patient start date is greater or equal to patient end 
date 
646,807 patients 
Restrict to patients with a Townsend Score 
631,747 patients 
 
Restrict to patients with a BCSP notification during period of interest 
445,533 BCSP notifications included 
360 practices 
299,315 distinct patients 
 
BCSP FOB test abnormal:  8,057 
BCSP test normal: 429,014 
BCSP FOB testing kit spoilt: 42 
BCSP FOB test incomplete participation: 8,420 
 
Exclude those with a high risk condition 
169 FAP records 
 
299,203 distinct patients 
360 practices 
Exclude those with a previous CRC diagnosis 
2143 CRC records before bcsp_fobt_evntdate 
 
297,735 distinct patients 
360 practices 
During Data 
Extraction 
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Patients latest BCSP Result (n=297,735) this included incomplete 
participation and spoilt kits 
BCSP FOB test abnormal: 6,338 
     BCSP FOB test normal: 285,432 
   BCSP FOB testing kit spoilt: 31 
BCSP FOB tst incmplt participt: 5,934 
 
Patients with positive/negative test (latest result included only)  
(n = 292,168) 360 practices 
6,362 abnormal 
285,806 normal 
 
Patients with more than one BCSP round electronic notification 
(n=297,735) this include incomplete participation and spoilt kits 
179,158 patients have 1 notification 
92,885 have 2 notifications 
24,498 have 3 notifications 
1,172 have 4 notifications 
21 have 5 notifications 
1 has 6 notifications 
 
Number of BCSP round electronic notifications (n=443,221) this includes 
incomplete participation and spoilt kits 
BCSP FOB test abnormal: 7,964 
BCSP FOB test normal: 426,866 
BCSP FOB testing kit spoilt: 42 
BCSP FOB tst incmplt participt: 8,349 
 
Number of BCSP round electronic notifications (n=443,221) this includes 
incomplete participation and spoilt kits 
BCSP FOB test abnormal: 7,964 
BCSP FOB test normal: 426,866 
BCSP FOB testing kit spoilt: 42 
BCSP FOB tst incmplt participt: 8,349 
 
For Test accuracy analysis: Restrict to patients with a diagnosis within 2 
years and those without diagnosis with at least 2 years of follow up. 
(n = 32,004) 
During Data 
Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Study flow diagram for data extraction from THIN (1st plot) and for data analysis (2nd plot). 
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3.2 Test Accuracy 
 
This analysis helped to determine if the data extracted based on the electronic BCSP 
notifications was valid by comparing to the FOBT results reported in the literature. There 
were 6,362 abnormal FOBT results and 285,806 normal FOBT results equating to a 
positivity of 2.18% out of those who had adequately participated. This is a similar positivity 
to that previously reported in the literature.76 The analysis is restricted to patients who 
have either had the outcome within 2 years or have a minimum of 2 years follow up after 
the index test (n=32,004). The two by two table for this analysis is presented below (Table 
8) providing a two-year sensitivity (screening round sensitivity) of 52.8% and specificity of 
96.3%. The mean age at FOBT was 66.08 (SD: 4.34) with 15,535 males and 16,469 females 
(51.46% female). This is also comparable to results reported in the literature providing 
validity to the data if used for a screening population.6 The positive predictive value was 
58.47%; i.e. 58.47% of people with a positive screening test have a colorectal cancer/polyp 
diagnosis. The negative predictive value was 95.36%; i.e. 95.36% of people with a negative 
test result do not have a colorectal cancer/polyp diagnosis. 
gFOBT 
result 
Cancer /Polyp 
Diagnosis  
Cancer/Polyp 
Diagnosis Free 
Abnormal 
533 colorectal cancers 
993 polyps 1,084 
Normal 
396 colorectal cancers 
967 polyps 28,031 
 
Table 8: 2 by 2 table of colorectal cancer/polyp diagnosis by guaiac faecal occult blood test (gFOBT) result 
 
3.3 Completeness of Records and Univariable Cox Regression 
 
3.3.1 Completeness of Records for a Derived Screening Population 
 
To determine the availability of data for a screening population which may be useful in a 
risk based prediction model, a cohort was derived of those aged 60-74 with a positive or 
negative result. Table 9 summarises the frequency of these data and the completeness of 
variables. Since symptoms and diagnoses are binary parameters these are 100% recorded 
for individuals if they had consulted their GP. Registration details were also highly 
recorded, e.g. age, sex and GP practice (100%). Other more opportunistic factors such as 
anthropometrics were highly recorded. Lab measurements depending on the parameter 
were observed for around 45% of the screening population derived from the THIN 
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database (MCV, haemoglobin and platelet count). Ferritin was rarely recorded (8.59%). 
Although QOF indicators have been introduced for recording ethnic group, this factor was 
recorded in 54.76% of patient records. There is evidence to suggest that the ethnic group 
records are not representative of the UK population and so this parameter was not used for 
multivariable analysis but would be an important variable to consider in future models as it 
can capture certain genetic and social components.50  
Lifestyle factors such as smoking status were extremely well recorded (99.44%) owing to 
the introduction of various QOF indicators for this parameter.51 Alcohol consumption in 
units per week was reasonably well recorded at 78.00%. A summary of the continuous 
predictors and lab measurements for those with a cancer/polyp diagnosis and those 
without is given in Table 10. Boxplots for the lab measurements are also given in Figure 3. 
Ferritin is a highly skewed variable and would be better log transformed but since ferritin 
was rarely recorded (8.59%) it was dropped from further multivariable analysis. 
Variable Frequency  
Total 
Observations Missing 
Percentage 
Recorded 
Percentage  
Missing 
Loss of Appetite       
  
Recorded 117     
  
Not Recorded 292051 292168 0 100.00 0.00 
Combined Abdominal Pain and Antispasmodic 
Prescription       
  
Recorded 20797     
  
Not Recorded 271371 292168 0 100.00 0.00 
Abdominal Pain       
  
Recorded 14209     
  
Not Recorded 277959 292168 0 100.00 0.00 
Flatulence       
  
Recorded 498     
  
Not Recorded 291670 292168 0 100.00 0.00 
Abdominal Mass       
  
Recorded 165     
  
Not Recorded 292003 292168 0 100.00 0.00 
Antispasmodic drug prescription       
  
Recorded 9667     
  
Not Recorded 282501 292168 0 100.00 0.00 
Anti-motility drug prescription       
  
Recorded 3616     
  
Not Recorded 288552 292168 0 100.00 0.00 
Laxative Drug       
  
Recorded 23248     
  
Not Recorded 268920 292168 0 100.00 0.00 
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Abnormal Rectal Examination 
 
    
  
Recorded 3     
  
Not Recorded 292165 292168 0 100.00 0.00 
Rectal Bleeding       
  
Recorded 2694     
  
Not Recorded 289474     100.00 0.00 
Venous Thromboembolism       
  
Recorded 916     
  
Not Recorded 291252 292168 0 100.00 0.00 
Tiredness       
  
Recorded 7176     
  
Not Recorded 284992 292168 0 100.00 0.00 
Weight Loss       
  
Recorded 1057     
  
Not Recorded 291111 292168 0 100.00 0.00 
Alcohol units per week (total observations) 227879     
  
Mean (SD) 9.50 (12.27)     
  
Min and Max 0-500 227879 64,289 78.00 22.00 
Family History of Gastrointestinal Cancer 
 
    
  
Recorded 4424     
  
Not Recorded 287744 292168 0 100.00 0.00 
Constipation       
  
Recorded 4263     
  
Not Recorded 287905 292168 0 100.00 0.00 
Diarrhoea       
  
Recorded 5870     
  
Not Recorded 286298 292168 0 100.00 0.00 
Sex       
  
Male 136569     
  
Female 155599 292168 0 100.00 0.00 
Age at Latest FOBT (total observations) 292168     
  
Mean (SD) 66.43 (4.47)     
  
Min and Max 59-75 292168 0 100.00 0.00 
Change in Bowel Habit 
 
    
  
Recorded 1656     
  
Not Recorded 290512 292168 0 100.00 0.00 
BMI (total observations) 280032     
  
Mean (SD) 27.48 (5.01)     
  
Min and Max 11.4-60 280032 12,136 95.85 4.15 
Height (total observations) 280670     
  
Mean (SD) 1.681 (0.10)     
  
Min and Max 1-2.41 280670 11,498 96.07 3.94 
Weight (total observations) 282655     
  
Mean (SD)  78.08 (16.53)     
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Min and Max 35-200 282655 9,513 96.74 3.26 
Weight % change between two most recent 
readings (total observations) 90,761     
  
Mean (SD) -0.07 (4.77)     
  
Min and Max -56.01-281.8 90,761 201,407 31.07 68.94 
BMI % change between two most recent 
readings (total observations) 90,516     
  
Mean (SD) -0.076 (4.62)     
  
Min and Max -55.95-170 90,516 201,652 30.98 69.02 
Ferritin Continuous (total observations) 25090     
  
Mean (SD) 
127.11 
(201.74)     
  
Min and Max 1-10575 25090 267,078 8.59 91.41 
Ferritin % change between two most recent 
readings (total observations) 10,290     
  
Mean (SD) 
43.689 
(334.26)     
  
Min and Max 
-99,910 - 
21900 10,290 281,878 3.52 96.48 
Ferritin (<15μg/L vs >=15μg/L ) 
 
    
  
<15μg/L 1252     
  
>=15μg/L 23838 25090 267,078 8.59 91.41 
Mean Cell Volume Continuous  129,523      
  
  91.110 (5.08)     
  
  50.6-143.3  129,523  162,645 44.33 55.67 
Mean Cell Volume % change between two 
most recent readings (total observations) 98,340       
  
Mean (SD) 0.066 (2.80)     
  
Min and Max 
-35.56-
79.350) 98,340   193,828 33.66 66.34 
Mean Cell Volume (<80fL vs >=80fL) 
 
    
  
<80fL  2073     
  
>=80fL 127450 129523 162,645 44.33 55.67 
Platelet Count Continuous (total observations) 129,728     
  
Mean (SD) 
245.609 
(66.00)     
  
Min and Max 1.76-1205 129,728 162,440 44.40 55.60 
Platelet Count % change between two most 
recent readings (total observations)  98,603     
  
Mean (SD) 0.963 (40.23)     
  
Min and Max 
-99.5-
10606.32  98,603 193,565 33.75 66.25 
Platelet Count (<=400x 109/L vs >400 x 109/L) 
 
    
  
>400 x 109/L 2764     
  
<=400x 109/L 126964 129728 162,440 44.40 55.60 
Hb Continuous (total observations) 130039     
  
Mean (SD) 13.921 (1.30)     
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Min and Max 2.86-23.8 130039 162,129 44.51 55.49 
Hb % change between two most recent 
readings 98,968     
  
Mean (SD) 0.322 (6.60)     
  
Min and Max -82.87-411.33 98,968 193,200 33.87 66.13 
Hb (<11g/dL vs >=11g/dL) 
 
    
  
<11g/dL  1948     
  
>=11g/dL 128091 130039 162,129 44.51 55.49 
Diabetes 
 
    
  
Recorded 32285     
  
Not Recorded 259883 292168 0 100.00 0.00 
Crohn’s disease 
 
    
  
Recorded 884     
  
Not Recorded 291284 292168 0 100.00 0.00 
Ulcerative Colitis 
 
    
  
Recorded 1797     
  
Not Recorded 290371 292168 0 100.00 0.00 
Irritable Bowel Syndrome 
 
    
  
Recorded 27112     
  
Not Recorded 265056 292168 0 100.00 0.00 
Diverticulitis  
 
    
  
Recorded 18611     
  
Not Recorded 273557 292168 0 100.00 0.00 
Previous Positive FOBTs 
 
    
  
0 290624     
  
1 1488     
  
2 54     
  
3 2 292168 0 100.00 0.00 
Previous Negative FOBTs       
  
0 176584     
  
1 91111     
  
2 23478     
  
3 987     
  
4 8 292168 0 100.00 0.00 
Previously screened with a FOBT       
  
No 175479     
  
Yes 116689 292168 0 100.00 0.00 
Previous polyps diagnosed 
 
    
  
Recorded 7271     
  
Not Recorded 284897 292168 0 100.00 0.00 
Primary care FOBT       
  
No 292136     
  
Yes 32 292168 0 100.00 0.00 
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Weight Loss (Percentage change since last two 
readings) 
 
    
  
<5 at baseline 82369     
  
 5-9.9  6768     
  
 =>10 1624 90761 201,407 31.07 68.94 
Latest FOBT Result 
 
    
  
BCSP FOB test abnormal (baseline) 6362     
  
BCSP FOB test normal 285806 292168 0 100.00 0.00 
Ethnic Group       
  
White (baseline) 151839     
  
Asian 4562     
  
Black 2048     
  
Mixed 610     
  
Other 931 159990 132,178 54.76 45.24 
Urban Rural        
  
Town & Fringe – Less sparse (baseline) 38328     
  
Town & Fringe – Sparse 2726     
  
Urban >10k - Less sparse 220911     
  
Urban >10k – Sparse 152     
  
Village, Hamlet & Isolated 22440     
  
Village, Hamlet & Isolated 2136 286693 5,475 98.13 1.87 
Townsend        
  
1 (baseline) 105661     
  
2 74316     
  
3 54656     
  
4 34592     
  
5 - most deprived 17407 286632 5,536 98.11 1.90 
Blood Group       
  
A (baseline) 3117     
  
AB 250     
  
B 741     
  
O 3340 7448 284,720 2.55 97.45 
Smoking Status       
  
Never smoked (baseline) 167941     
  
ex-smoker 97353     
  
current smoker 25244 290538 1,630 99.44 0.56 
Table 9: The frequency and completeness in recording of investigated variables for an English colorectal cancer 
screening population who are adequately screened (positive/negative result).  
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Patients with Colorectal Cancer/Polyp 
Diagnosis  
Patients without Colorectal Cancer/Polyp 
Diagnosis  
Variable Mean 
Standard 
Deviation Frequency Mean 
Standard 
Deviation Frequency 
Ferritin 109.45 141.70 336 127.35 202.43 24754 
Haemoglobin 
Concentration 13.91 1.48 1544 13.92 1.30 128495 
Mean Cell Volume 91.03 6.20 1537 91.11 5.07 127986 
Weight (kg) 81.55 17.41 2805 78.04 16.52 279850 
Height (m) 1.70 0.10 2794 1.68 0.10 277876 
Platelet count 246.26 71.08 1540 245.60 65.93 128188 
BMI 28.30 5.29 2786 27.48 5.01 277246 
Cigarettes per day 
amongst smokers 12.48 7.76 228 11.84 7.49 16340 
Age at FOBT 66.91 4.39 2,889 66.43 4.48 289,279 
Alcohol units 11.82 14.79 2307 9.47 12.24 225572 
Haemoglobin % 
change 0.19 7.83 1245 0.32 6.55 97723 
Mean cell volume  % 
change -0.08 3.34 1237 0.07 2.79 97103 
Ferritin % change 40.85 127.70 179 43.74 336.78 10111 
BMI % change -0.200 4.76 1175 -0.07 4.62 89341 
Platelet count  % 
change 0.79 16.55 1240 0.97 40.44 97363 
Weight  % change -0.21 4.77 1,179 -0.07 4.78 89,582 
Table 10: Summary of Continuous Predictors and Lab Measurements for those with a cancer/polyp diagnosis 
and those without. 
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Figure 3: Boxplots for laboratory test results 
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3.3.2 Univariable Cox Regression 
 
To determine the predictors with a strong independent association with colorectal 
cancer/polyps which could be included in a risk based prediction model, the univariable 
hazard ratios estimated using Cox Regression (with Efron ties) are presented for the 
variables of interest in Table 11.  
Predictors with the largest observed hazard ratios included previous positive FOBT results 
with a hazard ratio (HR) of 5.032 (CI: 4.18-6.05), previous polyps diagnosed before the 
latest FOBT result (this could have been in or outside the screening programme) with a HR 
of 3.182 (CI: 2.768-3.659) and a symptom of rectal bleeding/melaena recorded with a HR of 
3.118 (2.503-3.883). This means the cancer/polyp detection rate is 3 times as high for 
patients with previous polyps diagnosed or a rectal bleeding symptom and 5 times as high 
for those with previous positive FOBT results.  
Continuous variables with a significant association included, age at FOBT (HR 1.025: CI 
1.017-1.033), BMI (HR 1.029 CI: 1.022-1.036), height (HR 4.390: CI 3.001-6.421), weight (HR 
1.012 CI 1.010-1.010), ferritin (HR 0.999 CI 0.069-0.998), and alcohol consumption in units 
per week (HR 1.010 CI: 1.008-1.011). This means that the hazard rate for the diagnosis of 
colorectal cancer/polyps would increase by 2.5% for each additional year in age at FOBT. In 
addition, females were at lower risk of colorectal cancer/polyp diagnosis than males (HR 
0.656: CI 0.609-0.706).  
Categorising lab measurements to define clinically relevant cutoffs led to haemoglobin, 
ferritin and MCV having a significant effect on the diagnosis of colorectal cancer/polyps 
with HRs of 2 and above. A platelet count of more than 400 x 109/L on the other hand 
which indicates thrombocytosis, did not have a significant HR (P = 0.379). Analysing lab 
results as continuous parameters led to non-significant results at a p value of 0.1. 
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 Variable Observed Hazard 
Ratio (estimated 
from the data) 
Standard 
Error 
z   P>z 95% Confidence 
Interval 
Number of 
Observations 
Loss of Appetite 2.614 1.510 1.66 0.096 0.842 8.108 292,059 
Combined Abdominal Pain and 
Antispasmodic Prescription 1.424 0.089 5.67 0.000 1.261 1.610 292,059 
Abdominal Pain 1.424 0.105 4.79 0.000 1.232 1.646 292,059 
Flatulence 2.479 0.689 3.27 0.001 1.438 4.274 292,059 
Abdominal Mass 1.259 0.890 0.33 0.745 0.315 5.035 292,059 
Antispasmodic drug prescription 1.450 0.127 4.24 0.000 1.221 1.721 292,059 
Anti-motility drug prescription 1.535 0.209 3.15 0.002 1.176 2.005 292,059 
Laxative Drug 1.390 0.084 5.47 0.000 1.235 1.564 292,059 
Rectal Bleeding 3.118 0.349 10.15 0.000 2.503 3.883 292,059 
Venous Thromboembolism 1.421 0.395 1.26 0.206 0.824 2.451 292,059 
Tiredness 1.358 0.141 2.95 0.003 1.108 1.664 292,059 
Weight Loss 1.705 0.403 2.26 0.024 1.073 2.710 292,059 
Alcohol units per week 1.010 0.001 9.93 0.000 1.008 1.011 227,792 
Family History of Gastrointestinal 
Cancer 1.591 0.195 3.78 0.000 1.251 2.024 292,059 
Constipation 1.654 0.200 4.16 0.000 1.305 2.097 292,059 
Diarrhoea 1.778 0.177 5.79 0.000 1.463 2.160 292,059 
Sex             292,059 
Male - - - - - -   
Female 0.656 0.025 -11.23 0.000 0.609 0.706   
Age at Latest FOBT 1.025 0.004 5.91 0.000 1.017 1.033 292,059 
Change in Bowel Habit 2.609 0.406 6.17 0.000 1.924 3.539 292,059 
Weight % change between two most 
recent readings 0.994 0.006 -0.99 0.323 0.981 1.006 90,729 
BMI 
1.029 0.004 8.32 0.000 1.022 1.036 
279,927 
Height 
4.390 0.852 7.62 0.000 3.001 6.421 
280,563 
Weight 
1.012 0.001 11.05 0.000 1.010 1.01 
282,550 
BMI % change between two most 
recent readings 0.994 0.006 -0.87 0.385 0.982 1.007 90,484 
Ferritin Continuous 0.999 0.000 -1.82 0.069 0.998 1.000 25,082 
Ferritin % change between two most 
recent readings 1.000 0.000 -0.1 0.923 0.999 1.000 10,287 
Ferritin (<15μg/L vs >=15μg/L ) 2.054 0.377 3.93 0.000 1.434 2.942 25,082 
Mean Cell Volume Continuous 0.996 0.005 -0.88 0.381 0.986 1.005 129,481 
Mean Cell Volume % change 
between two most recent readings 0.981 0.010 -1.85 0.064 0.961 1.001 98,304 
Mean Cell Volume (<80fL vs >=80fL) 2.419 0.326 6.54 0.000 1.856 3.151 129,481 
Platelet Count Continuous 1.000 0.000 0.4 0.692 0.999 1.001 129,685 
Platelet Count % change between 
two most recent readings 1.000 0.001 -0.12 0.901 0.998 1.002 98,566 
Platelet Count (<=400x 109/L vs >400 
x 109/L) 1.155 0.190 0.88 0.379 0.837 1.594 129,685 
Hb Continuous 0.990 0.019 -0.52 0.605 0.953 1.029 129,996 
Hb % change between two most 
recent readings 0.997 0.005 -0.76 0.449 0.988 1.006 98,931 
Hb (<11g/dL vs >=11g/dL) 2.231 0.324 5.53 0.000 1.679 2.966 129,996 
Diabetes 1.470 0.076 7.49 0.000 1.329 1.627 292,059 
Crohn’s disease 1.038 0.346 0.11 0.912 0.539 1.996 292,059 
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Ulcerative Colitis 1.686 0.309 2.85 0.004 1.177 2.416 292,059 
Irritable Bowel Syndrome 1.141 0.069 2.17 0.030 1.013 1.286 292,059 
Diverticulitis  1.226 0.086 2.92 0.004 1.069 1.406 292,059 
Previous Positive FOBTs 5.032 0.474 17.16 0.000 4.184 6.052 292,059 
Previous Negative FOBTs 0.770 0.026 -7.8 0.000 0.721 0.822 292,059 
Previously screened with a FOBT 0.784 0.032 -6.01 0.000 0.724 0.849 292,059 
Previous polyps diagnosed 3.182 0.227 16.26 0.000 2.768 3.659 292,059 
Primary care FOBT 2.867 2.867 1.05 0.292 0.404 20.357 292,059 
Weight Loss (Percentage change 
since last two readings)             90,729 
<5 at baseline - - - - - -   
 5-9.9  1.060 0.115 0.54 0.592 0.857 1.310   
 =>10 0.948 0.214 -0.24 0.814 0.609 1.476   
Latest FOBT Result 
      
292,059 
BCSP FOB test normal (baseline) - - - - - - 
 
BCSP FOB test abnormal 55.849 2.086 
--
107.72 0.000 
51.90
8 60.090   
Ethnic Group             159,926 
White (baseline) 
      
  
Asian 0.996 0.151 -0.02 0.980 0.741 1.340   
Black 0.786 0.197 -0.96 0.337 0.480 1.286   
Mixed 1.364 0.483 0.88 0.382 0.681 2.732   
Other 0.565 0.253 -1.28 0.202 0.235 1.359   
Urban Rural             286,591 
Town & Fringe – Less sparse 
(baseline) 
      
  
Town & Fringe – Sparse 0.515 0.131 -2.6 0.009 0.313 0.849   
Urban >10k - Less sparse 0.876 0.046 -2.51 0.012 0.789 0.971   
Urban >10k – Sparse 1.741 1.008 0.96 0.339 0.559 5.418   
Village, Hamlet & Isolated 0.826 0.070 -2.26 0.024 0.700 0.975   
Village, Hamlet & Isolated 1.028 0.211 0.13 0.895 0.687 1.538   
Townsend              286,530 
1 (baseline) 
      
  
2 1.065 0.052 1.28 0.199 0.968 1.172   
3 1.041 0.056 0.75 0.456 0.937 1.157   
4 1.161 0.070 2.47 0.014 1.031 1.308   
5 - most deprived 1.387 0.102 4.43 0.000 1.200 1.603   
Blood Group (A at baseline)             7,444 
A (baseline) 
      
  
AB 0.442 0.450 -0.8 0.423 0.060 3.248   
B 0.708 0.343 -0.71 0.476 0.274 1.829   
O 0.975 0.254 -0.1 0.923 0.585 1.625   
Smoking Status             290,429 
Non-Smoker (baseline) 
      
  
ex-smoker 1.532 0.061 10.72 0.000 1.417 1.656   
current smoker 1.618 0.098 7.91 0.000 1.436 1.823   
Table 11: Univariable Cox Regression for considered variables with associated hazard ratios. 
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Fractional Polynomials for Continuous Variables 
Fractional polynomials can be used to provide flexible parameterisation for continuous 
variables and to determine the most appropriate functional form of a covariate in the 
model. This modelling method was investigated for; BMI, alcohol consumption in units per 
week, haemoglobin concentration, mean cell volume and platelet count. The most efficient 
model was selected using the likelihood ratio test at a p value of 0.1.  
For age at FOBT, the linear model and fractional polynomials of degree 1 (FP1) were the 
best fitting, using a 0.1 significance level the linear model is selected for model simplicity. 
For BMI, a fractional polynomial of degree 2 (FP2) has the best fit to these data (β1(BMI)3 + 
β2(BMI)3ln(BMI)). Alcohol units also have the best fit using an FP2 model (β1(alcohol)-0.5 + 
β2ln(alcohol)) as well as Hb concentration (β1(Hb)2 + β2(Hb)2ln(Hb)), mean cell volume 
(β1(MCV)0.5 + β2(MCV)0.5ln(MCV)) and platelet count (β1(platelet)0.5 + 
β2(platelet)0.5ln(platelet)) (Table 12). Any variable to the power zero is the natural log using 
the ‘fp’ function in Stata. Fractional polynomial component plots which show the fit of the 
model/fractional polynomial for each variable are shown in Figure 4 with the 95% 
confidence interval.  
Multivariable fractional polynomials were considered when developing the multivariable 
Cox models. 
Predictor Hazard Ratio Standard 
Error 
z P>z     95% CI 
β1(BMI)3 1.067 0.013 5.170 0.000 1.041 1.094 
β2(BMI)3ln(BMI) 0.964 0.008 -4.490 0.000 0.949 0.980 
β1(alcohol)-0.5 1.181 0.036 5.530 0.000 1.114 1.253 
β2ln(alcohol) 1.663 0.112 7.590 0.000 1.459 1.897 
β1(Hb)2 0.049 0.020 -7.340 0.000 0.022 0.109 
β2(Hb)2ln(Hb) 37.415 18.060 7.500 0.000 14.527 96.365 
β1(MCV)0.5 7.67E+07 1.67E+08 -8.370 0.000 1061691 5.54E+09 
β2(MCV)0.5ln(MCV) 0.135 0.098 8.310 0.000 0.033 0.560 
β1(platelet)0.5 0.135 0.098 -2.760 0.006 0.033 0.560 
β2(platelet)0.5ln(platelet) 29.252 31.229 3.160 0.002 3.609 237.085 
Table 12: Fractional polynomials for investigated continuous variables. Any variables to the power 0 is the 
natural log using the ‘fp’ function in Stata. 
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Figure 4: Fractional Polynomial component-plus-residuals plots with 95% confidence Intervals for; BMI (1st plot), 
Hb concentration (2nd plot), MCV (3rd plot), alcohol units per week (4th plot), platelet count (5th plot). The 
shaded region is the 95% confidence interval. 
3.4 Kaplan Meier Survival Curve Analysis 
 
This section helped to describe and check the validity of the data extracted for analysis and 
identified predictors which affect survival by comparing the survival functions of different 
groups/covariate patterns. 
3.4.1 Survival Analysis - Time to Diagnosis (Colorectal Cancer Free Survival) 
 
For survival analysis using the screening cohort there were 292,059 observations and 2889 
events (113,454,249 person years).  The median time to diagnosis (S(t0.5)) (or median 
survival time) after a FOBT and censoring at 2 years follow up was 383 days (see boxplot 
Figure 5). 
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Figure 5: Boxplot of time to diagnosis after the index date (latest FOBT) when censoring data at 2 year follow up 
for the derived screening cohort. 
 
The Kaplan-Meier estimate of the survivor function (S(t)) is a nonparametric maximum 
likelihood estimate (MLE) and is shown in Figure 6 with the corresponding risk table. The 
shallow decline for the first year shows that there are reasonably low numbers of 
individuals diagnosed. There is a slightly steeper gradient for year two with more 
individuals being diagnosed. 
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Time (days) Number at 
Risk 
Number of 
Events 
Survival Standard 
Error 
Lower 95% CI Upper 95% CI 
0 292168        0 1.000 0.000000 1.000         1.000 
100 253654     1588     0.994 0.000141 0.994         0.995 
 
200 214230      258     0.993 0.000157 0.993         0.994 
 
300 177810      243     0.992 0.000175 0.992         0.992 
400 140016      207     0.991 0.000197         0.990         0.991 
500 104172      216     0.989 0.000230         0.989         0.989 
 
600 70418      173     0.987 0.000274         0.986         0.988 
700 38789      161     0.984 0.000368         0.983         0.985 
 
Figure 6: Kaplan Meier estimate of the survivor function for time to diagnosis (colorectal cancer free survival)  
for the derived screening cohort with the corresponding risk table. 
 
A Kaplan Meier estimate (using 2 year censoring for follow up) is plotted for those with a 
negative FOBT and those with a positive FOBT in Figure 7 to determine the difference in 
cancer free survival between these groups of patients. The log-rank test for equality of 
survivor functions is significant between the two results (p <0.001). This test assesses if 
there is a statistical difference between the survival times between those with a positive 
and those with a negative FOBT. From the plot, as expected, those with a positive FOBT 
receive more diagnoses over time. Initially with the sharp decline in cancer free survival 
(increase in diagnosis) associated with follow up after a positive screening result by the 
BCSP. 
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Figure 7: Kaplan Meier estimate for colorectal cancer free survival using 2 year censoring for the screening 
cohort plotted by negative or positive FOBT. Time is in days. The associated risk table is also displayed below the 
plot. 
The Kaplan Meier estimates are plotted by sex in Figure 8 with a significant log-rank test 
(p<0.001). Males have a significant reduction in colorectal cancer free survival (increase in 
colorectal cancer/polyp diagnoses) over time compared to females for the two year follow 
up period with the difference becoming more apparent over time. This is most likely due to 
the increased risk of CRC and increased FOBT positivity seen in men versus women.77 
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Figure 8: Kaplan Meier estimates for colorectal cancer free survival plotted by sex for the derived screening 
cohort with associated risk table below the plot. 
3.4.2 Survival Analysis - Time to Death (Overall Survival) 
 
Time to death was investigated for the screening cohort covering the period 1st May 2009 
to 17th January 2017. The median time to death (from any cause) after a FOBT (S(t0.5)) (or 
median survival time) is 387 days (Figure 9). The Kaplan-Meier estimate of the survivor 
function (S(t)) for time to death is presented in Figure 10 below with the corresponding risk 
table. 
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Figure 9: Boxplot of time to death after the index date (latest FOBT) for the derived screening cohort covering 
the period 1st May 2009 to 17th January 2017. 
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Figure 10:  Kaplan Meier estimate for time to death for the derived screening population with associated risk 
table using the cohort covering the period 1st May 2009 to 17th January 2017. 
  
Time (days) Number at 
Risk 
Number of 
Events 
Survival Standard 
Error 
Lower 95% CI Upper 95% CI 
0 292168        2 1.000 4.84e-06         1.000 1.000 
100 255139      327     0.999 6.67e-05         0.999 0.999 
200 215792      468 0.997 1.14e-04         0.997 0.997 
300 179400      409 0.995 1.53e-04         0.994 0.995 
400 141521      504 0.992 2.07e-04         0.991 0.992 
500 105584      522     0.987 2.77e-04         0.987 0.988 
600 71706      475     0.982 3.69e-04         0.981 0.983 
700 39892      366     0.975 5.08e-04         0.974 0.976 
800 18720      268     0.966 7.89e-04         0.964 0.967 
900 13681      166     0.956 1.10e-03         0.953 0.958 
1000 10575 80 0.949 1.30e-03         0.947 0.952 
1100 8484 69 0.942 1.53e-03         0.939         0.945 
1200 6598 52 0.936 1.76e-03         0.933         0.939 
1300 5006 50 0.928 2.08e-03         0.924         0.932 
1400 3636 28 0.922 2.37e-03         0.917         0.927 
1500 2554 17 0.917 2.66e-03         0.912         0.922 
1600 1771 18 0.910 3.14e-03         0.903         0.916 
1700 1305 7 0.905 3.51e-03         0.899         0.912 
1800 909 3 0.903 3.75e-03         0.896         0.910 
1900 594 5 0.897 4.59e-03         0.888         0.906 
2000 352 3 0.892 5.40e-03         0.882         0.903 
2100 198 2 0.885 7.54e-03         0.870         0.899 
2200 97 1 0.879 9.18e-03 0.861         0.897 
2300 60 0 0.879 9.18e-03 0.861         0.897 
2400 41 0 0.879 9.18e-03 0.861         0.897 
2500 28 0 0.879 9.18e-03 0.861         0.897 
2600 16 0 0.879 9.18e-03 0.861         0.897 
2700 6 0 0.879 9.18e-03 0.861         0.897 
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The Kaplan Meier estimates for time to death (in days) are plotted by FOBT result in Figure 
11.  Those with a positive result are at increased risk of death for around the first 1250 
days, the risk then becomes similar and then for the last 1000 days those with negative 
FOBT results then appear to be at greatest risk. Presumably because cancers may have 
been missed (false negatives) or aggressive faster growing cancers have developed over the 
time period (interval cancers) which were missed/not present at screening. An alternative 
explanation may be because the positive FOBT group has seen quite a few ‘sicker’ people 
die due to CRC and thus after a certain time this makes them an overall ‘healthy’ group 
compared to the negatives.  
 
 
 
 
Figure 11: Kaplan Meier estimate for time to death for the derived screening cohort plotted by negative or 
positive FOBT. The associated risk table is also displayed below the plot. 
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3.4.3 Subgroup analysis negative FOBT 
  
For time to diagnosis (colorectal cancer free survival) and for a sample population of the 
screening cohort who just had negative FOBT results, there were 285,697 observations and 
1363 events (111,277,576 person years).  The Kaplan-Meier survival estimate is given in 
Figure 12 below with the corresponding risk table. 
 
Figure 12: Kaplan Meier estimate of time to diagnosis (colorectal cancer free survival) for those with negative 
FOBT results censored at 2 years of follow up. 
 
The Kaplan Meier estimates are plotted by sex in Figure 13. The log rank test of equality 
across strata is significant between males and females p<0.001 with FOBT negative males 
having a greater risk of diagnosis over time (a two year screening round) compared to FOBT 
negative females. This is as expected since males are in general at greater risk of 
developing colorectal cancer compared to females. 
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Figure 13: Kaplan Meier estimates of time to diagnosis (colorectal cancer free survival) plotted by sex for those 
with negative FOBT results censored at 2 years of follow up. 
 
Time to death (overall survival) was also analysed for this population using the Kaplan-
Meier survival estimate (Figure 14). For the population with just negative FOBT results 
there were 285,696 observations, 3606 failures and 119,018,674 person years. The last 
observed exit was at 2794 days. 
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Figure 14:  Kaplan Meier estimate of time to death for those with negative FOBT results. 
 
The Kaplan-Meier survival estimate is also presented by sex below (Figure 15) with a 
significant log-rank test for males with negative FOBT results versus females with negative 
FOBT results p<0.001. Males are at greater risk of death over the study period. 
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Figure 15: Kaplan Meier estimate of time to death for those with negative FOBT results by sex. This had a 
significant log rank test p=<0.0001. 
 
3.4.4 Subgroup analysis TP, TN, FP, FN 
 
Time to Diagnosis (Colorectal Cancer Free Survival) 
Kaplan-Meier estimates for true positive results (TP), true negatives (TN), false positives 
(FP) and false negatives (FN) are presented in Figure 16 below. This used a restricted 
dataset to ensure that everyone without a diagnosis had at least 2 years of follow up 
(n=32,004). The difference between the survival times between these groups is significant 
using a log-rank test (p<0.0001). FPs and TNs have a similar survival probability pattern. FNs 
have a constant rate of decline in survival (or increase in cancer diagnosis) over the study 
period. TPs have the steepest decline in survival probability as expected. 
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Figure 16: Kaplan-Meier estimates for time to diagnosis (colorectal cancer free survival) true positive results 
(TP), true negatives (TN), false positives (FP) and false negatives (FN) in the sample population with at least 2 
years follow up if undiagnosed. The associated risk table is presented below. 
Time to Death (Overall Survival) 
Kaplan Meier estimates using time to death as the outcome are presented for FNs, FPs, TNs 
and TPs below (Figure 17). The FNs end up doing worse later on than the TPs at around 
1000 days, this could be due to the effects of late diagnosis for FNs as they are less likely to 
have had diagnostic follow up/further investigations compared to TPs. In addition, FNs 
could have more aggressive cancers that develop after screening and TPs present at an 
earlier stage. FPs also appear to have fewer diagnoses than TNs possibly due to having 
some sort of diagnostic investigation putting them at lower risk of CRC compared to TNs. 
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Figure 17: Kaplan-Meier estimates for time to death for true positive results (TP), true negatives (TN), false 
positives (FP) and false negatives (FN) in the sample population with at least 2 years follow up if undiagnosed. 
The associated risk table is presented below. 
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3.5 Multivariable Analysis Risk Prediction Model Development (n=98,303) 
 
3.5.1 Cox Regression for Positive and Negative Results 
This section identified additional predictors from a multivariable model which have the 
potential to be added to a risk based model to make more accurate screening referral 
decisions. 
Survival models were built using Cox regression with backwards elimination and likelihood 
ratio testing for model selection, at a p-value of 0.05 using the ‘mfp’ function implemented 
in Stata.55 There were 98,303 patients, 1,197 failures and 38,005,604 total analysis time at 
risk. There were 2511 positive test results and 95,792 negative FOBT results. The median 
follow up time in days was 385 (95% CI: 383 to 388), the restricted mean survival time was 
722.181 (the largest observed analysis time was censored so the mean is underestimated). 
Original model had 33 degrees of freedom with all predictors considered, 45 degrees of 
freedom when including all considered interactions. 
The final model after assessing all eligible predictors included; FOBT result, smoking status, 
whether a patient had a diagnosis of Crohn’s disease, previous polyps diagnosed, 
flatulence, MCV of <80fL compared to a MCV of ≥80fL, alcohol consumption in units per 
week, family history of gastrointestinal cancer, abdominal pain/antispasmodic prescription, 
diarrhoea, sex, age at FOBT and change in bowel habit (Table 13). Significant interactions at 
the 0.05 p value level included FOBT result and age and MCV and age. The adjusted hazard 
ratios for this model are reported in Appendix 6. 
Multivariable fractional polynomials were used when model building to assess continuous 
predictors, both alcohol and age were centred around the mean with the natural log being 
used for alcohol consumption as this better fitted linearity. For this model, Harrell’s C 
statistic was 0.854 (95% CI: 0.841, 0.868) and Somers D 0.708. Harrell’s C statistic means 
that the predictors used in the model correctly identify the order of survival times for pairs 
of patients 85% of the time. The final model had 16 degrees of freedom with an AIC of 
23499.87 and BIC 23581.27 (N=1197 when calculating BIC)). Overall model fit was assessed 
using adjusted R2 which was 0.563 (bootstrapped CI 100 reps: 0.535, 0.596) and adjusted D 
was 2.321.73 78 Regular R2 was 0.568 with D statistic of 2.344. 
Interactions which were significant at the 0.05 p-value level were FOBT result and age at 
FOBT, MCV <80fL and age at FOBT. The model with the interaction was compared to the 
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model without the interaction using the likelihood ratio test. This was statistically 
significant at the 0.05 level which indicates that the interactions improve the fit of the 
model to the data (Prob > chi2 = 0.0019). 
 
 Variable Observed 
Coefficient 
Bootstrapped 
Standard 
Error 
z P>z [95% Confidence Intervals] 
MCV*age at FOBT interaction 0.086 0.042 2.04 0.041 0.004 0.169 
       
FOBT result*age at FOBT 
interaction -0.037 0.014 -2.63 0.009 -0.065 -0.009 
       
FOBT Result (positive) 3.741 0.061 61.61 0.000 3.622 3.860 
Smoking Status:       
ex-smoker 0.206 0.060 3.44 0.001 0.089 0.324 
current smoker 0.323 0.105 3.07 0.002 0.117 0.530 
       
Crohn’s Disease Diagnosis 
Recorded -0.722 0.425 -1.7 0.089 -1.555 0.110 
Previous Polyps Diagnosed 0.648 0.141 4.6 0.000 0.372 0.924 
Flatulence Symptom Recorded 0.850 0.433 1.96 0.050 0.000 1.700 
MCV <80fL  0.344 0.201 1.71 0.087 -0.050 0.738 
Alcohol consumption (units per 
week) 0.082 0.031 2.67 0.008 0.022 0.142 
Family History of 
Gastrointestinal Cancer 0.766 0.181 4.23 0.000 0.411 1.121 
Abdominal pain/antispasmodic 
prescription recorded 0.199 0.098 2.02 0.043 0.006 0.392 
Diarrhoea symptom 0.272 0.155 1.76 0.079 -0.031 0.575 
Sex -0.196 0.072 -2.72 0.007 -0.337 -0.055 
Age at FOBT 0.033 0.008 3.85 0.000 0.016 0.049 
Change in bowel habit 
symptom 0.908 0.200 4.55 0.000 0.517 1.300 
Table 13: Cox regression model (coefficients) after mfp selection for patients with a positive or negative FOBT. 
The continuous variable age at FOBT has been centred (age_at_FOBT-66.97), alcohol units have the following 
transformation (ln(X)+2.25: X = (ahd_alcohol_units+1)/100). The deviance of the model is 23,467.87. 
 
The linear predictor from the final model had a mean of 0.135 and a standard deviation of 
0.688 (range: -1.372 to 5.758). The distribution of the linear predictor is shown in Figure 18. 
The linear predictor is the linear combination of predictors in the model without the 
baseline hazard. Discrimination was also assessed by analysing the separation between 
Kaplan-Meier curves for 4 risk groups (where the linear predictor is divided into 4 groups) 
(see Figure 19). Separation is much greater for group four compared to the other groups 
which most likely reflects a positive FOBT result and quick referral pathway (shorter time to 
diagnosis compared to other groups).  
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Figure 18: Distribution of the linear predictor for the final multivariable model for patients with positive and 
negative FOBTs 
 
Figure 19: Kaplan Meier curves for 4 risk groups (in the screening cohort with positive and negative FOBTs), 
using the linear predictor which is divided into 4 using Cox’s method – see methods section. 
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3.5.2 Adjusting for Optimism 
 
The optimism of the model was assessed by calculating Van Houwelingen’s heuristic 
shrinkage which was 0.995 ((3130.160 - 16)/ 3130.156). The linear predictor was then 
reassessed after applying this shrinkage factor and compared to the original linear 
predictor; this had a mean of 0.135 (SD: 0.685) and range -1.365 to 5.728. The calibration 
slope after applying the shrunken linear predictor was 1.005 (whereas it would have been 
1.000 for the model which was not adjusted for optimism). Figure 20 shows visually how 
the survival is adjusted after applying shrinkage for a high risk individual with a linear 
predictor of value 4.885 and a low risk individual with a linear predictor of -1.119. 
 
Figure 20: Survival for a high risk individual with a linear predictor of 4.885 which is shrunk to 4.860 and for a 
low risk individual -1.119 which is shrunk to -1.113. These individuals are from the screening cohort with positive 
and negative FOBTs. 
To adjust performance statistics for optimism, internal validation was performed using 100 
bootstrap replications for the C statistic, c-slope, D statistic and R2 to quantify optimism. 
The optimism adjusted values for these performance parameters are displayed in Table 14.  
The bootstrapped uniform shrinkage factor (based on the optimism adjusted c-slope value) 
is slightly less (0.991) compared to the heuristic shrinkage (0.995). There was minimal 
optimism adjustment most likely due to the large sample size. 
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Statistic Apparent 
Performance 
Optimism (100 bootstrap 
replications) 
Optimism adjusted 
performance  
(apparent minus optimism) 
C statistic 0.854 0.004 0.850 
c-slope 1.000 0.009 0.991 
D statistic 2.344 0.046 2.298 
R2 0.568 0.010 0.558 
Table 14: Optimism calculated for the C statistic, c-slope, D statistic and R2 for the multivariable model 
developed using the screening cohort with positive and negative FOBTs. This uses 100 bootstrap replications and 
presents the corresponding optimism adjusted performance values. For bootstrap replications, the seed was set 
as ‘231398’ in Stata. 
3.5.3 Predicted Probabilities 
 
This analysis was performed to determine individual risk probabilities from the model and 
to determine the distribution of risk in the sample population based on the predictors in 
the multivariable model.  
The baseline survival for the Cox model was estimated non-parametrically at 2 years using 
the zero covariate value using the methods implemented in Stata. This was used along with 
the shrunken linear predictor to obtain the predicted probability of an individual being 
diagnosed with colorectal cancer/polyps at 2 years.  
Before shrinkage, the baseline survival at 2 years was 0.9906 after shrinkage the baseline 
survival was 0.9905. The change in baseline survival over the 2 year period is shown below 
for the original and shrunken baseline survival (Figure 21). The shrunken baseline hazard is 
estimated using the heuristic linear predictor.  
To generate risk probabilities both the heuristic linear predictor and the corresponding 
shrunken baseline survival were used for the final risk equation. The mean probability of 
being diagnosed with CRC or polyp within 2 years was 0.019 with a standard deviation of 
0.058 (Range: 0.002, 0.946). The final risk equation for a high risk participant is shown in 
Equation 2. 
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Figure 21: Baseline survivor versus the shrunken baseline survivor. The shrunken baseline survival at 2 years was 
estimated by setting the shrunken linear predictor as an offset and predicting the subsequent baseline survival. 
These results were derived from the screening cohort with positive and negative FOBTs. 
Survival Probability 
S(2) = S0(2)exp(LP) 
Where LP is the linear predictor and S0(2) is the baseline survival at 2 years. 
Event Probability 
P = 1 – S(2) 
 
High risk Participant Example: 
Survival Probability: 
0.29335536 = 0.9905431exp(4.8603225) 
Event Probability:  
0.70664464 = 1-0.29335536 
The probability of being diagnosed with CRC in a 2-year period for a high risk individual is 0.71. 
Full Equation: 
Survival Probability 
𝑆(2) = 0.991
exp(3.74𝑥1+⁡0.21𝑥2+⁡0.32𝑥3+(−0.72)𝑥4+⁡0.65𝑥5+⁡0.85𝑥6+⁡0.34𝑥7+0.08(ln(⁡
𝑥8+1
100 +2.25
))+⁡0.77𝑥9+⁡0.20𝑥10
+⁡0.27𝑥11+⁡(−0.20)𝑥12⁡+⁡0.03(𝑥13−66.97)+⁡0.91𝑥14+⁡0.09(𝑥13−66.97)𝑥7+(−0.04)(𝑥13−66.97)𝑥1)  
 
0.991 = the baseline survival at 2 years S0(2) 
Where S(2) is the survival probability at 2 years (probability of not being diagnosed with colorectal cancer/polyps) 
 
Event Probability 
P = 1 – S(2) 
 
Where P is the probability of colorectal cancer/polyp being diagnosed within 2 years of the latest FOBT date; 𝑥1 Latest FOBT 
result; 𝑥2 ex-smoker; 𝑥3 current smoker; 𝑥4 Crohn’s disease; 𝑥5 previous polyps; 𝑥6 flatulence; 𝑥7 MCV <80fL; 𝑥8 alcohol 
consumption; 𝑥9 family history of gastrointestinal cancer; 𝑥10 abdominal pain/antispasmodic prescription; 𝑥11 diarrhoea; 𝑥12 
sex; 𝑥13 age at FOBT,⁡𝑥14 Change in bowel habit.  
 
Equation 2: Final risk equation for the screening cohort with positive and negative FOBTs with the shrunken 
baseline survival and using shrunken linear predictor values to correct for optimism. 
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3.5.4 Calibration 
A calibration curve for the multivariable model adjusted for optimism is presented below 
for deciles of risk (Figure 22). For individuals at lower risk the model slightly underestimates 
the level of risk, whilst for the top risk group the model slightly overestimates the level of 
risk. 
The separation between the risk groups gives an indication of how well the model 
discriminates between those with the disease and those without. The first 9 groups are 
spaced closely together with the mean probability of the 10th group being far removed. This 
is most likely due to whether an individual has either a positive or negative FOBT. Those 
with a positive FOBT are designated at much higher risk. 
 
 
Risk 
Group 
Calibration Expected 
Probability 
Calibration Observed 
Probability 
Calibration observed 
lower bound 
Calibration observed 
upper bound 
1 0.006 0.008 0.013 0.005 
2 0.007 0.008 0.013 0.005 
3 0.008 0.009 0.014 0.006 
4 0.009 0.011 0.016 0.008 
5 0.009 0.009 0.013 0.006 
6 0.010 0.014 0.020 0.011 
7 0.011 0.017 0.022 0.013 
8 0.012 0.018 0.024 0.014 
9 0.014 0.021 0.027 0.016 
10 0.109 0.095 0.104 0.087 
Figure 22: Calibration plot of observed probability versus expected probability using the multivariable model. 
The corresponding risk groups for each decile of probability are presented in the table below the figure. 
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3.5.5 Cox Regression Diagnostics 
 
To test the proportional hazards assumption of the model, Schoenfeld residuals of the 
covariates were examined (Appendix 7). Significant results which had a p-value of less than 
0.05 (which suggest they potentially violate the proportional hazards assumption) included; 
FOBT result (positive), smoking status current and ex-smoker, Crohn’s disease, previous 
polyps and age at FOBT. The global test for the model also had a p-value <0.0001. Since this 
research uses a reasonably large dataset there is a lot of power to detect small deviations 
therefore graphical methods of proportional hazards were also assessed.  
The scaled Schoenfeld residuals were plotted for these covariates where a straight 
horizontal line supports that there is not a violation of the proportional hazards assumption 
(Figure 23). The lines are reasonably straight but do deviate slightly over time for example 
with previous polyps there is a slight increase over time and with ex-smokers. The 
abnormal FOBT result due to an increased number of earlier events has a steep decline and 
then levels out over time.  
Log-log plots were also plotted for these variables to assess proportionality by determining 
whether the lines are roughly parallel (Figure 24 & Figure 25). The latest FOBT result is 
roughly parallel over the time period due to the cut off of a two year follow up. Crohn’s 
disease does not appear to have proportional hazards and there are crossovers with 
previous polyps and smoking status. 
 
 
   
 
304 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
 
   
 
305 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
 
Figure 23: Schoenfeld residual plots for variables which had a p value of <0.05 when testing the proportional 
hazards assumption in the derived screening cohort. These variables included: Positive FOBT (1st plot), ex-smoker 
(2nd plot), previous polyps (3rd plot), age at FOBT (4th plot), current smoker (5th plot), Crohn’s disease (6th plot). 
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Figure 24: Log-log plots to test the Cox proportionality assumption for previous polyps (1st plot), FOBT result (2nd 
plot), and Age group (3rd plot - which was split into 2 equally sized groups) for the derived screening cohort). 
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Figure 25: Log-log plot to test the Cox proportionality assumption for Crohn’s disease (1st plot) and Smoking 
status (2nd plot) for the derived screening cohort. 
 
Overall model fit was assessed using Cox-Snell residuals by plotting the Nelson-Aalen 
cumulative hazard function against Cox-Snell residuals (Figure 26).79 This plot shows that 
the cumulative hazard function does not have an exponential distribution with hazard rate 
of one since the Cox-Snell residuals deviate from this line particularly at the tail end where 
there are fewer events. This suggests that perhaps a more flexible parametric model may 
have a better fit. 
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Figure 26: Assessment of overall model fit for the model derived from the screening cohort with positive and 
negative FOBTs using Cox-Snell residuals by plotting the Nelson-Aalen cumulative hazard function against Cox-
Snell residuals. For a good model fit, the cumulative hazard function should follow the Cox-Snell residuals. 
3.5.6 Parametric Survival Models 
 
Parametric models were investigated as an extension to Cox Regression to determine 
whether these types of model gave a better fit to the data and therefore more accurate 
parameter estimates. Parametric models also offer more with post-estimation, allowing 
predictions to be made at multiple time points. The generalised gamma, loglogistic and log 
normal parametric models use the accelerated time metric and can be used to derive time 
ratios which are arguably more interpretable compared to hazard ratios.34 The Weibull, 
exponential and Gompertz parametric models on the other hand have a proportional-
hazards parameterisation. The AIC was used to compare the different parametric survival 
models since the models do not require to be nested as with likelihood ratio testing (Table 
15). The smallest AIC and therefore the model which may fit the data best is the 
generalised gamma model. Generalised gamma models are useful when the hazard rises to 
a peak before dropping.40 This is a reasonable assumption in the setting here and could be 
investigated further. Furthermore, the generalised gamma distribution is a three-
parameter distribution which has a flexible hazard function allowing for many types of 
shape.60 The fit was investigated further by plotting Cox-Snell residuals (Figure 27), Nelson 
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Aalen cumulative hazard plots and Kaplan Meier function graphs for the parametric models 
to assess the fit visually. 
Model Observations 
Log likelihood 
null 
Log likelihood 
model 
Degrees of 
freedom AIC BIC 
Exponential 1,197 -8233.44 -6649.63 17 13333.25 13419.74 
Weibull 1,197 -8071.73 -6490.23 18 13016.47 13108.04 
Gompertz 1,197 -8141.97 -6545.09 18 13126.18 13217.75 
Lognormal 1,197 -8048.78 -6241.59 18 12519.19 12610.76 
Loglogistic 1,197 -8071.51 -6427.32 18 12890.65 12982.22 
Generalised 
gamma 1,197 -8071.95 -6159.85 19 12357.7 12454.36 
Table 15: Difference between the different parametric models for the model derived from the screening cohort 
with positive and negative FOBTs compared with the semi-parametric Cox regression model. 
Although all models show deviation from the reference line, the generalised gamma model 
has a better fit at the tail end of the data. The Nelson Aalen cumulative hazard plots were 
assessed for all the parametric models, there was similar fit to the data for all the models 
but the generalised gamma model had slightly better fit overall Figure 28. The Kaplan 
Meier function graphs show very similar fit for Weibull, generalised gamma, lognormal and 
loglogistic models (Figure 29).  
The coefficients for the generalised gamma model are reported in Table 16. 
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Figure 27: Cox Snell Residuals plotted for all considered parametric models, for the multivariable model derived 
from the screening cohort with positive and negative FOBTs, to assess model fit. 
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Figure 28: Nelson-Aalen cumulative hazard plots for all considered parametric models to assess model fit of the 
multivariable model derived from the screening cohort with positive and negative FOBTs.  
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Figure 29: Kaplan-Meier function graphs for all considered parametric models to assess model fit of the 
multivariable model derived from the screening cohort with positive and negative FOBTs. 
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3.5.7 Model Performance measures for the best fitting parametric models 
 
Based on the plots in the previous section and the AIC value, the generalised gamma model 
had the best fit to these data. The appropriateness of the lognormal and Weibull models 
were also assessed by determining whether the second ancillary parameter (kappa) was 
equal to 0 or 1.60 75 This was significant for kappa equal to 1 suggesting the Weibull model 
may also have an appropriate fit (p<0.001). Harrell’s C-statistic was very similar across all 
three parametric models; generalised gamma 0.859 (95% CI: 0.845, 0.872), Weibull 0.854 
(95% CI: 0.841, 0.868) and lognormal 0.857 (95% CI: 0.844, 0.871). These values were also 
comparable to the equivalent Cox Regression model (0.854 (95% CI: 0.841, 0.868)). The 
coefficients for the models are presented below in Table 16 to aid comparison, along with 
the discrimination and other performance measures where applicable. The Weibull model 
is presented both in the accelerated failure time and proportional hazards 
parameterisations for comparison between the other accelerated failure time models and 
Cox regression (which uses the proportional hazards assumption). 
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 Variable Weibull (AFT) 
coefficients 
Weibull (PH) 
coefficients 
Lognormal (AFT) 
coefficients 
Generalized 
gamma (AFT) 
coefficients 
Cox (PH) 
coefficients 
MCV*age at FOBT interaction -0.132 0.086 -0.130 -0.105 0.086 
FOBT result*age at FOBT 
interaction 0.059 -0.039 0.045 0.041 -0.037 
FOBT Result (positive) -5.766 3.765 -5.595 -5.656 3.741 
           
Smoking Status:          
ex-smoker -0.313 0.204 -0.276 -0.213 0.206 
current smoker -0.496 0.324 -0.462 -0.411 0.323 
           
Crohn’s Disease Diagnosis 
Recorded 1.126 -0.735 0.933 0.562 -0.722 
Previous Polyps Diagnosed -0.986 0.644 -1.075 -1.043 0.648 
Flatulence Symptom Recorded -1.270 0.829 -1.064 -0.780 0.850 
MCV <80fL  -0.514 0.336 -0.604 -0.653 0.344 
Alcohol consumption (units 
per week) -0.125 0.082 -0.097 -0.067 0.082 
Family History of 
Gastrointestinal Cancer -1.192 0.779 -0.925 -0.712 0.766 
Abdominal 
pain/antispasmodic 
prescription recorded -0.313 0.204 -0.351 -0.388 0.199 
Diarrhoea symptom -0.429 0.280 -0.531 -0.579 0.272 
Sex 0.307 -0.200 0.249 0.191 -0.196 
Age at FOBT -0.049 0.032 -0.030 -0.019 0.033 
Change in bowel habit 
symptom -1.399 0.913 -1.095 -1.011 0.908 
Constant 13.839 -9.036 13.455 12.919 - 
Ancillary parameter 0.653 0.653 2.911 4.459 - 
Kappa (Ancillary parameter 2 
for the gamma model) NA NA NA -1.209 - 
Log likelihood -6490.233 -6490.233 -6241.594 -6159.848 -11733.936a 
AIC 13016.470 13016.470 12519.190 12357.700 23499.87a 
BIC 13108.040 13108.040 12610.760 12454.360 23581.27a 
Harrell’s C Statistic (95%CI) 
0.854 
(0.841,0.868) 
0.854 
(0.841,0.868) 
0.857 (0.844, 
0.871) 
0.859 (0.845, 
0.872) 
0.854 (0.840, 
0.868) 
R2 0.759 0.571 0.270 -b 0.568 
D Statistic 3.628 2.361 0.971 
-b 
2.344 
Adjusted R2 (Bootstrap CI 100 
replications) 
0.755585 
(0.721523  
0.781859) 
0.566074 
(0.540843  
0.594144) 
0.260 
(0.241,0.293) 
-b 
0.563 (0.526, 
0.593) 
Optimism adjusted 
Calibration Slope (also 
shrinkage factor for linear 
predictor) 0.990 0.991 0.996 -c 0.991 
Optimism Harrell’s C Statistic 0.851 0.851 0.853 -c 0.850 
Optimism adjusted D statistic 
3.550 2.313 0.949 -b 2.298 
Optimism adjusted R2 
0.751 0.561 0.261 -b 0.558 
a The log likelihood/AIC/BIC from the Cox model is not comparable to parametric models since it uses partial likelihood 
whereas the other models use full maximum likelihood 
b The R2D measure is not available for the generalised gamma distribution  
c Optimism adjustment for the gamma model requires extensive computational time for bootstrapping in this dataset 
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Table 16: Comparison of the best fitting parametric models compared to the Cox model for a sample population 
with both negative and positive FOBT results. Model coefficients, model constants, ancillary parameters, AIC, 
BIC, R2, D statistic and optimism adjusted performance metrics are presented for comparison. The R2 used in this 
instance is Royston and Sauerbrei’s (2004) R2D measure of explained variation for survival models based on their 
index of discrimination (D).73 The adjusted R2 measure also considers the number of covariates in the model. For 
non-proportional hazards models R2 for explained variation is not interpretable but can be used as an index of 
determination.74 
The calibration of the models as assessed through calibration plots (Figure 31) was also 
similar to the equivalent Cox Regression (Figure 22). The generalised gamma and the 
lognormal models had a similar pattern for the observed versus predicted risk groups and 
the Weibull model had a similar pattern as compared to the Cox Regression model. The 
generalised gamma model had the closest alignment to the 45 degree line (representing 
good calibration). Calibration would ideally be tested in an external validation scenario to 
determine whether significant recalibration was required in a different sample population. 
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Figure 30: Calibration plot of observed probability versus expected probability using the Generalised Gamma 
model (top), Weibull model (middle) and lognormal model (bottom) for a sample population with both negative 
and positive FOBT results. 
 
  
   
 
320 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
3.6 Multivariable Analysis Risk Prediction Model Development (n=95,792) 
 
3.6.1 Cox Regression for Negative Results Only (n = 95,792) 
 
This analysis allowed the identification of additional predictors which could be used in a 
screening population with negative results for screening referral decisions. 
The FOBT has only a sensitivity of around 50% and so other factors could be used to 
determine whether a patient should be referred if they have had a negative result. The 
probabilities derived for the model developed in those with a positive or negative FOBT 
reflects the underlying screening pathway whereby those with a positive result are referred 
on quickly for diagnostic testing and so have a higher probability of diagnosis. Therefore, 
Cox regression was used to investigate if the additional information from the electronic GP 
record could be used to make better screening referral decisions for those with negative 
FOBT results. After setting the data up for survival analysis, there were 95,792 observations 
with 587 events and 37,154,249.5 total analysis time at risk. The median follow up time in 
days was 384 (95% CI: 381 to 386). Restricted mean diagnosis-free survival was 726.5 days. 
The original model had 31 degrees of freedom with all predictors considered (39 when 
including interactions). 
Model building used the same ‘mfp’ function as described in Section 3.5 using a p value of 
0.05 for backwards elimination, for testing between multivariable fractional polynomials 
for continuous variables and for interactions. The final model (Table 17) after assessing all 
eligible predictors included; smoking status, whether a patient had an IBS diagnosis, 
previous polyps diagnosed, flatulence, weight loss, MCV of <80fL compared to a MCV of 
≥80fL, family history of gastrointestinal cancer, abdominal pain/antispasmodic prescription, 
diarrhoea, sex, age at FOBT and change in bowel habit. There were no significant 
interactions (interactions investigated included; smoking status and age, smoking and sex, 
MCV and sex, MCV and age, age and sex) and a linear model had the best fit to continuous 
predictors during multivariable analysis (age at FOBT was centred). 
Apparent model performance parameters included Harrell’s C statistic which was 0.658 
(95% CI: 0.633, 0.683) and Somers D 0.316. Harrell’s C statistic means that the predictors 
used in the model correctly identify the order of survival times for pairs of patients 66% of 
the time. The final model had 13 degrees of freedom with an AIC of 12493.68 and BIC of 
12550.56 (N=587 when calculating BIC)). Overall model fit was assessed using adjusted R2 
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which was 0.151 (bootstrapped CI 100 reps: 0.122, 0.204.73 78 Regular R2 was 0.164 (95% CI: 
0.126, 0.204) with D statistic of 0.906. 
 
 Variable Observed 
Coefficient 
Bootstrapped 
Standard 
Error 
z P>z [95% Confidence Intervals] 
Smoking Status:       
ex-smoker 0.285 0.105 2.720 0.006 0.080 0.491 
current smoker 0.516 0.150 3.450 0.001 0.223 0.810 
             
IBS 0.258 0.125 2.070 0.039 0.014 0.502 
Previous Polyps Diagnosed 1.225 0.132 9.250 0.000 0.965 1.484 
Flatulence Symptom Recorded 0.953 0.505 1.890 0.059 -0.037 1.944 
Weight loss 0.867 0.343 2.530 0.011 0.195 1.539 
MCV <80fL  0.877 0.291 3.010 0.003 0.306 1.447 
Family History of 
Gastrointestinal Cancer 0.603 0.248 2.430 0.015 0.117 1.089 
Abdominal pain/antispasmodic 
prescription recorded 0.365 0.126 2.890 0.004 0.117 0.612 
Diarrhoea symptom 0.572 0.157 3.640 0.000 0.264 0.880 
Sex -0.323 0.077 -4.180 0.000 -0.475 -0.172 
Age at FOBT 0.034 0.010 3.480 0.000 0.015 0.053 
Change in bowel habit 
symptom 0.793 0.273 2.900 0.004 0.257 1.328 
Table 17: Cox regression model (coefficients) after ‘mfp’ selection for patients with a negative FOBT only. The 
continuous variable age at FOBT has been centred (age_at_FOBT-66.97). 
 
The linear predictor from this model had a mean of 0.151 and a standard deviation of 0.451 
(range: -0.593 to 4.398). The distribution of the linear predictor is shown in Figure 31. 
Discrimination was also assessed by analysing the separation between Kaplan-Meier curves 
for 4 risk groups (where the linear predictor is divided into 4 groups). Separation was 
greater for those in the higher risk groups (group 3 and 4), but was smaller for risk group 1 
and risk group 2 (Figure 32). 
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Figure 31: Distribution of the linear predictor for the final multivariable model derived from a population with 
negative FOBTs only. 
 
Figure 32: Kaplan Meier curves for 4 risk groups, using the linear predictor which is divided into 4 using Cox’s 
method, for the model derived from a population with negative FOBTs only. 
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3.6.2 Adjusting for Optimism 
 
The optimism of the model was assessed by calculating Van Houwelingen’s heuristic 
shrinkage which was 0.932 ((191.417- 13)/ 191.417). The linear predictor was then 
reassessed after applying this shrinkage factor and compared to the original linear 
predictor this had a mean of 0.140 (SD: 0.421) and range -0.553 to 4.099 (Figure 33). The 
calibration slope after applying the shrunken linear predictor was 1.073. Figure 34 shows 
visually how the survival is adjusted after applying shrinkage for a high risk individual with a 
linear predictor of value 3.039 and a low risk individual with a linear predictor of -0.593. 
The calibration slope after adjusting for optimism was 1.073. 
 
Figure 33: Survival probability plot for a high risk participant using the original linear predictor 3.039 and 
shrunken linear predictor 2.833 (from the model developed from the sample population with negative FOBTs 
only) 
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Figure 34: Survival for a high risk individual with a linear predictor of 3.039 which is shrunk to 2.833 and a low 
risk individual -0.593 which is shrunk to -0.553 (from the model developed from the sample population with 
negative FOBTs only). 
 
The optimism adjusted values for the C statistic, c-slope, D statistic and R2 these 
performance parameters are displayed in Table 18.  The bootstrapped uniform shrinkage 
factor (based on the optimism adjusted c-slope value) is slightly higher (0.944) compared to 
the heuristic shrinkage (0.932).  
 
Statistic Apparent 
Performance 
Optimism (100 bootstrap 
replications) 
Optimism adjusted 
performance  
(apparent minus optimism) 
C statistic 0.658 0.008 0.650 
c-slope 1.000 0.056 0.944 
D statistic 0.906 0.070 0.836 
R2 0.164 0.020 0.144 
Table 18: Optimism calculated for the C statistic, c-slope, D statistic and R2 using 100 bootstrap replications and 
the corresponding optimism adjusted performance values (from the model developed from the sample 
population with negative FOBTs only). For bootstrap replications the seed was set as ‘231398’ in Stata. 
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3.6.3 Predicted Probabilities 
 
This analysis was performed to determine individual risk probabilities from the model and 
determine the distribution of risk in the sample population based on the predictors in the 
multivariable model.  
The baseline survival for the Cox model was estimated non-parametrically at 2 years as 
0.989. After shrinkage the baseline survival was estimated as 0.988. The shrunken baseline 
hazard was estimated using the heuristic linear predictor and is depicted graphically in 
Figure 35. To generate risk probabilities the heuristic linear predictor and the 
corresponding shrunken baseline survival were used for the final risk equation. The mean 
probability of being diagnosed with CRC or polyp within 2 years was 0.015 with standard 
deviation 0.010 (Range: 0.007, 0.503). This distribution is plotted below in Figure 36. The 
final risk equation for a high risk participant is shown in Equation 3. 
A Nomogram for this model as an alternative method of presenting the risk equation is 
provided in Figure 37. The Nomogram gives the survival probability and therefore to obtain 
the event probability this would need to be subtracted from 1. 
 
Figure 35: Baseline survivor versus the shrunken baseline survivor derived from the model developed for a 
population with negative FOBTs only. The shrunken baseline survival at 2 years was estimated by setting the 
shrunken linear predictor as an offset and predicting the subsequent baseline survival. 
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Figure 36: Histogram of the individual probabilities of being diagnosed with colorectal cancer/polyp in a 2 year 
period for the model derived from a sample population with negative FOBTs only. This model uses the heuristic 
linear predictor and the corresponding shrunken baseline survival to generate event probabilities. 
Survival Probability 
S(2) = S0(2)exp(LP) 
Where LP is the linear predictor and S0(2) is the baseline survival at 2 years. 
Event Probability 
P = 1 – S(2) 
High risk Participant Example: 
Survival Probability: 
0.82114774 = 0.9884683exp(2.8325753) 
Event Probability:  
0.17885226 = 1-0.82114774 
The probability of being diagnosed with CRC in a 2-year period for a high risk individual is 0.18. 
 
Full Equation: 
 
Survival Probability 
𝑆(2) = 0.989exp(0.29𝑥1+⁡0.52𝑥2+⁡0.26𝑥3+⁡1.23𝑥4+⁡0.95𝑥5+⁡0.87𝑥6+⁡0.88𝑥7+⁡0.60𝑥8+⁡0.37𝑥9+⁡0.57𝑥10+⁡(−0.32)𝑥11+⁡0.03(𝑥12−66.97)+⁡0.79𝑥13) 
 
0.988 = the baseline survival at 2 years S0(2) 
Where S(2) is the survival probability at 2 years (probability of not being diagnosed with colorectal cancer/polyps) 
 
Event Probability 
P = 1 – S(2) 
Where P is the probability of colorectal cancer/polyp being diagnosed within 2 years of the latest FOBT date; 𝑥1 ex-smoker; 𝑥2 
current smoker; 𝑥3 IBS; 𝑥4 previous polyps; 𝑥5 flatulence; 𝑥6 weight loss; 𝑥7 MCV <80fL; 𝑥8 family history of gastrointestinal 
cancer; 𝑥9 abdominal pain; 𝑥10 diarrhoea; 𝑥11 sex; 𝑥12 age at FOBT; 𝑥13 change in bowel habit.  
 
Equation 3: Final risk equation for the model derived from participants with negative FOBT only, using the 
shrunken baseline survival and the shrunken linear predictor values to correct for optimism. 
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Figure 37: Nomogram for the final Cox Regression model for participants with a negative FOBT only which gives the colorectal cancer/polyp free survival 
probability. To obtain the event probability subtract the survival probability from 1.
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3.6.4 Calibration 
 
A calibration curve for the multivariable model adjusted for optimism is presented below 
for deciles of risk (Figure 38). Compared to the multivariable model including the FOBT 
result, the spacing between groups was more even but there was still a higher risk group, 
possibly due to the presence or absence of a strong predictor (e.g. previous polyps). In 
addition, most of the groups lie close to the line of equality, indicating good calibration. 
 
Risk Group 
Calibration Expected 
Probability 
Calibration Observed 
Probability 
Calibration observed 
lower bound 
Calibration observed 
upper bound 
1 0.008 0.007 0.012 0.004 
2 0.009 0.009 0.013 0.006 
3 0.010 0.009 0.013 0.006 
4 0.011 0.008 0.013 0.005 
5 0.012 0.011 0.016 0.008 
6 0.013 0.012 0.017 0.008 
7 0.014 0.020 0.026 0.015 
8 0.016 0.020 0.026 0.015 
9 0.019 0.017 0.022 0.013 
10 0.036 0.034 0.042 0.028 
Figure 38: Calibration plot of observed probability versus expected probability using the multivariable model of 
participants with negative FOBTs only. The corresponding risk groups for each decile of probability are presented 
in the table below the figure. 
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3.6.5 Cox Regression Diagnostics 
 
As with the model including both negative and positive FOBT results, Schoenfeld residuals 
were examined to test the proportional hazards assumption of the Cox Regression model 
(Appendix 7 for full results). Predictors with a p value of less than 0.05 included; smoking 
status (previous smoker) and age at FOBT. In addition, the global test of proportional 
hazards had a p value of 0.016. This statistical test is dependent on sample size and so the 
larger sample size means significance is more likely to be detected. Scaled Schoenfeld 
residual plots (Figure 39) along with the log-log plots (Figure 40) were plotted for these two 
significant variables. The Schoenfeld residual plots have a roughly straight line but the log-
log plots suggest they potentially violate the proportional hazards assumption. 
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Figure 39: Schoenfeld residual plots for variables which had a p value of <0.05 when testing the proportional 
hazards assumption in the multivariable model with negative FOBTs only. These variables included: ex-smoker 
(1st plot), age at FOBT (2nd plot). 
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Figure 40: Log-log plots to test the Cox proportionality assumption for smoking status (1st plot), and Age group 
(2nd plot - which was split into 2 equally sized groups) in the multivariable Cox Regression Model with negative 
FOBTs only. 
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The overall model fit was assessed using Cox-Snell residuals (Figure 41). The cumulative 
hazard function deviates from the line at the tail end but roughly follows an exponential 
distribution with a hazard rate of one. Parametric survival models were subsequently 
investigated to determine whether these more flexible models have a better fit. 
 
Figure 41: Assessment of overall model fit of the Cox Regression model (negative FOBTs population) using Cox-
Snell residuals and plotting the Nelson-Aalen cumulative hazard function against Cox-Snell residuals. For a good 
model fit, the cumulative hazard function should follow the Cox-Snell residuals. 
 
3.6.6 Parametric Survival Models 
 
Parametric models were investigated as an extension to Cox Regression to determine 
whether these types of model gave a better fit to the data. 
The AIC was used to compare the different parametric survival models (Table 19). The 
smallest AIC was achieved with the Gompertz model. Gompertz models are usually used for 
growth data where the shape of the hazard distribution is always increasing.40 The 
suitability of this model to the data may be because the number of events appears to 
increase after year two when analysing the KM survival probability curve. 
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Model 
Observatio
ns 
Log likelihood 
null 
Log likelihood 
model 
Degrees of 
freedom AIC BIC 
Exponential 587 -3866.88 -3771.922 14 7571.844 7633.094 
Weibull 587 -3840.105 -3744.628 15 7519.257 7584.882 
Gompertz 587 -3829.577 -3733.873 15 7497.746 7563.371 
Lognormal 587 -3851.828 -3754.748 15 7539.495 7605.121 
Loglogistic 587 -3840.337 -3744.852 15 7519.705 7585.33 
Generalised 
Gamma 
587 -3839.875 -3744.424 16 7520.848 7590.848 
Table 19: Model parameter comparisons for the parametric models derived from a sample population with 
negative FOBTs only. 
 
Overall model fit of the different parametric models was assessed using Cox-Snell residuals 
(Figure 42). Visually, the Gompertz and generalised gamma model have the better fit to the 
data compared to the other parametric models. The Nelson Aalen cumulative hazard plots 
had a very similar fit to the data for all the models (Figure 43). Finally, the Gompertz Kaplan 
Meier function plot had the best fit between the models (Figure 44).  
The coefficients for the Gompertz model are reported in Table 20. 
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Figure 42: Cox Snell Residuals plotted for all considered parametric models, derived from a sample population 
with negative FOBTs only, to assess model fit. 
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Figure 43: Nelson-Aalen cumulative hazard plots for all considered parametric models, derived from a sample 
population with negative FOBTs only, to assess model fit. 
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Figure 44: Kaplan-Meier function graphs for all considered parametric models, derived from a sample 
population with negative FOBTs only, to assess model fit 
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3.6.7 Model Performance measures for the best fitting parametric models 
 
Based on the AIC value which allows assessment of the relative fit of all the parametric 
models and the plots presented in the previous section, the Gompertz model had the best 
fit to the data. Table 20 shows the coefficients and the discrimination of the model in 
comparison to the Cox Regression model. Both the hazard ratios and coefficients are 
presented to aid comparison. The Gompertz and Cox regression models have very similar 
coefficients and the same discrimination as reflected by Harrell’s C statistic (95% CI: 0.658, 
0.633, 0.683). The Gompertz model has slightly less optimism as shown by the C-slope 
0.950 versus 0.944 but the differences between the two models are negligible. 
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 Variable Gompertz 
coefficients (PH) 
Gompertz Hazard 
Ratios (PH) 
Cox 
coefficients 
Cox Hazard Ratios 
Smoking Status:     
ex-smoker 0.286 1.331 0.285 1.330 
current smoker 0.521 1.684 0.516 1.676 
        
IBS 0.258 1.295 0.258 1.294 
Previous Polyps Diagnosed 1.225 3.4055 1.225 3.403 
Flatulence Symptom Recorded 0.959 2.610 0.953 2.594 
Weight loss 0.864 2.373 0.867 2.379 
MCV <80fL  0.877 2.403 0.877 2.403 
Family History of Gastrointestinal 
Cancer 
0.604 1.829 0.603 1.828 
Abdominal pain/antispasmodic 
prescription recorded 
0.364 1.439 0.365 1.440 
Diarrhoea symptom 0.575 1.776 0.572 1.772 
Sex -0.325 0.722 -0.323 0.724 
Age at FOBT 0.033 1.034 0.034 1.035 
Change in bowel habit symptom 0.788 2.199 0.793 2.209 
Constant 
-11.878 
6.94E-06 
 
- - 
Ancillary parameter 0.002 0.002 - - 
Log likelihood -3733.873 -6233.842
a 
AIC 7497.746 12493.680
a 
BIC (n=587) 7563.371 12550.560 
Harrell’s C Statistic (95%CI) 0.658 (0.633, 0.683) 0.658 (0.633, 0.683) 
R2 0.164  0.164  
D Statistic 0.906 0.906 
Adjusted R2 (Bootstrap CI 100 
replications) 
0.151 (0.113, 0.192) 0.151 (0.113, 0.191) 
Optimism adjusted Calibration Slope 
(also shrinkage factor for linear 
predictor) 
0.950 0.944 
Optimism Harrell’s C Statistic 0.650 0.650 
Optimism adjusted D statistic 0.852 0.836 
Optimism adjusted R2 0.147 0.144 
a The log likelihood/AIC/BIC from the Cox model is not comparable to parametric models since it uses partial likelihood 
whereas the other models use full maximum likelihood. 
Table 20: Comparison of the best fitting parametric model compared to the Cox model for a sample population 
with negative FOBT results. Model coefficients, model constants, ancillary parameters, AIC, BIC, R2, D statistic 
and optimism adjusted performance metrics are presented for comparison. The R2 used in this instance is 
Royston and Sauerbrei’s (2004) R2D measure of explained variation for survival models based on their index of 
discrimination (D. 73 The adjusted R2 measure also considers the number of covariates in the model. For non-
proportional hazards models R2 for explained variation is not interpretable but can be used as an index of 
determination.74 
A calibration plot for the Gompertz model is presented in Figure 45 below.  The decile 
groups show a similar pattern along the 45 degree line to the Cox regression calibration 
plot in Figure 38. These investigations suggest that the Gompertz model has a very similar 
fit to the Cox model. The advantages of the parametric models over their semi-parametric 
  
 
343 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
counterpart is that provided the underlying assumptions are true, they can give more 
precise parameter estimates. Furthermore, parametric models give greater flexibility with 
post-estimation since they can provide predicted survival and hazard functions, median 
survival times as well as predicted probabilties at different timepoints without a need to 
estimate the baseline hazard using non-parametric methods. 
 
Figure 45: Calibration plot of observed probability versus expected probability using the Gompertz parametric 
model for a sample population with negative FOBTs only. 
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4.0 DISCUSSION 
4.1 Statement of principal findings 
 
This chapter used the THIN database of anonymised GP records to investigate the 
availability of GP data for key predictors of colorectal cancer in the screening population 
and used these data to determine whether additional predictor information can be used to 
make more accurate screening referral decisions by developing two multivariable 
prediction models.  Descriptive analyses included determining diagnostic accuracy results 
of the FOBT and survival analyses investigating time to diagnosis (colorectal cancer free 
survival) and time to all cause death (overall survival) stratifying by FOBT result, sex and 2 
by 2 category (TP, TN, FP, FN). 
The test positivity (2.18% for the overall cohort), sensitivity (52.8%) and specificity (96.3%) 
of the guaiac FOBT were calculated for the derived screening population and were found to 
be similar to reported values in the literature.76 6  
Survival analysis based on time to diagnosis (colorectal cancer free survival) and time to 
death (overall survival) was investigated for the screening cohort stratified by FOBT result 
and sex. Patients with a positive FOBT had a much sharper rate of decline in survival 
(increase in diagnosis) compared with a negative test result (significant log-rank test for 
equality p<0.001). Males have a significant reduction in survival (increase in colorectal 
cancer/polyp diagnoses) over time compared to females for the two year follow up period.  
For time to all cause death, people with a positive FOBT were at increased risk for first 1250 
days, for the last 1000 days those with negative FOBT results appear to be at greatest risk. 
In addition, Kaplan Meier curves were plotted for TP, TN, FP, FN results for time to 
diagnosis and time to all cause death. For time to all cause death, the FNs end up doing 
worse later on than the TPs at around 1000 days, this could be due to the effects of late 
diagnosis for FNs as they are less likely to have had diagnostic follow up/further 
investigations compared to TPs. In addition, FNs could have more aggressive cancers that 
develop after screening and TPs present at an earlier stage. FPs also appear to have less 
diagnoses than TNs possibly due to having some sort of diagnostic investigation putting 
them at lower risk of CRC compared to TNs. 
Symptoms and diagnoses as binary parameters were 100% reported if a patient had 
consulted their GP. Lab measurements including platelet count, MCV and haemoglobin 
concentration were recorded for about 45% of those adequately screened with a positive 
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or negative FOBT result. Ferritin was less well reported at around 8.59%. Lifestyle factors 
such as smoking status were extremely well recorded (99.42%) and alcohol consumption 
was also fairly well recorded at 78.00%. 
Univariable Cox Regression revealed that screening history variables such as previous 
positive FOBT results and previous polyps diagnosed had the largest observed hazard ratios 
at 5.032 (CI:4.184-6.052) and 3.182 (CI:2.503-3.883) respectively. Rectal bleeding or 
melaena was the symptom with the highest HR 3.118 (2.503-3.883). Age, BMI and Alcohol 
consumption were all significant and females were at lower risk of colorectal cancer/polyp 
diagnosis than males (HR 0.656: CI 0.609-0.706). 
After these investigations, a multivariable Cox Regression model was built for the screening 
population with a positive or negative FOBT result (n=98,303). This model combined the 
FOBT result with other risk factors to identify additional predictors which could be included 
in a risk based model to make more accurate screening referral decisions. The final model 
included the following variables: FOBT result, smoking status, whether a patient had a 
diagnosis of Crohn’s disease, previous polyps diagnosed, flatulence, MCV of <80fL 
compared to a MCV of ≥80fL, alcohol consumption in units per week, family history of 
gastrointestinal cancer, abdominal pain/antispasmodic prescription, diarrhoea, sex, age at 
FOBT and change in bowel habit. Significant interactions at the 0.05 p value level included 
FOBT result and age and MCV and age.  
The optimism of the model was assessed by calculating Van Houwelingen’s heuristic 
shrinkage which was 0.995 and was applied to the linear predictor. The calibration slope 
after applying the shrunken linear predictor was 1.005. The shrunken linear predictor had a 
mean of 0.135 (SD: 0.685) and range -1.365 to 5.728. Internal validation using 100 
bootstrap replications was used to adjust the performance parameters for optimism giving; 
a C statistic of 0.850, c-slope of 0.991, D statistic 2.298 and R2 of 0.558. To generate risk 
probabilities both the heuristic linear predictor and the corresponding shrunken baseline 
survival were used for the final risk equation. The calibration plot shows the 10th group was 
far removed, most likely due to whether an individual has either a positive or negative 
FOBT. 
Overall model fit was assessed using Cox-Snell residuals and revealed that a semi-
parametric model may not provide the best fit to the data as the cumulative hazard 
function did not appear to have an exponential distribution with a hazard rate of one. The 
best fitting parametric survival models based on the AIC, cumulative hazard plots, Kaplan 
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Meier function plots and Cox-Snell residuals was the generalised gamma model. This model 
had similar discrimination (0.859 (95% CI: 0.845, 0.872)) to the Cox model (0.854 (95% CI: 
0.841, 0.868) and the observed versus predicted risk groups were slightly closer to the 45 
degree line on the calibration plots but were also comparable to the Cox model. A Wald 
test for the hypothesis of the kappa ancillary parameter of the gamma model being equal 
to 1 was significant suggesting a potentially good fit for the Weibull model also (C-statistic 
0.854 (95% CI: 0.841, 0.868)). 
Cox regression was then used to investigate additional predictors which could be used in a 
screening population with negative results (n=95,792) for screening referral decisions. The 
model was built using the same methods described above. Predictors which could be used 
to determine the risk of whether an individual has colorectal cancer/polyps included; 
smoking status, whether a patient had an IBS diagnosis, previous polyps diagnosed, 
flatulence, weight loss, MCV of <80fL compared to a MCV of ≥80fL, family history of 
gastrointestinal cancer, abdominal pain/antispasmodic prescription, diarrhoea, sex, age at 
FOBT and change in bowel habit.  
Van Houwelingen’s heuristic shrinkage which was 0.932 was applied to the linear predictor. 
The shrunken linear predictor had a mean of 0.140 (SD: 0.421) and range -0.553 to 4.099. 
Internal validation using 100 bootstrap replications was used to adjust the performance 
parameters for optimism giving; a C statistic of 0.650, c-slope of 0.944, D statistic 0.836 and 
R2 of 0.144. Absolute risk probabilities were produced using the shrunken linear predictor 
and baseline survival. The calibration plot produced showed better separation than the 
previous model due to the removal of FOBT. 
Parametric survival models were also investigated, with the Gompertz model having the 
best fit based on the AIC, cumulative hazard plots, Kaplan Meier function plots and Cox-
Snell residuals. The discrimination of the model was the same as the Cox regression model 
(C-statistic 0.658 (95% CI: 0.633, 0.683)) with a similar calibration as shown in the 
calibration plots. This suggests that a Cox regression model has the same performance in 
this sample population.  
  
  
 
347 
 
Chapter 5 Chapter five | Use of electronic GP data to improve CRC screening referral decisions 
4.2 Strengths and weaknesses of the study 
 
A major strength of the study is the sample size used for assessing test accuracy measures, 
survival analysis and developing the multivariable prediction models. The screening 
population derived from THIN can be considered representative of the average risk 
screening population when assessing demographic factors and test accuracy measures. 
The AEB date was derived as part of this THIN work and defines the start date at which GP 
practices started to receive electronic notifications from the NHS BCSP. This date acts as a 
level of quality assurance since before this date, paper records would have used and there 
would have been a bias to recording positive FOBT results. The electronic notifications use 
the same system as Pathlinks for laboratory test results. The AMR date was also identified 
for each practice as another level of quality assurance. Before this date each practice may 
not have routinely recorded patient deaths and de-registrations. Patflags (patient flags 
assigned by THIN) were used to check the integrity of the data and ensure quality. 
The QOF is an incentive programme for GP surgeries. Achievement points have been 
introduced for various conditions which has helped to improve recording of certain 
parameters in GP records. For instance, practices regularly record smoking status as part of 
the QOF. For Additional Health Data (AHD) variables (laboratory parameters) an external 
dataset was used to define the range of expected values to remove potential outliers and 
ensure the distribution of results were similar in the THIN dataset compared to routine lab 
measurements. This is reported further in Chapter 6. 
The extensive number of CRC predictors examined give an indication of what might be 
important for a screening population. The methods used to derive these data using Read 
codes and other strategies were thorough and subjected to review by two people, 
improving the reliability of the data extracted and giving confidence to the associations 
identified. This is also reported further in Chapter 6. 
Model development used the latest recommended methods in this field to ensure a 
reproducible, generalizable and well discriminating model was produced. For instance, the 
model was subjected to internal validation, used an appropriate sample size with enough 
events, was corrected for optimism, optimism adjusted performance measures were 
reported using bootstrapping and the model coefficients along with the baseline survival at 
2 years were supplied. Model development followed the TRIPOD guidelines and applied the 
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recommendations from the systematic review in Chapter 2 in terms of improving reporting 
of risk prediction studies. 
Limitations include those which relate to the study and those which relate to the GP record 
database. The sample size for model development was reduced based on using complete 
variable data. The factors which limited the sample size for this investigation were the 
laboratory results (Hb concentration, platelet count and MCV). The cancer/polyp detection 
rate for those with a laboratory record (for all three results) was around 1.19% and those 
without 0.83% (Pearson’s chi-squared p=<0.001). Multiple imputation was considered, 
however the missing data mechanism for the majority of these predictors would be 
‘Missing not at random’ (MNAR). Individuals who have a blood test result for example are 
more likely to have this investigation based on suggestive symptoms of a particular 
underlying disease. Furthermore, a study found that weight and blood pressure may be 
MAR (Missing at Random) but for lifestyle factors smoking and alcohol consumption, these 
were not MAR.80 This may have a corresponding effect on model parameter estimates. 
When assessing whether covariates followed the proportional hazards assumption, the 
Schoenfeld residual analyses and log-log plots suggested that some of the variables 
violated this assumption. However, since this research uses a reasonably large dataset 
there is a lot of power to detect small deviations. To deal with the potential non-
proportional hazards for some of the covariates, a time dependent variable can be included 
for the non-proportional predictors or the model can be stratified by the predictor. An 
alternative solution is to fit a model which does not have the proportional hazards 
assumption. 
The recording of cancer diagnoses could be enhanced using data linkage to cancer 
registries. For example, cause of death from the ONS could be used to improve reliability of 
results. Electronic recording of the cause of death has been shown to be incomplete even 
when free text entries are reviewed.81  
Not all patients will go to see their GP if they have symptoms, this study focussed on 
reported symptoms which could underestimate the number of people who actually have 
symptoms. This would mean that HRs could be underestimated if they are not reported.  
The screening population are different to those who present to primary care. However, 
steps were made during this analysis to define a screening cohort by limiting to those aged 
between 60-74 and those with a BCSP FOBT electronic result. The test accuracy measures, 
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sensitivity and specificity, of the FOBT were similar to those reported in other studies 
providing a layer of data validity.  
Limitations specific to primary care databases are that the data are collected during routine 
practice or consultation and therefore not primarily collected for research. There are 
several limitations arising from this, particularly in relation to missing data.82 For example, 
in primary care records there may be recording errors, incomplete data, misclassification 
(e.g. ex smoker as non smoker),83 variations in GP practice recording (Read codes, different 
operating systems, administrative procedures) or missed information from secondary care 
and pharmacies. Furthermore, data recording practices can change from outside influences 
such as the Quality Outcomes Framework (QOF) or from NICE guidance in England. 
Pathology and other laboratory test results (e.g. bowel cancer screening test results) were 
previously sent by letter, this has evolved over time due to increasing computerisation into 
electronic notifications, which may be considered more complete and less biased towards 
the recording of positive results. Furthermore, the frequency of the ‘Anaemia’ Read code in 
a recent prediction modelling study was found to decline in use over time, with a 
corresponding increase in the recording of a haemoglobin result.84 GP behaviour will also 
affect coding of information, for example they may have a preference to use certain codes 
or to record certain prescriptions or to justify the prescription of a particular drug. During a 
consultation, a GP may not record every symptom but may record the key features 
associated with a diagnosis. ‘Change in Bowel habit’, a predictor for colorectal cancer for 
instance was found to be used differently to recording a symptom of diarrhoea or 
constipation by GPs.84 
Incomplete data can lead to bias in parameter estimates or in sample selection (selection 
bias). Confounder variables and health indicators often have missing data.80 There are 
several strategies to deal with missing data which may give more precise parameter 
estimates and reduce selection bias.85 Multiple imputation for instance accounts for the 
uncertainty of missing data by producing multiple imputed datasets and combining the 
results across these datasets.85 86 This statistical approach can be used if the data are 
considered ‘missing at random’ (MAR) and leads to more accurate standard errors and p-
values compared to other methods.87 A ‘compete cases’ approach is often used by 
researchers, which can lead to biased estimates of predictor-outcome associations if 
missingness is associated with the outcome. Biased model performance estimates when 
compared to using the whole dataset and can also affect generalizability of the model.87 
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The removal of subjects due to the missingness of several different variables can lead to a 
reduction in the sample size causing a loss of power and therefore less precise parameter 
estimates. Other statistical approaches for handling missing data include creating a 
‘missingness category’ for the variables with missing data. This approach can fail to adjust 
correctly for confounding, introducing bias and is generally not recommended.87 88 Creating 
a ‘missingness category’ also leads to the categorisation of continuous predictors which in 
turn leads to a loss of information and is not recommended for risk prediction model 
development.89 90 Other strategies which are also considered biased include ‘last 
observation carried forward’, or ‘imputing the mean’ determined from the observed data; 
these approaches however do not account for the uncertainty of the missing values leading 
to standard errors which are underestimated.85  
Although multiple imputation is considered the least biased approach to handle missing 
data, there are issues with applying this method when using primary care data because the 
information is recorded for a clinical reason. For instance, a study investigating missing data 
in THIN and comparing results obtained using multiple imputation to two nationally 
representative datasets (The Health Survey for England and The British Regional Heart 
Survey) found that data was not missing at random for smoking and alcohol consumption.80 
A further example as described above is the use of lab test results or pathology data before 
the introduction of electronic notifications. Positive results from these laboratory tests 
were more likely to be recorded than those with normal results which would bias 
predictor-outcome associations. When data is not missing at random, it is suggested that 
sensitivity analyses investigating different missingness assumptions could be conducted; 
this approach could be considered in future EHR research.85 Missing data present in this 
study was reported fully using study flow diagrams and includes percentage completeness 
of variables so researchers can assess the applicability and generalizability of study findings 
for future prediction models.  
4.3 Strengths and weaknesses in relation to other studies 
 
The only study identified as using survival analysis modelling techniques from the 
systematic review in Chapter 2 was by Yen et al.1 . For this study, the FIT was combined 
with conventional risk factors obtained from a questionnaire along with lab results 
(triglyceride levels). This study used a cohort from Taiwan invited to population-based 
screening for colorectal neoplasia (n=54,921) to develop the model and another two 
datasets combined for external geographical validation (n=17,085). For the model 
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combining FIT with other factors to predict colorectal neoplasia, the AUC ROC was 0.835 
(95% CI: 0.821-0.849) in the development dataset and 0.861 (0.852-0.869) in the validation 
dataset. Although not directly comparable as this used an accelerated failure time model, 
the C statistic for the present study was 0.850 (adjusted for optimism) for the model which 
combined the FOBT with other risk predictors. The gFOBT has lower test accuracy than FIT 
but still had similar discriminatory power when including the other routinely available 
predictors. This study also has the advantage of using routine data instead of requiring 
further lab tests and questionnaires. 
There is differential verification of cancer in this dataset because it is real world data. 
Patients with a positive FOBT will have been offered further testing, increasing the 
probability of detecting cancer if present. Patients with a negative FOBT are less likely to 
have cancer if present, because they are likely to have fewer follow up tests over the 2 year 
period. Therefore, the model may overestimate the predictive power of FOBT and other 
variables used in the current pathway to determine whether to refer for colonoscopy, and 
underestimate the predictive power of those variables not used in the referral pathway. 
This is a necessary limitation of using routine data. Therefore this model can be used to 
highlight potential predictors for future models, but not necessarily to calculate absolute 
predictive ability due to the effects of the underlying screening pathway on model 
parameters. 
A survival analysis approach was taken to enable use of the longitudinal data, rather than a 
logistic regression model based on the sum of events in the 2 year period. Other similar 
studies which have investigated the risk of colorectal cancer in primary care from the 
presence of clinical features have used logistic regression to quantify the associations.20 21 
Survival analysis is a more efficient use of longitudinal primary care data which allows us to 
maximise events at the tail end and can take individual follow up into account compared to 
logistic regression. In addition, cancer detected soon after testing is more relevant to 
screening than a cancer detected 2 years later. On the other hand, the disadvantage of this 
approach is the greater weight given to earlier events as a result of follow up tests post 
positive FOBT, so may increase the effects of differential verification. 
Yen et al.1 adjusted the time to event for individuals with a FIT result of ≥100 ng/ml due to 
the earlier detection of colorectal cancer/adenoma within these individuals. A correction 
factor was applied to adjust the time to event for these individuals, a similar approach 
could be considered for the model developed in this study as those with positive FOBTs 
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would have quicker diagnosis due to the screening pathway. The dichotomised outcome 
makes this more complex but could be considered in future iterations. 
Perhaps the most comparable study is the model developed by Hippisley-Cox and 
Coupland15 who derived a risk prediction model using the QResearch database and Cox 
Regression to predict current colorectal cancer. This model was developed for use in a 
primary care setting to facilitate early referral for patients at high risk of existing colorectal 
cancer. Predictor variables retained in the final model included, age, family history of 
gastrointestinal cancer, anaemia, rectal bleeding, abdominal pain, appetite loss and weight 
loss (alcohol status and recent change in bowel habit were also significant for males). These 
predictors retained in the final model are similar to the predictors included in the final 
model in the current study. The AUC ROC was 0.89 for females and 0.91 in males in the 
validation sets. This has slightly higher performance than the current study (C statistic: 
0.850) but this model is used in a screening setting to predict both colorectal cancer and 
polyps. Both the current study and the study by Hippisley-Cox and Coupland15 estimate the 
baseline hazard by setting the covariates equal to zero, it may be better to centre the 
predictors by their mean in order to get the survival probability with the average of these 
predictors/characteristics for a person with average characteristics (e.g. age, gender, 
symptoms). 
4.4 Practical implications 
 
This is an exploratory analysis investigating the potential use of GP records in informing 
screening based decisions for Colorectal Cancer. The FIT will be implemented in Summer 
2018 in the NHS Bowel Cancer Screening Programme and this test will most likely have its 
own set of SNOMED codes to electronically notify GP practices about results. After a few 
years of follow up of this test, the methods used in this analysis can be repeated to look at 
the potential impact of combining the FIT (continuous test) with other risk factors (as 
opposed to the FOBT) which may enhance model performance and test accuracy further.  
Most factors retained in the multivariable model have a high level of recording. Laboratory 
parameters are the factors least well recorded and would only be requested if a GP 
suspects underlying abnormalities based on symptoms. Evidence suggests that blood 
results are important indicators of underlying cancers and other conditions.24-27 Other 
studies have shown the merit of using blood test results combined with screening tests.28 30 
FOBTs on their own may miss intermittent or low level bleeding whereas a blood 
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parameter such as anaemia (Hb Concentration) may detect these scenarios. The added 
effect of lab data may help to reduce false negatives and false positives from the screening 
test. Routine blood test results for those in the screening age range could be implemented 
in the future. For example, the NHS Health Check is offered to individuals aged 40-74 and 
this could include routine blood tests. 
After a positive FOBT, individuals are referred on to a specialist screening practitioner to 
discuss the positive result and suitability for colonoscopy. Not all individuals attend the SSP 
clinic (around 6%) and not all even if suitable for colonoscopy go on to have the diagnostic 
test (83% attend diagnostic examination).77 By having an indication of an individual’s risk of 
bowel cancer being diagnosed at colonoscopy compared to average, this could help both 
the patient and screening practitioner make a more informed clinical decision. Risk 
information can be presented to potentially help informed decision making and increase 
uptake of the reference standard as well as the screening test.91 92 If an individual has a lack 
of perceived risk, this can affect uptake. A nomogram, such as the one presented for the 
multivariable model in Section 3.6.3 could be used for this purpose. 
The choice of a parametric model over a semi-parametric one in this instance depends on 
several aspects including model performance parameters, clinical scenario, external 
validation and practical application. The Cox model has the most flexibility and is the most 
commonly implemented model in the literature with fully developed methods and 
applications. Furthermore, Cox Regression could be preferred for out of sample validation 
due to published guidance on the appropriate methods.63 Parametric models on the other 
hand can provide more precise parameter estimates provided the underlying assumptions 
are true and generally provide smooth estimates of the hazard and survival function.33 They 
allow the baseline hazard to be determined at many different time points enhancing post-
estimation measures. From a prediction modelling standpoint, this allows 
predictions/probabilities to be estimated at a range of different time values (e.g. 6 months, 
1 year, 2 years) with potentially more accuracy.  
In this study, the Nelson-Aalen cumulative hazard increases constantly for about 550 days 
and then has a sharper increase for the last 180 days for those with negative results. The 
performance of the parametric models compared to the Cox regression model was very 
similar and so the choice of model may come down to individual considerations. The 
covariate effect estimates for the scenario with negative FOBT results only showed very 
similar results between the Gompertz model and the Cox Regression model. The 
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generalized gamma model has three parameters so can fit the tail end of the data better 
compared to the other model types. The computational time was significantly longer when 
fitting the generalized gamma model over the other AFT models (and Cox regression) for a 
population with positive and negative FOBT results which can suggest difficulty with model 
convergence. External validation of model performance may show more difference 
between model types, although internal validation with bootstrapping did not show much 
difference between the models in this instance. In order to make out of sample predictions 
for the Cox model special measures such as interpolation or extrapolation are required 
which can limit its application.33 Flexible parametric models allow the hazard to be 
modelled more closely and can provide more accurate parameter estimates and 
predictions. If the parametric models showed a significant improvement in model 
performance then this could have provided further justification to investigate a flexible 
parametric model. These models tend to have a better fit but can be difficult to interpret 
and may overfit to the data which will have repercussions on external validation 
performance and generalisability. 
4.5 Future Research 
 
When patients sign up to a GP practice, their details are uploaded to the NHS Information 
Authority. The NHS Spine draws out these registration details over-night. Correspondingly 
the details of everyone who falls within the age range of screening (60-74) is extracted to 
the BCSS overnight to gain new patient details. The Spine is set to what information is 
drawn from the GP practice, but there is capacity to draw out additional information to the 
BCSS. The factors shown in this study to be predictive of colorectal cancer could be 
considered in the future to combine with the screening test to identify those at highest risk 
and who would benefit most from colonoscopy.  
This approach could be considered for a future risk based project once the FIT is 
implemented and the new SNOMED coding system defined for this test. There would be 
many issues relating to quality of data, how the data are handled by the GP and the use of 
different GP operating systems in the NHS. Health systems in the UK are also transitioning 
over to SNOMED CT clinical terminology and so Read codes will eventually cease to be 
used. As the FIT is implemented in the UK, GP records will begin to obtain more data on the 
FIT. The approaches used in this chapter could be used to investigate prediction models 
combining this newer test.  
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Although parametric models were investigated to determine whether these provided a 
better fit compared to using a Cox Regression model, the baseline hazard shape could be 
modelled better (particularly for the model combining FOBT with risk predictors) using a 
flexible parametric survival model. Royston-Parmar models are flexible parametric models 
which use restricted cubic splines to model the baseline hazard more closely.33 This model 
can be used to derive hazard ratios which give similar results to Cox Regression and can be 
used to produce absolute risk predictions.  
Personalised screening intervals could be investigated by plotting Kaplan Meier curves for 
time to diagnosis over 5 years stratified by a risk prediction model with different patterns 
of covariates. There is research to suggest, that the haemoglobin concentrations detected 
by the FIT are associated with the detection of adenomas in future screening rounds.93 
Other factors combined with the FIT could also be used to examine detection in future 
screening rounds. 
Longitudinal recording of laboratory test results and FIT screening results may provide an 
additional layer of information contributing to a risk score. This study considered predictors 
which were available/measured at the time of entry to the study with a time limit to ensure 
that the predictor was associated with the outcome if recorded. Further risk information 
can be derived by looking at the longitudinal change in certain parameters for instance lab 
test results. These are time dependent covariates and there are other survival analysis 
methods which can be used to capture this information over time. 
These models were developed for an English screening population utilising the NHS BCSP 
and the BCSS to record screening information. Scotland, Wales and Ireland have their own 
IT systems and procedures to notify GPs of results. In addition, Read codes are utilised in 
different ways according to the regions. Future research could look at developing models 
for different regions which would require different Read codes/clinical codes and IT 
screening systems. 
5.0 CONCLUSIONS 
 
This chapter has shown that there are several clinical predictors available from GP 
databases which are associated with colorectal cancer and polyps for an English average 
risk screening population. Furthermore, this research has identified predictors which could 
be considered for inclusion in a future risk adjusted screening model. Most factors 
contributing to the risk based models are well recorded. Laboratory parameters although 
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shown to be associated with colorectal cancer diagnosis are the least well recorded factors 
included in the final risk prediction model. Further data could potentially be drawn from 
primary care onto the BCSS for use in screening referral algorithms. Additional predictors 
which could be considered for inclusion in a future risk adjusted model include those which 
relate to screening history which have a strong association with the diagnosis of colorectal 
cancer/polyps (previous positive FOBT results and previous polyps diagnosed). Previous 
polyps diagnosed retained significance in both multivariable models. Interestingly, lifestyle 
factors, alcohol consumption and smoking status, were significant in the model for positive 
and negative FOBT results but just smoking in the model for negative FOBTs only (most 
likely explained by other variables within this model). Family history of gastrointestinal 
cancer was a strong predictor independently and in both multivariable models. Other 
variables common to both models included demographic characteristics age and sex as well 
as the following symptoms: abdominal pain/antispasmodic prescription, diarrhoea, change 
in bowel habit and flatulence.  Finally the blood test result for MCV was retained in both 
models. Similar analyses could be carried out with the FIT which is due to be introduced to 
the NHS BCSP along with corresponding SNOMED codes. This chapter identifies additional 
predictors for consideration in a future risk based screening model and helps to decide if 
someone with a negative FOBT would benefit from further investigation if they are at 
higher risk from other predictors. 
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7.0 APPENDICES 
 
Appendix 1: Frequency of Read codes used to diagnose bowel cancer from the 
THIN database. 
 
Read code Description  Frequency of Code used to record Bowel Cancer 
Bowel cancer detected by national screen 20 
Bowel scope (flexible sigmoidoscopy) scr 1 
Cancer of bowel 112 
Carcinoma of caecum 4 
Carcinoma of rectum 15 
Colonic cancer 83 
H/O Lower GIT Neoplasm 2 
Malig neop other site rectum, rectosigmo 2 
Malignant neoplasm of appendix 8 
Malignant neoplasm of ascending colon 38 
Malignant neoplasm of caecum 59 
Malignant neoplasm of colon 314 
Malignant neoplasm of colon NOS 56 
Malignant neoplasm of descending colon 11 
Malignant neoplasm of hepatic flexure of 8 
Malignant neoplasm of other specified si 2 
Malignant neoplasm of rectosigmoid junct 10 
Malignant neoplasm of rectum 202 
Malignant neoplasm of rectum, rectosigmo 15 
Malignant neoplasm of retrocaecal tissue 1 
Malignant neoplasm of sigmoid colon 120 
Malignant neoplasm of splenic flexure of 8 
Malignant neoplasm of transverse colon 11 
Malignant neoplasm rectum,rectosigmoid j 1 
Rectal carcinoma 102 
[M]Adenocarcinoma in adenomatous polyp 1 
[M]Adenocarcinoma in multiple adenomatou 1 
[M]Adenocarcinoma in tubulovillous adeno 3 
[M]Pseudomyxoma peritonei 7 
[M]Tubular adenocarcinoma 1 
[M]Tubular adenoma or adenocarcinoma NOS 1 
[M]Tubular adenomas and adenocarcinomas 68 
[M]Villous adenomas and adenocarcinomas 5 
 
Table A.1.1: The frequency of Read codes used to diagnose colorectal cancer from the THIN database. The Bowel Cancer 
Screening Programme Cancer Diagnosis code cannot be relied upon to distinguish between screen detected and clinically 
detected cancers based on the frequencies listed in the table. This is based on a 1% sample from the THIN database. 
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Appendix 2: Eligibility Criteria for Data Extraction 
 
Practice Criteria 
Practice Criteria Notes 
Practice Start Date: The latest of AMR, ABSD (Acceptable bowel cancer screening date – 
defined by researcher) and Vision date plus one year.  
ABSD date is saved as: 
practice_screening_start_date.dta 
Practice End Date: The last collection date from each practice  
Exclude practices not in England  
Exclude practices where the practice start date is greater than or equal to the practice 
end date 
Also dealt with later in the 
exclusion process when patients 
whose start date is >= their end 
date are excluded 
 
Table A.2.1: Practice eligibility criteria for data extraction. 
Patient Criteria 
Patient Criteria Notes 
Patient Observation Start: Later of Practice start date, 
registration date plus one year and age 59. 
Operationalised during data extraction as the beginning of the 
year in which the patient turns 60. This includes some period of 
time when they were aged 59. 
Patient Observation End: Earlier of Practice end date, 
De-registration or death and age 75. 
Operationalised during data extraction as the beginning of the 
year in which the patient turns 75. This includes some period of 
time when they were aged 75. 
Period Start (Patient Index Date) Latest Bowel Cancer 
Screening Programme FOBT result 
AHD results only 
lk_BCSP_FOBT_codes.dta 
Period End CRC/Polyp (Patient End Date): Earlier of 
patient observation end and outcome of interest 
(colorectal cancer diagnosis) 
lk_colorectal_cancer.dta 
lk_polyp.dta 
Generate from data 
Exclude if not permanently registered or applied for 
permanent registration  
(patflag) 
Exclude if patient observation start is greater than or 
equal to observation end 
 
Exclude if sex is not equal to male or female.  
Exclude if no screening FOBT record  
Exclude if CRC diagnosis prior to period start lk_colorectal_cancer.dta 
Exclude patients at high risk of bowel cancer due to 
inherited conditions - FAP (familial adenomatous 
polyposis) and Lynch syndrome (hereditary non 
polyposis colorectal cancer or HNPCC) – Read coded 
prior to FOBT. 
lk_HNPCC.dta 
lk_familial_adenomatous_polyposis.dta 
 
 
Table A.2.2: Patient eligibility criteria for data extraction. 
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Appendix 3: Scientific Review Committee Approval Letter 
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Appendix 4: Variable Definitions/Specification for Data Extraction 
 
Variable Name Definition 
BMI Latest record prior to FOBT 
Weight Latest record prior to FOBT 
Also can generate weight loss - from the most recent and 
previous weights.  
Calculated difference between two weights (<5% drop, 5 to 
9.9% drop or >=10% drop) 
Height Latest record prior to FOBT 
Smoking status Latest record prior to FOBT 
Alcohol Latest record prior to FOBT  
Units per week. 
Alcohol status can be worked out from AHD-recorded 
number of units per week, AHD Read code associated with 
the AHD code for alcohol consumption and a separate 
MEDICAL table Read code lookup used by QRisk2: 
‘lk_read_alcohol.dta’ 
 
Alcohol status (non-drinker; trivial [<1 unit/day]; light [1–2 
units/day]; moderate/heavy [≥3 units/day]) 
Mean cell volume  Continuous measure defined in AHD document 
All records prior to FOBT 
For analysis the latest record within 365 days so it is 
associated with the outcome. 
Ferritin Continuous measure defined in AHD document 
All records prior to FOBT 
For analysis the latest record within 365 days so it is 
associated with the outcome. 
Blood group Defined in AHD document 
Family history of colorectal cancer Defined in AHD document 
Platelet count Continuous measure defined in AHD document 
All records prior to FOBT 
For analysis the latest record within 365 days so it is 
associated with the outcome. 
FOBT Screening Outcome Defined in AHD document 
Primary FOBT result Defined in AHD document 
Haemoglobin concentration Continuous measure defined in AHD document 
All records prior to FOBT 
For analysis the latest record within 365 days so it is 
associated with the outcome. 
Table A.4.1: AHD variable definitions for data extraction. 
 
Variable Name Definition 
Abdominal mass 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Abdominal pain 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Abnormal rectal examination 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent.date. 
Change in bowel habit 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Colorectal Cancer Diagnosis Date of the first after the FOBT 
Constipation 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Crohn’s Disease Date of first diagnosis if prior to the FOBT date 
Diabetes  
Up to 365 days prior to the index date 
Date of first diagnosis if prior to the FOBT date 
Standard list of diabetes codes.  
Both types 
Diarrhoea For data extraction: Date of the most recent prior to the FOBT date. 
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Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Diverticulitis/Diverticulosis 
Only bowel diverticula 
For data extraction: Date of the most recent prior to the FOBT date 
if ever recorded. 
Family History of Colorectal Cancer If ever recorded prior to FOBT date 
FAP (familial adenomatous polyposis) 
As an exclusion factor (these patients are at higher risk than the 
average risk screening population) 
First ever record 
Ferritin (low levels) 
Also investigated in AHD table 
Latest recorded prior to FOBT 
Flatulence 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Flexible Sigmoidoscopy Record (BCSP) 
These codes should identify patients who have a record from the 
bowel cancer screening programme relating to flexible 
simoidoscopy 
FOBT Result (Primary Care) 
Also investigated in the AHD table 
Up to 365 days before latest FOBT result. 
FOBT Screening Outcome (Latest FOBT and previous 
FOBT tests) 
These codes should identify patients who have a record from the 
bowel cancer screening programme relating to the FOBT - allowing 
an individual’s screening history to be extracted. 
Also investigated in AHD table 
Hereditary Nonpolyposis Colorectal Cancer (HNPCC) 
As an exclusion factor (these patients are at higher risk than the 
average risk screening population) 
First ever record 
IBS (Irritable Bowel Syndrome) 
For data extraction: Date of the most recent prior to the FOBT date 
if ever recorded. 
Loss of appetite  
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Obesity 
Patients who have had an obesity diagnosis within 2 years of the 
index date. Also investigated in AHD table 
Polyp diagnosis (Prior to FOBT and after) 
Date of the most recent prior to the FOBT date if ever recorded. 
Date of the first after the FOBT date. 
Rectal bleeding/Melaena 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Thrombocytosis  
Platelet count will also be extracted from the AHD table 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Tiredness 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Ulcerative Colitis  Date of first diagnosis if prior to the FOBT date if ever recorded 
Venous Thromboembolism (VTE) which includes 
Pulmonary Embolism and Deep Vein Thrombosis 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Weight loss 
Also investigated in AHD table 
For data extraction: Date of the most recent prior to the FOBT date. 
Up to 365 days prior to the index date: Generate binary variable to 
indicate if the exposure is recent. 
Table A.4.2: Read code lookup variable definitions for data extraction. 
Variable Name Definition 
Anti-motility drugs (proxy for diarrhoea) Drug listed in  
drug_lk_antimotility 
Up to 365 days before latest FOBT 
Laxatives (proxy for constipation) Drug listed in  
drug_lk_laxative 
Up to 365 days before latest FOBT 
Antispasmodics (proxy for abdominal pain) Drug listed in  
drug_lk_antispasmodic 
Up to 365 days before latest FOBT 
 
Table A.4.3: Drug Code lookup variable definitions for data extraction. 
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Patient File (Variable Name) 
Patient ID 
Practice ID 
Registration date 
AMR date 
Vision date 
Date of death 
Date left practice (de-registration) 
Year of birth 
Sex 
Practice File (Variable Name) 
AMR date 
Vision date 
Last collection date 
PVI File Lookups (Variable Name) 
Townsend Quintile  
Ethnicity  
 
Table A.4.4: Data required from additional files in THIN: Patient file, Practice file, PVI file. 
Appendix 5: Table contents for Data Extraction and Analysis 
 
Variable Notes 
Patient ID Patient file 
Practice ID Patient file 
Registration date Patient file 
AMR date Practice file 
Included in the definition of the variable start_date 
Vision date Practice file 
Included in the definition of the variable start_date 
Screening start date (Acceptable bowel cancer screening 
date) 
practice_screening_start_date.dta 
Last collection date Practice file 
Included in the definition of the variable end_date 
Date of death Patient file 
Date left practice (de-registration) Patient file 
Year of birth Patient file 
Sex Patient file 
Ethnicity PVI 
Family history of Colorectal Cancer 
 
Latest record prior to FOBT 
AHD 
Medical Table 
Height Latest record prior to FOBT 
AHD 
Weight Latest record prior to FOBT 
AHD 
BMI Latest record prior to FOBT 
AHD 
Two columns for this: 
bmi_vision – The BMI recorded in the patient record  
bmi_calc – Recalculated BMI based on the weight recorded 
on that day and the median recorded height for that patient. 
Townsend Quintile Latest record prior to FOBT 
PVI 
Smoking AHD 
Date 
Latest record prior to FOBT 
Status 
Quantity (for those that have it) 
Alcohol AHD 
Date 
Latest record prior to FOBT 
Units per week 
Latest value for units per week given in column called 
ahd_alcohol_units. 
Latest medcode in AHD table also given: 
ahd_alcohol_medcode 
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FOBT Screening outcome AHD 
Medical Table 
(Index date) 
Date of the event 
Each Read code and data4 value (possible multiple records 
per patient) 
FOBT Primary care outcome AHD 
Medical Table 
Latest record prior to FOBT 
Each Read code and data4 value (possible multiple records 
per patient) 
Flexible Sigmoidoscopy Record (BCSP) 
Medical Table 
All records prior to FOBT 
Date 
(These codes should identify patients who have a record 
from the bowel cancer screening programme relating to 
flexible sigmoidoscopy screening) 
Colorectal Cancer diagnosis Medical Table 
Date of the first diagnosis after the screening FOBT 
Polyp diagnosis prior to the FOBT Medical Table 
Date of the most recent prior to the FOBT date. 
Polyp diagnosis after the FOBT  Medical Table 
Date of the first after the FOBT date. 
Blood Group AHD 
Latest record prior to FOBT 
Date 
Value 
Rectal bleeding/melaena  Medical Table 
Date of the most recent prior to the FOBT date. 
(NICE) 
Abdominal pain Medical Table 
Date of the most recent prior to the FOBT date. 
(NICE) 
Abdominal Pain (Drug table) Antispasmodic Prescription Drug table 
Most recent prior to the FOBT date 
Ferritin Medical Table (low ferritin) 
AHD 
Latest recorded prior to FOBT 
Date 
Value 
Additional table all ferritin dates and values. 
(NICE – Iron deficiency anaemia) 
Mean Cell Volume AHD 
Latest recorded prior to FOBT 
Date 
Value 
Additional table all mean cell volume dates and values. 
Constipation (Read coded) Medical Table 
Date of the most recent prior to the FOBT date. 
(NICE) 
Constipation (Drug coded) Drug table (laxative drugs) 
Date of the most recent prior to the FOBT date. 
Diarrhoea (Read coded) Medical Table 
Date of the most recent prior to the FOBT date. 
(NICE) 
Diarrhoea (Drug coded) Drug table (anti-motility drugs) 
Date of the most recent prior to the FOBT date. 
Change in Bowel Habit Medical Table 
Date of the most recent prior to the FOBT date. 
(NICE) 
Weight loss Medical Table 
AHD table calculation 
Two most recent at any time up until the FOBT date. 
Separate table with all the weights and corresponding dates 
(NICE) 
Calculation - Weight loss from the most recent and previous 
weights. Calculated difference between two weights (<5% 
drop, 5 to 9.9% drop or >=10% drop) 
Rectal bleeding or Melaena (one Read code list) Medical Table 
Date of the most recent prior to the FOBT date. 
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Crohns Disease Medical Table 
Date of first diagnosis if prior to the FOBT date 
Ulcerative colitis Medical Table 
Date of first diagnosis if prior to the FOBT date 
Haemoglobin Concentration   Latest recorded prior to FOBT 
Date 
Value 
Additional table all haemoglobin concentration dates and 
values. 
AHD 
Diabetes Medical Table 
Date of first diagnosis if prior to the FOBT date 
Bowel Diverticula Medical Table 
Date of the most recent prior to the FOBT date. 
IBS (Read coded) Medical Table 
Most recent prior to the FOBT date 
Abdominal mass Medical Table 
Date of the most recent prior to the FOBT date. 
Abnormal rectal examination Medical Table 
Date of the most recent prior to the FOBT date. 
Flatulence Medical Table 
Date of the most recent prior to the FOBT date. 
Tiredness Medical Table 
Date of the most recent prior to the FOBT date. 
Venous Thromboembolism (VTE) which includes Pulmonary 
Embolism and Deep Vein Thrombosis 
Medical Table 
Date of the most recent prior to the FOBT date. 
Thrombocytosis  
Medical Table 
Date of the most recent prior to the FOBT date. 
Platelet Count 
Latest recorded prior to FOBT 
Date 
Value 
Additional table all platelet count dates and values. 
AHD 
Loss of appetite Medical Table 
Date of the most recent prior to the FOBT date. 
Obesity 
Medical table 
Patients who have had an obesity diagnosis within 2 years of 
the index date 
Date of the most recent prior to the FOBT date. 
(Also investigated in AHD table) 
Table A.5.1: Table contents for extraction 
 
Intermediate Tables Containing: 
- Ferritin 
- Weight Loss 
- Mean Cell Volume 
- Haemoglobin Concentration 
- Platelet Count 
- FOBT Screening Outcome (may be multiple records per patient) 
- FOBT Primary Care Outcome (may be multiple records per patient) 
 
Patients will be followed-up until the earliest of the following dates: death; de-registration; 
CRC diagnosis; two years after their index date; and the date of the last data collection from 
their general practice. 
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Appendix 6: Hazard Ratios for the Cox Regression Model for a population with 
positive and negative FOBTs 
 
 Variable 
Estimated 
Hazard Ratio 
Bootstrapped 
Standard Error 
z P>z 
[95% Confidence 
Intervals] 
MCV*age at FOBT interaction 1.090 0.046 2.04 0.04 1.004 1.184 
FOBT result*age at FOBT interaction 0.964 0.014 -2.63 0.01 0.937 0.991 
FOBT Result (positive result) 42.122 2.557 61.61 0.00 37.397 47.445 
Smoking Status:       
ex-smoker 1.229 0.074 3.44 0.00 1.093 1.383 
current smoker 1.382 0.146 3.07 0.00 1.124 1.698 
       
Crohn’s Disease Diagnosis Recorded 0.486 0.206 -1.70 0.09 0.211 1.116 
Previous Polyps Diagnosed 1.912 0.269 4.60 0.00 1.450 2.520 
Flatulence Symptom Recorded 2.340 1.014 1.96 0.05 1.000 5.472 
MCV <80fL  1.411 0.284 1.71 0.09 0.951 2.092 
Alcohol consumption (units per week) 1.086 0.033 2.67 0.01 1.022 1.153 
Family History of Gastrointestinal 
Cancer 
2.151 0.390 4.23 0.00 1.508 3.068 
Abdominal pain/antispasmodic 
prescription recorded 
1.220 0.120 2.02 0.04 1.006 1.480 
Diarrhoea symptom 1.312 0.203 1.76 0.08 0.969 1.777 
Sex 0.822 0.059 -2.72 0.01 0.714 0.947 
Age at FOBT 1.033 0.009 3.85 0.00 1.016 1.051 
Change in bowel habit symptom 2.479 0.495 4.55 0.00 1.676 3.668 
Table A.6.1: Hazard ratios for final model derived from the sample population with positive and negative FOBT results. 
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Appendix 7: Cox Regression Diagnostics Schoenfeld Residuals 
 
 Variable Rho Chi2 
Degrees of 
freedom Prob>chi2 
MCV*age at FOBT interaction 0.000 0.00 1 0.999 
FOBT result*age at FOBT interaction -0.013 0.19 1 0.664 
FOBT Result      -0.650 536.43 1 0.000 
Smoking Status: 
- - 1 - 
ex-smoker 
0.067 5.52 1 0.019 
current smoker 
0.064 5.01 1 0.025 
Crohns Disease Diagnosis Recorded 
0.069 5.79 1 0.016 
Previous Polyps Diagnosed 
0.113 15.94 1 0.000 
Flatulence Symptom Recorded 
0.033 1.36 1 0.243 
MCV <80fL  
0.019 0.44 1 0.509 
Alcohol consumption (units per week) 
-0.020 0.51 1 0.476 
Family History of Gastrointestinal Cancer 
-0.040 1.97 1 0.161 
Abdominal pain/antispasmodic prescription 
recorded 0.005 0.03 1 0.869 
Diarrhoea symptom 
0.023 0.64 1 0.422 
Sex 
-0.019 0.48 1 0.490 
Age at FOBT 
0.068 5.16 1 0.023 
Change in bowel habit symptom 
-0.018 0.38 1 0.540 
          
Global test   584.44 16 0.000 
 
Table A.7.1: Test of proportional hazards using Schoenfeld Residuals. Significant results had a p-value of less than 0.05 and 
included; age at FOBT, previous polyps diagnosed, Crohn’s disease, current smoker, ex-smoker and FOBT result. For model 
with positive and negative FOBTs. 
Variable rho chi2 df Prob>chi2 
Smoking Status: - - 1 - 
ex-smoker 0.081 3.86 1 0.049 
current smoker 0.001 0 1 0.975 
IBS -0.016 0.15 1 0.695 
Previous Polyps Diagnosed 0.017 0.18 1 0.676 
Flatulence Symptom Recorded 0.042 1.03 1 0.310 
Weight loss -0.035 0.72 1 0.395 
MCV <80fL  -0.064 2.39 1 0.122 
Family History of Gastrointestinal Cancer -0.045 1.19 1 0.276 
Abdominal pain/antispasmodic prescription recorded -0.073 3.14 1 0.076 
Diarrhoea symptom -0.072 3.02 1 0.083 
Sex 0.015 0.14 1 0.708 
Age at FOBT 0.109 6.54 1 0.011 
Change in bowel habit symptom -0.039 0.9 1 0.342 
Global test  26.28 13 0.016 
 
Table A.7.2: Test of proportional hazards using Schoenfeld Residuals. Significant results had a p-value of less than 0.05 and 
included; age at FOBT, smoking status (Ex-Smoker). For a model with negative FOBT only. 
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THIN Data Extraction Methodology 
 
This research was carried out as part of an NIHR Infrastructure Doctoral Training Exchange 
(IDTE) Award based at the Institute of Applied Health Research at The University of 
Birmingham. IDTE supervisors were Professor Tom Marshall (TM) and Dr Ronan Ryan (RR) 
based in the Health Informatics team, Primary Care Division. 
ABSTRACT 
 
Background: The Health Improvement Network (THIN) is an anonymised GP record 
database derived from GP systems which use Vision software and provided for research by 
IMS Health. THIN provides data for over 587 practices (>5% coverage of the UK) covering 
more than 12 million patients. These data are arranged across four main file types linked by 
patient ID: patient file (for demographic information), the medical file (recording of 
symptoms and diagnoses), therapy file (for prescriptions) and Additional Health Data (AHD) 
file (laboratory test results). Diagnoses and symptoms are recorded using hierarchical Read 
codes and drug codes for prescriptions can be linked to the British National Formulary 
(BNF) Chapters. Most GP practices have electronic links with the bowel cancer screening 
system and so FOBT results and whether someone has participated in the programme is 
available in the database. Lab test results and FOBT results use the Pathlinks notification 
system which means test results are automatically sent through to primary care. In order to 
extract data from THIN for symptoms and diagnoses, Read code lists specifying the defined 
diagnosis/symptom need to be constructed. Similarly for prescriptions, drug code lists need 
to be defined. The AHD file is more complex and a strategy needs to be constructed in 
order to extract the data of interest, in the units of interest and within the 
acceptable/relevant range, particularly for laboratory test results. Finally, before 
approximately 2010, BCSP notifications were sent via letter to patients and practices. After 
this date, certain practices opted in to receive electronic notifications and a set of Read 
codes for this purpose was developed. In order to ensure data quality assurance for studies 
investigating screening programme results, dates need to be defined for individual 
practices to ensure electronic results are used. Before this date, practices may not have 
routinely recorded the results and this could have been biased towards positive results.  
This Chapter aims to describe the methodology used to: define acceptable periods of BCSP 
notifications for practices receiving electronic results – the acceptable electronic BCSP 
(AEB) date, extract laboratory/other variables from the AHD file, and compile Read code 
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lists for diagnoses and symptoms and drug code lists for prescriptions from THIN. These 
methods will improve the quality and validity of the data extracted for analysis and aid 
transparency and reproducibility of the methods for further electronic health record (EHR) 
research. 
Methods: For defining the AEB date, a rate of the frequency of bowel cancer screening 
notifications received per month by the number of patients registered in a practice aged 
60-74 was determined for each practice in THIN. An expected rate for each practice was 
also generated based on a 50% uptake rate and people being invited biennially. Line graphs 
with the expected monthly rate of electronic notifications and the actual monthly rate by 
practice were produced along with a locally weighted scatterplot smoothing (LOWESS) line 
and visually examined. Rules for visual interpretation of the start date of when electronic 
notifications were received were compiled by 3 reviewers based on a sample of the 
resultant graphs. The first reviewer made a decision blind to the 2nd reviewer on when the 
start date would be for each practice. A consensus meeting was used to discuss the results 
and a third reviewer intervened where a decision could not be made. The AHD file is more 
complex and requires a strategy to extract valid data. The method to extract FOBT 
screening notifications was an iterative process which systematically reviewed the different 
combinations of Read codes and value labels in the AHD file observed in a THIN 1% data 
sample, initially restricting by the ahdcode of interest (FOBT). The AHD file was then 
searched for any additional BCSP codes (from the above list) not restricting by ahdcode and 
the output was a series of rules which can be used to identify BCSP FOBT screening 
outcomes for all patients in the THIN database. A similar approach was taken for defining 
an AHD strategy for haemoglobin concentration. The method sequentially reviewed the 
numeric distribution of Hb values for combinations of Read codes and value labels 
observed in a THIN 1% sample. These were compared with a reference distribution for Hb 
to assess if they matched that distribution, required conversion before use, or were 
unlikely to contain Hb values and therefore excluded. Plausible Hb minimum and maximum 
values from an external source were then applied to the data as a final step in the method. 
The method for Read code list generation involved an iterative key word search strategy 
(informed by previous research and discussion with a clinician) and then identifying other 
parent and child stems for Read codes by exploiting the hierarchical nature of the codes. 
After a few cycles of running through this, the resulting Read code list was subject to two 
individual reviewers (the second being a clinician for validity). The results were presented 
for Bowel Cancer Diagnosis. Finally, drug code list generation involved a similar method to 
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the above. The British National Formulary was used to identify Chapters the drugs were 
mapped to as well as formulate a key word search under generic drug name.  All drugs 
mapped to the appropriate Chapter were included in the final list after removing any drugs 
which did not fit the definition used for the study (e.g. formulations type). The list was 
checked by two reviewers. 
Results: The initial review of the AEB date defined for each practice gave 353 practices for 
inclusion and 102 for exclusion. The second reviewer gave 363 for inclusion and 92 
practices for exclusion, giving 97.8% (445/455) agreement. The consensus meeting with the 
3rd reviewer gave the final 92 practices for exclusion and 363 for inclusion. Eighty per cent 
of practices were investigated for an AEB date. The agreed AEB start dates for these 
practices were used in Chapter 5 to define the population and data used for analysis. AHD 
strategies for bowel cancer screening notifications identified a series of rules which could 
be used to extract BCSP FOBT screening outcomes for all patients in the THIN database. 
This involved using medcodes for BCSP notifications with a definitive result. Other generic 
BCSP codes however needed to be combined with another ahdcode for a definitive 
outcome/result. The AHD strategy for haemoglobin concentration identified a reference 
distribution using pathology lab data and transformed values where appropriate so that the 
results used the same units and were recorded in the same way for analysis. Results which 
were outside the range of the reference distribution were excluded from extraction. Read 
code list generation resulted in a list of 42 codes used for bowel cancer diagnosis after 
being subject to a double reviewing process. Drug code list generation for laxatives resulted 
in a list of 450 codes after being subjected to a double reviewing process. 
Conclusions:  
The AEB date can be used in future studies as a layer of data quality assurance to ensure 
results used for analysis are ones which have been electronically received to the additional 
health data records. The methods derived to extract additional health data variables such 
as laboratory test results can be used for future studies requiring the same variables if 
tailoring the methods to the research question. By using an external dataset to define 
acceptable minimum and maximum values this also adds more validity to the data when 
applied in risk prediction models. There is a growing requirement to ensure Read 
code/Drug code lists as well as more recently their methods are transparent and available 
for future research studies. Data repositories exist for this purpose such as Clinical Codes 
set up by the University of Manchester. The strategies are fully documented in this chapter 
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along with code list examples at the end of this chapter. A systematic approach ensures a 
valid set of codes is produced for electronic health record analysis. This chapter has 
described the methods developed to extract data for the study in Chapter 5 but also which 
can be applied in other future studies to improve data validity and quality assurance.  
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1.0 INTRODUCTION 
 
The previous chapter describes a risk prediction modelling study using The Health 
Improvement Network (THIN) database of anonymised GP records. The objective of this 
chapter is to describe the methodology used to extract valid data from THIN used for the 
analyses in Chapter 5.  Methods are described for identifying the Acceptable Electronic 
BCSP (AEB) date for each GP practice receiving electronic notifications in THIN. Examples of 
the strategies developed to extract additional health data (AHD) variables are described 
with examples. Read code list development and definitions of variables used for the study 
in Chapter 5 are presented along with the methods used to derive drug code lists. This 
chapter can be used in conjunction with Chapter 5 to supplement further detail behind 
extracting a valid dataset for analysis and to ensure results are generalizable to the English 
BCSP population. 
1.1 Structure of the THIN Database and coding information 
 
Along with electronic GP record databases such as the Clinical Practice Research Datalink 
(CRPD) (formerly General Practice Research Database - GPRD) and QRESEARCH, THIN is a 
database of anonymised GP records used for health and medical research. This database is 
derived from GP systems which use the Vision operating system and is provided for 
research by IMS Health (now known as IQVIA). THIN provides data for over 587 practices 
(>5% coverage of the UK) covering more than 12 million patients. The data are made 
available for research by GPs entering notes onto the computer system, this is then 
anonymised and sent for collation in a database. Researchers then submit a protocol to the 
Scientific Review Committee (SRC) administered by IMS Health and if ethical approval is 
granted, the data is made available for research. 
THIN provides information on diagnoses, symptoms, prescriptions, laboratory tests and 
lifestyle factors across four standardised data files linked by patient ID.1 The patient file 
includes information such as registration to the practice, age and sex. The medical file 
contains information on diagnoses and symptoms, and the therapy file covers drug 
prescriptions.  The Additional Health Data (AHD) file contains a range of information 
including laboratory test results, anthropometric measurements, smoking status and 
vaccinations. Additional Information Services (AIS) can also be used to obtain information 
collected from GP or patient questionnaires and data from other sources.  
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The raw data behind electronic health records such as THIN is not in a form which is ready 
for research. The data required for analysis needs to be transformed and extracted using 
various coding systems.2 These coding systems can be exploited for data analysis by 
producing code lists for outcomes and covariates to extract from the database as well as 
identifying and researching a population with a particular disease condition or exposure. 
There are three main types of lookup which can be produced for THIN; Read code lists for 
use in the medical file (and also used in the AHD file), Drug code lists for use in the therapy 
file, and AHD codes for use in the Additional Health Data file. 
Read codes named after Dr James Read are used to record clinical information such as 
symptoms and diagnoses in the UK and are used in the THIN database. Read codes use a 
hierarchical system of recording which is not based on ICD (International Classification of 
Diseases) which is the case in much of Europe. There are around 100,000 alphanumeric 
Read codes used to record the clinical information, the main stems are provided in Table 1 
below.3 
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Stem Description 
0 Occupations 
1 History & symptoms 
2 Examination and signs 
3 Diagnostic procedures 
4 Laboratory procedures 
5 Radiology & physics in medicine 
6 Preventative procedures 
7 Operations, procedures & sites 
8 Other therapeutic procedures 
9 Administration 
A Infectious and parasitic diseases 
B Neoplasms 
C Endocrine, nutrition, metabolic and immunity disorders 
D Diseases of blood and blood forming organs 
E Mental disorders 
F Nervous system and sense organ diseases 
G Circulatory system diseases 
H Respiratory system diseases 
J Digestive system diseases 
K Genitourinary system diseases 
L Complications of pregnancy, childbirth and the puerperium 
M Skin & subcutaneous tissue diseases 
N Musculoskeletal and connective tissue diseases 
P Congenital anomalies 
Q Perinatal conditions 
R Symptoms, signs and ill-defined conditions 
S Injury & poisoning 
T Causes of injury and poisoning 
U External causes of morbidity and mortality 
Z Unspecified conditions 
Table 1: The main stems of Read code classification. Taken from Davé and Petersen3 
Prescriptions are linked to the British National Formulary (BNF) Chapter codes and can also 
be identified using their generic drug names. They are recorded in the THIN database as 
encrypted Multilex codes.3 Health systems in the UK are also transitioning over to SNOMED 
CT which is an international coding system allowing greater research opportunities and 
analysis of health data.4  
The AHD file contains information on lab test results, lifestyle data, immunisations and 
death data.1 Each record has an AHD code which defines the area of interest (for example, 
smoking, alcohol, lab test results) and then further information is obtained from other data 
fields including a ‘medcode’ field (which contains Read codes) adding an additional layer of 
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information. Lab test results for example have the numerical value, units and reference 
values used by the lab. Pathology labs in hospitals send electronic results through to GP 
practices using the NHS Spine and Pathology Messaging Implementation Project Messaging 
(PMIP) to automatically populate patient records.5 
GP practices have electronic links with the bowel cancer screening system using the same 
system that pathology labs use to send electronic results. Therefore, FOBT results and 
whether someone has participated in the programme are also available in the database. 
The AHD file stores the electronic BCSP notifications in THIN. 
1.2 Bowel Cancer Screening Programme Notifications 
 
The Bowel Cancer Screening Programme in England was rolled out in July 2006 and had 
national coverage by January 2010. Screening was offered to 60 to 69 year olds initially and 
extended to age 74 in 2010. The different hubs became involved in the screening 
programmes at different time points; Midlands and North West Hub started in July 2006, 
the Southern Hub September 2006, the London Hub October 2006, the North East Hub 
February 2007 and the Eastern Hub March 2007 (Steve Smith, personal communication). 
The Norwich screening centre started in July 2006. Although they are officially part of the 
Eastern Hub they started off independently for the first year and were subsequently 
transferred to the Eastern hub in July 2007 (Steve Smith, personal communication). 
The different screening programmes offered in the UK use different age ranges, code lists 
as well as screening systems (Scotland, Ireland, England, Wales, and Isle of Man). For 
example, Scotland’s IT system for colorectal cancer screening is called BoSS (Bowel 
Screening System). 
The Read codes currently used by the English BCSP for electronic notifications to primary 
care are listed in Table 2 and those by the Scottish Bowel Cancer Screening Programme in 
Table 3. In October 2013, Read Codes for Bowel Scope Screening were introduced (Table 
4). 
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Read Code Description 
6866 Bowel cancer screening programme: faecal occult blood result 
6867 Bowel cancer screening programme faecal occult blood testing kit spoilt 
686A Bowel cancer screening programme faecal occult blood test normal 
686B Bowel cancer screening programme faecal occult blood test abnormal 
686C Bowel cancer screening programme faecal occult blood testing incomplete participation 
9Ow2 No response to bowel cancer screening programme invitation 
Table 2: Set of Read codes used by the NHS BCSP in England to record colorectal cancer screening activity 
Read Code Description 
686A Bowel cancer screening programme faecal occult blood test normal 
686B Bowel cancer screening programme faecal occult blood test abnormal 
6867 Bowel cancer screening programme faecal occult blood testing kit spoilt 
68W2 Bowel Cancer Screening Programme – include reason of ‘Ineligible’ 
9Ow3 Bowel cancer screening programme faecal occult blood testing incomplete participation 
8IA3 Bowel Cancer Screening Declined 
9Ow2 No response to bowel cancer screening programme invitation 
66W2 Bowel Cancer Screening Programme - include reason of ‘Non-Responder’ 
Table 3: Set of Read codes used by the Scottish Bowel Cancer Screening Programme to record colorectal cancer 
screening activity. 
Read Code Description  
68W20 
Bowel Cancer Screening Programme bowel scope screening test (Term 30 description is BCSP bowel scope 
screen test) 
68W21 Bowel scope (flexible-sigmoidoscopy) screen: normal - no further action 
68W2C Bowel scope (flexible-sigmoidoscopy) screen: incidental findings 
68W23 Bowel scope (flexible-sigmoidoscopy) screen: referred for colonoscopy 
68W24 Bowel scope (flexible-sigmoidoscopy) screen: cancer detected 
68W27 Bowel scope (flexible-sigmoidoscopy) screening invitation declined 
68W28 Bowel scope (flexible-sigmoidoscopy) screening invitation: did not respond 
68W29 Bowel scope (flexible-sigmoidoscopy) appointment: did not attend 
68W2A Bowel scope (flexible-sigmoidoscopy) screening: attended but not screened 
68W2B Bowel scope (flexible-sigmoidoscopy) screening invitation: unsuitable at this time 
Table 4: Read code list for Bowel Scope Screening in the NHS BCSP in England 
Since 2010, the Bowel Cancer Screening System (BCSS) has sent results of the FOBT 
electronically to GP practices who have opted into this service using the same system as 
the Pathology Messaging Implementation Programme (PMIP).6 This service is also used by 
pathology labs to send laboratory results to primary care. The gFOBT results from screening 
are sent once daily overnight to the GP practices in batches. 
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1.3 Reproducible Research using THIN and other electronic GP databases 
 
Due to the level of detail which can be provided by THIN, each study must define the 
variables required in terms of Read Codes used for symptoms and diagnoses. For instance, 
the Read codes used for the diagnosis of colorectal cancer may only include certain types 
based on study objectives. The Reporting of studies Conducted using Observational 
Routinely-collected health data (RECORD) statement recommends that code lists are 
provided with published studies either within the journal or linked to a data repository.7 
This statement consists of 13 items specific for observational studies which use routinely 
collected health data. More recently, it has been suggested that the actual code set 
engineering methods should also be provided for greater transparency to other 
researchers.2 The inclusion of inappropriate codes and exclusion of appropriate ones is a 
recognised source of bias in studies of EHRs.8 
When using previously developed Read code lists from other studies (e.g. Clinical Codes 
Data Repository: https://clinicalcodes.rss.mhs.man.ac.uk/), care must be taken that the list 
applies to the study objectives. In addition, different practices use different Read codes and 
new Read codes are introduced over time or drop out of use so it is important to update 
lists appropriately. In addition, the Quality and Outcomes Framework (QOF) introduced in 
2004 has provided financial incentives for GPs to record certain clinical information.9 For 
example, there have been QOF incentive schemes for health indicators such as smoking,10 
diabetes,11 and severe mental illness12 which have affected the pattern and quality of 
reporting over time. Other temporal changes which affect recording patterns are the 
introduction and changes to NICE guidelines. 
The number of publications using EHR data in epidemiological and medical research has 
increased from around 80 in 2005 to more than 450 in 2015/2016.8 This trend is set to 
continue with the move to electronic data and computerisation within the NHS. For 
example, a change in health policy has required that all healthcare trusts will only use 
electronic referrals from GPs by October 2018.13 The methods for extracting data and using 
it for analysis therefore needs to be rigorous and reproducible. In addition, new methods 
are required to assimilate all this information and use it for health sciences research. 
Furthermore, data assurance in terms of which dates to include in analyses based on 
different events in time, such as the introduction of Vision software/switch overs must be 
investigated for data quality assurance. The Acceptable Mortality Reporting (AMR) date 
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and Acceptable Computer Usage (ACU) date have been derived for this purpose. The THIN 
database also includes several quality indicators such as patient flags (Patflags) in the 
Patient file. 
1.4 Quality Assurance Indicators Derived for THIN Studies 
 
Previous data quality filters have been developed for use in THIN.14 15 The AMR date was 
developed to define the periods of acceptable mortality reporting for each practice in 
THIN.14 Before this date, practices may not have routinely recorded deaths or de-
registrations. Applying this external standard to the data provides validity to the data 
extracted and removes under-reporting of death. The AMR date is supplied by THIN and is 
the date at which mortality reporting matches that of the general UK population. Studies 
using THIN apply the AMR date to each practice to define the start of patient follow up. The 
study reported in Chapter 5 to define the time period eligible for each practice used the 
latest of several dates including the AMR date to ensure validity of extracted data. 
Another data quality filter which has been developed for use in THIN is the ACU date.15 This 
date was developed to define periods of acceptable computer usage for each practice in 
THIN by using the criteria of one medical, one AHD and two therapy records per patient per 
year on average. When new software and computer systems were implemented in 
practices, there was a period of adaptation to the new systems by health care practitioners. 
As a result, diagnoses or other recordings could be affected following the adoption of this 
new technology.  The authors suggest using the latest of the AMR and ACU date to define 
the start of patient follow up and improve data quality.15  
Studies using recording/notification systems which have been implemented over time will 
therefore need additional quality filters to ensure recordings are valid and representative 
of the UK population. The Bowel Cancer Screening System (BCSS) was developed alongside 
the BCSP to record screening activity and results for patients eligible for screening. As 
described above, the screening programme was sequentially rolled out in July 2006 and 
practices were eligible to receive electronic notifications by opting into this service from 
the 1st April 2009. Before the adoption of this system, recording of BCSP FOBT results was 
input by practices on receipt of letters sent by the BCSP. Additional data on screening 
activity is also sent such as non-response, FOBT kit spoilt and incomplete participation. 
Correspondence with NHS Digital suggests that 88% of all GP practices now receive 
electronic GP communications (Stephen Halloran, personal communication). The remaining 
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practices may not serve the population of interest (University practices for example) or 
opted for paper reports which may give additional information (Stephen Halloran, personal 
communication). There are discussions of improving this interconnectivity between GP 
records and screening records. The electronic notifications are sent using the same system 
as the PMIP. There is therefore also scope for future research to define acceptable 
recording dates for lab test results received from pathology for the same reasons described 
above for the FOBT. 
1.5 Rationale 
 
In order to derive valid data for the study reported in Chapter 5; Read code and drug code 
lists along with AHD variables needed to be derived and tailored specifically to the study 
objectives to ensure that results are generalizable to the English BCSP population. Further 
to this, a date of acceptable electronic BCSP notifications was required to define practice 
inclusion and the start of patient follow up. 
The objective of this chapter was to describe the methodology used to derive; 
i) AEB date for each practice 
ii) AHD variable extraction with examples of FOBT screening outcomes and 
haemoglobin concentration 
iii) Read code lists with an example of bowel cancer diagnosis 
iv) Drug code lists with an example of laxatives 
This chapter can be used in conjunction with Chapter 5 to supplement further detail behind 
extracting the dataset for analysis. 
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2.0 METHODS & RESULTS 
 
Stata 14.0 was used to derive an AEB date, for AHD variable extraction methods and to 
compile Read code and Drug code lists for data extraction.  
3.0 Developing Methodology to define an AEB (Acceptable electronic 
BCSP) date 
 
3.1 Methods: Defining an AEB Date 
 
To derive an AEB date for each practice opted into receiving electronic BCSP notifications, 
the incidence of BCSP FOBT results for people aged 60-74 were examined. This revealed a 
time-point at which the practice started to receive the electronic notifications from the 
bowel cancer screening system. The uptake rate for bowel cancer screening is around 
50%16 and people are invited biennially. As a result, it is expected that approximately 25% 
of those aged 60-74 will have a FOBT result each year. Consequently, the time-point at 
which the practice starts to receive FOBT results can be identified by examining the date on 
which the frequency of Bowel Cancer Screening results (using the nationally agreed Read 
codes for reporting screening outcomes) in people aged over 60 rises to an expected 
monthly rate. The FOBT results from this date onwards will predominately be the 
electronically received notifications from the BCSP. 
3.1.1 Setting up a numerator/denominator for the AEB date 
 
THIN (Version: May 2016) was used to derive the AEB date. Only practices in England were 
considered for inclusion due to the differing Read codes used for recording results and 
different bowel cancer screening systems across the regions. Some preliminary analyses 
revealed that regions differ in the frequency and use of codes. Here the focus is on codes 
which are used by the English Bowel Cancer Screening Programme (BCSP) and bowel 
cancer screening system (BCSS). 
The frequency of BCSP notifications by number of patients registered in a practice age 60-
74 were investigated. The frequency of patients registered in a practice aged 60-74 for 
each month (and for each primary care practice in THIN) were obtained for use as a 
denominator. The numerator consisted of the frequency of electronic BCSP notifications 
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received per month. This rate was multiplied by 1000 before plotting on a line graph for 
each practice in England.  
An expected rate for each practice was also generated. It is expected that around 25% of 
those aged 60-74 will have a FOBT result each year (based on 50% uptake and biennially), 
this was divided by the number of patients registered a month and multiplied by 1000 for 
comparison and for overlaying on the line graph (monthly expected rate). 
The definitions of variables used to derive the AEB date are shown in Table 5. 
3.1.2 Denominator 
 
The denominator consisted of patients registered in that practice at the beginning of each 
month aged 60-74 (operationalised as 59-75 to ensure the recorded birthdays on THIN 
cover the population of interest). 
An eligibility start date variable was generated which was the maximum of the registration 
date, date aged 59, the Vision date or the 1st April 2009 (which was when practices had the 
ability to opt into electronic screening notifications). An eligibility end date variable was 
also generated which consisted of the minimum of the transfer date, date aged 75 and the 
collection date. Any records where the eligibility end date was less than or equal to the 
eligibility start date were removed from the analysis. 
The command ‘stset’ in Stata was then used to allow splitting of the data with the eligibility 
end date as the exit variable, by each patient ID and eligibility start date as the entry 
variable. This data was then split by month to determine the number of 
notifications/people registered a month. The patient-level data was then collapsed to 
provide a count of registered patients by practice and month for the denominator. 
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3.1.3 Numerator 
 
Both the AHD file and Medical file were used to derive the Bowel Cancer Screening codes 
of interest – the method to extract BCSP records is detailed in Section 4. The AHD file 
contains the electronic BCSP notifications and previously recorded paper based results. The 
medcode file could have also been used to record paper copies of results during a 
consultation and was also used to derive BCSP codes. This ensured all BCSP records were 
extracted. Any duplicate records were dropped from analysis to ensure that the numerator 
was not inflated. The data were made so that it was one line per patient by dropping any 
duplicates in terms of patient ID, Read code, event date and practice ID. To ensure that the 
event date is within the period of interest, any dates before 1st April 2009 (which is the date 
FOBT codes were released) were excluded. 
Generated Variable Description 
Numerator The frequency of electronic BCSP notifications received per month in each practice 
Using both AHD file and Medcode file (removing duplicate records to ensure one row per 
person event) 
Restricting to those who were aged 60-74 for the screening event (electronic notification) 
Within the period of interest (i.e. after 01 April 2009) 
Practices in England 
Eligibility start (to create denominator) The maximum of the registration date, date aged 59, the vision date or 1st April 2009 
(which was when the first practices had the ability to opt into electronic screening 
notifications) 
Eligibility end (to create denominator) The minimum of the transfer date, date aged 75 and the collection date 
Denominator Patients registered in that practice at the beginning of that month aged 60-74 
Practices in England 
Actual monthly rate by practice (based 
on number of monthly BCSP 
notifications over patients registered 
per month) 
actual_rate = (numerator/patients_registered)*1000 
Expected monthly rate by practice 
(based on patients registered per 
month) 
expected_monthly_rate = (((patients_registered*0.25)/12)/patients_registered)*1000 
 
Average 20.83 
Table 5: Variables created to set up a numerator/denominator for the AEB date 
3.1.4 Initial sort of practices for inclusion/exclusion – visual review 
 
Line graphs with the expected monthly rate of electronic notifications and the actual 
monthly rate by practice were produced along with a locally weighted scatterplot 
smoothing (LOWESS) line and visually examined. The LOWESS was plotted to assist with 
identifying the point at which practices receive electronic notifications as sometimes the 
recordings appeared intermittent.  
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Inclusion and exclusion criteria for GP practices and their BCSP electronic notification 
patterns were derived and agreed upon by the reviewers (Table 6). An initial sort was 
carried out by two reviewers (JC, TM) to decide which practices to include for date 
assignment or exclude based on the exclusion criteria below. A percentage agreement was 
calculated. A third reviewer (RR) resolved any disagreements so a consensus was reached. 
Exclusion criteria Inclusion criteria 
1. Too short a period to be useful or to judge stability (exclude) 1. There is a clear sharp increase in the rate of electronic 
notifications received (include) 
2. If the rate is too low (exclude) 2. A screening start date can be derived from the peaks 
(include) 
3. If the rate is 0 (exclude)  
4. Intermittent small peaks, no distinct rise (exclude)  
Table 6: Inclusion and exclusion criteria for GP practices and their BCSP electronic notification patterns. 
 
3.1.5 Assigning the AEB – visual review 
 
The month and year were recorded for each practice by one reviewer (JC) and a consensus 
meeting was carried out with a second reviewer (TM) to discuss interpretation of the start 
date (the change point) based on the rules in Table 7 below. A third reviewer (RR) in the 
consensus meeting was consulted if there was disagreement between the two reviewers 
(JC, TM). 
 
Rules for visual interpretation of the start date: 
 
1. Assess the first peak and take the start date as one month after the first peak to ensure consistency. 
2. If there are two or more distinct peaks, go by the second or last peak to ensure consistent results. 
3. For multiple peaks, if there is a period of several months at a low/zero rate then assess the next significant 
increase in notifications. 
 
Table 7: Rules for visual interpretation of the AEB start date for each included practice. 
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3.2 Results: Defining an AEB Date 
 
The THIN database version used for this analysis was May 2016 where data were recorded 
for 455 practices. The initial sort of these practices by the first reviewer (JC) gave 353 
practices for inclusion and 102 for exclusion. The second reviewer gave 363 for inclusion 
and 102 for exclusion giving 97.8% (445/455) agreement. The consensus meeting with the 
3rd reviewer gave the final 363 for inclusion and 92 practices for exclusion. Eighty per cent 
of practices were therefore investigated for an AEB date. Some practices may have been 
excluded because they had too short a duration before they stop contributing to THIN. In 
addition, some practices were excluded when it was not clear where the electronic 
notifications commenced (no distinct rise). 
3.2.1 Included Practices 
 
When deriving the AEB date for the included practices, the majority had a straightforward 
visual increase in the monthly rate of BCSP notifications over patients registered in the 
practice (263/363 practices had this electronic notification pattern). This pattern is shown 
in Figure 1 where the blue line shows the actual rate of BCSP notifications, the red 
horizontal line displays the expected rate of notifications (20.83). The green line is the 
LOWESS line used to assess the overall trend in the change of electronic notifications over 
time.  
The different patterns in electronic notifications seen by the practices can be influenced by 
practice behaviour, patient behaviour, the sending of lab results and the change/update in 
IT Systems such as Vision software. Patient behaviour in completing the test at home can 
cause delay (for example over Christmas and other holidays). Practices may have received 
results by letter and then changed to electronic notifications or updated IT systems at 
different time points leading to delays in the receipt of results.  
Figure 2 shows an example where there is no distinct increase in rate but the AEB date can 
still be derived. A big spike could mean there was a backlog of inputting/receiving results. 
Figure 3 shows an example where there is an initial peak followed by a few dips. Figure 4 
shows a clear increase but then the practice stops contributing to THIN. Figure 5 shows an 
intermittent peaking pattern with a small peak followed by a larger one; this scenario could 
be two practices merging together for example. Figure 6 shows many dips but also a 
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general upwards trend; the dips could be the sending of results in batches to practices by 
the lab.  
Other patterns showed peaks gradually decreasing over time which could reflect the 
movement of patients. Practices with prolonged gaps were still considered for inclusion 
since this could reflect a breakdown in computer software. All types of practices were 
considered so bias was not introduced. The derived AEB date for the included examples are 
shown in Table 8. 
Practice ID (pseudonymised) AEB Date 
0399 01/09/2012 
0084 01/07/2009 
0194 01/12/2011 
0165 01/10/2013 
0388 01/11/2010 
0451 01/04/2012 
Table 8: Examples of included practices and corresponding AEB Date. 
 
 
Figure 1: Example of a practice with a clear visual increase in the start of receiving electronic BCSP notifications. 
The blue line shows the actual rate of BCSP notifications, the red horizontal line displays the expected rate of 
notifications (20.83). The green line is the LOWESS line used to assess the overall trend in the change of 
electronic notifications over time. The AEB date for this practice was assessed as the 1st September 2012. 
 
Practice 0399 
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Figure 2: Example of a practice where there is no distinct increase in rate but the AEB date can still be derived. 
The blue line shows the actual rate of BCSP notifications, the red horizontal line displays the expected rate of 
notifications (20.83). The green line is the LOWESS line used to assess the overall trend in the change of 
electronic notifications over time. The AEB date for this practice was assessed as the 1st July 2009. 
 
Figure 3: Example of a practice where an initial peak followed by a few dips. The blue line shows the actual rate 
of BCSP notifications, the red horizontal line displays the expected rate of notifications (20.83). The green line is 
the LOWESS line used to assess the overall trend in the change of electronic notifications over time. The AEB 
date for this practice was assessed as the 1st December 2011. 
Practice 0084 
Practice 0194 
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Figure 4: Example of a practice where a visual peak is observed but then the practice stops contributing to THIN 
or receiving FOBT results. The blue line shows the actual rate of BCSP notifications, the red horizontal line 
displays the expected rate of notifications (20.83). The green line is the LOWESS line used to assess the overall 
trend in the change of electronic notifications over time. The AEB date for this practice was assessed as the 1st 
October 2013. 
 
Figure 5: Example of a practice where there is an intermittent peaking pattern with a small peak followed by a 
larger one. The blue line shows the actual rate of BCSP notifications, the red horizontal line displays the expected 
rate of notifications (20.83). The green line is the LOWESS line used to assess the overall trend in the change of 
electronic notifications over time. The AEB date for this practice was assessed as the 1st November 2010. 
Practice 0165 
Practice 0388 
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Figure 6: Example of a practice which shows many dips but there is also a general upwards trend. The blue line 
shows the actual rate of BCSP notifications, the red horizontal line displays the expected rate of notifications 
(20.83). The green line is the LOWESS line used to assess the overall trend in the change of electronic 
notifications over time. The AEB date for this practice was assessed as the 1st April 2012. 
3.2.2 Excluded Practices 
 
Examples of excluded practices are included below. Figure 7 shows a practice with very 
small peaks which suggests electronic notifications may not be being received. 
Alternatively, the practice could be very small or serve very few numbers in the age range 
of interest. Figure 8 presents a practice where there is a nil rate and therefore appears 
there is no recording of electronic notification activity (practice may not serve the age 
range of interest). Finally, Figure 9 shows a practice where there is an extremely low rate of 
notifications received intermittently. This could be due to paper copies of results perhaps 
being received by a smaller practice. 
 
  
Practice 0451 
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Figure 7: Example of a practice which is excluded. There are small peaks in notifications. The blue line shows the 
actual rate of BCSP notifications, the red horizontal line displays the expected rate of notifications (20.83). The 
green line is the LOWESS line used to assess the overall trend in the change of electronic notifications over time. 
 
Figure 8: Example of a practice which is excluded. There is a nil rate and appears to be no recording of screening 
notification activity. The blue line shows the actual rate of BCSP notifications, the red horizontal line displays the 
expected rate of notifications (20.83). The green line is the LOWESS line used to assess the overall trend in the 
change of electronic notifications over time. 
Practice 0412 
Practice 0092 
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Figure 9: Example of a practice which is excluded. There are irregular very small peaks in notifications and then 
the practice stops contributing to THIN. The blue line shows the actual rate of BCSP notifications, the red 
horizontal line displays the expected rate of notifications (20.83). The green line is the LOWESS line used to 
assess the overall trend in the change of electronic notifications over time. 
The AEB date for each included practice is given in Appendix 1. These dates were used 
when deriving the data from THIN for the study reported in Chapter 5 as a data quality 
filter and to define the period of interest. Any practices without an AEB date where 
excluded from the analysis, and when defining the practice start dates this was the latest of 
the AMR, AEB date and Vision date plus one year. 
 
  
Practice 0287 
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4.0 Devising a method to extract AHD File Variables 
 
The Additional Health Data file contains information on lab test results, lifestyle data, 
immunisations and death data.1 Each record has an AHD code which defines the area of 
interest (for example, smoking, alcohol, lab test results). Further information is obtained 
from data1 to data6 fields including a medcode field (which contains Read codes) adding an 
additional layer of information. For example, if the AHD code is for smoking, the other 
columns will give details such as whether someone is a current smoker, number of 
cigarettes a day, start date and stop date if applicable. Likewise with lab test results such as 
haemoglobin concentrations, the other fields will give additional information such as the 
numerical concentration, the units used to record this and the reference values used by 
labs which gives an indication of the validity of the result. AHD codes have a lookup in THIN 
to obtain the description. 
Laboratory measurements (such as blood test results) need to consider the different units 
which are recorded/used by pathology labs in England, the reference distribution for 
haemoglobin concentration (to ensure the correct units are used) and plausible minimum 
and maximum values from an external data source to remove potential outliers. 
For the study reported in Chapter 5, methods to extract variables from the AHD file were 
developed for the following: Blood group, family history of gastrointestinal cancer, FOBT 
primary care outcome, FOBT screening outcome, haemoglobin concentration, mean cell 
volume, ferritin concentration and platelet count. 
The methods for both the FOBT screening outcome and haemoglobin concentration are 
given as examples below. Documents for the methods for the other variables listed above 
are available from the author. 
4.1 Methods: Development of a method to identify FOBT screening outcomes 
from the AHD file in THIN 
 
Since 2010, the Bowel Cancer Screening System (BCSS) has been able to send the results of 
the FOBT electronically to GP practices using the same system as the PMIP service.17 The 
results are sent once daily overnight (every working day) to the GP practices in batches 
which are queued that day. Previously, since 2006 results were sent by hardcopy letter 
from the hub to the GP practices where the practice was responsible for recording the 
result in the patient records. The timing of hardcopy letters sent is determined by each 
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hub.17 There are a set of Read codes which have been generated for the English BCSP which 
differentiate from the test results of FOBTs requested and performed through primary 
care.   
 
This section describes the development of a method to extract FOBT screening outcomes 
from the AHD table in the THIN database. This enables the BCSP history to be extracted for 
an individual. 
 
The method was an iterative process which systematically reviewed the different 
combinations of Read codes and value labels in the AHD data observed in a THIN 1% 
sample, initially restricting by the ahdcode of interest (FOBT). The AHD data was then 
searched for any additional BCSP codes not restricting by ahdcode.  
 
Medcodes which gave a definitive outcome/result such as, ‘BCSP FOB test normal’ 
(686A.00) could be extracted without further information required from the data1-data6 
columns (in this case data4 was the column populated). This was the case for 94.53% of the 
data under the selected ahdcode ‘FOBT’ (4645/4914). The generic BCSP code on the other 
hand (‘Bowel cancer screening programme: faecal occult blood result’ (6866.00)) needed to 
be combined with one of the following ahdcodes from data4 to obtain a definitive 
outcome; P/N001 (negative), P/N002 (positive), PTH005 (normal), PTH010 (abnormal).  
Using this method, 3.03% of the data could be utilized this way (149/4914). Generic codes 
without further information could be dropped (2.44% of the data 120/4914). A further 28 
codes were identified when not restricting by ahdcode (all 9Ow2.00), this code did not 
need to be combined with further data as it was a definitive outcome. 
 
The output is a series of rules which will identify BCSP FOBT screening outcomes for all 
patients in the THIN database. Further work may be required to exclude individual 
influential outlying results from specific analyses. 
 
Data Source 
This analysis used a 1% random sample of all patients from THIN1601 as its data source. 
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Analysis Tools 
Stata version 14 was used to tabulate the frequency of Read code and value label 
combinations. The main command used to describe the data were ‘tabulate’. 
Procedure 
1. Identification of ahdcode(s) likely to contain BCSP FOBT Screening Outcomes. 
2. Restriction of medcodes (i.e. Read codes) to those associated with the BCSP. 
3. Tabulation of Read code and value label combinations by frequency. 
4. Search for BCSP FOBT Read codes which may have been recorded under another 
ahdcode.  
5. Description of the final method: a set of rules to be applied to identify BCSP FOBT 
Screening Outcomes. 
6. Example code for these rules in Stata 
 
4.2 Results: Development of a method to identify FOBT screening outcome from 
the AHD file in THIN 
 
4.2.1 Identification of ahdcode(s) likely to contain BCSP FOBT Screening Outcomes. 
 
The system lookup ahdcodes.dta was used to identify codes of interest to search in the 
ahd.dta (AHD file). The following ahd code was identified: 
Datafile Ahdcode Description 
TEST 1001400080 Faecal Occult Blood 
Table 9: Ahdcode identified from the system lookup table ahdcodes.dta. 
 
AHD codes were searched for the following key terms using regular expressions and 
scanning the data manually for: faecal occult blood test, FIT, Faecal immunochemical test, 
BCSP and screening. 
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4.2.2 Restriction of medcodes to those associated with the BCSP 
 
The medcodes associated with this ahdcode were summarised and any codes which were 
not associated with the BCSP were excluded from the analysis. 
Medcode Description Frequency 
6867.00 BCSP FOB testing kit spoilt 1 
4793.00 Faecal occult blood: trace 1 
8IA3.00 Bowel cancer screening declined 3 
68W2.00 Bowel cancer screening programme 6 
4795.00 Serial faecal occult blood normal 47 
4794.00 Faecal occult blood: positive 47 
479Z.00 Faecal occult blood NOS 71 
4791.00 Faecal occult blood requested 79 
686C.00 BCSP FOB tst incmplt participt 87 
686B.00 BCSP FOB test abnormal 92 
479..11 Faeces occult blood test 110 
6866.00 Bowel cancer screening programme: faecal occult blood result 269 
4792.00 Faecal occult blood: negative 564 
686A.00 BCSP FOB test normal 4465 
479..00 Faecal occult blood test 5669 
Table 10: Frequency of medcodes recorded under the Faecal Occult Blood 1001400080 AHD Code. The codes 
which have been scored out are those which were not related to the BCSP for FOBT results. 
The medcodes which were not related to the BCSP could be excluded from the analysis. 
These included: 4795.00, 4794.00, 479Z.00, 4791.00, 4793.00, 479..11, 4792.00, 479..00. 
68W2.00 relates to Bowel Scope Screening and was removed along with 8IA3.00 which is 
not one of the electronically sent codes from the BCSP. The other codes relate to FOBTs 
requested through primary care. 
6866.00 can be combined with other information to go within other categories (whether a 
positive or negative FOBT result) and is classed as a ‘generic code’. All other medcodes give 
a definitive outcome and can be used on their own without additional value labels (data1-
data6). 
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Medcode Description Frequency 
6867.00 BCSP FOB testing kit spoilt 1 
686C.00 BCSP FOB tst incmplt participt 87 
686B.00 BCSP FOB test abnormal 92 
6866.00 Bowel cancer screening programme: 
faecal occult blood result 
269 
686A.00 BCSP FOB test normal 4465 
Table 11: Medcodes of interest for FOBT Screening Outcomes after excluding those codes associated with 
primary care. 
4.2.3 Tabulation of Read code and value label combinations by frequency 
 
From scanning through the data1-data6 columns in the ahd.dta file, only data4 was 
populated with a value label. 
The units in the data4 column were summarised Table 12. 
Data4 Lookupdesc Frequency 
P/N002 Positive 17 
PTH010 Abnormal 71 
P/N001  Negative 564 
  930 
PTH005 Normal 3332 
Table 12: Value label descriptions for data derived from the AHD file relating to the ‘Faecal Occult Blood’ ahd 
code. 
Where there were no value labels this probably relates to the medcodes which do not 
need/have any further information. They give a definitive result on their own e.g. BCSP FOB 
test normal (686A.00). 
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The combinations of medcodes and value labels from data4 were summarised to 
determine how the data was generally being recorded (Table 13): 
data4 medcode Frequency Description of codes 
P/N002 686C.00 1 Positive/BCSP FOB tst 
incmplt particip 
 6867.00 1 BCSP FOB testing kit spoilt 
P/N002 6866.00 3 Positive/Bowel cancer 
screening programme: faecal 
occult 
 686B.00 8 BCSP FOB test abnormal 
P/N002 686B.00 13 Positive/BCSP FOB test 
abnormal 
PTH010 686B.00 71 Abnormal/BCSP FOB test 
abnormal 
 686C.00 86 BCSP FOB tst incmplt 
participt 
 6866.00 120 Bowel cancer screening 
programme: faecal occult 
blood 
P/N001 6866.00 146 Negative/Bowel cancer 
screening programme: faecal 
occult 
P/N001 686A.00 418 Negative/BCSP FOB test 
normal 
 686A.00 715 BCSP FOB test normal 
PTH005 686A.00 3332 Normal/ BCSP FOB test 
normal 
 Total 4914  
Table 13: Medcode and value label combination frequencies 
 
As identified above, 6866.00 (generic FOBT code) can be combined with the value labels in 
data4 (P/N001 (negative), P/N002 (positive), PTH005 (normal), PTH010 (abnormal)) to give 
definitive outcomes. All other medcodes can be used on their own as they give a definitive 
outcome. 
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4.2.4 Search for BCSP FOBT Read codes which may have been recorded under another 
ahdcode.  
 
In some instances, some of the screening codes (medcodes) may have been recorded 
under another ahdcode (other than the one relating to ‘Faecal Occult Blood’). The 
medcodes related to BCSP FOBT Screening Outcomes (identified from Read code lookups) 
were therefore searched in the whole 1% ahd file (i.e. not restricted by ahdcode). 
The following Read codes were searched for in the ahd data: 
 
6866. - Bowel cancer screening programme: faecal occult blood result 
6867. - Bowel cancer screening programme faecal occult blood testing kit spoilt 
686A. - Bowel cancer screening programme faecal occult blood test normal  
686B. - Bowel cancer screening programme faecal occult blood test abnormal 
686C. - Bowel cancer screening programme faecal occult blood testing incomplete participation 
9Ow2. - No response to bowel cancer screening programme invitation 
 
 
By tabulating the ahdcode, two other ahdcodes were identified (1001400153 and 
1001400329) which are used to record BCSP outcomes. These were not frequently used: 
ahdcode Freq Percent         Cumulative % 
1001400080 4,914  99.43        99.43 
1001400153 8        0.16        99.60 
1001400329 20 0.40 100.00 
Total 4,942 100.00  
Table 14: AHD codes from all the Read codes related to BCSP FOBT Screening Outcome. 
Tabulating the medcodes, identified that there was an additional medcode not covered by 
the ahdcode for ‘Faecal Occult Blood’. 
Medcode Freq. Percent Cumulative % 
6866.00 269         5.43 5.43 
6867.00 1 0.02 5.45 
686A.00 4,465 90.18 95.64 
686B.00 92 1.86 97.50 
686C.00 87         1.76 99.25 
9Ow2.00 28 0.57 100.00 
Total 4,942 100.00  
Table 15: All medcodes from the ahd data file not restricted by ahd code. 
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The additional 28 codes from the other ahdcodes are related to the 90w2.00 Read code 
(No response to bowel cancer screening programme invitation). A rule can be included to 
search the whole of the ahd file for this Read code or from the additional ahdcodes 
(1001400153, 1001400329). It also has a ‘definitive outcome’ so does not need to be 
combined with further data/information from data4. 
The uptake of the gFOBT is between 50-60% and therefore a similar proportion of ‘no 
response to bowel cancer screening programme invitation’ codes are expected as the 
proportion of FOBT result codes derived from THIN. However, this is not the case from the 
data derived. A significantly smaller number of ‘no response codes’ are seen in this dataset 
which suggests that this code is not being used for this purpose. This could be because it is 
mainly the test result (positive/negative) that the GP has responsibility to record.  
4.2.5 Description of the final method: a set of rules to be applied to identify BCSP FOBT 
Screening Outcomes. 
 
Based on all of the above investigations the following rules can be used to extract data for 
patients with FOBT Screening Outcomes. 
1. Select all records with ahdcode 1001400080 (Faecal Occult Blood)  
 
2. Keep any records when the medcode is equal to the following:  
"6866\.00|6867\.00|686A\.00|686B\.00|686C\.00|9Ow2\.00" 
 
3. Definitive BCSP code can be a medcode on its own. 
686A.00 – BCSP FOB test normal 
686B.00 – BCSP FOB test abnormal 
686C.00 – BCSP FOB tst incomplt participt 
6867.00 – BCSP FOB testing kit spoilt 
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4. Generic BCSP code (6866.00) needs to be combined with a data4 ahdcode for a definitive 
outcome (P/N001 (negative), P/N002 (positive), PTH005 (normal), PTH010 (abnormal)). 
 
6866.00 – Bowel cancer screening programme: faecal occult blood result 
5. Recode the description of the above ‘generic code plus data4 ahdcodes’ to fall into one 
of the defined categories (BCSP FOB test normal/BCSP FOB test abnormal). See Table 16. 
 
Category medcode Generic Combinations also classed under this category 
BCSP FOB test normal 686A.00 
 
Under AHD code 
1001400080 (Faecal Occult 
Blood) 
6866.00 – Bowel cancer screening programme: faecal occult 
blood result 
 
With ahdcode of:  
P/N001 Negative 
PTH005 Normal 
BCSP FOB test abnormal 686B.00 
 
Under AHD code 
1001400080 (Faecal Occult 
Blood) 
6866.00 – Bowel cancer screening programme: faecal occult 
blood result 
 
With ahdcode of: 
P/N002 Positive 
PTH010 Abnormal 
Table 16: Summary of combinations to include to identify BCSP FOBT Screening Outcomes. 
 
6. Drop records with a Generic BCSP code but no further codes/information recorded 
under data4 (6866.00 on its own). 
 
7. Include 9Ow2.00 under any ahdcode - No response to bowel cancer screening 
programme invitation (this does not need to be combined with anything else as it gives a 
‘definitive’ outcome). 
 
8. Drop if the event date is missing for any of these outcomes as the FOBT outcome date is 
required for the index date and to build a picture of screening history/analysis. 
These rules are summarised in Table 17.  
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Summary: 
Category medcode Generic Combinations also classed under this category 
BCSP FOB test normal 686A.00 
 
Under AHD code 
1001400080 (Faecal Occult 
Blood) 
6866.00 – Bowel cancer screening programme: faecal occult 
blood result 
 
With ahdcode of:  
P/N001 Negative 
PTH005 Normal 
BCSP FOB test abnormal 686B.00 
 
Under AHD code 
1001400080 (Faecal Occult 
Blood) 
6866.00 – Bowel cancer screening programme: faecal occult 
blood result 
 
With ahdcode of: 
P/N002 Positive 
PTH010 Abnormal 
BCSP FOB tst incomplt 
participt 
686C.00 
 
Under AHD code 
1001400080 (Faecal Occult 
Blood) 
- 
Bowel cancer screening 
declined 
8IA3.00 
 
Under AHD code 
1001400080 (Faecal Occult 
Blood) 
- 
BCSP FOB testing kit spoilt 6867.00 
 
Under AHD code 
1001400080 (Faecal Occult 
Blood) 
- 
No response to bowel cancer 
screening programme 
invitation 
9Ow2.00 
 
Under any ahdcode 
- 
Table 17: Summary of the combinations of medcodes and data4 codes used to extract BCSP outcomes. 
4.2.6 Example code for these rules  
 
The example code for use in Stata using the rules above is provided in Appendix 4. 
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4.3 Methods: Development of a method to identify haemoglobin concentration 
values in THIN 
 
Haemoglobin concentration (Hb) is a continuous value which has been most commonly 
recorded by pathology services as grams of haemoglobin per litre of blood (g/L) or grams of 
haemoglobin per decilitre of blood (g/dL). The Pathology Harmony Initiative18 notified all 
UK laboratories to standardise the units for full blood counts including Haemoglobin level 
and MCHC to g/L in April 2012.18 For example, 12 g/dL should now be reported as 120 g/L. 
UK laboratories then made this switch over the next year and ideally by 31st March 2013. 
This section describes the development of a method to extract valid Hb values from the 
AHD table in the THIN database.  
The method was an iterative process which systematically reviewed the numeric 
distribution of Hb values for combinations of Read codes and value labels observed in a 
THIN 1% sample. These were compared with a reference distribution for Hb to assess if 
they matched that distribution, required conversion before use, or were unlikely to contain 
Hb values and therefore excluded. Plausible Hb minimum and maximum values from an 
external source were then applied to the data as a final step in the method. 
Approximately 36.56% of Hb values associated with the final ahdcode of interest were Read 
coded or labelled differently than the reference distribution. This higher than expected 
proportion is due to the temporal change from the reference units of g/dL to g/L for UK 
laboratories in 2012. A transformation was then applied to approximately 30.87% of the 
values before use (i.e. these were values over 26.5 which would need to be divided by ten 
to be in the same units 74,769/242,214). Approximately 0.0045% of results (11 results out 
of 242,214 observations were outside the 1.6-26.5 range) were excluded as they were 
unlikely to contain valid Hb results. 
The output is a series of rules which will identify valid Hb results for all patients in the THIN 
database. Further work may be required to exclude individual influential outlying values 
from specific analyses. 
Data Source 
This analysis used a 1% random sample of all patients from THIN1601 as its data source. 
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Analysis Tools 
Stata version 14 was used to tabulate the frequency of Read code and value label 
combinations. The main commands used to describe the data were ‘tabulate’ and 
‘histogram’. 
Procedure 
1. Identification of ahdcode(s) likely to contain Hb values. 
2. Identification of a suitable reference distribution for Hb.  
3. Tabulation of Read code and value label combinations by frequency. 
4. Review of individual candidate distributions.  
5. Identification of GP requested plausible minimum and maximum values to be 
applied. 
6. Description of the final method: a set of rules to be applied to identify valid Hb 
values. 
4.4 Results: Development of a method to identify haemoglobin concentration 
values in THIN 
 
4.4.1 Identification of ahdcode(s) likely to contain Hb values 
 
The system lookup ahdcodes.dta were used to identify codes of interest to search in the 
ahd file (ahd.dta). 
The following codes were identified: 
datafile ahdcode description 
TEST 1001400317 Haematology screening tests 
TEST 1001400277 Carboxyhaemoglobin 
TEST 1001400214 Haemoglobin variants 
TEST 1001400044 Mean corpuscular haemoglobin 
TEST 1001400027 Haemoglobin 
Table 18: Potential ahdcodes which could contain Hb values. 
The 1001400027 ‘Haemoglobin’ ahdcode was the most relevant code to be used for data 
extraction. 
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The mean corpuscular haemoglobin of a sample is the average mass of haemoglobin in 
each red blood cell, and carboxyhaemoglobin measures haemoglobin combined with 
carbon monoxide.19 These codes were therefore not included for further investigation. 
In addition, ‘Haematology screening tests’ when investigated in the ahd table did not give 
medcodes relating to haemoglobin concentration. See Table 19 below. 
description Frequency Percent Cumulative % 
APTT inhibitor screening test 1 0.02 0.02 
Haematology screening test 17 0.27 0.29 
Haemoglobinopathy screening test 585 9.27 9.56 
Haemolysis screening test 5,517 87.45 97.00 
Sickle cell disease screening test 1 0.02 97.02 
Sickle cell test negative 15 0.24 97.26 
Sickle solubility test 129 2.04 99.30 
Thrombophilia screening test 44 0.70 100.00 
    Total 6,309 100 
 Table 19: Medcode descriptions associated with the ahdcode relating to ‘Haematology Screening Tests’. 
 
Finally, ‘Haemoglobin variants’ also did not give medcodes relating to the overall 
haemoglobin concentration and so this ahdcode was excluded from further analysis (Table 
20). 
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description        Frequency Percent Cumulative % 
Electrophoresis - Hb 254 4.06 4.06 
Haemoglobin A 369 5.90 9.97 
Haemoglobin A2 level 1,275 20.40 30.37 
Haemoglobin C level 11 0.18 30.54 
Haemoglobin D level 11 0.18 30.72 
Haemoglobin E level 3 0.05 30.77 
Haemoglobin F 1,495 23.92 54.69 
Haemoglobin O level 1 0.02 54.70 
Haemoglobin S Level 172 2.75 57.46 
Haemoglobin acid electrophoresis 3 0.05 57.50 
Haemoglobin alkaline electrophoresis 133 2.13 59.63 
Haemoglobin electrophoresis 1,520 24.32 83.95 
Haemoglobin variant NOS 65 1.04 84.99 
Haemoglobin variant test 392 6.27 91.26 
Haemoglobin variants 106 1.70 92.96 
Haemoglobinopathy DNA studies 10 0.16 93.12 
Kleihauer test 4 0.06 93.18 
Methaemoglobin level 8 0.13 93.31 
Oxyhaemoglobin level 3 0.05 93.36 
Red cell Haemoglobin A2 estimation 391 6.26 99.62 
Red cell haemoglobin S estimation 22 0.35 99.97 
Unstable haemoglobin level 2 0.03 100.00 
  
    
Total 6,250 100.00   
Table 20: Medcode descriptions associated with the ahdcode relating to Haemoglobin Variants. 
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4.4.2 Identification of a suitable reference distribution for Hb 
 
Reference values for an adult can be obtained from haematology textbooks, path labs, 
haematologists, or from internet sources (e.g. 
http://labtestsonline.org.uk/understanding/analytes/haemoglobin/tab/test )  
The Oxford Handbook of Clinical Haematology20 gives the following reference values for an 
adult: 
Normal values in an adult are approximately: 
-130 to 180 g/L (13 to 18 g/dL) of blood for males 
-115-165g/L (11.5-16.5 g/dL) of blood for females 
In most cases, the most common Read code and unit value label for the ahdcode of interest 
(identified from the ahd.dta file) is likely to be the lab result of interest, reported in the 
units of interest. This combination was taken as the reference distribution as it included the 
normal ranges described above. A further visual comparison of this Hb distribution with the 
distribution from an external data source was used to validate this decision. 
 
4.4.3 Tabulation of Read code and value label combinations by frequency 
 
The field called data2 in the ahd table contained continuous numeric values for records 
with the ahdcode of interest. For Read code (medcode field) and value label (data3 field) 
combinations, values were dropped if they were equal to 0, as this is biologically 
implausible and if they were missing. 
A new variable was generated called ‘value’ by converting the values stored as text in data2 
into numeric format so that the distribution could be observed. 
The medcodes were then analysed to see which ones were relevant for Hb continuous 
values (Table 21). 
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Medcode description Frequency 
423..00 Haemoglobin estimation 228570 
423..11 Hb estimation 12922 
4237.00 Haemoglobin normal 330 
424..00  Full blood count - FBC 135 
4235.00 Haemoglobin low 126 
423Z.00   Haemoglobin estimation NOS 58 
4236.00 Haemoglobin borderline low 31 
4239.00 Haemoglobin high 15 
4234.00 Haemoglobin very low 9 
42J..00 Neutrophil count 9 
423B.00 Haemoglobin abnormal 8 
4238.00 Haemoglobin borderline high 3 
4232.00   Haemoglobin requested 2 
D21z.00  Anaemia unspecified 2 
4231.00 Haemoglobin not estimated 1 
4233.00 Haemoglobin - sample sent 1 
423C.00 Haemoglobin H inclusion 1 
Table 21: All medcodes recorded under the ahd code for haemoglobin (1001400027). 
 
The 42J..00 (neutrophil count) medcode was removed as this is not a relevant medcode for 
Hb. The other medcodes were included as they relate to Hb concentration. 
The data3 column gives the unit ‘value labels’ for this subset of data. The text description 
(lookupdesc field) for each value label (data3 field) was derived from the system lookup 
table called ahdlookups.dta (Table 22). 
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data3 lookupdesc Frequency 
MEA056 g/dL 162903 
MEA057 g/L 66320 
MEA000 null value 6885 
  5717 
<None>  296 
g/dl.  32 
g/L  27 
MEA001 % 13 
g/l  11 
g/dL.   5 
MEA194 g/mol 3 
MEA049 g 2 
MEA015 /day 1 
MEA026 1 1 
MEA037 10*9/L 1 
MEA051 g(hgb) 1 
MEA055 g/d 1 
MEA080 mg 1 
MEA097 mmol/mol 1 
MEA114 pg 1 
gms/dl  1 
Table 22: Unit value labels recorded under data3 
 
The most frequent unit was g/dL, as this was the most commonly used unit in UK 
laboratories. There were also high numbers of values using the unit g/L due to laboratories 
standardising their units from 2012 onwards.18 The g/L unit would require conversion to 
match the reference distribution in this circumstance. This was taken into account when 
looking at the different value label and medcode combinations. 
All the possible medcode and unit code combinations were generated and ordered by most 
frequent. The first group combinations were labelled covering a cumulative percentage of 
over 99% of the data (Table 23). 
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Group Combination number data3 medcode Frequency Percentage of Total Cumulative % 
1 MEA056 423..00 153671 0.634 0.634 
2 MEA057 423..00 64853 0.268 0.902 
3 MEA056 423..11 8779 0.036 0.938 
4 MEA000 423..00 6496 0.027 0.965 
5  423..00 3185 0.013 0.978 
6  423..11 2512 0.010 0.989 
7 MEA057 423..11 1446 0.006 0.995 
Table 23: Unit value labels and medcode combinations. Blank boxes relate to when there is no value label. 
assigned. 
Median values were generated for each Read code (medcode field) and value label (data3 
field) combination, this helps when there are bimodal/multimodal distributions (Table 24). 
For example, the unit/medcode combination for different peaks in the distribution can be 
identified, which allows separation/conversion of the data if required.  
data3 medcode Median value of Hb Frequency 
MEA056 423..00 13.40 153671 
MEA057 423..00 135.00 64853 
MEA056 423..11 13.20 8779 
MEA000 423..00 13.70 6496 
 
423..00 108.00 3185 
 
423..11 131.00 2512 
MEA057 423..11 132.00 1446 
<None> 423..00 13.50 296 
MEA056 4237.00 13.50 172 
MEA000 423..11 13.55 154 
MEA000 4237.00 12.90 152 
MEA056 424..00 13.55 134 
MEA056 4235.00 10.90 66 
MEA056 423Z.00 13.50 53 
MEA000 4235.00 11.80 38 
g/dl. 423..00 13.20 28 
MEA000 4236.00 11.30 27 
g/L 423..11 134.00 19 
 
4235.00 11.40 15 
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g/l 423..00 142.00 11 
MEA056 4239.00 120.00 11 
g/L 423..00 121.00 8 
MEA057 4235.00 100.00 7 
MEA000 423B.00 10.60 7 
MEA001 423..00 8.00 7 
MEA056 42J..00 4.57 7 
MEA000 4234.00 82.00 6 
g/dL. 423..00 13.40 5 
MEA057 4237.00 125.00 5 
MEA057 423Z.00 134.00 4 
g/dl. 423..11 10.75 4 
MEA001 423..11 3.35 4 
MEA000 4239.00 133.00 4 
MEA057 4236.00 114.00 3 
MEA194 423..00 132.00 3 
MEA056 4238.00 15.30 2 
MEA056 4232.00 11.40 2 
MEA056 4234.00 5.60 2 
 
D21z.00 57.40 2 
MEA001 42J..00 47.95 2 
MEA049 423..00 12.45 2 
MEA114 423..00 29.70 1 
MEA057 4234.00 76.00 1 
MEA080 423..00 115.00 1 
MEA056 423B.00 11.50 1 
MEA015 423..11 24.08 1 
 
4236.00 11.50 1 
MEA097 423..11 54.00 1 
gms/dl 423..00 12.00 1 
MEA056 423C.00 14.10 1 
 
4237.00 12.30 1 
MEA026 423..11 13.50 1 
MEA055 423..00 14.20 1 
MEA056 4231.00 144.00 1 
MEA057 424..00 122.00 1 
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MEA051 423..11 13.00 1 
 
423Z.00 14.10 1 
MEA037 423..00 12.30 1 
MEA000 4238.00 14.90 1 
MEA056 4233.00 13.00 1 
Table 24: Median value of Hb for each unit value label and medcode combination. Blank boxes relate to when 
there is no value label. 
4.4.4 Review of individual candidate distributions.  
 
A new variable called ‘combogroup’ was generated and assigned a group combination 
number for each Read code (medcode field) and value label (data3 field) pair investigated 
(See Table 23 above). 
4.4.4.1 Reference Distribution Group Combination 1 (MEA056 and 423..00) 
 
The reference distribution is the most common Read code (medcode field) and value label 
(data3 field) combination. The other most frequent combinations were compared to this 
group and the remaining small groups were then combined together for analysis once over 
95% of the data was covered. In this case, the most frequent Read code and unit value 
label combination was when data3 was MEA056 (g/dL) and the medcode was 423..00 
(haemoglobin estimation). 
 
This pair was assigned as combogroup 1. 
 
A histogram was produced to summarise the distribution and to determine the maximum 
and minimum values. Below is the code used in Stata to produce Figure 10: 
hist value if medcode=="423..00" & data3=="MEA056", width(1) 
summarize value if medcode=="423..00" & data3=="MEA056" 
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Variable Obs Mean Std.Dev. Min Max 
Value 153,671     15.4 15.8         0.2         228.0 
Figure 10: The plot shows frequency density by haemoglobin value concentration for the reference distribution 
(MEA056 g/dL and medcode 423..00 haemoglobin concentration) 
The reference range is between 11.5-18 g/dL of blood.  
Based on the maximum value observed, there could be a distribution higher than expected 
for this medcode and value label pair. Therefore, the values of haemoglobin over 50 g/dL 
were investigated and all values for this pair were tabulated to analyse the frequencies at 
higher values. Below is the code used in Stata to produce Figure 11. 
hist value if medcode=="423..00" & data3=="MEA056" & value>50, width(1) frequency  
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Figure 11: Hb values above 50 for the reference distribution (MEA056 g/dL and medcode 423..00 haemoglobin 
concentration). 
This distribution is about ten times the value of the lower distribution; therefore it can be 
concluded that these values might have been given the incorrect value label. The next most 
common value label is ‘g/L’ which is ten times the ‘g/dL’ unit. 
Based on the GP requested plausible values from the external data source a cut-point was 
chosen to separate these two distributions. 
Conclusion: If the value is over 26.5 for this unit then divide by 10 based on the GP 
requested plausible ranges. 
4.4.4.2 Group Combination 2 (MEA057 and 423..00) 
 
The next most common medcode and value label combination was compared with the 
reference distribution. This was MEA057 g/L and 423..00 haemoglobin estimation. This 
combination was assigned as combogroup 2. 
The code used in Stata to produce the histogram and summary statistics for Figure 12 is 
shown below. 
hist value if medcode=="423..00" & data3=="MEA057", width(1)  
summarize value if medcode=="423..00" & data3=="MEA057" 
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Variable Obs Mean Std.Dev. Min Max 
Value 64,853 133.9 17.3 0.4 241.0 
Figure 12: Distribution (Hb value) for MEA057 and 423..00. 
Figure 12 shows that there could be a second lower peak at about 15 g/L in the distribution 
of values which is lower than expected for this medcode and unit pair. Therefore, the 
values of Hb lower than 50 g/L were tabulated for this pair to see the frequencies/any 
peaks at lower values (Figure 13). See Stata code below: 
 
hist value if medcode=="423..00" & data3=="MEA057"& value<50, frequency 
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Figure 13: Hb values below 50 for combination group 2 (MEA057 and 423..00). 
Based on the GP requested plausible values, a cut-point was chosen for these two 
distributions to utilise all the data. 
Conclusion: If the value is over 26.5 then divide by 10. 
4.4.4.3 Group Combination 3 (MEA056 and 423..11) 
 
The next most common value label and medcode pair was MEA056 g/dL and 423..11 (Hb 
estimation). This was assigned as combogroup 3.  
 
Below is the Stata code used to produce Figure 14: 
 
hist value if medcode=="423..11" & data3=="MEA056", width(1) 
summarize value if medcode=="423..11" & data3=="MEA056" 
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Variable Obs Mean Std. Dev. Min Max 
Value 8,779     19.5      27.2        1.8 183.0 
Figure 14: Distribution (Hb value) for MEA056 and 423..11. 
 
There is a potential higher distribution present since the reference range is between 11.5-
18 g/dL of blood. Based on the maximum value, there could be a distribution higher than 
expected for this medcode and unit pair. Therefore, values of Hb over 50g/dL were 
tabulated for this pair to inspect the frequencies at higher values. 
hist value if medcode=="423..11" & data3=="MEA056" & value>50, width(1) 
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Figure 15: Hb values above 50 for combination group 3 (MEA056 and 423..11). 
Again this is about ten times the value of the lower distribution, it can therefore be 
concluded that these values may have been given the incorrect unit label.  
The next most common unit label is g/L which is ten times 12-18 g/dL of blood.  
Based on the GP requested plausible values, a cut-point was chosen for these two 
distributions to utilise all the data. 
Conclusion: If the value is over 26.5 then divide by 10.  
4.4.4.4 Group Combination 4 (MEA000 and 423..00) 
 
The next most common value label and medcode combination was MEA000 (null value) 
and 423..00 (haemoglobin estimation).  
This was assigned as combogroup 4.  
The histogram and summary statistics for Figure 16 was produced using the following Stata 
code.  
hist value if medcode=="423..00" & data3=="MEA000", width(1) 
summarize value if medcode=="423..00" & data3=="MEA000" 
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Variable Obs Mean Std. Dev. Min Max 
Value 6,496     53.9 1387.4 1.7 110000.0 
Figure 16: Distribution (Hb value) for MEA000 and 423..00 
 
Since there was a very large value (over 100,000) present for this combination, the 
distribution could not be visualized in detail. The data was therefore summarised and this 
identified that there was a maximum value of 110,000. This could not be explained by any 
other unit and was outside the GP requested plausible ranges.  
To determine how many values there were in this top range, the data was tabulated using 
the following Stata code:  
 
tabulate value if medcode=="423..00" & data3=="MEA000" 
 
There were only one or two values this high (See Table 25) so it was concluded that these 
are potential outliers and have been inputted/recorded incorrectly. 
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Value Frequency Percent Cumulative Percent 
179 1 0.02 99.94 
187 1 0.02 99.95 
195 1 0.02 99.97 
20000 1 0.02 99.98 
110000 1 0.02 100.00 
Table 25: Frequency of higher Hb values for MEA000 and 423..00. 
Large values such as these will be taken into account when setting the GP requested 
plausible maximum value (e.g. exclude values over 265 g/L or 26.5 g/dL). 
By limiting the Hb value to below 200, the distribution could be analysed more closely. The 
Stata code for Figure 17 is given below: 
hist value if medcode=="423..00" & data3=="MEA000" & value<200, width(1) frequency 
 
 
Figure 17: Hb values below 200 for combination group 4 (MEA000 and 423..00). 
Two distributions were visible again as seen in the previous combination groups.  
The cut-off was then set to above 50 but below 200, so the higher distribution could be 
visualised (Figure 18). 
Stata code given below: 
hist value if medcode=="423..00" & data3=="MEA000" & value>50 & value<200 
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Figure 18: Hb values below 200 and over 50 for combination group 4 (MEA000 and 423..00). 
The lower distribution was visualised by restricting the Hb value to below 50.  
Stata code given below (Figure 19): 
hist value if medcode=="423..00" & data3=="MEA000" & value<50 
 
Figure 19: Hb values below 50 for combination group 4 (MEA000 and 423..00). 
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Based on the GP requested plausible values, a cut point was chosen for these two 
distributions to utilise all the data. 
Conclusions: If the value is over 26.5 then divide by 10.  
If the values are over 26.5 after conversion they can be excluded from the analysis as this is 
outside the GP requested range seen in the external data. 
4.4.4.5 Group Combination 5 (‘No unit’ and 423..00) 
 
The next most common combination was ‘no unit’ and 423..00.  
This was assigned as combo group 5. 
The histogram and summary statistics for Figure 20 were produced using the following 
Stata code.  
hist value if medcode=="423..00" & data3=="", width(1)  
summarize value if medcode=="423..00" & data3=="" 
 
Variable Obs Mean Std. Dev. Min Max 
Value 3,185     77.2     61.0 6.0 185.0 
Figure 20: Distribution (Hb value) for ‘No unit’ and 423..00 
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Based on the GP requested plausible values a cut-point was chosen for these two 
distributions to utilise all the data. 
Conclusion: If the value is over 26.5 then divide by 10.  
4.4.4.6 Group Combination 6 (‘No unit’ and 423..11) 
 
The next most common combination was ‘no unit’ and 423..11. This was assigned as combo 
group 6 and the histogram and summary statistics for Figure 21 were produced using the 
following Stata code: 
hist value if medcode=="423..11" & data3=="", width(1) 
  
summarize value if medcode=="423..11" & data3=="" 
 
Variable Obs Mean Std. Dev. Min Max 
Value 2,512     124.4      31.8          10.0 188.0 
Figure 21: Distribution (Hb value) for ‘No unit’ and 423..11 
Based on the GP requested plausible values, a cut-point was chosen for these two 
distributions to utilise all the data. 
Conclusion: If the value is over 26.5 then divide by 10. 
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4.4.4.7 Group Combination 7 (MEA057 and 423..11) 
 
The next most common combination was MEA057 and 423..11.  
This was assigned as combogroup 7. 
The histogram and summary statistics for Figure 22 were produced using the following 
Stata code: 
hist value if medcode=="423..11" & data3=="MEA057", width(1)  
 
summarize value if medcode=="423..11" & data3=="MEA057" 
 
Variable Obs Mean Std. Dev. Min Max 
Value 1,446     128.6     26.8 9.0 184.0 
Figure 22: Distribution (Hb value) for MEA057 and 423..11 
Based on the GP requested plausible values, a cut-point was chosen for these two 
distributions to utilise all the data. 
 
Conclusion: If the value is over 26.5 then divide by 10. 
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4.4.4.8 Remaining Group Combinations 
 
For the final step, the remaining infrequent value label and medcode combinations were 
investigated altogether. Ninety-nine per cent of the data have been covered using the 
combinations above so this was investigating a much smaller amount of data (Figure 26). 
combogroup Frequency Percent Cum. 
1 153,671 63.44 63.44 
2 64,853 26.78 90.22 
3 8,779 3.62 93.84 
4 6,496 2.68 96.53 
5 3,185 1.31 97.84 
6 2,512 1.04 98.88 
7 1,446 0.60 99.47 
(all remaining combinations) . 1,272 0.53 100.00 
    Total 242,214 100 
 Table 26: Frequency of different group combinations of medcodes and value labels. 
 
The following Stata code was used to summarise the remaining group combinations: 
hist value if combogroup==.,  
summarize value if combogroup==. 
The distribution of the remaining group combinations is shown in Figure 23. 
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Variable Obs Mean Std. Dev. Min Max 
Value 1,272 23.6 32.6 1.0 163.0 
Figure 23: Distribution (Hb value) for all remaining group combinations. 
 
The histogram shows a bimodal distribution as observed in previous combinations. 
Hb values below 50 were then investigated using the following Stata code (Figure 24): 
hist value if combogroup==. & value<50, frequency 
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Figure 24: Hb values below 50 for remaining group combinations. 
To investigate the distribution for values over 50 the following Stata code was used (Figure 
25): 
hist value if combogroup==. & value>50, frequency 
 
Figure 25: Hb values above 50 for remaining group combinations 
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Based on the GP requested plausible values, a cut-point was chosen for these two 
distributions to utilise all the data. 
Conclusion: If the value is over 26.5 then divide by 10. 
4.4.5 Identification of GP requested plausible minimum and maximum values to be 
applied 
 
The distribution of values obtained from a local hospital laboratory for GP requested Hb 
tests in the past three years was compared with the observed THIN distribution.  
The distribution of Hb values from local lab data is shown in Figure 26. This distribution is 
for both males and females, for all ages in the recommended g/L units. The minimum result 
reported by the laboratory was 16 g/L and the maximum was 265 g/L. Summary statistics 
for this local lab data are also shown in Table 27. 
 
Figure 26: Distribution of Hb values from local lab data for GP requested tests. 
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Percentiles Smallest 
  1% 91 16 
  5% 108 32 
  10% 116 40 Obs 103,801 
25% 126 40 Sum of Wgt. 103,801 
     50% 137 
 
Mean 136.04 
  
Largest Std. Dev. 16.35 
75% 147 246 
  90% 156 252 Variance 267.39 
95% 161 256 Skewness -0.39 
99% 172 265 Kurtosis 4.13 
 
Percentile Hb Value 
0.001 32 
0.01 48 
0.1 68 
1 91 
25 126 
50 137 
75 147 
99 172 
99.9 185 
99.99 213 
99.999 256 
Table 27: Summary statistics for Hb values from local lab data for GP requested tests 
 
For the reference distribution derived from THIN (the most common medcode and unit 
value label combination), the following values/distribution are shown in Table 28 and 
Figure 27. Since there was a bimodal distribution for the reference distribution due to the 
presence of two different units, the Hb value was restricted to below (or equal to) 26.5 for 
these investigations. The following Stata code is listed below. 
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summarize value if medcode=="423..00" & data3=="MEA056" & value<=26.5, detail 
 
hist value if medcode=="423..00" & data3=="MEA056" & value<=26.5 
 
_pctile value  if medcode=="423..00" & data3=="MEA056" & value<=26.5, p(0.001, 0.01, 
0.1, 1, 25, 50, 75, 99, 99.9, 99.99, 99.999) 
 
return list 
 
Percentiles Smallest 
  1% 8.7 0.2 
  5% 10.4 0.42 
  10% 11.2 0.9 Obs 150,912 
25% 12.3 0.95 Sum of Wgt. 150,912 
     50% 13.4 
 
Mean 13.31 
  
Largest Std. Dev. 1.69 
75% 14.4 21.1 
  90% 15.4 21.3 Variance 2.859 
95% 15.9 22.4 Skewness -0.449 
99% 16.9 22.4 Kurtosis 3.99 
 
Percentile Hb Value 
0.001 0.4 
0.01 3.4 
0.1 6.4 
1 8.7 
25 12.3 
50 13.4 
75 14.4 
99 16.9 
99.9 18.1 
99.99 19.6 
99.999 22.4 
Table 28: Summary statistics for Hb values for the THIN reference distribution (limited to below 26.5 g/dL due to 
the bimodal distribution). 
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Figure 27: Distribution of Hb values from the THIN database for the reference distribution (restricted to below 
26.5 g/dL due to the bimodal distribution). 
 
By limiting the data to below 26.5 g/dL these THIN results roughly match the local lab data 
(when converting units by multiplying by ten) particularly when comparing median values 
and the density. Therefore, this external data can be used for defining minimum and 
maximum results to the derived haemoglobin concentrations. 
 
Minimum – 16 g/L (1.6 g/dL) 
Maximum – 265 g/L (26.5 g/dL) 
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4.4.6 Description of the final method: a set of rules to be applied to identify valid Hb 
values. 
 
Based on all of the above investigations the following rules can be applied to extract data 
for patients with a continuous Hb concentration result. 
1. Select all records with ahdcode 1001400027 (This is haemoglobin). 
2. Drop records with medcode 42J..00. (This is the medcode for neutrophil count.) 
3. If the value in the data2 field is over 26.5 then divide by ten (these are mostly g/L) to 
convert them to the reference units in this case g/dL. 
e.g.  
generate value = data2 
replace value = (value/10) if value>26.5 & !missing(value) 
 
4. Drop records where the value is outside the range 1.6-26.5. (These are the minimum and 
maximum values reported by the hospital laboratory for GP initiated Hb. This will also 
remove any values which are missing or equal to 0.) 
5. Drop records where the event date is missing. (They cannot be used in any analyses 
without a date.) 
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5.0 Compiling Read Code Lists 
 
In order to extract the relevant data in Chapter 5, a clinical code/Read code list was 
generated for over 30 different clinical features and risk factors. Translation of symptoms 
into clinical Read codes was informed by previous work by Professor Tom Marshall which 
analysed predictors of colorectal cancer.21 In addition, the ClinicalCodes repository set up 
by the University of Manchester and funded by the NIHR was also used to help develop 
code lists (https://clinicalcodes.rss.mhs.man.ac.uk/).22 
The methodology described by Davé and Peterson3 along with the THIN Data Guide for 
Researchers1 was used to help inform a strategy for code set engineering. An evolving and 
iterative search strategy was used to search the Read code dictionary provided with THIN 
for key words using the ‘regexm’ function implemented in Stata. From the keyword search 
it was then possible to identify relevant parent and child stems for Read codes. These 
additional stems were then browsed for inclusion and all possible terms relating to a 
particular symptom or/diagnosis were extracted into an Excel Spreadsheet. This resulting 
Read code list was then subjected to review by one individual before being second 
reviewed by a clinician with expertise within that field for code set validation. This final 
Read code list was then used to extract bowel cancer screening diagnoses from the THIN 
database for analysis. 
In some instances, previous code lists were examined to identify keywords for the iterative 
search strategy and to examine Read code stems to ensure no key terms were missed. 
5.1 Read Code List Development for Bowel Cancer Diagnosis 
 
This section reports the derivation of a Read code list for Bowel Cancer Diagnosis; the key 
outcome used for analysis in Chapter 5. An evolving and iterative search strategy was used 
to search the Read Code dictionary for key words using the ‘regexm’ function (regular 
expressions) implemented in Stata. This search strategy was kept broad since detailed 
review of the preliminary list will remove any irrelevant terms. Key terms were discussed 
with another reviewer/clinician and previous lists from ClinicalCodes and other previous 
research were used when compiling the search. 
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Words encompassing the region of interest (bowel, colon, caecum, gastrointestinal tract 
etc) along with synonyms for cancer (e.g. neoplasia, carcinoma, cancer, adenocarcinoma) 
were combined in the search strategy. The final search strategy developed in Stata is 
shown in Table 29. 
 
 
Table 29: Key word search strategy for bowel cancer diagnosis developed in Stata 14. 
 
The Read code dictionary includes a description with the relevant Read code and 
associated stems. The resulting list of Read codes and the corresponding descriptions from 
the initial search were examined and saved in an Excel Spreadsheet. A note was made for 
any codes which could be removed based on this initial review. For instance, most of the 
bowel cancer screening codes were not relevant for this particular term. In addition, codes 
such as the ‘QCancer colorectal cancer risk calculator’ (38GT000) could be marked for 
exclusion. See Table 30 for an extract of the key word search results in Stata. 
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Table 30: Extract of results from Stata using the key word search complied for bowel cancer diagnosis 
From this initial list, the Read code hierarchies of relevance could be examined. For bowel 
cancer diagnosis the code stems B….00 (Neoplasms), B….11 (Cancers) and 68…00 
(Screening) were of relevance.  
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Since Read codes are hierarchical, all relevant parent codes along with the child codes (and 
sibling codes) were assessed for inclusion above and below these values (see Table 31 for 
an example). 
Read Code Description Code Type 
B13..00 Malignant neoplasm of colon Parent code 
B130.00 Malignant neoplasm of hepatic flexure of colon Child code 
B131.00 Malignant neoplasm of transverse colon Child code 
B132.00 Malignant neoplasm of descending colon Child code 
B133.00 Malignant neoplasm of sigmoid colon Child code 
B134.00 Malignant neoplasm of caecum Child code 
B134.11 Carcinoma of caecum Sibling code 
Table 31: Hierarchical relationships between Read codes used for malignant neoplasm of Colon as an example. 
By browsing the parent stems, the following relevant stems displayed in Table 32 were of 
relevance. By looking at the hierarchies as well as the key word search, additional Read 
codes could be identified.  
 
browse if regexm(medcode, "^B\..*|^B1.*|^B5.*|^B8.*|^B9.*|^BA.*|^BB.*|^By.*|^Bz.*") 
& case ==0 
browse if regexm(medcode, "^68\..*|^681.*|^686.*|^68P.*|^68Q.*|^68W.*|^68Z.*") & 
case ==0 
 
Table 32: Read code stems of relevance search for bowel cancer diagnosis in Stata. 
The relevant child stems from this search were then browsed for inclusion. All possible 
relevant Read codes were extracted into Excel and sorted by Medcode. The key word 
search was then adjusted to include any additional terms/synonyms which may have been 
initially missed but identified by analysing the hierarchies. This cycle of key word search 
followed by hierarchical inclusion continued until all key terms had been identified along 
with the corresponding hierarchies. 
This resulting Read code list was then subjected to review by one individual to determine 
which terms should be included along with the relevancy to the research question. The 
decision of the reviewer was marked clearly in an Excel spreadsheet. This list was then 
provided to a clinician for a second review before discussing the final list, providing a form 
of code set validation (See Appendix 2 for 1st and 2nd reviewer decisions). Read code 
frequency tables provided by THIN in ancillary tables were used to determine how often a 
Read code was used to aid with decision making. 
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The final consensus Read code list had 42 codes and was then used to extract bowel cancer 
diagnoses from the THIN database for analysis (Appendix 2).  This strategy ensured that all 
key terms were identified for extraction with clinician input. 
6.0 Compiling Drug Code Lists 
 
The drug code dictionary in THIN contains encrypted drug codes, generic drug names as 
well as the BNF Chapters the drug may be mapped to.  This was used to produce drug code 
lists for use in Chapter 5 and included; antispasmodics, anti-motility drugs and laxatives. It 
was investigated further as to whether these prescriptions also related to the 
corresponding symptom and were combined into one variable where appropriate. This was 
the case for abdominal pain and antispasmodic prescription since they had very similar 
hazard ratios. 
The drug code strategy built upon previous methodology described by Davé and Petersen3 
as well as the THIN Data Guide for Researchers produced by IMS Health1. 
6.1 Drug Code List Development for Laxatives 
 
This section describes the methods used to derive a laxative drug code list. These 
prescriptions can be used as a proxy for a symptom of constipation. 
To formulate a key word search using the generic name listed in the drug code dictionary, 
the British National Formulary (www.bnf.org) was used to identify that laxative drugs were 
listed under Chapter 1.6. There are 4 main types of laxative: Bulk-forming laxative (1.6.1), 
stimulant laxatives (1.6.2), faecal softeners (1.6.3) and osmotic laxatives (1.6.4).  Since the 
drug codes and generic drug names are mapped to BNF codes this was then used to 
generate the search strategy along with clinician input.  
Other drug codes for laxative drugs may be listed under other BNF Chapters. In addition, 
over time new drugs are introduced and old drugs are removed and may be mapped to 
different BNF Chapters as the BNF is published every 6 months. The key word search will be 
able to identify these additional drug codes. 
The key word search code used in Stata is shown in Table 33. 
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replace case=1 if 
regexm(lcase,"ispaghula|fibrelief|fybogel|isogel|ispagel|regulan|methylcellulose|cele
vac|sterculia|normacol")  
 
replace case=1 if 
regexm(lcase,"bisacodyl|sodium.*picosulfate|dulcolax|pico.*liquid|pico.*perles|docusa
te.*sodium|dioctyl.*sodium.*sulphosuccinate|dioctyl|docusol|norgalax.*micro-
enema|glycerol|gylcerin|senna|sennoside|manevac|senokot|sodium.*picosulfate|dulcolax"
)  
 
replace case=1 if regexm(lcase,"arachis.*oil|liquid.*paraffin") 
 
replace case=1 if regexm(lcase, 
"lactulose|macrogol|polyethylene.*glycol|laxido|molaxole|movicol|norgine|magnesium.*s
alt|magnesium.*hydroxide|magnesium.*sulphate|phosphates.*rectal|carbalax|sodium.*acid
.*phosphate|sodium.*dihydrogen.*phosphate|fleet|casen.*fleet|phosphates.*enema|sodium
.*citrate|microlette.*micro.*enema|micralax|relaxit") 
 
Table 33: Iterative Search Strategy performed in Stata for laxative drugs. 
All drug codes in Chapter 1.6 were added to the growing code list to ensure all potentially 
relevant codes had been added. The Stata code to add all the drug codes in Chapter 1.6 is 
provided in Table 34 below. 
 
replace case=1 if (regexm(bnfcode1, "^01\.06\.00")|regexm(bnfcode2, 
"^01\.06\.00")|regexm(bnfcode3, "^01\.06\.00"))& case ==0 
replace case=1 if (regexm(bnfcode1, "^01\.06\.01")|regexm(bnfcode2, 
"^01\.06\.01")|regexm(bnfcode3, "^01\.06\.01"))& case ==0 
replace case=1 if (regexm(bnfcode1, "^01\.06\.02")|regexm(bnfcode2, 
"^01\.06\.02")|regexm(bnfcode3, "^01\.06\.02"))& case ==0 
replace case=1 if (regexm(bnfcode1, "^01\.06\.03")|regexm(bnfcode2, 
"^01\.06\.03")|regexm(bnfcode3, "^01\.06\.03"))& case ==0 
replace case=1 if (regexm(bnfcode1, "^01\.06\.04")|regexm(bnfcode2, 
"^01\.06\.04")|regexm(bnfcode3, "^01\.06\.04"))& case ==0 
 
Table 34: Stata code to add the drugs from Chapter 1.6 to the growing drug code list for laxatives. 
 
Any mention of dantron was removed as advised by the clinician (this drug is for terminally 
ill patients) along with certain types of drug formulation which are detailed in the drug 
code dictionary. For example, dressings, paediatric medications and creams were all 
excluded. This reduced the final list to review (see Table 35). 
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//Remove any mention of dantron as this is for terminally ill patients 
replace case=0 if regexm(lcase, "dantron|co.*danthramer|co.*danthrusate") 
 
//Scan through the types of drugs genericname 
//Remove drugs which are creams, dressings, paediatric medications etc 
replace case=0 if regexm(lcase, 
"dressing|poultice|eye|paediatric|injection|ear.*drop|cream|biscuit|syringe|ointment|
bath.*additive|bath.*oil|emollient|soap|shampoo") 
 
//Can we remove any by formulation? 
tab formulation 
replace case=0 if regexm(formulation, "dressings|drops|paediatric|infant 
suppositories") 
 
Table 35: Stata code to remove formulations or drugs which are not of interest for the drugcode list review for 
laxatives. 
It was then investigated whether the drug codes identified were mapped to another 
Chapter by tabulating the combinations of bnfcodes included in the drug code dictionary 
(Table 36). There were 71 combinations, with Chapter 1.6 being the most frequently used. 
Several of the drug codes identified from the search mapped to Chapter 13 (Skin) and 
Chapter 7 (genito-urinary system). These were removed after the key word search but 
before re-adding all the drug codes mapped to Chapter 1.6 to ensure no codes in BNF 
Chapters 1.6 were missed (Chapter 1.6 could be in bnfcode1, bnfcode2 or bnfcode 3 
column). Stata code shown below in Table 37. 
bnfcode1 bnfcode2 bnfcode3 Combination Frequency 
01.06.02.00 01.01.01.00 01.06.03.00 1 
12.03.04.00 12.03.01.00 00.00.00.00 1 
09.05.01.03 00.00.00.00 00.00.00.00 1 
09.04.04.02 00.00.00.00 00.00.00.00 1 
13.10.05.00 00.00.00.00 00.00.00.00 1 
13.07.00.00 00.00.00.00 00.00.00.00 1 
12.03.03.00 00.00.00.00 00.00.00.00 1 
01.03.01.00 00.00.00.00 00.00.00.00 1 
01.01.01.00 01.06.04.00 00.00.00.00 1 
13.11.05.00 00.00.00.00 00.00.00.00 1 
12.03.05.00 00.00.00.00 00.00.00.00 1 
04.05.01.00 00.00.00.00 00.00.00.00 1 
13.02.01.00 13.02.01.01 00.00.00.00 1 
23.01.00.00 00.00.00.00 00.00.00.00 1 
09.04.01.00 00.00.00.00 00.00.00.00 1 
01.06.04.00 13.01.01.00 00.00.00.00 1 
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01.01.01.00 01.01.00.00 00.00.00.00 1 
13.02.01.01 00.00.00.00 00.00.00.00 1 
13.15.00.00 00.00.00.00 00.00.00.00 1 
07.06.00.00 00.00.00.00 00.00.00.00 1 
09.06.04.00 00.00.00.00 00.00.00.00 1 
24.00.00.00 00.00.00.00 00.00.00.00 1 
01.06.00.00 01.06.04.00 00.00.00.00 2 
01.04.01.00 00.00.00.00 00.00.00.00 2 
05.05.01.00 01.06.02.00 05.05.01.00 2 
02.12.00.00 00.00.00.00 00.00.00.00 2 
01.06.05.00 01.06.04.00 00.00.00.00 2 
13.05.02.00 00.00.00.00 00.00.00.00 2 
01.02.01.00 00.00.00.00 00.00.00.00 2 
01.01.02.02 00.00.00.00 00.00.00.00 2 
01.07.01.00 00.00.00.00 00.00.00.00 2 
05.01.12.00 00.00.00.00 00.00.00.00 2 
01.02.00.00 00.00.00.00 00.00.00.00 2 
01.00.00.00 01.01.00.00 00.00.00.00 2 
01.06.02.00 01.06.01.00 01.06.02.00 2 
01.06.03.00 01.06.03.00 00.00.00.00 2 
01.01.02.01 00.00.00.00 00.00.00.00 2 
13.04.00.00 00.00.00.00 00.00.00.00 3 
01.06.04.00 01.01.01.00 00.00.00.00 3 
01.06.00.00 01.06.02.00 00.00.00.00 3 
04.05.01.00 01.06.01.00 00.00.00.00 3 
01.06.02.00 01.06.02.00 01.06.01.00 3 
01.06.04.00 01.06.05.00 00.00.00.00 3 
01.01.02.00 00.00.00.00 00.00.00.00 3 
01.01.01.03 00.00.00.00 00.00.00.00 3 
07.04.04.00 00.00.00.00 00.00.00.00 3 
01.06.00.00 00.00.00.00 00.00.00.00 3 
13.01.00.00 00.00.00.00 00.00.00.00 3 
01.06.05.00 01.06.05.00 01.06.02.00 4 
01.02.00.00 01.06.01.00 01.02.00.00 4 
09.05.02.01 00.00.00.00 00.00.00.00 4 
01.01.01.01 00.00.00.00 00.00.00.00 5 
01.02.00.00 01.02.00.00 01.06.01.00 5 
01.06.04.00 01.06.03.00 01.01.01.00 5 
13.09.00.00 00.00.00.00 00.00.00.00 6 
13.02.01.02 00.00.00.00 00.00.00.00 6 
03.09.01.00 00.00.00.00 00.00.00.00 6 
01.01.01.00 01.01.01.00 00.00.00.00 7 
03.09.02.00 00.00.00.00 00.00.00.00 7 
01.06.05.00 00.00.00.00 00.00.00.00 8 
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01.01.01.00 00.00.00.00 00.00.00.00 9 
13.02.01.00 00.00.00.00 00.00.00.00 10 
01.06.01.00 01.06.01.00 00.00.00.00 10 
01.06.03.00 00.00.00.00 00.00.00.00 13 
07.04.03.00 00.00.00.00 00.00.00.00 19 
01.06.04.00 01.06.04.00 00.00.00.00 22 
99.00.00.00 00.00.00.00 00.00.00.00 23 
00.00.00.00 00.00.00.00 00.00.00.00 41 
01.06.01.00 00.00.00.00 00.00.00.00 83 
01.06.04.00 00.00.00.00 00.00.00.00 119 
01.06.02.00 00.00.00.00 00.00.00.00 127 
Table 36: Combination frequencies of bnfcodes included in the drug code dictionary for the drug code list for 
review for laxatives. 
 
 
replace case=0 if regexm(bnfcode1, "^13\..*|^07\..*") 
 
Table 37: Stata code to remove drug codes mapped to Chapters which are not of relevance to the final drugcode list for review 
for laxatives 
The Anatomical Therapeutic Chemical (ATC) classification system can be used as a final 
check to assess drug ingredients but an ATC code is not present for all records. These are 
alphanumeric codes developed by the World Health Organisation to classify drugs. This 
would involve searching for laxative drugs under ATC codes beginning with A06A* (drugs 
for constipation). Drug code frequency tables provided by THIN in ancillary tables were 
used to determine how often a certain drug code was used to aid with decision making. 
This final list was subjected to a first review and then for validity by a second reviewer with 
clinical expertise in this area. The consensus drug code list had 450 codes (Appendix 3). 
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7.0 DISCUSSION 
 
7.1 Statement of Principle Findings 
 
This chapter has presented the methodology used to define acceptable periods of BCSP 
notifications for practices receiving electronic results (AEB date). The initial review of the 
AEB date defined for each practice identified 353 practices for inclusion and 102 for 
exclusion. The second reviewer gave 363 for inclusion and 92 practices for exclusion which 
is a 97.8% (445/455) agreement. Eighty percent of practices were investigated for an AEB 
date. In 2017, NHS Digital suggested that 88% of GP practices receive electronic BCSP 
notifications (NHS Digital, Personal Communication). The difference of 8% may be 
explained since this study used THIN May 2016 Version so it might be that practices have 
updated their notification systems since this time. Reasons for exclusion of practices was if 
they had a zero rate of notifications received or extremely low numbers of irregular peaks 
or if they had too short a duration before they stopped contributing to THIN which may 
make up the missing 8% (about 36 practices). In addition, some practices were excluded 
where it was not clear when the electronic notifications commenced. The different 
patterns in electronic notifications seen by the practices can be influenced by practice 
behaviour, patient behaviour, the sending of lab results and the change/update in IT 
Systems such as Vision software. 
This chapter also detailed the methods used to extract AHD variables using the examples of 
BCSP notifications and a lab test result of haemoglobin concentration. The AHD file is more 
complex in structure compared to the Medcode file and therefore requires more 
investigation before data extraction. Generating an ahdcode list (like with Read codes and 
Drug code extraction) would not be sufficient to extract the level of detail required for a 
study.  
For BCSP outcomes this approach involved using Read codes for BCSP notifications with a 
definitive result from the AHD file. Other generic BCSP codes however needed to be 
combined with other ahdcodes for a definitive outcome/result. For haemoglobin 
concentration, the method sequentially reviewed the numeric distribution of Hb 
concentration values for combinations of Read codes and unit value labels observed in a 
THIN 1% sample. These were compared with a reference distribution for Hb concentration 
to assess if they matched that distribution, required conversion before use, or were 
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unlikely to contain Hb values and therefore excluded. Plausible Hb minimum and maximum 
values from an external source were then applied to the data as a final step in the method.  
The methods used to compile Read code lists were presented using the example of ‘bowel 
cancer diagnoses’. Although previous studies or clinical code repositories may have the 
associated Read codes presented alongside the paper, Read code lists need to be tailored 
to each research question and study. The outcome of interest in Chapter 5 was colorectal 
cancer or polyp diagnosis and so the methods to derive code lists for bowel cancer 
diagnosis was described. Read code list generation involved an iterative key word search 
strategy (informed by previous research and discussion with a clinician) and then 
identifying other parent and child stems for Read codes by exploiting their hierarchical 
nature. After a few cycles of running through this method, the resulting Read code list was 
subject to two individual reviewers (the second being a clinician for validity). The final 
consensus list was made up of 42 codes for bowel cancer diagnosis. 
The method of drug code list development is presented for laxative prescriptions. Drug 
code list generation involved a similar method to the above. The British National Formulary 
was used to identify Chapters the drugs were mapped to as well as formulate a key word 
search under generic drug name.  All drugs mapped to the appropriate Chapter in the BNF 
were included in the final list after removing any drugs which did not fit the definition used 
for the study reported in Chapter 5 (e.g. formulations or other indications). The list was 
subjected to two reviewers. The final drug code list for laxatives resulted in a list of 450 
codes. 
7.2 Strengths and Weaknesses  
 
This study is the first to present the methodology used to define an AEB date for research 
studies using BCSP data from a Primary Care Database. Chapter 5 used the AEB date to 
help define a bowel cancer screening programme cohort for analysis as well as to provide 
validity to the data.  
For defining the AEB date, a common x and y axis was used to aid comparison of the graphs 
and to identify the change point. Validity of the chosen AEB date for each practice was 
enhanced by having a second reviewer and consensus meeting where a 3rd reviewer 
contributed where necessary. The approach of using pairs of reviewers to assign dates was 
also used by the study which developed the AMR date.14  
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A limitation of the AEB date development was that the AEB date identified for each 
practice could be considered subjective which can introduce bias. A set of rules for 
inclusion and exclusion of practices as well as identifying the date was derived for use by 
both the 1st and 2nd reviewer to improve consistency. There was strong agreement in the 
consensus meeting for these dates. In addition to this, a reference line and LOWESS were 
plotted alongside the actual notification rate to assist with decision making. Another 
approach to visual interpretation is using computer derived change point analysis to auto-
categorise the practice plots. However, due to the variety of patterns seen in the plot 
outputs this was not feasible. 
A key strength of this chapter is the level of detail which is presented to aid the 
reproducibility of the research. Reporting guidelines such as the RECORD statement23  
recommend that full clinical code lists and algorithms are presented alongside the research 
(RECORD 7.1). For instance, clinical codes could also be published alongside the journal 
article or placed in a data repository such as ClinicalCodes22. More recently it has been 
suggested that this perhaps does not go far enough and that researchers should also 
provide some form of ‘meta-data’ to go alongside the clinical code lists so other 
researchers can critique, amend or apply similar methods in future research.2 For instance, 
it has been suggested that the initial set of synonyms used to search for the clinical codes 
could be included.2 Related to this, is using the statistical software Stata to develop these 
methods since do-files enhance replication and reproducibility. Stata code is presented 
within the chapter to aid the method to be adapted or used in further research. 
Code set validity is strengthened by having an expert clinician as a second reviewer and to 
assist with compiling key words for the search strategy. This approach has been 
recommended by a review of clinical code set engineering to reduce Type I errors (where a 
code is wrongly included).2 It has also been suggested that this approach could be extended 
further by using an expert panel to decide on the final clinical code lists.2 24 Furthermore, by 
using a broad set of synonyms, building on previous code lists, exploiting the hierarchical 
nature of codes and following an iterative process (by including additional synonyms based 
on codes discovered by searching code hierarchy) this helps to reduce type II errors (where 
a code is incorrectly excluded).2 
By defining both prescriptions and symptoms, the related prescription could be used as an 
indicator for disease in Chapter 5. For instance, antispasmodic prescription was found to 
have a similar hazard ratio to the symptom of abdominal pain and this was combined into 
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one variable. Other studies have also investigated using laxatives as a proxy to a 
constipation symptom and anti-motility drugs as a proxy to a symptom of diarrhoea.21 25 
This approach increased the sensitivity of code lists and identification of a particular clinical 
feature. 
When devising a search strategy for Read code and Drug code list development, the 
‘regexm’ (regular expressions) function was used in Stata.26 This function is more flexible 
than the ‘strpos’ function,27 for building a keyword search strategy and allows different 
combinations of words to be searched as well as truncated forms. The ‘strpos’ function was 
used as an example in the study by Davé and Petersen3 which reports methods for 
developing medical and drug code lists. The more flexible ‘regular expressions’ approach 
was used in the current study to build an extensive search strategy.  
Another key strength when developing a strategy to extract lab data from the AHD file is 
the use of a reference distribution obtained from a local hospital laboratory for GP 
requested Hb tests. To ensure the distribution of lab test results are consistent with other 
datasets and to remove potential outliers from analysis, this external local hospital dataset 
was used to set minimum and maximum Hb values to the data extracted from THIN. This 
improves the validity of the data further and the associations found in Chapter 5.  
Olier et al.24 present the methodology used to develop a list of clinical codes and provide 
accompanying Stata and R commands. This method is applicable to different coding 
systems which has the added advantage of being used for SNOMED CT which will be 
implemented in all practices by the end of 2018.4 Although the methodology used in the 
current study is specific to Read code Version 2 which is used in the THIN database, the 
principles are equally valid for new coding systems. At the time of planning and carrying 
out the study in Chapter 5, THIN used Read code Version 2 for documenting clinical signs 
and symptoms. In addition, database providers will provide interim tables for codes to 
enable this transition and the use of Read code lists. 
7.4 Practical implications 
 
The methods used for defining the AEB date and the resultant dates extracted for each 
practice can be used in future studies using BCSP data. The AEB date can be used to provide 
quality assurance to the data as well as to help define a screening cohort for analysis from 
data which is principally used for primary care based studies. This is the approach taken for 
the study reported in Chapter 5. 
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Although these methods were developed in THIN a similar approach can be applied in 
other electronic health care databases such as the CPRD and QRESEARCH as a data quality 
assurance filter for BCSP studies. Further to this, electronic screening programme 
notifications for other national programmes such as breast cancer and cervical screening 
can be investigated to define screening cohorts for analysis and for data quality assurance. 
Different regions in the UK have separate IT systems to record screening activities for their 
regional screening programmes. The methods can therefore also be applied to practices in 
Scotland, Ireland, Wales and the Isle of Man. 
Although there have been several studies which report the methodology of Read code and 
Drug code list development,3 8 24 28 as far as can be identified no studies have reported their 
methods for AHD variable extraction. This is a much more complex data structure and it is 
perhaps even more paramount to detail the methods used to derive valid data, particularly 
when involving quantitative measures such as lab test results. The methods reported in this 
chapter can be used when defining new variables for use in the THIN database. 
The Read code and Drug code lists along with the methods for their construction can be 
used or amended for use to fit a particular research question by other researchers in future 
studies. Any publications from this Chapter and Chapter 5 will publish the clinical code lists 
(as well as other forms of meta-data) alongside the journal article as recommended by 
reporting guidelines and reviews.2 23 
Further investigations into the temporal changes in code recording for clinical indicators 
could be investigated. For instance, with the introduction of QOF incentives or changes in 
NICE guidelines, there would be a corresponding effect on what is recorded for a particular 
condition. The usage of one particular Read code could reduce over time with the increase 
in the use of another. The odds ratios (or hazard ratios) could also be analysed over a 
certain timespan to determine whether there is a change in recording or change in the 
prevalence/incidence rates of a disease. 
7.5 Future research 
 
The methods used to derive the AEB date in this chapter could be transferred for use in 
identifying acceptable lab test reporting dates (from pathology labs) since the BCSP use the 
same system used by NHS pathology labs to send results through to GP surgeries. 
Pathology labs would have switched over from paper based records to electronic 
notifications and so a similar approach to the one reported here could be used as a layer of 
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quality assurance to the data extracted. This is because it is more likely that data before 
electronic notifications would have been less complete, as well as biased towards reporting 
abnormal results. 
As clinical reporting switches over to SNOMED CT in the NHS, the methods reported in this 
study can be adapted for use with this clinical terminology system. A standardised 
approach such as the three-stage process reported by Watson et al.8 which does not rely 
on the hierarchical structure of Read codes, would be more appropriate in this 
circumstance for SNOMED CT code list development. For instance, sources of clinical 
information which could be used to help define the clinical feature of interest include, 
ICD10, BMJ Best Practice Guidelines, International Classification of Primary Care (ICPC) and 
NICE Clinical Knowledge Summaries.8 The three-stage process also includes a modified 
Delphi approach with primary care practitioners to reach a consensus of the most relevant 
codes.2 
A quantitative Faecal Immunochemical test code exists for SNOMED CT,29 it is unknown at 
this stage whether these codes will be adopted by the NHS BCSP or whether the more 
generic FOBT codes will be retained. If the quantitative FIT amount is sent to GPs this level 
of information can be used in a variety of ways including for research, to indicate the level 
of risk to an individual which may help uptake30 and to determine longitudinal changes to 
FIT. 
8.0 CONCLUSIONS 
 
The AEB date can be used in future studies as a layer of data quality assurance to ensure 
results used for analysis are ones which have been electronically received to the additional 
health data records. The AEB date can also help to derive an average risk BCSP cohort for 
analysis from electronic primary care records by limiting the population to the age range 
for screening 60-74 and excluding those with high risk familial syndromes. With the 
increasing popularity of electronic health record research, it is essential that the methods 
used to compile clinical code lists as well as extracting additional health data are rigorous 
and reproducible in order to produce valid results. The methods described for additional 
health data variables such as haemoglobin concentration can be used for future studies or 
amended for other types of lab test result. By using an external dataset to define 
acceptable minimum and maximum values this also adds more validity to the data when 
applied in risk prediction models. There is a push to ensure Read code / Drug code lists are 
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transparent and available for future research studies which ties into the trend for 
reproducible research (for instance through repositories such as ClinicalCodes). The 
definition of diagnoses and symptoms using these Read codes need to be specific to the 
research question and the researcher must tailor lists for their own use. Changes in the 
clinical terminology system used in the NHS in the form of SNOMED CT will require an 
adaptation of these methods but using similar principles to those reported here. This 
chapter has described the methods developed to extract data for the study reported in 
Chapter 5 but also which can be applied in other future studies to improve data validity and 
quality assurance.  
The final chapter is the thesis discussion (Chapter 7) presenting a summary of the findings 
from each chapter and the corresponding future perspectives in this area of research. 
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10.0 APPENDICES 
Appendix 1 – Acceptable Electronic BCSP (AEB) date derived for each practice 
using THIN (Version May 2016) 
 
Practice ID (pseudonymised) Screening Start Date Practice Inclusion 
0036 01oct2011 Y 
0242 01apr2013 Y 
0341   N 
0267   N 
0333 01apr2013 Y 
0258 01mar2011 Y 
0255 01jul2010 Y/S 
0235   N 
0298 01jan2010 Y 
0083 01jul2009 Y 
0264 01sep2009 Y 
0351 01jul2012 Y 
0275 01jul2013 Y 
0285 01sep2012 Y 
0383   N 
0214 01jun2011 Y 
0361 01mar2013 Y 
0400 01feb2013 Y 
0381   N 
0382 01nov2010 Y 
0376 01sep2012 Y 
0136 01apr2013 Y 
0014   N 
0343 01apr2011 Y 
0311   N 
0002 01jun2011 Y 
0416 01dec2010 Y 
0031   N 
0165 01oct2013 Y 
0399 01sep2012 Y 
0070 01sep2011 Y/S 
0110 01jun2013 Y 
0247 01jan2011 Y 
0419 01aug2013 Y 
0377   N 
0004 01jul2011 Y 
0388 01nov2010 Y 
0115 01jan2012 Y 
0132 01dec2013 Y 
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0335 01sep2012 Y 
0260 01feb2011 Y 
0248 01nov2010 Y 
0003 01oct2012 Y 
0370   N 
0398 01jul2013 Y/S 
0037 01mar2014 Y 
0405 01nov2011 Y/S 
0237   N 
0200 01mar2011 Y 
0100 01jul2013 Y/S 
0257   N 
0010 01oct2010 Y 
0211   N 
0071 01nov2010 Y 
0429 01mar2011 Y 
0321   N 
0287   N 
0159   N 
0130   N 
0174   N 
0407 01may2014 Y 
0041 01oct2010 Y 
0180   N 
0276 01jan2011 Y 
0296 01oct2012 Y 
0114 01may2009 Y 
0229 01sep2012 Y 
0409 01jul2009 Y 
0436 01apr2014 Y 
0234   N 
0355 01feb2012 Y 
0326 01jul2014 Y 
0413 01may2014 Y 
0086 01may2013 Y 
0271 01jun2013 Y 
0395 01oct2010 Y 
0019   N 
0313 01apr2013 Y 
0081 01jul2013 Y 
0446 01jul2012 Y 
0072 01feb2011 Y/S 
0125 01jul2011 Y 
0282 01apr2011 Y 
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0449 01apr2011 Y 
0091   N 
0306   N 
0431 01dec2010 Y 
0327 01jul2012 Y 
0365   N 
0001 01feb2011 Y 
0228   N 
0290 01nov2011 Y 
0314 01jun2009 Y 
0256   N 
0278 01aug2011 Y 
0101 01oct2013 Y 
0181 01aug2013 Y 
0088 01mar2013 Y 
0025 01feb2011 Y 
0149 01sep2013 Y 
0273 01nov2010 Y 
0195   N 
0198 01jul2013 Y 
0140 01oct2010 Y 
0384 01apr2011 Y 
0309 01sep2012 Y 
0065 01mar2011 Y 
0084 01jul2009 Y 
0455   N 
0337 01feb2011 Y 
0433 01jul2013 Y 
0166   N 
0364 01jul2011 Y 
0283 01jul2012 Y 
0344 01nov2011 Y 
0162 01oct2014 Y 
0240 01apr2014 Y 
0020   N 
0015 01jun2012 Y 
0270 01jun2011 Y 
0151 01jul2010 Y 
0170   N 
0318 01jan2013 Y 
0373   N 
0203 01nov2010 Y 
0356   N 
0139 01apr2013 Y 
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0060 01apr2011 Y 
0277 01jul2011 Y 
0378 01may2010 Y 
0334 01may2011 Y 
0008 01jan2011 Y 
0263 01sep2012 Y 
0108   N 
0207 01jan2013 Y 
0048   N 
0026 01apr2011 Y 
0122 01sep2012 Y 
0360 01jul2013 Y 
0011 01sep2014 Y 
0426 01apr2014 Y 
0225 01jan2012 Y 
0386 01jun2013 Y 
0389 01apr2013 Y 
0216 01jan2013 Y 
0182 01sep2014 Y 
0423 01apr2013 Y 
0164 01jun2013 Y 
0171 01jan2011 Y 
0117 01may2013 Y 
0080 01may2011 Y 
0411 01feb2013 Y 
0250 01may2013 Y/S 
0281   N 
0294 01mar2013 Y 
0199 01aug2012 Y 
0241 01nov2013 Y/S 
0385   N 
0051 01aug2012 Y 
0322 01sep2014 Y 
0412   N 
0190 01may2011 Y 
0030 01apr2013 Y 
0319   N 
0112 01feb2011 Y 
0286 01mar2011 Y 
0116 01jun2012 Y 
0292   N 
0268   N 
0372 01aug2013 Y/S 
0201 01aug2012 Y 
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0067 01apr2011 Y 
0178 01dec2010 Y 
0017 01dec2010 Y 
0252   N 
0254 01nov2012 Y 
0236 01nov2010 Y 
0043 01nov2010 Y 
0092   N 
0293 01may2013 Y 
0274 01nov2010 Y 
0121 01feb2013 Y/S 
0284 01nov2014 Y 
0435   N 
0055 01mar2013 Y 
0176 01mar2011 Y 
0075   N 
0315 01aug2013 Y 
0147 01jul2015 Y 
0193   N 
0039 01jul2012 Y 
0059 01aug2013 Y 
0049   N 
0047 01nov2013 Y 
0336 01jul2011 Y 
0097 01feb2013 Y 
0050 01mar2011 Y/S 
0454 01feb2011 Y 
0111 01jan2013 Y 
0445 01mar2014 Y 
0024 01may2013 Y 
0208 01sep2013 Y 
0391 01dec2011 Y 
0167 01apr2011 Y 
0146 01jan2012 Y 
0066   N 
0157 01jul2012 Y 
0332 01nov2014 Y 
0219 01oct2012 Y 
0408 01jul2014 Y/S 
0076 01feb2011 Y 
0403 01oct2012 Y 
0406 01dec2014 Y 
0302 01feb2011 Y 
0052 01mar2012 Y 
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0161 01mar2013 Y 
0440   N 
0244 01may2011 Y 
0224 01feb2013 Y 
0380   N 
0123 01oct2012 Y 
0099   N 
0415   N 
0129 01nov2010 Y 
0295 01feb2011 Y 
0153 01mar2011 Y 
0401 01jul2012 Y 
0077 01apr2013 Y 
0231 01sep2012 Y/S 
0194 01dec2011 Y 
0329 01jan2012 Y 
0350 01sep2014 Y 
0452 01apr2014 Y 
0202 01aug2009 Y 
0213 01may2009 Y 
0450 01jan2013 Y 
0299 01jan2014 Y 
0196   N 
0434 01jul2012 Y 
0184   N 
0245 01dec2012 Y 
0102   N 
0451 01apr2012 Y 
0186 01jun2011 Y 
0369 01jun2012 Y 
0441   N 
0104 01nov2013 Y 
0197   N 
0118 01sep2013 Y 
0044 01jul2011 Y 
0185 01jul2011 Y/S 
0414 01apr2014 Y 
0392 01feb2011 Y 
0068   N 
0107 01mar2013 Y 
0188 01may2014 Y 
0144 01sep2012 Y 
0430 01jul2012 Y 
0262 01jul2011 Y 
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0128   N 
0007 01aug2013 Y 
0058 01jul2012 Y 
0300 01feb2012 Y 
0425 01jun2011 Y/S 
0253 01dec2009 Y 
0141   N 
0308 01may2011 Y 
0347 01aug2013 Y 
0339 01nov2010 Y 
0363 01mar2011 Y 
0218   N 
0046 01nov2009 Y 
0305 01jul2012 Y 
0142 01nov2010 Y 
0418   N 
0062 01jun2011 Y 
0127 01may2011 Y 
0362   N 
0374   N 
0307 01may2012 Y 
0045   N 
0089 01oct2012 Y 
0346 01apr2011 Y 
0143   N 
0227 01oct2013 Y/S 
0150 01mar2010 Y 
0172 01oct2013 Y 
0368 01jul2011 Y 
0133 01oct2013 Y 
0222 01mar2014 Y 
0352 01feb2011 Y 
0016   N 
0421 01oct2014 Y 
0331 01may2012 Y 
0422 01dec2010 Y 
0085 01apr2013 Y 
0265   N 
0297   N 
0272   N 
0338 01jul2011 Y 
0138 01sep2011 Y 
0183 01jul2012 Y 
0191   N 
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0353 01mar2013 Y 
0221   N 
0090 01jun2012 Y 
0444 01aug2013 Y 
0158 01nov2013 Y/S 
0145   N 
0056 01jan2012 Y 
0371   N 
0074 01nov2011 Y 
0324 01may2011 Y 
0291 01jun2014 Y 
0134 01feb2011 Y 
0217 01aug2011 Y 
0009 01sep2011 Y 
0021 01may2014 Y 
0087 01may2013 Y 
0173 01mar2011 Y 
0266   N 
0410 01dec2010 Y 
0233 01apr2011 Y 
0033 01feb2015 Y 
0328 01feb2011 Y 
0029   N 
0192 01oct2012 Y 
0312   N 
0154 01sep2012 Y 
0325 01apr2012 Y 
0005   N 
0053   N 
0246 01sep2014 Y 
0342 01oct2013 Y/S 
0120 01aug2013 Y 
0249 01jan2013 Y/S 
0063 01may2011 Y 
0288 01apr2011 Y 
0387 01nov2011 Y 
0187 01apr2012 Y 
0230 01dec2012 Y 
0358 01oct2011 Y 
0105 01jul2011 Y 
0243 01mar2011 Y 
0301 01oct2012 Y 
0119 01apr2014 Y/S 
0303 01nov2015 Y/S 
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0289 01apr2011 Y 
0006 01mar2013 Y 
0027 01may2011 Y 
0417   N 
0054 01jul2012 Y 
0354 01may2014 Y 
0379 01aug2013 Y 
0320 01feb2011 Y 
0124 01feb2014 Y 
0367   N 
0135 01mar2011 Y 
0098 01feb2011 Y 
0345 01sep2014 Y 
0018 01dec2010 Y 
0113 01oct2010 Y 
0156 01aug2010 Y 
0420 01feb2013 Y 
0238   N 
0439 01oct2013 Y/S 
0261 01may2013 Y 
0348 01feb2014 Y 
0442 01may2009 Y 
0169 01nov2010 Y 
0126 01oct2012 Y 
0095 01may2013 Y 
0082 01feb2014 Y 
0152   N 
0013 01apr2014 Y 
0340 01apr2014 Y/S 
0109 01nov2014 Y 
0232   N 
0357 01apr2011 Y 
0148 01nov2014 Y 
0177 01nov2012 Y 
0453 01sep2010 Y/S 
0096 01nov2013 Y 
0204 01apr2011 Y 
0393 01nov2010 Y 
0073 01nov2013 Y 
0280 01sep2013 Y 
0206 01aug2012 Y 
0093   N 
0057 01may2013 Y/S 
0226 01mar2011 Y 
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0437 01feb2011 Y 
0279 01aug2013 Y 
0223 01may2014 Y 
0304 01jan2011 Y 
0432 01aug2013 Y 
0310 01dec2012 Y 
0212 01jan2014 Y 
0131 01nov2014 Y 
0061 01feb2012 Y 
0448 01mar2011 Y 
0023 01dec2013 Y 
0042 01apr2013 Y 
0404 01nov2010 Y 
0447 01nov2010 Y 
0366 01nov2013 Y 
0012 01feb2011 Y 
0438 01feb2014 Y 
0038 01aug2012 Y 
0269 01sep2014 Y 
0078 01jul2011 Y/S 
0064 01apr2014 Y 
0163   N 
0106 01nov2013 Y 
0209 01oct2009 Y 
0215 01mar2011 Y 
0220   N 
0079 01apr2011 Y 
0155 01jan2014 Y 
0040 01mar2011 Y 
0330 01nov2014 Y 
0069 01sep2011 Y 
0316 01aug2012 Y 
0022 01aug2013 Y 
0034   N 
0359   N 
0394   N 
0402 01aug2012 Y/S 
0175 01mar2011 Y 
0032 01oct2014 Y 
0251 01jul2014 Y 
0424 01jun2012 Y/S 
0094 01jan2010 Y 
0427 01jun2012 Y 
0428 01jan2012 Y/S 
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0189 01feb2011 Y 
0028 01nov2013 Y 
0317 01sep2013 Y 
0396 01jul2012 Y 
0259 01mar2011 Y 
0205   N 
0103 01nov2010 Y 
0397 01apr2011 Y 
0168 01sep2013 Y 
0323 01nov2013 Y 
0137 01mar2011 Y 
0239   N 
0160 01dec2010 Y 
0443 01may2014 Y 
0210 01jul2009 Y 
0035 01jan2015 Y 
0375 01jul2013 Y 
0349 01nov2010 Y 
0179 01mar2011 Y 
0390 01nov2010 Y 
Table A.1.1: Acceptable Electronic BCSP (AEB) date derived for each practice using THIN (Version May 2016).  
Original practice ID (pracid on THIN database) and the practice region is available from the authors on request. 
Appendix 2 – Read Code Lists for Bowel Cancer Diagnosis  
 
Medcode (Bowel cancer diagnosis) description 
14CC.00 H/O Lower GIT Neoplasm 
68W2400 Bowel scope (flexible sigmoidoscopy) screen: cancer detected 
9Ow1.00 Bowel cancer detected by national screening programme 
B13..00 Malignant neoplasm of colon 
B130.00 Malignant neoplasm of hepatic flexure of colon 
B131.00 Malignant neoplasm of transverse colon 
B132.00 Malignant neoplasm of descending colon 
B133.00 Malignant neoplasm of sigmoid colon 
B134.00 Malignant neoplasm of caecum 
B134.11 Carcinoma of caecum 
B135.00 Malignant neoplasm of appendix 
B136.00 Malignant neoplasm of ascending colon 
B137.00 Malignant neoplasm of splenic flexure of colon 
B138.00 Malignant neoplasm, overlapping lesion of colon 
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B13y.00 Malignant neoplasm of other specified sites of colon 
B13z.00 Malignant neoplasm of colon NOS 
B13z.11 Colonic cancer 
B14..00 Malignant neoplasm of rectum, rectosigmoid junction and anus 
B140.00 Malignant neoplasm of rectosigmoid junction 
B141.00 Malignant neoplasm of rectum 
B141.11 Carcinoma of rectum 
B141.12 Rectal carcinoma 
B142000 Malignant neoplasm of cloacogenic zone 
B14y.00 Malig neop other site rectum, rectosigmoid junction and anus 
B14z.00 Malignant neoplasm rectum,rectosigmoid junction and anus NOS 
B180200 Malignant neoplasm of retrocaecal tissue 
B18y000 Malignant neoplasm of mesocolon 
B18y100 Malignant neoplasm of mesocaecum 
B18y200 Malignant neoplasm of mesorectum 
B1z0.11 Cancer of bowel 
BB52000 [M]Adenocarcinoma in tubulovillous adenoma 
BB5L100 [M]Adenocarcinoma in adenomatous polyp 
BB5L300 [M]Adenocarcinoma in multiple adenomatous polyps 
BB5M.00 [M]Tubular adenomas and adenocarcinomas 
BB5M100 [M]Tubular adenocarcinoma 
BB5Mz00 [M]Tubular adenoma or adenocarcinoma NOS 
BB5R800 [M]Adenocarcinoid tumour 
BB5U.00 [M]Villous adenomas and adenocarcinomas 
BB5U100 [M]Adenocarcinoma in villous adenoma 
BB5U200 [M]Villous adenocarcinoma 
BB5Uz00 [M]Villous adenoma or adenocarcinoma NOS 
BB83.00 [M]Pseudomyxoma peritonei 
 A.2.1: Final Read code list for Bowel Cancer Diagnosis. 
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medcode description JC_decision TM_decision Notes 
122F.00 No family history of bowel cancer 0   
1241.12 FH: Bowel cancer 0   
124F.00 FH: Bowel cancer 0   
14CB.00 H/O Upper GIT Neoplasm 0   
14CC.00 H/O Lower GIT Neoplasm 1 Include Specific enough? 
1J0J.00 Suspected gynaecological cancer 0   
38GT000 QCancer colorectal cancer risk 
calculator 
0   
6864.00 Large bowel neoplasm screen 0   
6864.11 Colon neoplasm screen 0   
6864.12 Rectal neoplasm screen 0   
6866.00 Bowel cancer screening 
programme: faecal occult blood 
result 
0   
68W2.00 Bowel cancer screening programme 0   
68W2000 Bowel Cancer Screening 
Programme bowel scope screening 
test 
0   
68W2400 Bowel scope (flexible 
sigmoidoscopy) screen: cancer 
detected 
1 Include  
68W2500 Bowel scope (flexi-sig) screen: 
suspected cancer detected 
0   
8CAo.00 Patient given advice about bowel 
cancer 
0   
8Hn1.00 Fast track referral for suspected 
gynaecological cancer 
0   
8Hn4.00 Fast track referral for suspected 
colorectal cancer 
0  Not definitive enough 
8IA3.00 Bowel cancer screening declined 0   
8OA5.00 Prov of written info about bowel 
cancer screening programme 
0   
9Ni2.00 Did not attend bowel cancer 
screening programme nurse clinic 
0   
9Ni3.00 Did not attend bowel cancer 
screening 
0   
9Nic000 DNA fast track suspected 
gynaecological cancer clinic 
0   
9Np7.00 Seen in fast track suspected 
colorectal cancer clinic 
0   
9Ow..00 Bowel cancer screening programme 
administration 
0   
9Ow1.00 Bowel cancer detected by national 
screening programme 
1 Include  
9Ow2.00 No response to bowel cancer 
screening programme invitation 
0   
9Ow3.00 Not eligible for bowel cancer 
screening programme 
0   
9Ow4.00 Bowel cancer screening programme 
telephone invitation 
0   
9Ow5.00 Bowel cancer screening programme 
invitation letter sent 
0   
A4z1.00 Adenoviral meningitis 0   
B....00 Neoplasms 0  Parent code/not specific enough 
B....11 Cancers 0  Parent code/not specific enough 
B1...00 Malignant neoplasm of digestive 
organs and peritoneum 
0  Not specific enough? 
B1...11 Carcinoma of digestive organs and 0  Not specific enough? 
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peritoneum 
B13..00 Malignant neoplasm of colon 1 Include  
B130.00 Malignant neoplasm of hepatic 
flexure of colon 
1 Include  
B131.00 Malignant neoplasm of transverse 
colon 
1 Include  
B132.00 Malignant neoplasm of descending 
colon 
1 Include  
B133.00 Malignant neoplasm of sigmoid 
colon 
1 Include  
B134.00 Malignant neoplasm of caecum 1 Include  
B134.11 Carcinoma of caecum 1 Include  
B135.00 Malignant neoplasm of appendix 1 Include  
B136.00 Malignant neoplasm of ascending 
colon 
1 Include  
B137.00 Malignant neoplasm of splenic 
flexure of colon 
1 Include  
B138.00 Malignant neoplasm, overlapping 
lesion of colon 
1 Include  
B139.00 Hereditary nonpolyposis colon 
cancer 
0 Exclude Not including HNPCC as high risk 
group not average risk 
B13y.00 Malignant neoplasm of other 
specified sites of colon 
1 Include  
B13z.00 Malignant neoplasm of colon NOS 1 Include  
B13z.11 Colonic cancer 1 Include  
B14..00 Malignant neoplasm of rectum, 
rectosigmoid junction and anus 
1 Include  
B140.00 Malignant neoplasm of 
rectosigmoid junction 
1 Include  
B141.00 Malignant neoplasm of rectum 1 Include  
B141.11 Carcinoma of rectum 1 Include  
B141.12 Rectal carcinoma 1 Include  
B142000 Malignant neoplasm of cloacogenic 
zone 
1 Include Rare tumour of the anorectal 
region 
B14y.00 Malig neop other site rectum, 
rectosigmoid junction and anus 
1 Include  
B14z.00 Malignant neoplasm 
rectum,rectosigmoid junction and 
anus NOS 
1 Include  
B180200 Malignant neoplasm of retrocaecal 
tissue 
1 Include  
B18y000 Malignant neoplasm of mesocolon 1 Include  
B18y100 Malignant neoplasm of 
mesocaecum 
1 Include  
B18y200 Malignant neoplasm of 
mesorectum 
1 Include  
B1z..00 Malig neop oth/ill-defined sites 
digestive tract/peritoneum 
0   
B1z..00 Malig neop oth/ill-defined sites 
digestive tract/peritoneum 
0   
B1z0.00 Malignant neoplasm of intestinal 
tract, part unspecified 
0   
B1z0.00 Malignant neoplasm of intestinal 
tract, part unspecified 
0   
B1z0.11 Cancer of bowel 1 Include  
B1z2.00 Malignant neoplasm, overlapping 
lesion of digestive system 
0   
B1zy.00 Malignant neoplasm other spec 
digestive tract and peritoneum 
0   
B1zz.00 Malignant neoplasm of digestive 
tract and peritoneum NOS 
0   
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B5...00 Malignant neoplasm of other and 
unspecified sites 
0   
B5...11 Carcinoma of other and unspecified 
sites 
0   
B57..00 Secondary malig neop of 
respiratory and digestive systems 
0  Secondary 
B57..11 Metastases of respiratory and/or 
digestive systems 
0   
B57..12 Secondary carcinoma of respiratory 
and/or digestive systems 
0 Exclude  
B575.00 Secondary malignant neoplasm of 
large intestine and rectum 
0 Exclude Unsure whether to include 
secondary malignant - I suppose 
screening would detect these so 
perhaps I should? 
B575000 Secondary malignant neoplasm of 
colon 
0 Exclude Unsure whether to include 
secondary malignant 
B575100 Secondary malignant neoplasm of 
rectum 
0 Exclude Unsure whether to include 
secondary malignant 
B575z00 Secondary malig neop of large 
intestine or rectum NOS 
0 Exclude Unsure whether to include 
secondary malignant 
B57y.00 Secondary malignant neoplasm of 
other digestive organ 
0   
B57z.00 Secondary malig neop of 
respiratory or digestive system NOS 
0   
B58..00 Secondary malignant neoplasm of 
other specified sites 
0   
B58..11 Secondary carcinoma of other 
specified sites 
0   
B58yz00 Secondary malignant neoplasm of 
other specified site NOS 
0   
B58z.00 Secondary malignant neoplasm of 
other specified site NOS 
0   
B59..00 Malignant neoplasm of unspecified 
site 
0   
B590.00 Disseminated malignancy NOS 0   
B590.11 Carcinomatosis 0   
B591.00 Other malignant neoplasm NOS 0   
B592.00 Malignant neoplasms of 
independent (primary) multiple 
sites 
0   
B593.00 Primary malignant neoplasm of 
unknown site 
0   
B594.00 Secondary malignant neoplasm of 
unknown site 
0   
B595.00 Malignant tumour of unknown 
origin 
0   
B59z.00 Malignant neoplasm of unspecified 
site NOS 
0   
B5y..00 Malignant neoplasm of other and 
unspecified site OS 
0   
B5z..00 Malignant neoplasm of other and 
unspecified site NOS 
0   
B713.00 Benign neoplasm of colon 0  Benign 
B713.12 Benign neoplasm of ileocaecal 
valve 
0  Benign 
B713000 Benign neoplasm of hepatic flexure 
of colon 
0  Benign 
B713100 Benign neoplasm of transverse 
colon 
0  Benign 
B713200 Benign neoplasm of descending 
colon 
0  Benign 
B713300 Benign neoplasm of sigmoid colon 0  Benign 
B713400 Benign neoplasm of caecum 0  Benign 
B713500 Benign neoplasm of appendix 0  Benign 
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B713600 Benign neoplasm of ascending 
colon 
0  Benign 
B713700 Benign neoplasm of splenic flexure 
of colon 
0  Benign 
B713800 Benign neoplasm of colostomy site 0  Benign 
B713900 Benign neoplasm of ileocaecal 
valve 
0  Benign 
B713z00 Benign neoplasm of colon NOS 0  Benign 
B714.00 Benign neoplasm of rectum and 
anal canal 
0  Benign 
B714000 Benign neoplasm of rectosigmoid 
junction 
0  Benign 
B714100 Benign neoplasm of rectum 0  Benign 
B714z00 Benign neoplasm of rectum or anal 
canal NOS 
0  Benign 
B718200 Benign neoplasm of retrocaecal 
tissue 
0  Benign 
B718300 Benign neoplasm of mesocolon 0  Benign 
B718400 Benign neoplasm of mesorectum 0  Benign 
B8...00 Carcinoma in situ 0   
B80..00 Carcinoma in situ of digestive 
organs 
0   
B80..11 Ca-in-situ of G.I. tract 0   
B803.00 Carcinoma in situ of colon 0  TM - Polyp. Strictly speaking this 
is not a cancer. It is “in situ” if 
the malignant cells break do not 
through the basement 
membrane. It is a cancer if they 
do. Not all “in situ” become 
cancer – probably only a 
minority progress. 
B803000 Carcinoma in situ of hepatic flexure 
of colon 
0  Polyp 
B803100 Carcinoma in situ of transverse 
colon 
0  Polyp 
B803200 Carcinoma in situ of descending 
colon 
0  Polyp 
B803300 Carcinoma in situ of sigmoid colon 0  Polyp 
B803400 Carcinoma in situ of caecum 0  Polyp 
B803500 Carcinoma in situ of appendix 0  Polyp 
B803600 Carcinoma in situ of ascending 
colon 
0  Polyp 
B803700 Carcinoma in situ of splenic flexure 
of colon 
0  Polyp 
B803800 High grade dysplasia of colon 0  TM - Polyp. Again, not quite 
cancerous. The cells look more 
like malignant cells but because 
it is dysplasia it is confined 
within the basement 
membrane. 
B803z00 Carcinoma in situ of colon NOS 0  Polyp 
B804.00 Carcinoma in situ of rectum and 
rectosigmoid junction 
0  Polyp 
B804000 Carcinoma in situ of rectosigmoid 
junction 
0  Polyp 
B804100 Carcinoma in situ of rectum 0  Polyp 
B804z00 Carcinoma in situ of rectum or 
rectosigmoid junction NOS 
0  Polyp 
B80z.00 Carcinoma in situ of other and 
unspecified digestive organs 
0  Polyp 
B80zz00 Carcinoma in situ of digestive 0  Polyp 
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organs NOS 
B8yyz00 Carcinoma in situ of other specified 
site NOS 
0  Polyp 
B8z..00 Carcinoma in situ NOS 0  Polyp 
B9...00 Neoplasms of uncertain behaviour 0  Polyp 
B90..00 Neop uncertain behaviour of 
digestive and respiratory system 
0  Not specific enough 
B902.00 Neop of uncertain behaviour 
stomach, intestines and rectum 
0  Not specific enough 
B902400 Neoplasm of uncertain behaviour 
of colon 
0  TM - I am not really sure what to 
say about this one. It implies it is 
not known to be malignant so I 
would not call it a cancer. 
It is not obvious that it refers to 
a polyp so I would not call it a 
polyp. 
So in my opinion neither cancer 
nor polyp 
B902500 Neoplasm of uncertain behaviour 
of rectum 
0  TM - I am not really sure what to 
say about this one. It implies it is 
not known to be malignant so I 
would not call it a cancer. 
It is not obvious that it refers to 
a polyp so I would not call it a 
polyp. 
So in my opinion neither cancer 
nor polyp 
B902600 Neoplasm of uncertain or unknown 
behaviour of appendix 
0  TM - I am not really sure what to 
say about this one. It implies it is 
not known to be malignant so I 
would not call it a cancer. 
It is not obvious that it refers to 
a polyp so I would not call it a 
polyp. 
So in my opinion neither cancer 
nor polyp 
B902z00 Neop of uncertain behaviour 
stomach, intestine or rectum NOS 
0  Not specific enough 
B905.00 Neop of uncertain behaviour other 
and unspec digestive organ 
0   
B93..00 Neop uncertain behaviour other 
and unspec sites and tissues 
0   
B93y.00 Neoplasm of uncertain behaviour 
of other specified sites 
0   
B93yz00 Neop of uncertain behaviour of 
other specified sites NOS 
0   
B93z.00 Neop uncertain behaviour other 
unspec site and tissue NOS 
0   
B9y..00 Neoplasm of uncertain behaviour 
otherwise specified 
0   
B9z..00 Neoplasm of uncertain behaviour 
NOS 
0   
BA...00 Unspecified nature neoplasm 0   
BA0..00 Neoplasm of unspecified nature 0   
BA00.00 Neoplasm of unspecified nature of 
digestive system 
0   
BA0y.00 Neoplasm of unspecified nature of 
other specified sites 
0   
BA0z.00 Neoplasm of unspecified nature 
NOS 
0   
BAz..00 Neoplasm of unspecified nature 
NOS 
0   
BB51000 [M]Adenocarcinoma in situ in 
villous adenoma 
0  TM - Polyp. Within the polyp 
there are cancerous cells but 
they are confined by the 
basement membrane. Hence 
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“pre-cancerous” and not cancer.  
BB51100 [M]Adenocarcinoma in situ in 
tubulovillous adenoma 
0  TM - Polyp. Within the polyp 
there are cancerous cells but 
they are confined by the 
basement membrane. Hence 
“pre-cancerous” and not cancer.  
BB52000 [M]Adenocarcinoma in 
tubulovillous adenoma 
1 Include TM - almost certainly a bowel 
cancer 
BB57.00 [M]Adenocarcinoma, intestinal 
type 
0  Not specific enough 
BB5L.00 [M]Adenomatous and 
adenocarcinomatous polyps 
0  Polyp. - probably means there is 
more than one 
BB5L000 [M]Adenomatous polyp NOS 0   
BB5L011 [M]Polypoid adenoma 0  Same as above synonym 
BB5L100 [M]Adenocarcinoma in 
adenomatous polyp 
1 Include  
BB5L200 [M]Adenocarcinoma in situ in 
adenomatous polyp 
0  Polyp. Within the polyp there 
are cancerous cells but they are 
confined by the basement 
membrane. Hence “pre-
cancerous” and not cancer.  
BB5L300 [M]Adenocarcinoma in multiple 
adenomatous polyps 
1 Include  
BB5Lz00 [M]Adenomatous or 
adenocarcinomatous polyp NOS 
0  TM - Polyp 
BB5M.00 [M]Tubular adenomas and 
adenocarcinomas 
1 Include  
BB5M000 [M]Tubular adenoma NOS 0  TM - Polyp 
BB5M100 [M]Tubular adenocarcinoma 1 Include  
BB5Mz00 [M]Tubular adenoma or 
adenocarcinoma NOS 
1 Include TM- cancer 
BB5N.00 [M]Adenomatous and 
adenocarcinomatous polyps of 
colon 
0  TM - polyp 
BB5N.11 [M]Adenoma or or 
adenocarcinoma in polyposis coli 
0  Higher risk not included 
BB5N000 [M]Adenomatous polyposis coli 0   
BB5N011 [M]Adenomatosis NOS 0   
BB5N012 [M]Familial polyposis coli 0  Not including FAP as higher risk 
BB5N100 [M]Adenocarcinoma in 
adenomatous polposis coli 
0   
BB5N200 [M]Multiple adenomatous polyps 0   
BB5N211 [M]Multiple polyposis 0   
BB5Nz00 [M]Adenomatous or 
adenocarcinomatous polyps of the 
colon NOS 
0  TM - polyp 
BB5R200 [M]Carcinoid tumour, argentaffin, 
NOS 
0  TM - exclude 
BB5R211 [M]Argentaffinoma NOS 0  TM - exclude 
BB5R300 [M]Carcinoid tumour, argentaffin, 
malignant 
0  TM - Exclude 
BB5R600 [M]Mucocarcinoid tumour, 
malignant 
0   
BB5R611 [M]Goblet cell tumour 0   
BB5R700 [M]Composite carcinoid 0   
BB5R800 [M]Adenocarcinoid tumour 1 Include Form of appendiceal carcinoid 
BB5R900 [M]Neuroendocrine carcinoma 0   
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BB5RA00 [M]Merkel cell carcinoma 0   
BB5Rz00 [M]Carcinoid tumours NOS 0   
BB5U.00 [M]Villous adenomas and 
adenocarcinomas 
1 Include  
BB5U000 [M]Villous adenoma NOS 0  Type of Polyp 
BB5U011 [M]Villous papilloma 0  Type of Polyp 
BB5U100 [M]Adenocarcinoma in villous 
adenoma 
1 Include TM - Cancer 
BB5U200 [M]Villous adenocarcinoma 1 Include  
BB5U300 [M]Tubulovillous adenoma 0  Type of polyp 
BB5U311 [M]Papillotubular adenoma 0  Type of polyp 
BB5U312 [M]Villoglandular adenoma 0  Type of polyp 
BB5Uz00 [M]Villous adenoma or 
adenocarcinoma NOS 
1 Include TM - cancer 
BB6..00 [M]Adnexal and skin appendage 
neoplasms 
0   
BB60.00 [M]Skin appendage adenoma and 
carcinoma 
0   
BB60000 [M]Skin appendage adenoma 0   
BB60100 [M]Skin appendage carcinoma 0   
BB60z00 [M]Skin appendage adenoma or 
carcinoma NOS 
0   
BB6z.00 [M]Adnexal and skin appendage 
neoplasm NOS 
0   
BB7..00 [M]Mucoepidermoid neoplasms 0   
BB70.00 [M]Mucoepidermoid tumour 0   
BB71.00 [M]Mucoepidermoid carcinoma 0   
BB7z.00 [M]Mucoepidermoid neoplasm 
NOS 
0   
BB8..00 [M]Cystic, mucinous and serous 
neoplasms 
0   
BB82000 [M]Mucinous adenoma 0   
BB82100 [M]Mucinous adenocarcinoma 0   
BB82111 [M]Colloid adenocarcinoma 0   
BB82112 [M]Gelatinous adenocarcinoma 0   
BB82113 [M]Mucoid adenocarcionoma 0  Not specific enough 
BB82114 [M]Mucous adenocarcinoma 0  Not specific enough 
BB82z00 [M]Mucinous adenoma or 
adenocarcinoma NOS 
0   
BB83.00 [M]Pseudomyxoma peritonei 1 Include Rare type of cancer that usually 
begins in your appendix 
BB84.00 [M]Mucin-producing 
adenocarcinoma 
0  Not specific enough 
BB85.00 [M]Signet ring carcinoma 0  Not specific enough 
BB85000 [M]Signet ring cell carcinoma 0  Not specific enough 
BB85100 [M]Metastatic signet ring cell 
carcinoma 
0  Not specific enough 
BB85111 [M]Krukenberg tumour 0  Not specific enough 
BB85z00 [M]Signet ring carcinoma NOS 0  Not specific enough 
BB8z.00 [M]Cystic, mucinous or serous 
neoplasm NOS 
0  Not specific enough 
BBL..00 [M]Complex mixed and stromal 
neoplasms 
0  Not specific enough 
By...00 Neoplasms otherwise specified 0   
  
472 
 
Chapter 6 Chapter six | THIN Data Extraction Methodology 
Byu..00 [X]Additional neoplasm 
classification terms 
0   
Byu1.00 [X]Malignant neoplasm of digestive 
organs 
0   
Byu1200 [X]Malignant neoplasm of intestinal 
tract, part unspecified 
0   
Byu1300 [X]Malignant neoplsm/ill-defin sites 
within digestive system 
0   
ByuC.00 [X]Malignant neoplasm of ill-
defined, secondary and unspeci 
0   
ByuC000 [X]Malignant neoplasm of other 
specified sites 
0   
ByuC100 [X]Malignant neoplasm/overlap 
lesion/other+ill-defined sites 
0   
ByuC400 [X]Secondary malignant 
neoplasm/oth+unspcfd digestive 
organs 
0   
ByuC700 [X]Secondary malignant neoplasm 
of other specified sites 
0   
ByuC800 [X]Malignant neoplasm without 
specification of site 
0   
ByuE.00 [X]Malignant 
neoplasms/independent (primary) 
multiple sites 
0   
ByuE000 [X]Malignant 
neoplasms/independent(primary)m
ultiple sites 
0   
ByuF.00 [X]In situ neoplasms 0   
ByuF000 [X]Carcinoma in 
situ/other+unspecified parts of 
intestine 
0   
ByuF100 [X]Carcinoma in situ of other 
specified digestive organs 
0   
ByuF200 [X]Carcinoma in situ of digestive 
organ, unspecified 
0   
ByuFE00 [X]Carcinoma in situ of other 
specified sites 
0   
ByuH.00 [X]Neoplasms of uncertain and 
unknown behaviour 
0   
ByuH000 [X]Neoplasm/uncertain+unknown 
behaviour/oth digestive organs 
0   
ByuH900 [X]Neoplasm/uncertain+unknown 
behavior/other specified sites 
0   
ByuHA00 [X]Neoplasm of uncertain and 
unknown behaviour, unspecified 
0   
Bz...00 Neoplasms NOS 0   
F011600 Meningitis due to adenovirus 0   
F011611 Adenovirus meningitis 0   
ZV10017 [V]Personal history of malignant 
neoplasm of rectum 
0  Not a new diagnosis? TM- I 
agree, history of past cancer 
ZV76400 [V]Screening for malignant 
neoplasm of colon or rectum 
0   
Table A.2.2: Bowel Cancer Diagnosis Read Code review list with 1st and 2nd reviewer decisions. 1= include, 0=exclude for JC 
decision. 
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Appendix 3 – Drug Code List for Laxative Drugs 
 
Drugcode (Laxative 
drug 04/2017) genericname 
50937978 Sodium dihydrogen phosphate anhydrous 340mg / Sodium bicarbonate 250mg suppositories 
52289979 Macrogol compound oral powder sachets NPF sugar free 
53912979 Macrogol compound oral powder sachets npf 
54399979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
55041978 Macrogol compound half-strength oral powder sachets NPF sugar free 
55042978 Macrogol compound half-strength oral powder sachets NPF sugar free 
55044978 Macrogol compound oral powder sachets NPF sugar free 
55530979 Macrogol compound half-strength oral powder sachets NPF sugar free 
55687978 Macrogol compound half-strength oral powder sachets npf sugar free 
55691978 Macrogol compound oral powder sachets NPF sugar free 
60079979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
60080979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
60081979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
60321979 Lactulose 10g/15ml oral solution 15ml sachets sugar free 
61925979 Macrogol compound oral liquid npf sugar free 
62538979 Bisacodyl 7.5mg suppositories 
63328979 Ispaghula husk oral powder sugar free 
64079979 Magnesium sulfate powder 
64080979 Magnesium sulfate powder 
64082979 Magnesium sulfate powder 
64919979 Macrogol compound oral powder sachets NPF sugar free 
67744994 Sodium citrate compound 5ml enema 
69800979 Sodium dihydrogen phosphate dihydrate 680mg / sodium bicarbonate 500mg suppositories 
69801979 Sodium dihydrogen phosphate dihydrate 680mg / sodium bicarbonate 500mg suppositories 
70855979 Generic senokot dual relief tablets 
71251979 Lactulose 10g oral powder sachets 
71568979 Sodium acid phosphate 700mg / potassium dihydrogen phosphate 305mg tablets 
73183978 Glycerol liquid 
73184978 Macrogol compound half-strength oral powder sachets npf sugar free 
74430978 Macrogol compound oral powder sachets NPF sugar free 
74431978 Macrogol compound oral powder sachets NPF sugar free 
74432978 Macrogol compound oral powder sachets NPF sugar free 
76191978 Macrogol compound oral powder sachets NPF sugar free 
78367979 Fig 500microlitres/5ml / senna fruit 400microlitres/5ml oral solution 
78536978 Macrogol compound oral powder sachets NPF sugar free 
78815979 Glycerol 750microlitres/5ml / sucrose 1.7g/5ml oral solution 
79487979 Methylcellulose 200mg/5ml oral solution 
80868979 Bisacodyl 2.5mg/5ml oral suspension 
80870979 Bisacodyl 5mg/5ml oral suspension 
80950998 Lactulose 10g/15ml oral solution 15ml sachets sugar free 
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81322998 Macrogol compound oral liquid NPF sugar free 
81324998 Macrogol oral solution 
81715998 Sodium picosulfate with magnesium citrate powder for oral solution 
81843998 Generic senokot comfort tablets 
81847998 Glycerol 750microlitres/5ml / sucrose 1.7g/5ml oral solution 
81870998 Glycerol 750microlitres/5ml / sucrose 1.7g/5ml oral solution 
81919998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
81938998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
81959998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
81972998 Ispaghula husk 90% granules sugar free 
82005998 Macrogol compound oral powder sachets npf sugar free 
82013998 Sodium picosulfate 2.5mg capsules 
82156998 Sodium citrate compound 5ml enema 
82288998 Bisacodyl 10mg/30ml enema 
82305998 Macrogol 4000 10g oral powder sachets sugar free 
82306998 Macrogol compound oral powder sachets NPF sugar free 
82314998 Glycerol 750microlitres/5ml oral solution sugar free 
82325998 Glycerol 750microlitres/5ml oral solution sugar free 
82445998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
82446998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
82491998 Ispaghula husk 3.4g/sachet sugar free powder 
82493998 Ispaghula husk 3.4g/sachet sugar free powder 
82641998 Glycerol 750microlitres/5ml oral solution sugar free 
82642978 Sodium dihydrogen phosphate anhydrous 680mg / sodium bicarbonate 500mg suppositories 
82692998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
82693998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
82701998 Macrogol compound oral powder sachets NPF sugar free 
82703998 Macrogol compound oral powder sachets NPF sugar free 
82726978 Glycerol 500microlitres/5ml / ipecacuanha liquid extract 9.8microlitres/5ml oral solution 
82757978 Glycerol 750microlitres/5ml oral solution sugar free 
82761978 Lubiprostone 24microgram capsules 
82762978 Lubiprostone 24microgram capsules 
83053998 Macrogol compound oral powder sachets npf sugar free 
83112998 Macrogol 13.7g powder 
83113998 Macrogol compound oral powder sachets npf 
83177978 Macrogol compound oral powder sachets NPF sugar free 
83203998 Macrogol compound oral powder sachets NPF sugar free 
83841998 Generic dual lax extra strong tablets 
83888998 Macrogol compound oral powder sachets npf 
84124998 Docusate 100mg capsules 
84262978 Macrogol compound oral powder sachets NPF sugar free 
84308998 Generic lepicol powder 
84309998 Ispaghula husk with lactobacillus and bifidobacteria oral powder 
84329998 Glycerol 750microlitres/5ml oral solution sugar free 
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84658998 Glycerol 1.36g/5ml / glucose liquid 280mg/5ml oral solution 
84659998 Glycerol 1.36g/5ml / glucose liquid 280mg/5ml oral solution 
84793998 Macrogol compound oral powder sachets NPF sugar free 
84804998 Generic senokot dual relief tablets 
84900979 Magnesium sulfate powder 
84920979 Methylcellulose powder 
85071998 Generic Moviprep A oral powder 112g sachets 
85288998 Sodium acid phosphate 15.6% oral solution (1mmol/ml) 
85334998 Sodium dihydrogen phosphate 15.6% oral solution (1mmol/ml) 
85537978 Glycerol 4g suppositories 
85840998 Docusate 100mg capsules 
85843998 Bisacodyl 5mg gastro-resistant tablets 
86028979 Liquid paraffin light liquid 
86207979 Glycerol liquid 
86367979 Macrogol compound half-strength oral powder sachets NPF sugar free 
86476979 Macrogol 4000 10g oral powder sachets sugar free 
86509979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
86510979 Ispaghula husk 3.5g sugar free granules 
86510998 Senna 7.5mg/5ml oral solution sugar free 
86511998 Senna 7.5mg/5ml oral solution sugar free 
86512998 Senna 7.5mg/5ml oral solution sugar free 
86587998 Ispaghula husk 3.5g/sachet sugar free granules 
86588998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
86589998 Ispaghula husk 3.5g/sachet sugar free granules 
86890998 Cascara dry extract 130mg / senna leaf 32mg tablets 
86891998 Cascara dry extract 130mg / senna leaf 32mg tablets 
86955998 Ispaghula husk 90% granules 
87141979 Sterculia 62% granules 7g sachets gluten free 
87142979 Sterculia 62% granules gluten free 
87143979 Sterculia 62% granules gluten free 
87144979 Sterculia 62% granules gluten free 
87146979 Sterculia 62% / Frangula 8% granules 7g sachets gluten free 
87147979 Sterculia 62% / Frangula 8% granules 7g sachets gluten free 
87148979 Sterculia 62% / Frangula 8% granules gluten free 
87149979 Sterculia 62% / Frangula 8% granules 7g sachets gluten free 
87217979 Senna fruit 12.4% / ispaghula 54.2% granules 4g sachets 
87278998 Sodium dihydrogen phosphate dihydrate 1.69g / sodium bicarbonate 1.08g suppositories 
87282998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
87283998 Ispaghula husk 3.5g/sachet sugar free granules 
87624998 Glycerol 750microlitres/5ml / sucrose 1.7g/5ml oral solution 
87625998 Glycerol 750microlitres/5ml / sucrose 1.7g/5ml oral solution 
87626998 Glycerol 750microlitres/5ml oral solution sugar free 
87650998 Macrogol compound half-strength oral powder sachets NPF sugar free 
88071998 Macrogol 4000 10g powder 
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88168998 Senna 15mg tablets 
88181998 Methylcellulose 4% solution 
88409998 Lactulose 3.1-3.7g/5ml oral solution 
88463998 Docusate 50mg/5ml oral solution sugar free 
89059997 Ispaghula husk gluten-free sugar free granules 
89059998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
89127998 Macrogol compound oral powder sachets NPF sugar free 
89227998 Senna 15mg tablets 
89230998 Macrogol compound half-strength oral powder sachets npf sugar free 
89364998 Glycerol 4g suppositories 
89374998 Glycerol 750mg/5ml oral solution 
89380998 Ispaghula husk 3.5g/sachet powder 
89381997 Senna 15mg tablets 
89381998 Senna 15mg tablets 
89383998 Senna 7.5mg tablets 
89417998 Senna 15mg tablets 
89550998 Phosphates formula b enema 
89551998 Phosphates enema (Formula B) 128ml long tube 
89552998 Phosphates enema (Formula B) 128ml standard tube 
89617998 Ispaghula husk 3.5g sugar free granules 
89619979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
89644998 Magnesium sulfate powder 
89795998 Sodium picosulfate 5mg/5ml oral solution sugar free 
89886998 Phenolphthalein yellow 120mg / rhubarb 27.5mg tablets 
89887998 Phenolphthalein yellow 120mg / rhubarb 27.5mg tablets 
89906998 Bisacodyl 5mg gastro-resistant tablets 
90122998 Senna 15mg tablets 
90221998 Lactulose 3.1-3.7g/5ml oral solution 
90275998 Sodium sulphate ppwder 
90297979 Sodium citrate compound 5ml enema 
90297998 Senna 7.5mg tablets 
90298979 Sodium citrate compound 5ml enema 
90347998 Liquid paraffin with magnesium hydroxide and sodium bicarbonate suspension 
90348998 Liquid paraffin / Magnesium hydroxide oral emulsion sugar free 
90459998 Aloin 38mg tablets 
90460998 Aloin 38mg tablets 
90494998 Dioctyl sulphosuccinate with phenolphthalein 100mg+60mg tablets 
90642998 Macrogol compound half-strength oral powder sachets NPF sugar free 
90671998 Sodium lauryl sulphoacetate with sodium citrate enema 
90672998 Sodium citrate with sodium lauryl sulphoacetate enema 
90673998 Sodium phosphate with sodium acid phosphate (10.8g with 24.4g)/45ml oral solution sugar free 
90676998 
Sodium dihydrogen phosphate dihydrate 542mg/ml / Disodium hydrogen phosphate dodecahydrate 
240mg/ml oral solution sugar 
90677998 Sodium citrate with sodium lauryl sulphoacetate enema 
90678998 Sodium dihydrogen phosphate dihydrate 542mg/ml / Disodium hydrogen phosphate dodecahydrate 
  
477 
 
Chapter 6 Chapter six | THIN Data Extraction Methodology 
240mg/ml oral solution sugar 
90841998 Macrogol compound oral powder sachets NPF sugar free 
90859998 Senna 12mg tablets 
90860998 Senna 12mg pills 
90901998 Macrogol 4000 10g oral powder sachets sugar free 
91375998 Bisacodyl 5mg gastro-resistant tablets 
91481997 Magnesium hydroxide oral suspension 
91604998 Methylcellulose 450 liquid 
91945998 Glycerol 750microlitres/5ml oral solution sugar free 
92212998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
92241998 Senna 2.5mg/5ml oral solution 
92363990 Macrogol compound oral powder sachets NPF sugar free 
92566998 Ispaghula husk 3.4g/sachet powder 
92570997 Ispaghula husk 6g/sachet sugar free powder 
92570998 Ispaghula husk 3.4g/sachet powder 
92606990 Phosphates enema (Formula B) 128ml long tube 
92607990 Phosphates enema (Formula B) 128ml standard tube 
92663998 Lactulose sachets 
92664998 Lactulose 10g/sachet powder 
92777998 Lactulose 3.1-3.7g/5ml oral solution 
92791990 Sodium picosulfate 5mg/5ml oral solution sugar free 
92839998 
Sodium dihydrogen phosphate dihydrate 18.1% / Disodium hydrogen phosphate dodecahydrate 8% 
133ml enema 
92939998 Lactulose 3.1-3.7g/5ml oral solution 
93004990 Docusate 100mg capsules 
93049992 Sodium citrate compound 5ml enema 
93125992 Ispaghula husk 3.5g/sachet sugar free granules 
93295997 Magnesium hydroxide 415mg/5ml oral suspension sugar free 
93295998 Magnesium hydroxide 300mg chewable tablets 
93329998 Wheat fibre powder 
93392992 Cascara eli 
93443992 Ispaghula husk micronised + dextrose 
93510998 Liquid paraffin liquid 
93515998 Sterculia 62% / alverine 0.5% granules 
93758998 Senna 2.5mg/5ml oral solution 
93763992 Normacol x gra 
93810998 Sodium dihydrogen phosphate anhydrous 1.936g effervescent tablets 
93822998 Liquid paraffin & light liquid paraffin 7%+18% emulsion 
93841992 Celevac liq 
93924998 Methylcellulose 400mg tablets 
93967998 Sodium citrate compound 5ml enema 
93968998 Sodium citrate compound 5ml enema 
93992992 Trifyba wheat husk pow 
94120998 Magnesium sulphate enema 
94121998 Magnesium sulphate enema 
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94132998 Arachis oil 130ml enema 
94165998 Sodium acid phosphate & sodium bicarbonate 1.69g+1.08g suppositories 
94202996 Magnesium hydroxide with aluminium hydroxide 300mg+600mg/5ml oral suspension 
94203997 Magnesium hydroxide with aluminium hydroxide 300mg + 600mg tablet 
94347998 Phenolphthalein with liquid paraffin liquid 
94348998 Phenolphthalein with belladonna & ipecacuhana tablet 
94351998 
Magnesium hydroxide with oxetacaine and aluminium hydroxide 100mg+10mg+200mg/5ml oral 
suspension 
94359998 Magnesium hydroxide with ambutonium and aluminium hydroxide sugar free oral suspension 
94399998 Senna fruit 12.4% / Ispaghula 54.2% granules 
94459996 Bisacodyl 2.74mg/ml rectal solution 
94459997 Bisacodyl 10mg suppositories 
94676990 Senna 7.5mg tablets 
94700990 Glycerol liquid 
94728992 Bisacodyl 10 mg tab 
94746998 Senna fruit 12.4% / Ispaghula 54.2% granules 
94775992 Methylcellulose granules 
94820990 Magnesium sulfate powder 
94915990 Liquid paraffin light liquid 
94926992 Dioctyl sodium sulphosuccinate 20 mg tab 
94976998 Docusate compound 5ml enema 
94996998 Bisacodyl with dioctyl sodium sulphosuccinate tablets 
94998998 Bisacodyl 5mg gastro-resistant tablets 
95023992 Phosphates enema (Formula B) 128ml standard tube 
95062992 Glycerol 4g suppositories 
95066992 Glycerin & ichthammol sup 
95067992 Glycerin 150 mg sup 
95161992 Sterculia 62% granules gluten free 
95252998 Sterculia 62% / Frangula 8% granules 7g sachets gluten free 
95253997 Sterculia 80% granules 
95253998 Sterculia 62% granules gluten free 
95267992 Ispaghula husk 49% powder 
95271998 Generic Picolax oral powder 16.1g sachets sugar free 
95272996 Sodium picosulfate 2.5mg capsules 
95272997 Sodium picosulfate powder for oral solution 
95272998 Sodium picosulfate 5mg/5ml oral solution sugar free 
95277992 Methylcellulose mouthwash sol 
95295998 Sodium dihydrogen phosphate dihydrate 1.69g / sodium bicarbonate 1.08g suppositories 
95296996 Phosphates enema (Formula B) 128ml long tube 
95296997 Phosphates enema (Formula B) 128ml long tube 
95296998 Phosphates enema (Formula B) 128ml standard tube 
95297998 Sodium acid phosphate suppositories 
95298996 Senna 15mg/5ml granules 
95298997 Senna 7.5mg/5ml oral solution sugar free 
95298998 Senna 7.5mg tablets 
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95336992 Sterculia 62% granules gluten free 
95337992 Sterculia 62% granules gluten free 
95344998 Ispaghula husk 49% powder 
95345996 Ispaghula husk 6g oral powder sachets gluten free sugar free 
95345997 Ispaghula husk 3.4g oral powder sachets gluten free sugar free 
95345998 Ispaghula husk gluten-free sugar free 3.6g effervesant powder 
95346996 Ispaghula husk gluten-free 3.4g powder 
95346997 Ispaghula husk gluten-free sugar free granules 
95346998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
95408992 Liquid paraffin & light liquid paraffin 7%+18% emulsion 
95548998 Phenolphthalein with magnesium sulphate tablet 
95549996 Phenolphthalein 120mg chewable tablet 
95724992 Vegetable laxative tab 
95726992 Ispaghula husk 66% granules 
95731990 Senna 7.5mg tablets 
95775992 Veracolate tab 
95813992 Sodium picosulphate/magnesium cit sach 
95857998 Methylcellulose-450 500mg tablets 
95858996 Methylcellulose 900mg/10ml gel 
95858997 Methylcellulose 64% granules 
95858998 Methylcellulose 500mg tablets 
95900992 Colocynth & jalap co (vegetable laxative tab 
95923998 Ispaghula husk 3.5g / Mebeverine 135mg effervescent granules sachets sugar free 
95948992 Liquid paraffin / Magnesium hydroxide oral emulsion sugar free 
95951990 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
95966990 Senna 7.5mg tablets 
96030996 Lactulose 3.1-3.7g/5ml oral solution 
96030997 Lactulose 3.35g/5ml flavoured Oral solution 
96030998 Lactulose 3.35g/5ml Oral solution 
96055992 Phenolphthalein gum 97.2 mg 
96172990 Lactulose 3.1-3.7g/5ml oral solution 
96297990 Lactulose 3.1-3.7g/5ml oral solution 
96319992 Magnesium sulphate/phenolphthalein 300 mg tab 
96320996 Docusate 100mg capsules 
96320997 Docusate 50mg/5ml oral solution sugar free 
96320998 Docusate sodium 100mg tablets 
96321998 Docusate sodium with sorbitol enema 
96322998 Docusate sodium with bisacodyl tablets 
96323997 Docusate 100mg capsules 
96325996 Docusate 120mg/10g enema 
96325997 Docusate 50mg/5ml oral solution sugar free 
96325998 Docusate sodium 100mg tablets 
96347990 Senna 7.5mg tablets 
96368990 Lactulose 3.1-3.7g/5ml oral solution 
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96388992 Phenolphthalein 130 mg tab 
96413990 Bisacodyl 5mg gastro-resistant tablets 
96439992 Sennoside b 15 mg gra 
96622990 Liquid paraffin liquid 
96700992 Liq paraffin & phenolphthalen mix 
96758990 Lactulose 3.1-3.7g/5ml oral solution 
96816990 Lactulose 3.1-3.7g/5ml oral solution 
96909992 Lactulose 3.1-3.7g/5ml oral solution 
96980992 Bran (wheat) 2 gm tab 
97064990 Liquid paraffin oral emulsion 
97065990 Liquid paraffin / Magnesium hydroxide oral emulsion sugar free 
97081990 Bisacodyl 10mg suppositories 
97198992 Wheat husk extract (concentrated) pow 
97205992 Cremaffin emu 
97311992 Dioctyl sodium/sorbitol enema .1 % liq 
97401997 Senna 15mg/5ml granules 
97401998 Senna 7.5mg/5ml oral solution sugar free 
97402998 Senna 7.5mg tablets 
97408998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
97409998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free 
97444992 Fibrous grain extract/fibrous citrus ext 375 mg tab 
97534992 Glycerol 4g suppositories 
97543988 Glycerol 4g suppositories 
97623992 Ispaghula husk 66 % gra 
97629992 Ispaghula husk 90 % gra 
97654998 Liquid paraffin light liquid 
97655998 Docusate compound 5ml enema 
97658990 Glycerol 1.36g/5ml / glucose liquid 280mg/5ml oral solution 
97664992 Liq paraffin/light liq paraffin 7 % mix 
97665992 Liq paraffin sterile liq 
97666992 Liquid paraffin / Magnesium hydroxide oral emulsion sugar free 
97667992 Liq paraffin & cascara emulsion emu 
97668992 Liq paraffin emulsion mix 
97691990 Liquid paraffin liquid 
97710990 Senna 7.5mg tablets 
97743992 Methylcellulose 450 mg/5ml liq 
97744990 Lactulose 3.1-3.7g/5ml oral solution 
97744992 Methylcellulose 900 mg mix 
97750990 Glycerol 4g suppositories 
97752998 Docusate 120mg/10g enema 
97782990 Bisacodyl 5mg gastro-resistant tablets 
97868992 Paraffin oil liq 
97907990 Senna 7.5mg tablets 
97945990 Glycerol 4g suppositories 
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98023992 Senna 7.5mg tablets 
98044992 Phosphates enema (Formula B) 128ml long tube 
98051998 Cascara tablets 
98052998 Castor oil liquid 
98053998 Figs compound liquid 
98054998 Liquid paraffin oral emulsion 
98062998 Liquid paraffin / Magnesium hydroxide oral emulsion sugar free 
98095998 Senna 1mg/ml liquid 
98099990 Liquid paraffin / Magnesium hydroxide oral emulsion sugar free 
98127992 Sterculia 98 % gra 
98153992 Syrp of figs liq 
98159990 Glycerol 4g suppositories 
98160990 Glycerol 4g suppositories 
98215998 Methylcellulose granules 
98243992 Vita fiber tab 
98249998 Senna & ispaghula 12.4%+54.2% granules 
98251997 Phosphates formula b enema 
98251998 Phosphates enema (Formula B) 128ml standard tube 
98252998 Arachis oil retention enema 
98255998 Sterculia 62% granules gluten free 
98256998 Sterculia 62% / Frangula 8% granules gluten free 
98269998 Wheat fibre powder 
98272998 Bisacodyl 2.74mg/ml rectal solution 
98274998 Bisacodyl 10mg suppositories 
98433998 Magnesium sulfate powder 
98437996 Magnesium hydroxide 300mg chewable tablets 
98437997 Magnesium hydroxide oral suspension 
98437998 Magnesium hydroxide oral suspension 
98453998 Magnesium sulphate with phenolphthalein tablet 
98509990 Liquid paraffin liquid 
98556998 Lactitol 10g oral powder sachets 
98557998 Lactitol 10g oral powder sachets 
98583990 Bisacodyl 10mg suppositories 
98584989 Bisacodyl 5mg gastro-resistant tablets 
98585989 Bisacodyl 10mg suppositories 
98585990 Bisacodyl 5mg gastro-resistant tablets 
98651990 Lactulose 3.1-3.7g/5ml oral solution 
98692990 Magnesium hydroxide oral suspension 
98822988 Glycerol 750microlitres/5ml oral solution sugar free 
98839990 Glycerol liquid 
98859992 Vitafibre 
98889998 Sodium citrate compound 5ml enema 
98918996 Glycerol 4g suppositories 
99019998 Ispaghula husk 3.5g / Mebeverine 135mg effervescent granules sachets sugar free 
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99086990 Methylcellulose powder 
99136988 Liquid paraffin oral emulsion 
99136989 Liquid paraffin liquid 
99136990 Liquid paraffin light liquid 
99137989 Liquid paraffin liquid 
99137990 Liquid paraffin oral emulsion 
99138990 Liquid paraffin liquid 
99170990 Lactulose 3.1-3.7g/5ml oral solution 
99171990 Lactulose 3.1-3.7g/5ml oral solution 
99188997 Ispaghula husk 3.6g/sachet powder 
99188998 Ispaghula husk 3.4g/sachet sugar free powder 
99193990 Glycerol liquid 
99194988 Glycerol 4g suppositories 
99195988 Glycerol 4g suppositories 
99210998 Bran tabs 
99224998 Sterculia 80% granules 
99245998 Sodium dihydrogen phosphate anhydrous 1.936g effervescent tablets 
99268990 Bisacodyl 10mg suppositories 
99340998 Sterculia 62% / Frangula 8% granules 7g sachets gluten free 
99394998 
Magnesium hydroxide with oxetacaine and aluminium hydroxide 100mg+10mg+200mg/5ml oral 
suspension 
99401979 Glycerol 4g suppositories 
99416979 Lactulose 3.1-3.7g/5ml oral solution 
99417979 Lactulose 3.1-3.7g/5ml oral solution 
99424979 Sodium picosulfate 5mg/5ml oral solution sugar free 
99425998 Sodium citrate compound 5ml enema 
99426979 Senna 7.5mg tablets 
99433979 Senna 7.5mg tablets 
99457979 Bisacodyl 5mg gastro-resistant tablets 
99462979 Senna fruit 12.4% / Ispaghula 54.2% granules 
99472990 Liquid paraffin light liquid 
99473989 Liquid paraffin oral emulsion 
99473990 Liquid paraffin liquid 
99489998 Sodium picosulfate 5mg/5ml liquid 
99509998 Phenolphthalein with magnesium sulphate tablet 
99524998 Ispaghula husk 90% granules 
99528990 Magnesium hydroxide oral suspension 
99535990 Lactulose 3.1-3.7g/5ml oral solution 
99536990 Lactulose 3.1-3.7g/5ml oral solution 
99537990 Lactulose 3.1-3.7g/5ml oral solution 
99577990 Glycerol liquid 
99578988 Glycerol 4g suppositories 
99579988 Glycerol 4g suppositories 
99601998 Macrogol npf 10g powder 
99608998 Bran tabs 
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99717998 Lactulose 3.35g/5ml syrup 
99721997 Sodium picosulfate 2.5mg capsules 
99721998 Bisacodyl 5mg gastro-resistant tablets 
99722998 Docusate sodium with bisacodyl tablets 
99780989 Bisacodyl 5mg gastro-resistant tablets 
99780990 Bisacodyl 10mg suppositories 
99781989 Bisacodyl 10mg suppositories 
99781990 Bisacodyl 5mg gastro-resistant tablets 
99815998 Methylcellulose 900mg/10ml mixture 
99845998 Methylcellulose 500mg tablets 
99903992 Rhubarb & soda ammoniated mix 
99954989 Sodium acid phosphate powder 
99954990 Sodium dihydrogen phosphate dihydrate powder 
99955997 Magnesium hydroxide with simeticone and aluminium hydroxide oral suspension 
99984990 Magnesium sulfate powder 
Table A.3.1: Final drug code list for laxatives. 
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Appendix 4 – Stata Code for Select Examples 
//------------------------------------------------------------------------------ 
//*****CODE TO DERIVE BCSP FOBT SCREENING OUTCOMES FROM AHD DATA***** 
//------------------------------------------------------------------------------ 
 
//Load in the data 
use ahd.dta 
//------------------------------------------------------------------------------ 
keep if regexm(medcode, "6867\.00|6866\.00|686A\.00|686B\.00|686C\.00|9Ow2\.00") 
//------------------------------------------------------------------------------ 
 
merge m:1 medcode using /Volumes/JC/thin1509/stata/systemlookups/readcodes.dta, 
keep(master match) 
drop _merge 
 
//Generate new variable and make it = to description 
gen FOBToutcome=description  
tab FOBToutcome 
tab description 
 
  description |      Freq.     Percent        Cum. 
----------------------------------------+----------------------------------- 
                 BCSP FOB test abnormal |         92        1.86        1.86 
                   BCSP FOB test normal |      4,465       90.35       92.21 
            BCSP FOB testing kit spoilt |          1        0.02       92.23 
         BCSP FOB tst incmplt participt |         87        1.76       93.99 
Bowel cancer screening programme: fae.. |        269        5.44       99.43 
No response to bowel cancer screening.. |         28        0.57      100.00 
----------------------------------------+----------------------------------- 
                                  Total |      4,942      100.00 
 
//------------------------------------------------------------------------------ 
 
//replace FOBToutcome = "BCSP FOB test normal" if ((medcode=="6866.00|68W2.00") & 
(data4== "PTH005|P/N001"))  
replace FOBToutcome = "BCSP FOB test normal" if medcode=="6866.00" & data4== "PTH005"  
replace FOBToutcome = "BCSP FOB test normal" if medcode=="6866.00" & data4== "P/N001"  
 
replace FOBToutcome = "BCSP FOB test abnormal" if medcode=="6866.00" & data4== 
"P/N002"  
replace FOBToutcome = "BCSP FOB test abnormal" if medcode=="6866.00" & data4== 
"PTH010"   
 
tab FOBToutcome 
 
  FOBToutcome |      Freq.     Percent        Cum. 
----------------------------------------+----------------------------------- 
                 BCSP FOB test abnormal |         95        1.92        1.92 
                   BCSP FOB test normal |      4,611       93.30       95.22 
            BCSP FOB testing kit spoilt |          1        0.02       95.24 
         BCSP FOB tst incmplt participt |         87        1.76       97.01 
Bowel cancer screening programme: fae.. |        120        2.43       99.43 
No response to bowel cancer screening.. |         28        0.57      100.00 
----------------------------------------+----------------------------------- 
                                  Total |      4,942      100.00 
//------------------------------------------------------------------------------ 
//When there is a generic BCSP readcode and no other value recorded, this is not 
helpful so drop it 
drop if medcode=="6866.00" & !regexm(data4, "PTH005|P/N001|P/N002|PTH010")  
//------------------------------------------------------------------------------ 
tab FOBToutcome 
 
  FOBToutcome |      Freq.     Percent        Cum. 
----------------------------------------+----------------------------------- 
                 BCSP FOB test abnormal |         95        1.97        1.97 
                   BCSP FOB test normal |      4,611       95.62       97.59 
            BCSP FOB testing kit spoilt |          1        0.02       97.62 
         BCSP FOB tst incmplt participt |         87        1.80       99.42 
No response to bowel cancer screening.. |         28        0.58      100.00 
----------------------------------------+----------------------------------- 
                                  Total |      4,822      100.00 
 
//------------------------------------------------------------------------------ 
Table A.4.1: Stata code to derive BCSP FOBT screening outcomes from AHD data 
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//------------------------------------------------------------------------------ 
//*****BOWEL CANCER DIAGNOSIS***** 
//------------------------------------------------------------------------------ 
use readcodes.dta 
generate lcase=lower(description) 
gen case = 0 
//------------------------------------------------------------------------------ 
 
//Iterative search strategy 
 
replace case=1 if regexm(lcase,"colo.*cancer") 
replace case=1 if regexm(lcase,"colo") & regexm(lcase,"neop|carcinoma|adeno|cancer") 
replace case=1 if regexm(lcase,"bowel") & regexm(lcase,"neop|carcinoma|adeno|cancer") 
replace case=1 if regexm(lcase,"rect") & regexm(lcase,"neop|carcinoma|adeno|cancer") 
replace case=1 if regexm(lcase,"caec") & regexm(lcase,"neop|carcinoma|adeno|cancer") 
replace case=1 if regexm(lcase,"append") & 
regexm(lcase,"neop|carcinoma|adeno|cancer") 
replace case=1 if regexm(lcase,"git") & regexm(lcase,"neop|carcinoma|adeno|cancer") 
 
browse if case ==1 
 
//------------------------------------------------------------------------------ 
//Extract these into Excel document 
//------------------------------------------------------------------------------ 
 
//Looking at additional stems identified of relevance from the above; codes beginning  
//with B and 68 appear to be of relevance 
//Look above and below for relevant terms 
//Below gives the parent stems 
 
browse if regexm(medcode, "^B.\.") 
 
browse if regexm(medcode, "^B.\.*\.00") 
browse if regexm(medcode, "^68.\.*\.00") 
//------------------------------------------------------------------------------ 
//From the above, identified that the following stems may be of relevance 
browse if regexm(medcode, "^B\..*|^B1.*|^B5.*|^B8.*|^B9.*|^BA.*|^BB.*|^By.*|^Bz.*") & 
case ==0 
browse if regexm(medcode, "^68\..*|^681.*|^686.*|^68P.*|^68Q.*|^68W.*|^68Z.*") & case 
==0 
 
//No additional codes identified from the above 68 parent stem 
//------------------------------------------------------------------------------ 
//browse and extract those which are relevant into Excel document 
//------------------------------------------------------------------------------ 
 
//Looking at BB(morphology in more detail as large number of results, to narrow down) 
browse if regexm(medcode, "^BB.\.") 
 
//Perhaps morphology is not relevant here, to confirm with Tom, otherwise indicate - 
morphology could be relevant so include 
//the child stems of relevance 
 
browse if regexm(medcode, 
"^BB.\.*|^BB0.*|^BB1.*|^BB2.*|^BB4.*|^BB5.*|^BB7.*|^BB8.*|^BBa.*|^BBB.*|^BBM.*|^BBm.*
|^BBT.*|^BBY.*|^BBy.*|^BBz.*") & case ==0 
 
//------------------------------------------------------------------------------ 
//Reload final Excel back into Stata and sort by medcode before formatting in Excel 
 
 import excel "/Users/jennifercooper/Desktop/Bham THIN/1.Creating lookups for 
THIN/lookups_readcodes.xlsx", sheet("colorectalcancer (2)") cellrange(A3:F253) 
firstrow clear 
 
 sort medcode 
//------------------------------------------------------------------------------ 
//END 
 
 Table A.4.2: Stata code used to derive a Read code list for Bowel Cancer Diagnosis  
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//------------------------------------------------------------------------------ 
//*****LAXATIVE DRUGS PROXY FOR CONSTIPATION***** 
//------------------------------------------------------------------------------ 
use drugcodes.dta 
 
//------------------------------------------------------------------------------ 
4 main types of laxative: 
 
1.6.1 Bulk-forming laxatives 
1.6.2 Stimulant laxatives 
1.6.3 Faecal softeners 
1.6.4 Osmotic laxatives 
 
//Read text to determine which ones to include for acute constipation. 
generate lcase=lower(genericname) 
gen case = 0 
//------------------------------------------------------------------------------ 
//Get an idea for keyword searches looking at Chapter from drug code dictionary  
//as well as hardcopy BNF 
 
browse if (regexm(bnfcode1, "^01.06")|regexm(bnfcode2, "^01.06")|regexm(bnfcode3, 
"^01.06"))& case ==0 
//------------------------------------------------------------------------------ 
//1. Search generic name for results based on drugs listed in the bnf.  
//This allows you to identify drugs which have been mapped to different Chapters. 
//Iterative search strategy 
 
replace case=1 if 
regexm(lcase,"ispaghula|fibrelief|fybogel|isogel|ispagel|regulan|methylcellulose|cele
vac|sterculia|normacol")  
replace case=1 if 
regexm(lcase,"bisacodyl|sodium.*picosulfate|dulcolax|pico.*liquid|pico.*perles|docusa
te.*sodium|dioctyl.*sodium.*sulphosuccinate|dioctyl|docusol|norgalax.*micro-
enema|glycerol|gylcerin|senna|sennoside|manevac|senokot|sodium.*picosulfate|dulcolax"
)  
//We wont include Dantron as this is for terminally ill patients 
replace case=1 if regexm(lcase,"arachis.*oil|liquid.*paraffin") 
replace case=1 if regexm(lcase, 
"lactulose|macrogol|polyethylene.*glycol|laxido|molaxole|movicol|norgine|magnesium.*s
alt|magnesium.*hydroxide|magnesium.*sulphate|phosphates.*rectal|carbalax|sodium.*acid
.*phosphate|sodium.*dihydrogen.*phosphate|fleet|casen.*fleet|phosphates.*enema|sodium
.*citrate|microlette.*micro.*enema|micralax|relaxit") 
 
//------------------------------------------------------------------------------ 
//Put this stage in after investigations of tabulating the bnfcodes to see if we  
//can remove any common ones that are not 01.06 
 
//Get rid of those matched to Chapter 13, Chapter 7 
//At this stage get rid of those which mention another Chapter as we re-add  
//the drugs mapped to 01.06 below. 
 
replace case=0 if regexm(bnfcode1, "^13\..*|^07\..*") 
//------------------------------------------------------------------------------ 
//2. search the BNF Chapters (identified from keyword search as well as from hardcopy 
book)  
//for those where case=0 
 
//We are interested in: 
//1.6.1 Bulk-forming laxatives 
//1.6.2 Stimulant laxatives 
//1.6.3 Faecal softeners 
//1.6.4 Osmotic laxatives 
 
//Also interested in those drugs not mapped to a Chapter - 0 or 1 
 
replace case=1 if (regexm(bnfcode1, "^01\.06\.00")|regexm(bnfcode2, 
"^01\.06\.00")|regexm(bnfcode3, "^01\.06\.00"))& case ==0 
replace case=1 if (regexm(bnfcode1, "^01\.06\.01")|regexm(bnfcode2, 
"^01\.06\.01")|regexm(bnfcode3, "^01\.06\.01"))& case ==0 
replace case=1 if (regexm(bnfcode1, "^01\.06\.02")|regexm(bnfcode2, 
"^01\.06\.02")|regexm(bnfcode3, "^01\.06\.02"))& case ==0 
replace case=1 if (regexm(bnfcode1, "^01\.06\.03")|regexm(bnfcode2, 
"^01\.06\.03")|regexm(bnfcode3, "^01\.06\.03"))& case ==0 
replace case=1 if (regexm(bnfcode1, "^01\.06\.04")|regexm(bnfcode2, 
"^01\.06\.04")|regexm(bnfcode3, "^01\.06\.04"))& case ==0 
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//------------------------------------------------------------------------------ 
 
//exclude 
 
//we do not want to include dantron as for terminally ill patients 
replace case=0 if regexm(lcase, "dantron|co.*danthramer|co.*danthrusate") 
 
//Scan through the types of drugs genericname 
//we dont want creams, dressings etc 
replace case=0 if regexm(lcase, 
"dressing|poultice|eye|paediatric|injection|ear.*drop|cream|biscuit|syringe|ointment|
bath.*additive|bath.*oil|emollient|soap|shampoo") 
 
//Can we remove any by formulation? 
tab formulation 
replace case=0 if regexm(formulation, "dressings|drops|paediatric|infant 
suppositories") 
 
 
//double check there are not any further ones that could be removed. 
 
//------------------------------------------------------------------------------ 
browse if case==1 
keep if case==1 
 
//569 observations 
//------------------------------------------------------------------------------ 
 
//Looking at which Chapters we could potentially remove 
 
tab bnfcode1 
tab bnfcode2 
tab bnfcode3 
 
//Go by bnfcode1 as that is the first Chapter the drug is mapped to? 
 
//All combinations below: 
 
preserve 
 gen dummy=1 
 collapse (count) dummy, by (bnfcode1 bnfcode2 bnfcode3) 
 sort dummy 
restore 
 
//71 combinations, can we get rid of some which definitely do not map to the right 
Chapter? 
//13 seems to be a common Chapter for skin, we could remove this above by replacing 
case with 0  
//before we add all those Chapters that mention 01.06 
//Also Chapter 7 obstetrics is a relatively common Chapter. 
//------------------------------------------------------------------------------ 
 
//Exclude drugs which do not seem relevant (do not match drugs in the correct 
Chapter)  
//and do not have a bnf code which matches onto the correct Chapter. 
 
//------------------------------------------------------------------------------ 
//ATC search as final check for drug ingredients 
 
 
//------------------------------------------------------------------------------ 
//Final list for checking 
keep if case==1 
 
//------------------------------------------------------------------------------ 
 
Table A.4.3: Stata code used to derive a Drug code list for laxative drugs 
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Thesis Discussion 
1.0 Summary of Findings 
The studies in this thesis contribute to determining the value of risk adjusted colorectal 
cancer screening using the FIT through developing risk prediction models which can be 
used to guide referral decisions in screening.  
The systematic review aimed to identify risk prediction models which combine the FIT 
result with risk predictors for colorectal cancer screening referral decisions and to 
determine whether they perform better than screening using the FIT alone. Before 
developing a model it is best practice to identify and build upon risk prediction models 
which have been previously developed. This review identified that there was some 
evidence to suggest that including additional predictors with the FIT result can improve 
model performance and test accuracy, relative to FIT only. Biomarkers (e.g. TIMP-1, sCD26 
and CEA) and routinely available demographic factors (e.g. age, sex, BMI) gave improved 
performance metrics which suggested that improvement could be achieved using routine 
data alone without additional laboratory testing. 
Routine data were used to develop the risk prediction models using both the BCSS and the 
anonymised primary care database THIN. The interconnectivity of GP records with other 
healthcare systems including screening is described in Chapters 5 & 6. Data for participants 
invited to the NHS BCSP are drawn from GP records and onto the NHS Spine. These 
connections can be exploited for further research.  
This thesis uses three types of modelling strategy to develop risk prediction models: logistic 
regression, which is seen as the most common method used in the literature; artificial 
neural networks which is a flexible machine learning approach; and survival analysis in the 
form of Cox Regression to make use of the longitudinal nature of primary care records. 
Parametric models were also explored as an extension to Cox regression using the same 
predictors to determine whether model performance and fit was improved.  
The predictors considered for risk prediction model development from the BCSS included 
demographic characteristics such as age, sex, IMD and previous screening history. 
Temperature and its effect on FIT positivity was also investigated by utilising open source 
data from the UK Met Office. Richer predictors could be obtained from primary care 
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records, e.g. symptoms, diagnoses of previous conditions, lab test results, anthropometrics 
and drug prescriptions. 
Model building strategies used backwards elimination and integrated some form of internal 
validation to adjust for optimism and improve generalisability of the models. The outcomes 
investigated used colorectal cancer and advanced adenoma for the logistic regression and 
neural network models. For the Cox Regression model, both colorectal cancer and 
colorectal polyps were considered as a combined endpoint. The risk prediction models are 
presented as risk equations to ensure reproducibility and to enable external validation if 
required. 
Model performance was assessed using discrimination (area under the ROC curve) as well 
as calibration (calibration plots and Hosmer-Lemeshow statistics). Discrimination improved 
from 0.63 with FIT only to 0.66 for the risk-adjusted logistic regression model (p=0.01). This 
was further improved when applying an artificial neural network model using the same 
predictors with an AUC of 0.69. A ROC test confirmed this difference was significantly 
different (p<0.001).  There was also a corresponding increase in test accuracy when 
applying the model as a test. At a threshold of 160 μg/g, which is the anticipated NHS BCSP 
cut point, the ANN had a sensitivity of 35.15% and a specificity of 85.57% compared to a 
sensitivity of 33.15% and specificity of 84.69% for the equivalent logistic regression model. 
The FIT only as a comparator had a sensitivity of 30.78% at the same specificity.  
Two risk prediction models were developed in Chapter 5 to help identify predictors which 
could be considered for inclusion in a future risk adjusted screening model. The first model 
combined the FOBT result (both positive and negative) with other predictors available from 
THIN to determine individual risk. The second was developed to investigate if the additional 
information from the electronic GP record could be used to make better screening referral 
decisions for those with negative FOBT results only. Optimism adjusted performance 
statistics for the model combining FOBT included a C-statistic of 0.850, c-slope of 0.991, D 
statistic 2.298 and R2 of 0.558. The model for negative FOBTs only had a C-statistic of 0.650, 
c-slope of 0.944, D statistic 0.836 and R2 of 0.144.  
 
Parametric survival models were also investigated as an extension to these two models. 
The generalised gamma model had the best fit based on the AIC, cumulative hazard plots, 
Kaplan Meier function plots and Cox-Snell residuals for a sample population with both 
negative and positive FOBT results. The discrimination for the generalised gamma model 
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was very similar (0.859 (95% CI: 0.845, 0.872)) to the equivalent Cox Regression model 
(0.854 (95% CI: 0.841, 0.868)). Calibration was slightly better for the generalised gamma 
model but still comparable to the Cox regression model. A Wald test for the hypothesis of 
the kappa ancillary parameter of the gamma model being equal to 1 was significant 
suggesting a potentially good fit for the Weibull model also (C-statistic 0.854 (95% CI: 
0.841, 0.868)). For the sample population with negative FOBT results only, the Gompertz 
model provided the best fit when comparing the AIC and residual plots of other parametric 
models. With regards to model performance, the discrimination of the Gompertz model 
was the same as the equivalent Cox regression (C-statistic 0.658 (0.633, 0.683)) with a 
similar calibration. The covariate effect estimates also showed very similar results between 
the Gompertz model and the Cox model. The choice of the most appropriate model 
depends on several factors including practical application, model fit, out of sample 
(external) validation, how well the model follows the baseline hazard and whether 
assumptions of the model are met. A Cox Regression model was used to estimate predicted 
probabilities in this instance as similar studies have used this approach aiding comparability 
of results1 2 and due to the flexibility of the parameterisation of the baseline hazard.3 4 
 
In order to derive valid data for the analyses in Chapter 5 using the THIN database, the 
methods behind data extraction and for improving data validity are described in Chapter 6. 
The AEB date identified the point at which GP practices started to receive electronic 
notifications from the BCSP and was used as a layer of data quality assurance and to define 
a screening cohort for analysis.  Data are stored in four main files in THIN using clinical 
coding systems: Patient File, Medical File, Therapy File and Additional Health Data File. The 
methods used to extract lab test results and other predictors from the AHD file were 
described. The methods used to develop Read Code lists to extract information on 
symptoms and diagnoses were described. Drug code list development to extract 
information relating to prescriptions was also detailed. The reporting of this chapter ties 
into the growing interest in electronic health records and the need for reproducibility and 
transparency in the methods used to analyse them. 
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2.0 Summary of Chapters 
Chapter two reports a systematic review which aimed to identify risk prediction models 
which combine the FIT result with risk indicators for colorectal cancer screening referral 
decisions and to determine whether they perform better than regular screening using the 
FIT alone. Eight studies were included from reviewing 54 full text articles. Discrimination 
ranged from 0.676-0.960 for risk adjusted FIT (reported in 6/8 studies) and 0.683-0.902 for 
FIT only (reported in 4/8 studies). Calibration using the Hosmer-Lemeshow statistic ranged 
from 0.276-0.940 for risk adjusted FIT (reported in 3/8 studies); and calibration plots were 
presented in just one study. Where test accuracy measures were included (4/8 studies), 
sensitivity ranged from 21.9% to 88% for risk adjusted FIT at a range of set specificities 
from 90-97.7%. FIT only sensitivity ranged from 19.7% to 82% at the same specificities. 
Although this could not be tested formally in a meta-analysis, there was evidence to 
suggest both model performance and test accuracy improved by combining the FIT with 
other risk predictors. Both the integration of lab results/biomarkers and routinely available 
demographic factors gave improved performance metrics. Age and sex were the most 
consistently included predictors, high performing models also included lifestyle information 
such as smoking and alcohol consumption as well as family history of cancer. Lab test 
results associated with greater model performance included TIMP-1, CEA, sCD26 and 
calgranulin B. Further evidence is required to confirm which biomarkers and other 
predictors should be included. This suggested that improvement in discrimination and test 
accuracy could be achieved using routine data alone without additional laboratory testing. 
None of the models could be considered ready to apply in practice and most suffered from 
methodological issues with statistical analysis which was rated as high risk of bias for all but 
one of the identified studies. Seven studies used a form of logistic regression and only one 
used survival analysis. There were no studies in this review which assessed machine 
learning approaches, which have been shown to have similar or superior performance to 
more conventional regression techniques. 
Chapter three developed a risk prediction model combining routinely available predictors 
from the BCSS with the FIT to determine whether model performance and test accuracy 
were improved in an average risk screening population, compared to FIT alone. Model 
development used logistic regression and backwards elimination with cross validation. The 
final model included, log of the FIT result, age, sex and screening history. Discrimination 
improved from 0.628 for FIT only to 0.659 for the risk-adjusted model. The sensitivity 
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improved from 30.78% to 33.15% at similar specificity using a threshold of 160 μg/g, which 
is an anticipated threshold for the NHS BCSP. The risk-adjusted screening algorithm 
detected 13 additional advanced adenomas compared to FIT only. The use of routine data 
has a distinct advantage as no additional data needed to be collected from participants. 
This risk model mainly improved detection in men and would need further investigation if 
applied in practice. Positive FIT results occur more frequently in men compared to women5 
without risk adjustment. The BCSS should be explored for further risk indicators in the 
future, particularly relating to previous screening results. Machine learning algorithms 
were identified as a potential avenue to explore in Chapter 2 and have the potential to 
improve model performance and test accuracy further without additional data collection.  
Chapter four develops a feed forward ANN using the same routine predictors investigated 
in Chapter 3 and cross-validation used to aid comparison. There is evidence to suggest that 
ANN models outperform logistic regression in certain scenarios and it has been suggested 
that both methods are investigated in a complementary manner.6-9 The final network had 5 
input nodes, 3 hidden layer nodes and 1 output node with a weight decay of 0.01 (cross 
validated deviance was 2077.7). The network was pruned by removing 4 connections 
leaving the model with 18 connection weights, helping to improve the generalisability of 
the model. The AUC for the ANN was 0.69 compared with 0.66 for the logistic regression 
model, this was statistically significant (p<0.001). Calibration was good as indicated by the 
Hosmer-Lemeshow statistic (0.892), giving a similar result to the logistic regression model 
(0.898). In terms of test accuracy, the ANN had a higher sensitivity compared to the logistic 
regression model (35.15%). Eleven additional advanced adenomas were detected using the 
ANN over the logistic regression model. Model development is fully reported and the full 
equation given which is an often cited disadvantage of studies using machine learning 
approaches.10 With the shift to larger and more complex electronic health data, machine-
learning algorithms may be better placed to deal with larger amounts of data and non-
linear predictors when compared with conventional models such as logistic regression. 
Another approach to improving model performance is to consider a richer set of predictors. 
Model performance metrics including Nagelkerke’s R2, AUC and the deviance suggested 
that the prediction of cancer/advanced adenomas is not fully captured by the predictors 
used in both the logistic regression and ANN models. The BCSS receives data for its 
participants from the NHS Spine which houses demographic information for those aged 60-
74 drawn from GP records. There is capacity to draw further information from the NHS 
Spine or from GP records to improve screening referral decisions. EHRs from primary care 
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have a richer level of data than that available on the BCSS and may add a further dimension 
to risk prediction models. 
Chapter five investigated the use of electronic primary care databases to improve 
colorectal cancer screening referral decisions. Potential predictors from the database which 
may enhance a future risk adjusted model were investigated along with the data 
completeness of these predictors. The THIN database of anonymised GP records was used 
to define a screening population by identifying practices which receive electronic BCSP 
notifications in England and for participants aged 60-74. The positivity of the FOBT in this 
cohort was similar to that reported in the literature (2.18%). Data were generally well 
recorded for reported symptoms (100%), smoking status had 99.44% completeness and 
alcohol consumption 78% completeness. The least complete factors included lab results 
(platelet count, MCV, and haemoglobin at around 45%, and ferritin at 8.59%). Univariable 
analysis using Cox Regression was used to estimate hazard ratios (HR) for >30 key clinical 
features of colorectal cancer driven from the literature. Screening based factors had the 
strongest association with colorectal cancer/polyps. Previous positive FOBT results had a 
HR of 5.03 (CI: 4.18-6.05) and previous polyps diagnosed before the latest FOBT result had 
a HR of 3.18 (CI: 2.77-3.66). The Cox Regression model which combined the FOBT result 
(n=98,303; 1197 colorectal cancer/polyps) included 13 predictors and 2 interactions 
including; MCV, various symptoms/diagnoses and whether previous polyps had been 
diagnosed. The optimism adjusted performance metrics gave a C-statistic of 0.850, c-slope 
of 0.991, D statistic 2.298 and R2 of 0.558. Parametric models were investigated as an 
extension with the generalised gamma model providing marginally better model 
performance with a C-statistic of 0.859 versus 0.854 (apparent performance) for the 
equivalent Cox Regression model and slightly better calibration as reflected in the 
calibration plots.  
Since the guaiac FOBT sensitivity is around 50%, analysis was then repeated for a 
population with negative FOBT results only to determine whether additional factors could 
be used for screening referral decisions despite a negative test result. The model 
investigating negative results only (n = 95,792; 587 colorectal cancer/polyps) included a 
similar pattern of variables. Performance metrics included a C-statistic of 0.650, C-Slope of 
0.944, D statistic 0.836 and R2 of 0.144. The parametric model with the best fit to the data 
was the Gompertz model. This model had the same discrimination as the equivalent Cox 
regression (C-statistic 0.658) with very similar calibration plots. This study has shown that 
there are several clinical predictors available from GP databases which are associated with 
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colorectal cancer and polyps for an average risk screening population. Furthermore, this 
research has identified predictors which could be considered for inclusion in a future risk 
adjusted screening model.  The prediction models estimate an individual’s absolute risk of 
colorectal cancer and these methods could be used in future models to identify 
participants at highest risk for screening referral decisions. Additional data could be drawn 
from primary care onto the BCSS using the NHS Spine to contribute to a referral algorithm. 
Chapter six describes the methodology used to extract valid data from THIN for the 
analysis in Chapter 5.  A method was developed to define acceptable periods of BCSP 
notifications for practices receiving electronic results – the acceptable electronic BCSP 
(AEB) date. The frequency of bowel cancer screening notifications received per month by 
the number of patients registered in a practice aged 60-74 was determined for each 
practice in THIN. An expected rate for each practice was also generated, based on a 50% 
uptake rate and adults being invited biennially. Line graphs, with the expected monthly 
rate of electronic notifications and the actual monthly rate by practice were visually 
examined for the start date by two reviewers. There was 97.8% agreement for practices 
included in this assessment. The agreed AEB start dates for these practices were used in 
Chapter 5 to define the population and data used for analysis. AHD strategies for bowel 
cancer screening notifications identified a series of rules which could be used to extract 
BCSP FOBT screening outcomes for all patients in the THIN database. The AHD strategy for 
haemoglobin concentration identified a reference distribution using pathology lab data and 
transformed values where appropriate so that the results used the same units and were 
recorded in the same way for analysis. Results which were outside the range of the 
reference distribution were excluded from extraction. Read code list generation resulted in 
a list of 42 codes used for bowel cancer diagnosis after being subject to a double reviewing 
process. Drug code list generation for laxatives resulted in a list of 450 codes. The AEB date 
can be used in future studies as a layer of data quality assurance to ensure results used for 
analysis are ones which have been electronically received to the AHD records. There is a 
growing requirement to ensure Read code/Drug code lists as well as more recently their 
methods are transparent and available for future research studies. The methods for 
producing Read code lists, drug code lists and AHD variables are fully reported. 
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3.0 Original Contributions 
This research adds to the growing body of methodological and empirical research for risk 
prediction models, screening and EHRs. 
 
The systematic review crosses both diagnostic accuracy and risk prediction model 
paradigms by assessing the model as a test and including both PROBAST and QUADAS-2 for 
quality appraisal. This approach is also carried forward into Chapters 3 & 4 when 
developing a logistic regression and neural network model; test accuracy (sensitivity and 
specificity) was assessed by setting the recall rate the same (this generates the same 
specificity) and analyzing the corresponding effect on sensitivity.  
 
As far as can be identified this is the first instance of a risk adjusted approach combining 
the FIT in a prediction model being investigated in the UK. Chapters 3 & 4 developed the 
model using screening data available directly from the BCSS. Using data routinely available 
from the screening programme makes it easier to implement such a model into clinical 
practice. 
 
In addition, machine learning methods (artificial neural networks) have not been previously 
considered for developing a model which combines FIT for screening decisions. One of the 
main criticisms identified by the TRIPOD guidelines for machine learning algorithms is a lack 
of transparency in the methods adopted for model development. The model building 
process was fully described and the risk equation provided with the study to aid 
reproducibility and transparency. 
 
A novel method of utilizing a primary care database for a screening population was 
developed and applied in Chapters 5 & 6. The AEB date allows a researcher to identify 
when electronic BCSP notifications started to be received by each GP practice. This is a 
mark of quality assurance of the data since before this time paper records would have been 
used which are often biased towards abnormal results and may be incomplete. This AEB 
date was used to help define a screening cohort from the THIN database for developing a 
risk prediction model. 
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The methodology for extracting Additional Health Data (AHD) for particular variables is, as 
far as can be identified, previously unreported. This is a more complex data structure to 
use compared to the Medical File and Therapy data. The methods for extracting FOBT 
screening outcomes as well as for haemoglobin results are fully reported along with the 
corresponding Stata commands to improve transparency in the area of EHRs. This has been 
recommended in recent guidelines and publications.11 12 
 
The results reported in this thesis are in themselves an original contribution to the 
literature. Risk adjusted screening has been shown in Chapters 2, 3 & 4 to perform better 
than using the screening test alone. Both model performance and test accuracy were 
improved using this approach and an increase in the advanced adenoma/colorectal cancer 
detection rate was observed. Further research is required once this model is updated and 
externally validated to confirm these results in the form of an impact analysis or 
randomised controlled trial of risk adjusted screening versus regular screening. 
 
Further to this, a risk adjusted approach using logistic regression performs better than FIT 
alone, but an artificial neural network was shown to have even greater performance. The 
neural network can provide the absolute risk for each individual like with a logistic 
regression model. In addition, with the shift to larger and more complex electronic health 
data, machine-learning algorithms may be better placed to deal with larger amounts of 
data and non-linear predictors when compared with conventional methods. 
 
The risk adjusted logistic regression model compared to FIT only showed a greater 
detection rate in men versus women. The neural network on the other hand helped to 
equalise this disparity. Just as when assessing new health technologies, which might 
change the spectrum or profile of diagnosed disease (as well as the corresponding balance 
of benefits and harms), risk prediction models need to be assessed in a similar way since in 
this instance the proportion of cancers being identified was greater in men. 
  
   
 
 
 
497 
 
Chapter 7 Chapter seven | Discussion 
4.0 Practical Implications 
Prediction model studies must follow the complete pathway from model development, to 
external validation and finally model impact before they are considered for implementation 
in practice. This research has identified key predictors for use in a screening referral 
algorithm from the BCSS. There is capacity on this information system to include further 
predictors in a risk score. There are further BCSS variables which warrant investigation 
particularly relating to screening history. A risk adjusted approach using the routinely 
available predictors from BCSS has been discussed by key stakeholders in the BCSP and it 
has been suggested that additional research is carried out to identify further predictors 
from the BCSS and to externally validate an updated model. 
 
Each of the models developed in this thesis gave the full model equation for external 
validation and absolute risk probabilities for screening referral by setting an appropriate 
risk threshold. This approach will allow those at higher risk to be referred onto 
colonoscopy, whilst those at lower risk are placed back into the screening pool for 
continued surveillance. This approach helps to maximise benefits, minimise harms and 
make the most effective use of a limited colonoscopy resource. Absolute risk probabilities 
can also be used for risk communication to improve screening uptake and informed 
decision making.13 14 A Nomogram such as the one presented in Chapter 5, can be used for 
such a purpose. 
 
There are several barriers which have hindered the widespread application of machine 
learning approaches such as ANN’s in practice.15-22 Reasons include the ‘black box’ nature 
of the models which are more difficult to interpret,6 23 computational transportability for 
external validation or implementation,16 clinician trust or acceptability, the lack of methods 
to update machine learning algorithms when applied in a new setting or for recalibration19 
22 and the lack of reporting the model equation or providing ‘software objects’16 in 
publications.  Efforts were therefore made within this thesis to provide the full risk 
equation for external validation and to enable the algorithm to be applied in computers 
with minimal software requirements enhancing computational transportability. In addition, 
methods to aid the interpretability of the model were presented including Garson’s 
algorithm to show relative importance of variables, neural network structure plots, patient 
profiles to show which risk factors may contribute to higher risk probabilities and the 
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predictiveness curve to assess the fit of the model as well as the clinical utility. ANN model 
development is described in detail in Chapter 4 and the risk equation gives an absolute risk 
probability like with the logistic regression model.  
 
The logistic regression model developed in Chapter 3 detects more cancers/advanced 
adenomas in males compared to females but the neural network helps to level out this 
difference by increasing the number of high risk adenomas detected in women and halving 
the number of false positive results for women. This difference seen between the sexes 
warrants further investigation based on screening programme aims. 
 
The analyses reported in Chapter 5 use a GP database to identify predictors which could be 
considered for inclusion in a future risk adjusted screening model for screening referral 
decisions. Screening history variables had a strong association with the diagnosis of 
colorectal cancer/polyps. Predictors which retained significance in the multivariable models 
and which could be considered in future risk based models included: MCV result, smoking 
status, family history of gastrointestinal cancer, age, sex, abdominal pain/antispasmodic 
prescription, diarrhoea, flatulence and change in bowel habit. The interconnections 
between GP records and the BCSS can be exploited further by drawing off more 
information onto the NHS Spine. Further to this, other studies have shown the merit of 
using blood test results combined with screening tests,24 25 and the MCV was retained in 
both prediction models in this research. Routine blood test results for those in the 
screening age range could be implemented in the future. For example, the NHS Health 
Check is offered to individuals aged 40-74 and this could include routine blood tests. 
 
The choice of the most appropriate model to use in practice depends on a multitude of 
factors, not just model performance.  Determining the most appropriate model to use 
whether it be a semi-parametric Cox regression model, parametric model, logistic 
regression or neural network will depend firstly on the nature of the data and underlying 
assumptions and then on model performance parameters. External validation and impact 
studies will then provide the necessary evidence on out of sample performance and patient 
outcomes. The parametric models in Chapter 5 for instance were found to have a similar 
performance to the Cox Regression models. For parametric models, the hazard is assumed 
to follow a specific statistical distribution,4 whereas the Cox model has more flexibility with 
no restrictions on the shape of the hazard. However, if parametric models fit the baseline 
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hazard more closely, then more accurate coefficient estimates can be derived (smaller 
standard errors) and they offer more with post-estimation. The choice of parametric model 
should also be based on whether the shape of the hazard follows the appropriate statistical 
distribution of the model.26 Further investigations therefore of the external performance of 
these models would need to be investigated with a consideration of how they would be 
applied. For instance, considering whether being able to derive risks for multiple time 
points is a useful application in this screening setting. 
 
From an external validation perspective, machine learning algorithms are often harder to 
assess if based on ‘software objects’ or if the model equation is not fully reported. For 
complex random forest models for example, equations could span many pages. The full 
equation for the neural network was fully reported in Chapter 4 to allow external 
validation and to allow implementation into statistical software (such as the BCSS). Issues 
may be encountered if the model requires recalibration/updating when testing in a 
different setting as these methods are not fully developed for this type of algorithm.16 The 
methods for externally validating a logistic regression model are however fully developed 
and updating the model only requires a simple change to the intercept. More recently, 
guidance for external validation of a Cox Regression model has also been published,27 28 
although out of sample validation requires interpolation or extrapolation whereas 
parametric models can estimate predictions at a number of time points29. 
 
A model may perform better in terms of discrimination and calibration, like with the neural 
network model versus the logistic regression model, but usability (including presentation of 
the model) and how the model would be applied also plays a part on whether 
implemented in practice. Neural networks as discussed above are more difficult to 
interpret and are therefore not ‘trusted’ as much as tried and tested medical statistical 
approaches. Acceptability of these different risk adjusted approaches to both clinicians and 
patients would also need to be investigated before implementing in practice. Acceptability 
is considered in several of the National Screening Committee criteria for deciding whether 
to implement or change a component of a screening programme (Criteria 6 and 12 for 
example). Other important elements which would need to be considered are the 
presentation of the risk information to patients, GPs or Specialist Screening Practitioners 
(SSPs). Currently the BCSP are planning on reporting either a positive or negative result to a 
patient based on a FIT threshold (not the underlying numerical result which relates to risk). 
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For informed decision making, knowing your level of risk may cause worry if just under the 
probability threshold chosen, or may help to push an individual to go for colonoscopy if 
they are at substantially higher risk, or even cause an individual to pursue lifestyle changes. 
Reporting and presenting the level of risk with one of these statistical models would 
therefore require further investigation. 
 
The methods used for defining the AEB date and the resultant dates extracted for each 
practice can be used in future studies using BCSP data. The AEB date can be used to 
provide quality assurance to the data as well as to help define a screening cohort for 
analysis from data which is principally used for primary care based studies. Similar methods 
can be applied on other EHRs and for screening programmes in different regions. The 
methods reported in Chapter 6 for AHD variable extraction, Read code list and drug code 
list development can be used or amended for other studies using primary care databases. 
5.0 Future Research 
Updating Models and external validation studies 
 
The risk based models developed in Chapters 3 & 4 can be refined and updated by utilising 
additional risk predictors available from the BCSS as well as using follow up information 
once the FIT is rolled out in 2018. This refined model could then be assessed in a further 
dataset using FIT for external validation (for instance, Scotland have implemented the FIT 
along with the Isle of Man).  
 
The impact of the risk prediction model could be investigated by recalling an individual if 
either the FIT result alone or the risk based model suggests cancer could be detected at 
colonoscopy and assessing the corresponding diagnostic accuracy and patient outcomes. 
The systematic review identified that there were no prediction model impact studies in this 
area combining FIT with other factors. Based on the results reported in Chapters 3 & 4, this 
approach would result in an estimated additional 109 colonoscopies out of 40,000 people 
invited.  
 
The BCSS has an inbuilt function of using 1/n data for screening participants. For the pilot, 1 
out of every 28 invitations was assigned a FIT; a similar approach here could be used to 
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assess risk adjusted screening or to assign a range of thresholds so data can be retained for 
future analysis. 
 
Many risk prediction models are developed but fewer undergo external validation and even 
fewer have an impact analysis.27 30-32 Ideally, models should be externally validated by a 
separate research team as a gold standard approach to model development and validation. 
The models in this research, although they improve discrimination have a less than perfect 
performance (area under the curve range 0.66-0.69 and for Cox Regression from 0.65-
0.85). Externally validated models which have less than perfect performance require an 
impact analysis to determine if a risk adjusted approach is better than usual care.33  An 
intermediate step could apply decision modelling techniques to assess the potential 
consequences of the model.33 Future research in this area should therefore consider the 
whole prediction model pathway to ensure models with high predictive performance and 
which show patient benefit are applied in clinical practice.  
 
External validation of Cox models compared to logistic regression is not frequently cited in 
the literature due to higher complexity associated with the baseline hazard function. 
Recent guidance has however recently been published in this area.28 
 
Risk Based Screening Intervals 
 
Timing or the ‘intended moment of using the model’ is an important consideration of the 
CHARMS checklist.34 A risk based approach could be implemented at various points along 
the colorectal cancer screening pathway. This research focused on a diagnostic risk 
prediction model at the time of the screening test in order to assist with identifying those 
at highest risk for referral. The PROGRESS research group argue that assessing future 
outcome of risk (prognosis) may be a better approach than assessing diagnosis.35 They 
state that diagnosis is a dichotomy at a single point in time and clinicians now have greater 
access to continuous measures of risk.35 36 Based on these arguments, future research could 
assess a baseline FIT result (along with other factors) to determine personalised screening 
intervals (or for post-screening surveillance). People at increased risk of colorectal cancer 
could receive more frequent screens whereas those at lower risk could receive fewer 
screens. This approach could make screening programmes more cost effective. Studies 
have shown for instance that the baseline FIT concentration is a predictor of incident 
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colorectal neoplasia and is also related to detection of colorectal neoplasia in the next 
screening round.37 38 
 
Assessing Diagnostic Accuracy of a Model 
 
Assessing the diagnostic accuracy of the risk prediction model used as a screening test, 
depends on the timing of the model and the subsequent potential role of the test. Three 
roles have been defined for a new test: replacement, triage and add-on, and a variety of 
study designs can be used for comparing a new test with an existing test.39 The risk 
prediction model combining the FIT could be considered as a replacement test due to its 
higher accuracy. Once a model has been externally validated it can be assessed against the 
FIT only in an RCT or a paired study whereby the patients are tested with the model, the 
screening test and the reference standard. Alternatively, a model can be used as a triage 
before the screening test to preselect a population for further testing; studies have 
implemented questionnaires for this approach.40 Finally, a prediction model can be used as 
an-add on after the screening test to reduce the number of false positives. Biomarkers may 
have this role in the future.33 
 
Prediction model methods 
 
The models developed using survival analysis applied Cox Regression as a modelling 
technique. There are more flexible parametric survival models which exist including the 
Royston-Parmar model.41 Chapter 5 does extend the Cox Regression model to other 
parametric models and compares the model fit, but the Royston-Parmar models offer 
unique advantages. For instance, they fit a restricted cubic spline allowing greater flexibility 
when modelling the baseline hazard function, can incorporate time dependent effects and 
estimate hazard rates at all time points. Future studies should consider comparing this 
model to other approaches and following the guidance in terms of reporting, as discussed 
by Ng et al.42 
 
For studies using longitudinal data with repeatedly measured variables, there could be 
different approaches to incorporate these changes in a prediction model to improve 
individual risk prediction. For instance, the change in the FIT concentration over screening 
rounds could be a strong risk indicator for colorectal cancer. Furthermore, blood test 
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results or biomarker levels could change over time which may reflect an underlying 
disease. More guidance and research is required in this area for the best way to model 
these changes. A recent article published in the Diagnostic and Prognostic Research journal 
applied 6 different methods to model a repeatedly measured predictor; all measurements, 
a single best measurement, summary measurement (mean or maximum), the change 
between subsequent measurements, conditional measurements and growth curve 
parameters.43 The latter was the most flexible and retained predictive quality. Approaches 
such as these should be considered in future studies to improve individual risk prediction 
performance. 
 
Although the TRIPOD statement gives recommendations for the reporting of studies 
developing validating or updating a prediction model, the focus is on regression 
techniques. Some of the principles are equally valid to machine learning algorithms but 
further more specific items are required when reporting such studies. A common theme 
identified in the literature pertaining to ANNs for instance is that the model building 
procedure is often not adequately reported.7 Model building approaches are also less 
formalised compared to logistic regression so each study tends to have a different 
approach. In order to produce well performing models which are reproducible, further 
guidelines on building neural networks and other machine learning algorithms should be 
developed to improve both external validation and confidence in a clinical setting. 
 
Finally, future research could include the consideration of dynamic risk prediction models 
which continually learn or update based on new information.44-46 The underlying 
prevalence of disease may change, or more information obtained on a risk cohort which 
would require an update of the original model coefficients. 
 
Electronic Health Records 
 
Lifestyle factors, lab parameters, symptoms and other conditions have been identified as 
predictors, which help to explain an individual’s level of risk for colorectal cancer in 
Chapter 5 and could be included in a future risk adjusted screening algorithm. The 
importance of such factors could be considered by offering routine blood tests as part of 
NHS Health Checks or drawing further information from GP records onto the screening 
database for use in a pre-selection algorithm. The interconnections between the IT systems 
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used for primary care and screening would require greater investigation to determine the 
feasibility of such an approach. When the FIT is implemented in the NHS BCSP, SNOMED CT 
codes and the FIT result could be sent to primary care which could be utilised in research. 
 
The increasing use of EHRs in both clinical practice and research is leading to development 
of methods to best utilise and extract this data for research. The methods described in 
Chapter 6 can be taken forward in other studies to improve quality and validity of data 
used in this area. Due to the complexity and detail of information available, novel 
approaches to develop risk prediction models will be required in the future. Machine 
learning algorithms have shown promise in this research and could be applied for more 
complex datasets due to their flexibility. Further to this, there are both coded information 
and free text information stored in EHRs. Methods for free text extraction using text mining 
techniques warrant investigation in order to utilise this important source of information 
and can retain anonymity of an individual. 
5.0 Conclusions and Recommendations 
The research in this thesis has identified the potential of risk-adjusted screening using the 
FIT for making screening referral decisions. Several growing trends have been identified 
related to this research area including the increased number of studies in prediction model 
research, and the growing use of electronic health records as well as the reproducibility 
and transparency of methods in this area. Machine learning approaches are abundant in 
other fields of research but tend to be replaced by more conventional methods in health 
research due to their supposed ‘black box’ nature. The reporting and quality of risk 
prediction model studies is often cited as low quality; this was evident in the systematic 
review in Chapter 2 where most studies had high risks of bias, particularly in relation to 
statistical analysis. This is set to improve with the publication of guidelines for developing 
and reporting models. This thesis endeavored to report methods and model development 
fully and to provide risk equations by following the TRIPOD guidelines and PROGRESS 
principles.10 35 
 
A relatively simple model which combines routinely available predictors available from the 
BCSS has shown a significant improvement above just applying the FIT on its own. Before 
such an approach can be implemented in practice, the model will need to consider further 
predictors available from the BCSS, externally validate the model in another dataset and 
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carry out an impact study to assess the effects on patient outcomes. A clear gap in 
prediction model research identified from the systematic review in Chapter 2 and from the 
literature is the lack of external validation studies and, even rarer, impact studies for risk 
prediction models. Applying a prediction model is essentially applying a new technology 
and as such the spectrum and characteristics of the diagnosed disease may differ. This 
needs to be investigated before applying a risk prediction model in practice, despite many 
models being implemented with a lack of evidence behind their use in guidelines.31 Future 
risk prediction model research projects should therefore consider the whole pathway from 
development to impact, ensuring a separate dataset for external validation and ideally 
contacting/collaborating with external researchers to carry this out (reduction in bias) as 
well as planning the assessment of model impact.  
 
Machine learning approaches have shown improvement in performance above and beyond 
the usual standard statistical methodology. Provided model development is clearly 
reported and transparent to other researchers to validate results, these methods warrant 
further investigation. The growing use of EHRs and their more detailed and complex nature 
may mean machine learning methods are better suited to modelling this data. Future 
prediction model guidelines should consider reporting of machine learning models and 
their development. Researchers should ensure methodological transparency of the models 
and investigate methods to make these approaches more accessible to users (e.g. 
visualization tools) to improve the adoption of machine learning approaches in practice and 
to allow external validation by other research groups.18 47 
 
Lifestyle, lab parameters, symptoms and other conditions have been identified as 
predictors, which help to explain an individual’s level of risk for colorectal cancer in 
Chapter 5 and could be considered for inclusion in a future risk adjusted screening model. 
The importance of such factors could be considered by offering routine blood tests perhaps 
as part of health checks or drawing further information from GP records onto the screening 
database for use in a pre-selection algorithm. It has been suggested that predicting future 
risk is more valuable than assessing current risk of disease. This can be achieved in a 
screening programme by assessing an individual’s risk at a baseline point and tailoring 
aspects of screening based on this result. For instance, risk based screening intervals have 
been discussed in FIT research groups and involve lengthening or shortening an individual’s 
screening interval based on their risk. The ‘intended moment’ of using a risk prediction 
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model can be investigated at different points along the screening pathway as an approach 
to personalize screening. 
 
With the implementation of the FIT by the end of 2018 in the BCSP, there are many further 
opportunities for research and investigating a risk adjusted approach to screening with the 
end goal of improving early detection of colorectal cancer and ultimately patient outcomes. 
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